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Background: Progesterone prophylaxis is widely used to prevent preterm birth but is not licensed and
there is little information on long-term outcome.
Objective: To determine the effect of progesterone prophylaxis in women at high risk of preterm birth on
obstetric, neonatal and childhood outcomes.
Design: Double-blind, randomised placebo-controlled trial.
Setting: Obstetric units in the UK and Europe between February 2009 and April 2013.
Participants: Women with a singleton pregnancy who are at high risk of preterm birth because of either a
positive fibronectin test or a negative fibronectin test, and either previous spontaneous birth at ≤ 34 weeks+0
of gestation or a cervical length of ≤ 25 mm.
Interventions: Fibronectin test at 18+0 to 23+0 weeks of pregnancy to determine risk of preterm birth.
Eligible women were allocated (using a web-based randomisation portal) to 200 mg of progesterone or
placebo, taken vaginally daily from 22+0 to 24+0 until 34+0 weeks’ gestation. Participants, caregivers and
those assessing the outcomes were blinded to group assignment until data collection was complete.
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Main outcome measures: There were three primary outcomes, as follows: (1) obstetric – fetal death or
delivery before 34+0 weeks’ gestation; (2) neonatal – a composite of death, brain injury on ultrasound scan
(according to specific criteria in the protocol) and bronchopulmonary dysplasia; and (3) childhood – the
Bayley-III cognitive composite score at 22–26 months of age.
Results: In total, 96 out of 600 (16%) women in the progesterone group and 108 out of 597 (18%)
women in the placebo group had the primary obstetric outcome [odds ratio (OR) 0.86, 95% confidence
interval (CI) 0.61 to 1.22]. Thirty-nine out of 589 (7%) babies of women in the progesterone group and
60 out of 587 (10%) babies of women in the placebo group experienced the primary neonatal outcome
[OR 0.62, 95% CI 0.38 to 1.03]. The mean Bayley-III cognitive composite score of the children at 2 years of
age was 97.3 points [standard deviation (SD) 17.9 points; n = 430] in the progesterone group and 97.7
points (SD 17.5 points; n = 439) in the placebo group (difference in means –0.48, 95% CI –2.77 to 1.81).
Limitations: Overall compliance with the intervention was 69%.
Harms: There were no major harms, although there was a trend of more deaths from trial entry to 2 years
in the progesterone group (20/600) than in the placebo group (16/598) (OR 1.26, 95% CI 0.65 to 2.42).
Conclusions: In this study, progesterone had no significant beneficial or harmful effects on the primary
obstetric, neonatal or childhood outcomes.The OPPTIMUM trial is now complete. We intend to participate
in a comprehensive individual patient-level data meta-analysis examining women with a singleton
pregnancy with a variety of risk factors for preterm birth.
Trial registration: Current Controlled Trials ISRCTN14568373.
Funding: This trial was funded by the Medical Research Council (MRC) and managed by the National
Institute for Health Research (NIHR) on behalf of the MRC–NIHR partnership.
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Plain English summary
P rogesterone is widely used to prevent preterm birth (birth of the baby before 37 weeks’ gestation), butit has not been approved by government bodies for this purpose. Additionally, we do not know how
progesterone will affect the baby in the longer term. We wanted to find out what effect progesterone
given to women at high risk of preterm birth would have on rates of preterm birth, the health of the
newborn baby and the health of the offspring at the age of 2 years.
In total, 1197 women at risk of preterm birth helped with the study. We did a test to look at the risk of
preterm birth in those who agreed. We gave half of the women who were at increased risk progesterone
and the other half a dummy treatment (placebo). Neither the women nor the researchers knew which
treatment the women were getting until the end of the study. We recorded how long pregnancy lasted
and the health of the baby shortly after birth and at 2 years of age.
We found that progesterone had no significant benefits or harms on either the rate of preterm birth or
the health of the baby. This means that progesterone might not be helpful for women at risk of preterm
birth. This information should be considered by expert groups making guidelines and doctors advising
pregnant women, and needs to be discussed with pregnant women considering taking it. Potentially,
this research could prevent the exposure of large numbers of pregnant women and their babies to
unnecessary progesterone.
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Scientific summary
Background
Progesterone prophylaxis is widely used to prevent preterm birth, but does not have licensing approval,
and there is little information on long-term outcome.
Objective
To determine the effect of progesterone prophylaxis in women at high risk of preterm birth on obstetric,
neonatal and childhood outcomes.
Design
Double-blind, randomised placebo-controlled trial.
Setting
Obstetric units in the UK and Europe.
Participants
Women with a singleton pregnancy who were at a high risk of preterm birth.
Interventions
Fibronectin test at 18+0 to 23+0 weeks of pregnancy to determine the risk of preterm birth. Women with a
positive fibronectin test and selected women with a negative fibronectin test were randomised to 200 mg
of progesterone or placebo taken vaginally from 22+0 to 24+0 weeks’ until 34+0 weeks’ gestation.
Main outcome measures
There were three primary outcomes, as follows: (1) obstetric – fetal death or delivery before 34+0 weeks’
gestation; (2) neonatal – a composite of death, brain injury on ultrasound scan (according to specific
criteria in the protocol) and bronchopulmonary dysplasia; and (3) childhood – the Bayley-III cognitive
composite score at 22–26 months of age.
Results
In total, 96 out of 600 (16%) women in the progesterone group and 108 out of 597 (18%) women in the
placebo group experienced the primary obstetric outcome [odds ratio (OR) 0.86, 95% confidence interval
(CI) 0.61 to 1.22]. Thirty-nine out of 589 (7%) babies of women in the progesterone group and 60 out of
587 (10%) babies of women in the placebo group experienced the primary neonatal outcome [OR 0.62,
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95% CI 0.38 to 1.03]. The Bayley-III cognitive composite score at age 2 years for the child was 97.3 points
[standard deviation (SD) 17.9 points] in the progesterone group and 97.7 points (SD 17.5 points) in the
placebo group (difference in means –0.48, 95% CI –2.77 to 1.81).
Limitations
Overall compliance with the intervention was 69%.
Conclusions
In this study, progesterone had no significant beneficial or harmful effects on the primary obstetric,
neonatal or childhood outcome.
Future work
We hope to participate in a comprehensive individual patient-level data meta-analysis examining women
with a singleton pregnancy and with a variety of risk factors for preterm birth.
Trial registration
This trial is registered as ISRCTN14568373.
Funding
This trial was funded by the Medical Research Council (MRC) and managed by the National Institute for
Health Research (NIHR) on behalf of the MRC–NIHR partnership.
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Chapter 1 Introduction
The OPPTIMUM study was conceived in 2007, after two large randomised trials1,2 suggested thatprogestogens prevent preterm delivery and may improve neonatal outcomes. At the conception of
the study, we firmly believed that understanding the long-term effects of progesterone on the baby
(either good or bad) would be important for both women and caregivers in deciding when preterm birth
prophylaxis with progesterone would be important.
By the time OPPTIMUM was completed in 2015, the question of the long-term effects of progesterone,
when given for preterm birth prophylaxis, remained important. Preterm birth is the single biggest cause
of neonatal mortality and morbidity, with rates of 7.6% in the UK in 2015.3 Although there has been a
modest decline in rates of preterm birth in the USA since 2006, to 11.4% in 2013,4 no such change
has been observed in the UK. Worldwide, 15 million babies are born preterm each year, accounting for
2 million deaths within the first month after birth and 77 million disability-adjusted life-years, 3.1% of the
global total.5 The economic burden is huge.
Since starting OPPTIMUM in 2008, further randomised trials have been published examining the efficacy
of progestogens to prevent preterm birth. One of two formulations of progestogen are commonly used:
(1) a synthetic hormone, 17α-hydroxyprogesterone caproate (17α-OHP), injected intramuscularly; and
(2) ‘natural’ progesterone, usually administered vaginally. Several systematic reviews, the most recent
by the Cochrane collaboration,6 and one individual patient-level data meta-analysis7 have summarised
the effect of progestogens on obstetric and neonatal outcomes. We performed a literature search on
11 July 2016 to identify any randomised trials in which asymptomatic women with a singleton pregnancy
were given progesterone or progestogens with the aim of preventing preterm birth that were published
since the search date of the Cochrane meta-analysis (January 2013). The only relevant published study was
OPPTIMUM,8 the study described in this report.
The Cochrane review6 summarises the data by preterm birth risk (e.g. previous preterm birth or cervical
shortening). In women with a previous preterm birth, progestogen prophylaxis reduces preterm birth
before 34 weeks’ gestation, perinatal mortality, birthweight of < 2500 g and rates of neonatal death
(Table 1).
In women with cervical shortening, progestogens reduce the risk of preterm birth before 34 weeks’
gestation, but have no significant effect on perinatal mortality, birthweight of < 2500 g or neonatal death
(Table 2).
In contrast, in the individual patient-level data meta-analysis7 restricted to women with cervical shortening,
progesterone prophylaxis reduced both rates of preterm birth and composite adverse neonatal outcomes
with relative risks of 0.58 and 0.57, respectively (Table 3).
TABLE 1 Effects of progestogens compared with placebo on preterm birth and associated complications in women
with a previous preterm birth. Data from Dodd et al.6
Outcome Progesterone group, n/N Placebo group, n/N Risk ratio 95% CI
Preterm birth < 34 weeks’ gestation 30/302 78/300 0.31 0.14 to 0.69
Perinatal mortality 35/801 59/652 0.50 0.33 to 0.75
Birthweight of < 2500 g 94/418 97/274 0.58 0.42 to 0.79
Neonatal death 21/801 39/652 0.45 0.27 to 0.76
CI, confidence interval.
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The reasons for the discrepancy in results for the outcomes for women with a short cervix are not clear.
It is possible that the additional statistical power conferred by analysis of the individual patient-level data
is responsible for the significant reduction reported in the Romero et al.7 paper but not the Cochrane
review.6 Alternative explanations are that 17α-OHP is ineffective in women with a short cervix and that
inclusion of these data in the Cochrane review,6 but not in the Romero et al.7 paper, accounts for the
difference in results. Regardless, there is a consensus from both these systematic reviews6,7 that
progesterone prevents preterm birth, at least in women with a short cervix, but disagreement about
whether or not this reduction in preterm birth is associated with improved outcomes for the baby.
17α-hydroxyprogesterone caproate (Makena®; Amag Pharmaceuticals, Waltham, MA, USA) is the only
progestogen licensed for preterm birth prevention in the USA, with the licensing application having
been supported by data from the Meis et al.9 trial. The indication for use is to reduce preterm birth in
women with a history of spontaneous preterm birth in a previous singleton pregnancy, where the index
pregnancy is a singleton pregnancy.10
Although 17α-OHP and progesterone are both progestogens, they are somewhat different drugs and may
have different effects. A licensing application was submitted to the US Food and Drug Administration
(FDA) for progesterone based on data from a large randomised trial of progesterone to prevent preterm
birth in women with a short cervix,11 but the FDA advisory panel voted 13 to 4 against it.12
The primary rationale for the OPPTIMUM study was that the long-term effects of progesterone prophylaxis to
prevent preterm birth on the child are unknown. It is plausible that preventing preterm birth could be harmful:
preterm birth is known to be associated with high rates of intrauterine infection and/or inflammation,13 and
intrauterine infection is known to have deleterious effects on the baby.14 The absence of adverse effects in
the short term does not mean that there will be no long-term harm. For example, in the ORACLE II trial,15,16
maternal administration of antibiotics to prevent preterm birth had no effect on the baby in the short term,
but there was an increase in the rate of cerebral palsy at 7 years of age with each of co-amoxicillin and
erythromycin, with some evidence of higher rates when both antibiotics were given together.
TABLE 2 Progestogens vs. placebo in women with cervical shortening. Data from Dodd et al.6
Outcome Progesterone group, n/N Placebo group, n/N Risk ratio 95% CI
Preterm birth < 34 weeks’ gestation 41/219 64/219 0.64 0.45 to 0.90
Perinatal mortality 21/698 28/691 0.74 0.42 to 1.29
Birthweight of < 2500 g 188/693 202/686 0.92 0.78 to 1.09
Neonatal death 11/791 20/780 0.55 0.26 to 1.13
CI, confidence interval.
TABLE 3 Individual patient-level data meta-analysis on vaginal progesterone in women with a short cervix.
Data from Romero et al.7
Outcome Relative risk 95% CI
Preterm birth before 33 weeks’ gestation 0.58 0.42 to 0.80
Respiratory distress syndrome 0.48 0.30 to 0.76
Composite neonatal morbidity and mortality 0.57 0.40 to 0.81
CI, confidence interval.
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Hence, the purpose of the OPPTIMUM study was to determine whether or not, in women at high risk
of preterm labour, 200 mg of prophylactic vaginal natural progesterone, inserted once daily from 22 to
34 weeks’ gestation, compared with placebo:
i. improves obstetric outcome by lengthening pregnancy and, thus, reduces the incidence of preterm
delivery (before 34 weeks’ gestation)
ii. improves neonatal outcome by reducing a composite of death and major morbidity
iii. leads to improved childhood cognitive and neurosensory outcomes at age 2 years.
A successful grant application was submitted to the Medical Research Council (MRC) in 2007 to test these
hypotheses.
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Chapter 2 Methods
The OPPTIMUM study methodology is described in detail in the published protocol17 and in the ‘working’protocol of this paper. An abbreviated version is also described in the main publication8 summarising
the results of the study.
Study design
In summary, this was a randomised controlled double-masked study. The participants were pregnant
women at risk of preterm birth, and were approached in, and recruited from, one of 65 antenatal clinics in
the UK and one antenatal clinic in Sweden between February 2009 and April 2013. The study was in two
phases: (1) a screening phase and (2) a treatment phase.
Inclusion and exclusion criteria
Eligibility for the screening phase was conferred by the inclusion criteria of:
l all women aged ≥ 16 years
l gestational age established by scan at ≤ 16 weeks to ensure that the estimated date of delivery was
accurate (or the consultant had to be confident that the gestation dates were accurate)
l signed consent form
l one of the following – history in a previous pregnancy of either previous preterm birth; second
trimester loss (at ≥ 16 weeks’ or ≤ 37 weeks’ gestation); preterm premature rupture of the fetal
membranes (≤ 37 weeks’ gestation); or, in this pregnancy, a short cervical length (≤ 25 mm) on
ultrasound scan at 18+0 to 24+0 weeks’ gestation or a previous history of any cervical procedure to treat
abnormal smears (i.e. large loop excision, laser conisation, cold knife conisation or radical diathermy).
Exclusion criteria were:
l known significant congenital structural or chromosomal fetal anomaly
l known sensitivity or contraindication to or intolerance of progesterone (listed contraindications
including known allergy or hypersensitivity to progesterone, severe hepatic dysfunction, undiagnosed
vaginal bleeding, mammary or genital tract carcinoma, thrombophlebitis, thromboembolic disorders,
cerebral haemorrhage and porphyria)
l suspected or proven rupture of the fetal membranes at the time of recruitment
l multiple pregnancy
l prescription or ingestion of medications known to interact with progesterone (e.g. bromocriptine,
rifamycin, ketoconazole or ciclosporin)
l women currently prescribed progesterone or who have taken progesterone beyond 18 weeks’ gestation.
In the early phases of the study, the excipient of the study drug contained arachis (peanut) oil; hence,
those with peanut allergies were excluded. However, midway through the study, the excipient was
changed to sunflower oil. Once the supply of a drug containing arachis oil was removed, peanut allergy
was removed as a contraindication; hence, two Summary of Product Characteristics (SmPCs) are shown in
Appendix 1.
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Interventions
Women participating in the screening phase had a fibronectin test performed between 18+0 and 23+6 weeks’
gestation inclusive. Initially, eligibility for the treatment phase was conferred only by a positive fibronectin
test result. However, as described in the published protocol,17 these criteria were changed partway through
the study, when we realised that we were missing women at medium risk of preterm birth. Thereafter,
eligibility for the treatment phase was conferred by eligibility for the screening phase and any of i–iii:
i. a positive fetal fibronectin (fFN) test in combination with a history in a previous pregnancy of any of
preterm birth, second trimester loss, premature fetal membrane rupture or a positive fFN test in
combination with a history of cervical procedure to treat abnormal smears
ii. history in a previous pregnancy of spontaneous preterm birth at, or before, 34+0 weeks’ gestation
(regardless of the fFN test result)
iii. a cervical length in this pregnancy of ≤ 25 mm (regardless of the fFN test result).
Women recruited into the treatment phase were randomised to treatment with either 200 mg of
progesterone inserted (by the participant) vaginally once daily from 22–24 weeks’ gestation to 34+0 weeks’
gestation, or to an identical-appearing placebo. Progesterone and placebo were in the form of a pessary.
The dose used was 200 mg daily. The choice of dose was pragmatic and relied on efficacy and safety
outcomes from existing studies, given that the mechanism of action was (and still is) uncertain and the
plasma (and/or uterine) concentration of progesterone required to reduce preterm delivery was (and still is)
unknown. When the study was planned, the doses of vaginal progesterone used in completed trials were
100 mg (n = 142)2 or 200 mg;18 200 mg was the dose that UK obstetricians were using off-label for
preterm birth prevention. A variety of doses were used in subsequent large trials, including 90 mg daily11
and 200 mg daily.18 With no indication of any safety issue at any dose, we believed it was prudent to use
the higher dose to minimise the risk of using a dose lower than the minimal clinically effective dose.
There was no restriction on prior or concomitant therapy, other than women who were currently prescribed
or taking progesterone or who had taken progesterone beyond 18 weeks’ gestation in the index pregnancy.
Administration of other agents or strategies aimed at preventing preterm birth (e.g. cervical cerclage)
or improving the outcome (e.g. tocolytics or corticosteroids for fetal lung maturation) were not prohibited.
We recorded the number of women who had cervical cerclage.
Governance and oversight
Quality assurance of the data was achieved by following data management procedures at the study data
centre [Robertson Centre for Biostatistics (RCB)] and data monitoring at study sites. Data management at
the RCB was carried out in accordance with a prespecified management plan. The electronic case report
form (eCRF) included point-of-entry validation checks. During the trial, additional data validation checks
were carried out periodically, with data queries issued to study sites for resolution. Prior to database lock,
final data validation checks were carried out and all queries were resolved, when possible. During the
trial, study statisticians produced reports for the Trial Steering Committee (TSC) and Independent Data
Monitoring Committee (IDMC). Issues of data quality identified by study statisticians were reported to
study data management staff and queried when appropriate, and/or included in future routing data
validation checks. TSC and IDMC meetings provided opportunities for external, independent review of
summary data, with additional feedback on potential data quality issues being incorporated into ongoing
data quality checks.
Data monitoring at study sites consisted of on-site periodic monitoring and site closure visits including a
review of 100% consent forms and participant eligibility and a 10% check of primary outcome data
against the eCRF. Site initiation visits were conducted at all participating sites. This included a site set-up
METHODS
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visit consisting of protocol, eCRF and procedure training for staff. Further onsite monitoring and closure
visits were conducted, each included a review of investigator site files, site delegation logs, staff
qualifications and training (Good Clinical Practice, curricula vitae), and pharmacy documentation.
Outcomes
The primary outcomes for the study were obstetric (fetal death or delivery before 34+0 weeks’ gestation),
neonatal [a composite of death, brain injury on ultrasound scan (according to specific criteria in the
protocol) and bronchopulmonary dysplasia] and childhood (the Bayley-III cognitive composite score at
22–26 months of age).
Secondary outcomes are as listed in the protocol. Definitions for both primary and secondary outcomes are
listed in the protocol. A statistical analysis plan was prepared and finalised before data lock, unblinding
and data analysis and is shown in Appendix 2. In brief, data were analysed by intention to treat (ITT),
with supplementary sensitivity analyses of a per-protocol (PP) data set and with multiple imputation for
missing data. Additional exploratory subgroup analyses were performed. Mixed-effects logistic regression
or linear regression was used to compare outcomes between the treatment groups, with study centre as a
random effect and treatment allocation and previous pregnancy (≥ 14 weeks) as fixed effects. p-values for
the primary analysis of the primary outcomes were adjusted for multiple comparisons.
This trial is registered as ISRCTN14568373.
A summary of the study was registered on the International Standard Randomised Controlled Trial Number
(ISRCTN) register (reference number 14568373). The study was also registered with the Medicines and
Healthcare products Regulatory Agency (MHRA) (22931/0009/001-0001, later revised to 01384/0208/001-0007)
and received ethics approval from the Scotland A Research Ethics Committee (reference 08/MRE00/6). Oversight
of the study was performed by a TSC and a Data Monitoring Committee (see Norman et al.8 for more details).
There was no formal patient and public involvement (PPI) in the design of the study, although the clinicians
involved in study design informally consulted the pregnant women they were looking after. PPI in study
oversight was achieved through participation of two successive individual patient representatives on the
TSC (the second was recruited after the first was unable to continue because of other commitments) and
by participation of a charity representative, Jane Brewin. As a chief executive office of Tommy’s baby
charity, Jane Brewin acted as a ‘voice’ for women undergoing preterm birth.
We were aware that securing childhood outcome data would be one of the challenges of the study, given
the long interval between birth and interaction with the study team, and the invitation to the Bayley-III
cognitive composite score test. We used the following strategies to increase contact with participants (i.e.
the pregnant woman): sending them a letter immediately after birth, a letter at 6 months, a questionnaire
at 12 months, a card and teddy bear gift for the child’s first birthday, a further 12-month reminder, a letter
at 18 months and a birthday card and a small gift for the child at 2 years of age. Partway through the
study we also set up a Facebook (www.facebook.com; Facebook, Inc., Menlo Park, CA, USA) page with
pictures of the babies (permission and pictures were supplied by the parents) and began to offer a £50
voucher for participation in the Bayley-III cognitive composite score test. We also asked for details of a
third person as a contact point (often the participant’s own mother) and we used this strategy to access
difficult-to-contact women, including those who had moved after the birth of their child.
The study was reported in accordance with CONSORT (Consolidated Standards of Reporting Trials)
guidelines.19
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Chapter 3 Results
Recruitment and retention
Recruitment and retention to the study is described in the original paper.8 Briefly, 15,132 patient records
were reviewed for eligibility, 5833 women were tested with a fFN test, 1228 women were randomly
assigned and 1226 were part of the ITT population. Follow-up data were obtained for 1197 women for the
obstetric outcome, 1176 babies for the neonatal outcome and 869 children for the childhood outcome.
Demographic and other baseline characteristics
The baseline characteristics and other demographics of participating women (by treatment allocation) are
shown in Tables 4 and 5.
TABLE 4 Inclusion criteria at randomisation: ITT population. Number of observed values, number of missing values,
number and percentage per category or mean, standard deviation, median and quartiles, minimum and maximum
for all patients and by treatment
Criterion All
Trial group
Placebo Progesterone
History of delivery/pregnancy loss at ≥ 16 and < 37 weeks’ gestation
Nobs (Nmiss) 1225 (1) 610 (0) 615 (1)
No, n (%) 118 (9.6) 61 (10.0) 57 (9.3)
Yes, n (%) 1107 (90.4) 549 (90.0) 558 (90.7)
Previous preterm premature rupture of fetal membranes before or at 37 weeks’ gestation
Nobs (Nmiss) 1225 (1) 610 (0) 615 (1)
No, n (%) 581 (47.4) 312 (51.1) 269 (43.7)
Yes, n (%) 644 (52.6) 298 (48.9) 346 (56.3)
Cervical length of ≤ 25mm on ultrasound scan at 18+0 to 24+0 weeks’ gestation
Nobs (Nmiss) 1225 (1) 610 (0) 615 (1)
No, n (%) 1000 (81.6) 506 (83.0) 494 (80.3)
Yes, n (%) 225 (18.4) 104 (17.0) 121 (19.7)
Any cervical procedure to treat abnormal smears
Nobs (Nmiss) 1196 (30) 594 (16) 602 (14)
No, n (%) 1000 (83.6) 502 (84.5) 498 (82.7)
Yes, n (%) 196 (16.4) 92 (15.5) 104 (17.3)
Positive fFN test at 22–24 weeks’ gestation
Nobs (Nmiss) 1225 (1) 610 (0) 615 (1)
No, n (%) 882 (72.0) 430 (70.5) 452 (73.5)
Yes, n (%) 343 (28.0) 180 (29.5) 163 (26.5)
continued
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TABLE 4 Inclusion criteria at randomisation: ITT population. Number of observed values, number of missing values,
number and percentage per category or mean, standard deviation, median and quartiles, minimum and maximum
for all patients and by treatment (continued )
Criterion All
Trial group
Placebo Progesterone
Negative fFN test at 22–24 weeks’ gestation and previous spontaneous preterm birth before or at 34 weeks’ gestation
Nobs (Nmiss) 1175 (51) 585 (25) 590 (26)
No, n (%) 337 (28.7) 179 (30.6) 158 (26.8)
Yes, n (%) 838 (71.3) 406 (69.4) 432 (73.2)
Negative fFN test at 22–24 weeks’ gestation and cervical length of ≤ 25mm between 18 and 24 weeks’ gestation in index
pregnancy
Nobs (Nmiss) 1175 (51) 585 (25) 590 (26)
No, n (%) 1057 (90.0) 532 (90.9) 525 (89.0)
Yes, n (%) 118 (10.0) 53 (9.1) 65 (11.0)
Nmiss, number of women with missing data; Nobs, number of observations.
TABLE 5 Baseline characteristics at randomisation: ITT population. Number of observed values, number of missing
values, number and percentage per category or mean, standard deviation, median and quartiles, minimum and
maximum for all patients and by treatment
Characteristic All
Trial group
Placebo Progesterone
Age (years)
Nobs (Nmiss) 1225 (1) 610 (0) 615 (1)
Mean (SD) 31.4 (5.7) 31.4 (5.8) 31.5 (5.6)
Median (IQR) 31.5 (27.4–35.7) 31.4 (27.2–35.7) 31.5 (27.6–35.6)
Range 16.8–49.2 17.5–49.2 16.8–45.9
Height (cm)
Nobs (Nmiss) 1221 (5) 607 (3) 614 (2)
Mean (SD) 163.5 (6.6) 163.6 (6.4) 163.5 (6.7)
Median (IQR) 163.0 (159.0–168.0) 163.0 (159.0–168.0) 164.0 (159.0–168.0)
Range 144.0–183.0 144.0–183.0 147.0–183.0
Weight (kg)
Nobs (Nmiss) 1221 (5) 607 (3) 614 (2)
Mean (SD) 71.6 (17.1) 71.4 (16.7) 71.9 (17.5)
Median (IQR) 68.0 (60.0–81.0) 68.0 (59.0–82.0) 68.0 (60.0–80.0)
Range 41.0–186.0 43.0–145.0 41.0–186.0
BMI (kg/m2)
Nobs (Nmiss) 1221 (5) 607 (3) 614 (2)
Mean (SD) 26.8 (6.3) 26.7 (6.1) 26.9 (6.4)
Median (IQR) 25.5 (22.3–29.8) 25.4 (22.2–29.7) 25.6 (22.5–29.8)
Range 15.2–80.5 15.6–54.4 15.2–80.5
RESULTS
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TABLE 5 Baseline characteristics at randomisation: ITT population. Number of observed values, number of missing
values, number and percentage per category or mean, standard deviation, median and quartiles, minimum and
maximum for all patients and by treatment (continued )
Characteristic All
Trial group
Placebo Progesterone
Systolic blood pressure (mmHg)
Nobs (Nmiss) 1219 (7) 608 (2) 611 (5)
Mean (SD) 111.9 (12.4) 112.4 (12.2) 111.3 (12.5)
Median (IQR) 110.0 (102.0–120.0) 110.0 (104.0–120.0) 110.0 (100.0–120.0)
Range 78.0–189.0 78.0–159.0 82.0–189.0
Diastolic blood pressure (mmHg)
Nobs (Nmiss) 1219 (7) 608 (2) 611 (5)
Mean (SD) 66.0 (8.6) 66.2 (8.6) 65.7 (8.5)
Median (IQR) 65.0 (60.0–71.0) 66.0 (60.0–71.0) 64.0 (60.0–70.0)
Range 40.0–104.0 41.0–104.0 40.0–98.0
Smoking
Nobs (Nmiss) 1220 (6) 607 (3) 613 (3)
No, n (%) 984 (80.7) 482 (79.4) 502 (81.9)
Yes, n (%) 236 (19.3) 125 (20.6) 111 (18.1)
Alcohol consumption
Nobs (Nmiss) 1223 (3) 609 (1) 614 (2)
No, n (%) 1160 (94.8) 575 (94.4) 585 (95.3)
Yes, n (%) 63 (5.2) 34 (5.6) 29 (4.7)
Drug use
Nobs (Nmiss) 1223 (3) 609 (1) 614 (2)
No, n (%) 1206 (98.6) 600 (98.5) 606 (98.7)
Yes, n (%) 17 (1.4) 9 (1.5) 8 (1.3)
In full-time education
Nobs (Nmiss) 1216 (10) 607 (3) 609 (7)
No, n (%) 1175 (96.6) 590 (97.2) 585 (96.1)
Yes, n (%) 41 (3.4) 17 (2.8) 24 (3.9)
Years in full-time education
Nobs (Nmiss) 1122 (53) 568 (22) 554 (31)
Mean (SD) 13.5 (3.1) 13.5 (3.0) 13.5 (3.1)
Median (IQR) 13.0 (11.0–16.0) 13.0 (11.0–16.0) 13.0 (11.0–16.0)
Range 1.0–31.0 1.0–30.0 3.0–31.0
Educated in the UK
Nobs (Nmiss) 1206 (20) 602 (8) 604 (12)
No, n (%) 211 (17.5) 109 (18.1) 102 (16.9)
Yes, n (%) 995 (82.5) 493 (81.9) 502 (83.1)
continued
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TABLE 5 Baseline characteristics at randomisation: ITT population. Number of observed values, number of missing
values, number and percentage per category or mean, standard deviation, median and quartiles, minimum and
maximum for all patients and by treatment (continued )
Characteristic All
Trial group
Placebo Progesterone
Highest level of education if in the UK
Nobs (Nmiss) 975 (20) 488 (5) 487 (15)
No formal qualifications, n (%) 99 (10.2) 56 (11.5) 43 (8.8)
Entry Level Certificate/Foundation Diploma,
n (%)
13 (1.3) 6 (1.2) 7 (1.4)
GCSE/Standard/O Level, n (%) 327 (33.5) 164 (33.6) 163 (33.5)
A Level, AS Level, Highers, BTEC, n (%) 137 (14.1) 70 (14.3) 67 (13.8)
Certificate of Higher Education/City & Guilds,
n (%)
53 (5.4) 25 (5.1) 28 (5.7)
Diploma HE/FE/HND/HNC, n (%) 69 (7.1) 33 (6.8) 36 (7.4)
Graduate certificate, diploma, n (%) 14 (1.4) 10 (2.0) 4 (0.8)
Degree, n (%) 158 (16.2) 72 (14.8) 86 (17.7)
Professional qualifications, n (%) 40 (4.1) 19 (3.9) 21 (4.3)
PG certificate, diploma, masters, doctorate,
n (%)
65 (6.7) 33 (6.8) 32 (6.6)
Ethnic group
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
White, n (%) 895 (73.1) 446 (73.2) 449 (73.0)
Chinese, n (%) 1 (0.1) 1 (0.2) 0 (0.0)
Other ethnic group, n (%) 17 (1.4) 5 (0.8) 12 (2.0)
Mixed
White/black Caribbean, n (%) 17 (1.4) 8 (1.3) 9 (1.5)
White/black African, n (%) 3 (0.2) 0 (0.0) 3 (0.5)
White/Asian, n (%) 2 (0.2) 1 (0.2) 1 (0.2)
Other mixed background, n (%) 6 (0.5) 3 (0.5) 3 (0.5)
Asian
Indian, n (%) 30 (2.5) 16 (2.6) 14 (2.3)
Pakistani, n (%) 45 (3.7) 23 (3.8) 22 (3.6)
Bangladeshi, n (%) 5 (0.4) 4 (0.7) 1 (0.2)
Other Asian background, n (%) 23 (1.9) 7 (1.1) 16 (2.6)
Black
Caribbean, n (%) 47 (3.8) 27 (4.4) 20 (3.3)
African, n (%) 119 (9.7) 59 (9.7) 60 (9.8)
Other black background, n (%) 14 (1.1) 9 (1.5) 5 (0.8)
RESULTS
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TABLE 5 Baseline characteristics at randomisation: ITT population. Number of observed values, number of missing
values, number and percentage per category or mean, standard deviation, median and quartiles, minimum and
maximum for all patients and by treatment (continued )
Characteristic All
Trial group
Placebo Progesterone
Ethnic group
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
White, n (%) 895 (73.1) 446 (73.2) 449 (73.0)
Black, n (%) 180 (14.7) 95 (15.6) 85 (13.8)
Asian, n (%) 104 (8.5) 51 (8.4) 53 (8.6)
Mixed, n (%) 28 (2.3) 12 (2.0) 16 (2.6)
Other, n (%) 17 (1.4) 5 (0.8) 12 (2.0)
Gestation at fFN test, weeks
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
Mean (SD) 22.9 (0.6) 22.9 (0.6) 22.9 (0.6)
Median (IQR) 22.9 (22.4–23.4) 22.9 (22.4–23.4) 22.9 (22.4–23.4)
Range 21.7–27.1 22.0–27.1 21.7–26.6
Fetal anomaly scan done
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 63 (5.1) 34 (5.6) 29 (4.7)
Yes, n (%) 1163 (94.9) 576 (94.4) 587 (95.3)
Fetal anomaly scan result
Nobs (Nmiss) 1163 (0) 576 (0) 587 (0)
Normal, n (%) 1150 (98.9) 569 (98.8) 581 (99.0)
Defined abnormality, n (%) 7 (0.6) 4 (0.7) 3 (0.5)
Uncertain abnormality, n (%) 6 (0.5) 3 (0.5) 3 (0.5)
Amniocentesis done
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 1218 (99.3) 607 (99.5) 611 (99.2)
Yes, n (%) 8 (0.7) 3 (0.5) 5 (0.8)
Results of amniocentesis
Nobs (Nmiss) 8 (0) 3 (0) 5 (0)
Normal, n (%) 8 (100.0) 3 (100.0) 5 (100.0)
Other, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Chorionic villus sampling done
Nobs (Nmiss) 1225 (1) 610 (0) 615 (1)
No, n (%) 1216 (99.3) 607 (99.5) 609 (99.0)
Yes, n (%) 9 (0.7) 3 (0.5) 6 (1.0)
continued
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TABLE 5 Baseline characteristics at randomisation: ITT population. Number of observed values, number of missing
values, number and percentage per category or mean, standard deviation, median and quartiles, minimum and
maximum for all patients and by treatment (continued )
Characteristic All
Trial group
Placebo Progesterone
Results of chorionic villus sampling
Nobs (Nmiss) 9 (0) 3 (0) 6 (0)
Normal, n (%) 9 (100.0) 3 (100.0) 6 (100.0)
Other, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Cervical length (mm)
Nobs (Nmiss) 712 (514) 351 (259) 361 (255)
Mean (SD) 28.5 (10.8) 28.8 (11.1) 28.2 (10.6)
Median (IQR) 30.0 (22.0–36.0) 30.0 (22.5–36.0) 30.0 (22.0–36.0)
Range 0.0–84.0 0.0–84.0 0.0–58.0
Risk
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
Low, n (%) 882 (71.9) 429 (70.3) 453 (73.5)
High, n (%) 344 (28.1) 181 (29.7) 163 (26.5)
Any previous pregnancy
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 52 (4.2) 28 (4.6) 24 (3.9)
Yes, n (%) 1172 (95.8) 581 (95.4) 591 (96.1)
Number of previous pregnancies
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
Mean (SD) 2.6 (2.0) 2.7 (1.9) 2.6 (2.0)
Median (IQR) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0)
Range 0.0–14.0 0.0–12.0 0.0–14.0
Any previous pregnancy of ≥ 14 weeks’ gestation
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 75 (6.1) 38 (6.2) 37 (6.0)
Yes, n (%) 1149 (93.9) 571 (93.8) 578 (94.0)
Number of previous pregnancies of ≥ 14 weeks’ gestation
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
Mean (SD) 1.9 (1.4) 1.9 (1.4) 1.9 (1.4)
Median (IQR) 2.0 (1.0–2.0) 2.0 (1.0–3.0) 2.0 (1.0–2.0)
Range 0.0–13.0 0.0–10.0 0.0–13.0
Any previous live birth
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 197 (16.1) 97 (15.9) 100 (16.3)
Yes, n (%) 1027 (83.9) 512 (84.1) 515 (83.7)
RESULTS
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TABLE 5 Baseline characteristics at randomisation: ITT population. Number of observed values, number of missing
values, number and percentage per category or mean, standard deviation, median and quartiles, minimum and
maximum for all patients and by treatment (continued )
Characteristic All
Trial group
Placebo Progesterone
Number of previous live births
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
Mean (SD) 1.5 (1.3) 1.6 (1.3) 1.5 (1.3)
Median (IQR) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0)
Range 0.0–13.0 0.0–10.0 0.0–13.0
Any previous pregnancy that ended with baby alive and well
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 646 (52.8) 321 (52.7) 325 (52.8)
Yes, n (%) 578 (47.2) 288 (47.3) 290 (47.2)
Number of previous pregnancies that ended with baby alive and well
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
Mean (SD) 0.8 (1.2) 0.8 (1.2) 0.8 (1.2)
Median (IQR) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0)
Range 0.0–13.0 0.0–10.0 0.0–13.0
History of induced labour or elective caesarean section
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 1065 (87.0) 524 (86.0) 541 (88.0)
Yes, n (%) 159 (13.0) 85 (14.0) 74 (12.0)
History of miscarriage
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 701 (57.3) 335 (55.0) 366 (59.5)
Yes, n (%) 523 (42.7) 274 (45.0) 249 (40.5)
History of ectopic pregnancy
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 1193 (97.5) 600 (98.5) 593 (96.4)
Yes, n (%) 31 (2.5) 9 (1.5) 22 (3.6)
History of termination of pregnancy
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 1085 (88.6) 542 (89.0) 543 (88.3)
Yes, n (%) 139 (11.4) 67 (11.0) 72 (11.7)
History of termination of pregnancy before 14 weeks’ gestation
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 1106 (90.2) 554 (90.8) 552 (89.6)
Yes, n (%) 120 (9.8) 56 (9.2) 64 (10.4)
continued
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Baseline characteristics of women in each of the treatment groups
The statistical analysis output (see Appendix 3) shows demographics of participants for whom information
on the obstetric outcome, neonatal outcome, childhood outcome and survival at 2 years of age was and
was not available. Smokers and those without formal qualifications were somewhat over-represented
among those for whom the outcomes were unavailable (e.g. for obstetric outcome smokers, 25% vs.
19.2%; and, for no formal qualifications, 25.0% vs. 9.8%), but there were no other obvious differences
by outcome availability.
Primary outcomes
The primary outcomes for the study (by treatment group) are shown in Table 6.
Secondary outcomes
The secondary clinical outcomes for the study (again by treatment group) are shown in Table 7. Odds
ratios (ORs) and 95% confidence intervals (CIs) for these outcomes are shown in the main paper.8 For the
neonatal outcome, there were outcomes on 587 babies in the placebo group and 589 babies in the
progesterone group. Reasons for unavailability of outcomes in the placebo group were consent withdrawn
TABLE 5 Baseline characteristics at randomisation: ITT population. Number of observed values, number of missing
values, number and percentage per category or mean, standard deviation, median and quartiles, minimum and
maximum for all patients and by treatment (continued )
Characteristic All
Trial group
Placebo Progesterone
History of termination of pregnancy at ≥ 14 weeks’ gestation
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 1201 (98.0) 596 (97.7) 605 (98.2)
Yes, n (%) 25 (2.0) 14 (2.3) 11 (1.8)
History of live birth followed by neonatal death
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 1059 (86.5) 524 (86.0) 535 (87.0)
Yes, n (%) 165 (13.5) 85 (14.0) 80 (13.0)
History of live birth followed by death other than neonatal
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 1208 (98.7) 604 (99.2) 604 (98.2)
Yes, n (%) 16 (1.3) 5 (0.8) 11 (1.8)
History of stillbirth
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 1129 (92.2) 561 (92.1) 568 (92.4)
Yes, n (%) 95 (7.8) 48 (7.9) 47 (7.6)
A Level, Advanced Level; AS Level, Advanced Subsidiary Level; BMI, body mass index; BTEC, Business and Technology
Education Council; FE, Further Education; GCSE, General Certificate of Secondary Education; HE, Higher Education;
HNC, Higher National Certificate; HND, Higher National Diploma; IQR, interquartile range; Nmiss, number of women with
missing data; Nobs, number of observations; O Level, ordinary level; PG, postgraduate; SD, standard deviation.
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TABLE 6 Summaries of primary outcome measures for all patients and according to treatment groups
Outcome All
Trial group Adjusted OR or
difference in means
(95% CI)Placebo Progesterone
Death or delivery before 34 weeks
Nobs (Nmiss) 1197 (29) 597 (13) 600 (16)
No, n (%) 993 (83.0) 489 (81.9) 504 (84.0) 0.86 (0.61 to 1.22)
Yes, n (%) 204 (17.0) 108 (18.1) 96 (16.0)
Death, brain injury or severe chronic lung disease
Nobs (Nmiss) 1176 (50) 587 (23) 589 (27)
No, n (%) 1077 (91.6) 527 (89.8) 550 (93.4) 0.62 (0.38 to 1.03)
Yes, n (%) 99 (8.4) 60 (10.2) 39 (6.6)
Bayley-III cognitive composite score at age 2 years (children who are alive only)
Nobs (Nmiss) 833 (393) 423 (187) 410 (206)
Mean (SD), points 99.6 (14.9) 99.5 (15.0) 99.7 (14.7)
Median (IQR), points 100.0 (90.0–105.0) 100.0 (90.0–105.0) 100.0 (90.0–110.0)
Range, points 55.0–149.0 55.0–149.0 55.0–145.0
Bayley-III cognitive composite score at age 2 years (scores imputed for deaths)
Nobs (Nmiss) 869 (357) 439 (171) 430 (186)
Mean (SD), points 97.5 (17.7) 97.7 (17.5) 97.3 (17.9) –0.48 (–2.77 to 1.81)
Median (IQR), points 100.0 (90.0–105.0) 100.0 (90.0–105.0) 100.0 (90.0–105.0)
Range, points 49.0–149.0 49.0–149.0 49.0–145.0
CI, confidence interval; IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations;
OR, odds ratio; SD, standard deviation.
TABLE 7 Secondary clinical outcomes, by treatment group
Outcome All
Trial group
Placebo Progesterone
Summaries of secondary outcome measures at delivery and in the neonatal period for all patients and according
to treatment groups
Gestational age at delivery (weeks)
Nobs (Nmiss) 1197 (29) 597 (13) 600 (16)
Mean (SD) 36.9 (4.2) 36.8 (4.2) 36.9 (4.1)
Median (IQR) 38.3 (35.7–39.6) 38.3 (35.4–39.7) 38.1 (36.0–39.4)
Range 22.4–42.7 22.4–42.7 23.0–42.1
Delivery before 34 weeks
Nobs (Nmiss) 1197 (29) 597 (13) 600 (16)
No, n (%) 993 (83.0) 489 (81.9) 504 (84.0)
Yes, n (%) 204 (17.0) 108 (18.1) 96 (16.0)
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TABLE 7 Secondary clinical outcomes, by treatment group (continued )
Outcome All
Trial group
Placebo Progesterone
Fetal death (miscarriage or stillbirth)
Nobs (Nmiss) 1197 (29) 597 (13) 600 (16)
No, n (%) 1182 (98.7) 590 (98.8) 592 (98.7)
Yes, n (%) 15 (1.3) 7 (1.2) 8 (1.3)
Neonatal death
Nobs (Nmiss) 1197 (29) 597 (13) 600 (16)
No, n (%) 1190 (99.4) 591 (99.0) 599 (99.8)
Yes, n (%) 7 (0.6) 6 (1.0) 1 (0.2)
Brain injury
Nobs (Nmiss) 1158 (68) 574 (36) 584 (32)
No, n (%) 1106 (95.5) 540 (94.1) 566 (96.9)
Yes, n (%) 52 (4.5) 34 (5.9) 18 (3.1)
Severe chronic lung disease
Nobs (Nmiss) 1154 (72) 574 (36) 580 (36)
No, n (%) 1119 (97.0) 556 (96.9) 563 (97.1)
Yes, n (%) 35 (3.0) 18 (3.1) 17 (2.9)
Need for surfactant administration
Nobs (Nmiss) 1156 (70) 573 (37) 583 (33)
No, n (%) 1064 (92.0) 528 (92.1) 536 (91.9)
Yes, n (%) 92 (8.0) 45 (7.9) 47 (8.1)
Necrotising enterocolitis
Nobs (Nmiss) 1155 (71) 574 (36) 581 (35)
No, n (%) 1124 (97.3) 561 (97.7) 563 (96.9)
Yes, suspected, n (%) 16 (1.4) 5 (0.9) 11 (1.9)
Yes, medical treatment only, n (%) 10 (0.9) 4 (0.7) 6 (1.0)
Yes, required drain or laparotomy, n (%) 5 (0.4) 4 (0.7) 1 (0.2)
Infection
Nobs (Nmiss) 1154 (72) 573 (37) 581 (35)
No, n (%) 1074 (93.1) 537 (93.7) 537 (92.4)
Yes, n (%) 80 (6.9) 36 (6.3) 44 (7.6)
Number of discrete episodes with positive blood culture in those with infection
Nobs (Nmiss) 73 (7) 33 (3) 40 (4)
0, n (%) 37 (50.7) 14 (42.4) 23 (57.5)
1, n (%) 28 (38.4) 16 (48.5) 12 (30.0)
2, n (%) 7 (9.6) 3 (9.1) 4 (10.0)
4, n (%) 1 (1.4) 0 (0.0) 1 (2.5)
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TABLE 7 Secondary clinical outcomes, by treatment group (continued )
Outcome All
Trial group
Placebo Progesterone
Number of discrete episodes with positive cerebrospinal fluid culture in those with infection
Nobs (Nmiss) 74 (6) 34 (2) 40 (4)
0, n (%) 71 (95.9) 34 (100.0) 37 (92.5)
1, n (%) 2 (2.7) 0 (0.0) 2 (5.0)
2, n (%) 1 (1.4) 0 (0.0) 1 (2.5)
Highest level of care in delivery room
Nobs (Nmiss) 1165 (61) 584 (26) 581 (35)
Minimal (none or tactile stimulation) , n (%) 924 (79.3) 456 (78.1) 468 (80.6)
Intubation plus chest compressions and/or adrenaline, n (%) 3 (0.3) 0 (0.0) 3 (0.5)
Suction, n (%) 7 (0.6) 4 (0.7) 3 (0.5)
Suction and facial O2 only, n (%) 39 (3.3) 19 (3.3) 20 (3.4)
Mask ventilation only, n (%) 100 (8.6) 56 (9.6) 44 (7.6)
Intubation, n (%) 86 (7.4) 47 (8.0) 39 (6.7)
Intubation plus chest compressions, n (%) 6 (0.5) 2 (0.3) 4 (0.7)
Number of days of normal care
Nobs (Nmiss) 1151 (75) 570 (40) 581 (35)
Mean (SD) 1.7 (2.0) 1.7 (2.3) 1.7 (1.6)
Median (IQR) 1.0 (1.0–2.0) 1.0 (0.0–2.0) 1.0 (1.0–2.0)
Range 0.0–28.0 0.0–28.0 0.0–12.0
Number of days of special care
Nobs (Nmiss) 1151 (75) 570 (40) 581 (35)
Mean (SD) 3.5 (9.6) 4.2 (10.6) 2.9 (8.3)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–1.0) 0.0 (0.0–0.0)
Range 0.0–92.0 0.0–85.0 0.0–92.0
Number of days of level 2 care
Nobs (Nmiss) 1149 (77) 569 (41) 580 (36)
Mean (SD) 2.2 (9.5) 2.2 (8.4) 2.1 (10.4)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Range 0.0–137.0 0.0–74.0 0.0–137.0
Number of days of level 1 care
Nobs (Nmiss) 1149 (77) 569 (41) 580 (36)
Mean (SD) 1.9 (7.7) 1.8 (7.3) 1.9 (8.1)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Range 0.0–75.0 0.0–75.0 0.0–64.0
Maternal or child serious adverse events during pregnancy and birtha
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 1097 (89.5) 540 (88.5) 557 (90.4)
Yes, n (%) 129 (10.5) 70 (11.5) 59 (9.6)
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TABLE 7 Secondary clinical outcomes, by treatment group (continued )
Outcome All
Trial group
Placebo Progesterone
Death or moderate/severe neurodevelopmental impairment
Nobs (Nmiss) 818 (408) 419 (191) 399 (217)
No, n (%) 700 (85.6) 368 (87.8) 332 (83.2)
Yes, n (%) 118 (14.4) 51 (12.2) 67 (16.8)
Moderate/severe neurodevelopmental impairment
Nobs (Nmiss) 782 (444) 403 (207) 379 (237)
No, n (%) 700 (89.5) 368 (91.3) 332 (87.6)
Yes, n (%) 82 (10.5) 35 (8.7) 47 (12.4)
Components of neurodevelopmental disability
Motor
Nobs (Nmiss) 917 (309) 456 (154) 461 (155)
No, n (%) 909 (99.1) 452 (99.1) 457 (99.1)
Yes, n (%) 8 (0.9) 4 (0.9) 4 (0.9)
Cognitive function
Nobs (Nmiss) 913 (313) 452 (158) 461 (155)
No, n (%) 876 (95.9) 434 (96.0) 442 (95.9)
Yes, n (%) 37 (4.1) 18 (4.0) 19 (4.1)
Hearing
Nobs (Nmiss) 931 (295) 465 (145) 466 (150)
No, n (%) 928 (99.7) 463 (99.6) 465 (99.8)
Yes, n (%) 3 (0.3) 2 (0.4) 1 (0.2)
Speech and language
Nobs (Nmiss) 891 (335) 446 (164) 445 (171)
No, n (%) 859 (96.4) 432 (96.9) 427 (96.0)
Yes, n (%) 32 (3.6) 14 (3.1) 18 (4.0)
Vision
Nobs (Nmiss) 913 (313) 466 (144) 447 (169)
No, n (%) 909 (99.6) 462 (99.1) 447 (100.0)
Yes, n (%) 4 (0.4) 4 (0.9) 0 (0.0)
Respiratory
Nobs (Nmiss) 847 (379) 434 (176) 413 (203)
No, n (%) 837 (98.8) 431 (99.3) 406 (98.3)
Yes, n (%) 10 (1.2) 3 (0.7) 7 (1.7)
Gastrointestinal
Nobs (Nmiss) 844 (382) 432 (178) 412 (204)
No, n (%) 831 (98.5) 428 (99.1) 403 (97.8)
Yes, n (%) 13 (1.5) 4 (0.9) 9 (2.2)
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TABLE 7 Secondary clinical outcomes, by treatment group (continued )
Outcome All
Trial group
Placebo Progesterone
Renal
Nobs (Nmiss) 848 (378) 434 (176) 414 (202)
No, n (%) 844 (99.5) 433 (99.8) 411 (99.3)
Yes, n (%) 4 (0.5) 1 (0.2) 3 (0.7)
Admitted to hospital
Nobs (Nmiss) 850 (376) 434 (176) 416 (200)
No, n (%) 751 (88.4) 383 (88.2) 368 (88.5)
Yes, n (%) 99 (11.6) 51 (11.8) 48 (11.5)
Admitted to hospital for respiratory reason
Nobs (Nmiss) 127 (1099) 63 (547) 64 (552)
No, n (%) 79 (62.2) 39 (61.9) 40 (62.5)
Yes, n (%) 48 (37.8) 24 (38.1) 24 (37.5)
Admitted to hospital for surgery
Nobs (Nmiss) 118 (1108) 56 (554) 62 (554)
No, n (%) 96 (81.4) 49 (87.5) 47 (75.8)
Yes, n (%) 22 (18.6) 7 (12.5) 15 (24.2)
Admitted to hospital for other reason
Nobs (Nmiss) 119 (1107) 56 (554) 63 (553)
No, n (%) 92 (77.3) 43 (76.8) 49 (77.8)
Yes, n (%) 27 (22.7) 13 (23.2) 14 (22.2)
Number of hospitalisations
Nobs (Nmiss) 858 (368) 437 (173) 421 (195)
0, n (%) 750 (87.4) 386 (88.3) 364 (86.5)
1, n (%) 87 (10.1) 42 (9.6) 45 (10.7)
2, n (%) 15 (1.7) 5 (1.1) 10 (2.4)
3, n (%) 2 (0.2) 2 (0.5) 0 (0.0)
4, n (%) 2 (0.2) 1 (0.2) 1 (0.2)
7, n (%) 1 (0.1) 1 (0.2) 0 (0.0)
11, n (%) 1 (0.1) 0 (0.0) 1 (0.2)
Summaries of secondary outcome measures at 2-year follow-up for all patients and according to treatment
groups: SDQ
Emotional problems scale
Nobs (Nmiss) 669 (557) 341 (269) 328 (288)
Mean (SD) 1.1 (1.2) 1.1 (1.2) 1.1 (1.2)
Median (IQR) 1.0 (0.0–2.0) 1.0 (0.0–1.0) 1.0 (0.0–2.0)
Range 0.0–10.0 0.0–10.0 0.0–7.0
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TABLE 7 Secondary clinical outcomes, by treatment group (continued )
Outcome All
Trial group
Placebo Progesterone
Conduct problems scale
Nobs (Nmiss) 668 (558) 342 (268) 326 (290)
Mean (SD) 2.6 (1.8) 2.7 (1.8) 2.6 (1.8)
Median (IQR) 2.0 (1.0–4.0) 2.0 (1.0–4.0) 2.0 (1.0–3.8)
Range 0.0–10.0 0.0–10.0 0.0–8.0
Hyperactivity scale
Nobs (Nmiss) 649 (577) 334 (276) 315 (301)
Mean (SD) 4.3 (2.3) 4.2 (2.4) 4.5 (2.3)
Median (IQR) 4.0 (3.0–6.0) 4.0 (2.0–6.0) 4.0 (3.0–6.0)
Range 0.0–10.0 0.0–10.0 0.0–10.0
Peer problems scale
Nobs (Nmiss) 663 (563) 345 (265) 318 (298)
Mean (SD) 2.0 (1.6) 2.0 (1.7) 2.1 (1.6)
Median (IQR) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0)
Range 0.0–7.0 0.0–7.0 0.0–7.0
Prosocial scale
Nobs (Nmiss) 659 (567) 339 (271) 320 (296)
Mean (SD) 6.1 (2.2) 6.3 (2.2) 5.9 (2.3)
Median (IQR) 6.0 (5.0–8.0) 6.0 (5.0–8.0) 6.0 (4.0–8.0)
Range 0.0–10.0 0.0–10.0 0.0–10.0
Total difficulties scale
Nobs (Nmiss) 597 (629) 302 (308) 295 (321)
Mean (SD) 10.0 (4.9) 9.8 (4.9) 10.2 (4.9)
Median (IQR) 9.0 (7.0–12.0) 9.0 (6.0–12.0) 9.0 (7.0–13.0)
Range 0.0–30.0 0.0–30.0 0.0–30.0
Impact scale
Nobs (Nmiss) 828 (398) 424 (186) 404 (212)
Mean (SD) 0.2 (1.1) 0.2 (1.0) 0.2 (1.2)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Range 0.0–10.0 0.0–10.0 0.0–10.0
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation;
SDQ, Strengths and Difficulties Questionnaire.
a Up to and including day 1 after birth.
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after initiation of treatment (n = 18), lost to follow-up (n = 3) and missing data (n = 2). In the progesterone
group these figures were 13, 6 and 8, respectively; a further two women in the progesterone group
withdrew consent before treatment was initiated. For the childhood outcome, there were outcomes on
439 children in the placebo group and 430 children in the progesterone group. Reasons for unavailability in
the placebo group were consent withdrawn after initiation of treatment (n = 42), lost to follow-up (n = 100)
and missing data (n = 29). In the progesterone group these figures were 45, 116 and 25, respectively, plus
the two women in the progesterone group who withdrew before treatment was initiated.
Women’s views on treatment were ascertained by questionnaire on two occasions post delivery (3 months
and 6 months) and are shown in Tables 8 and 9, respectively.
The EuroQol-5 Dimensions (EQ-5D) health utility scores at various time points during the study, with
changes between these time points, are shown in Table 10.
TABLE 8 Women’s views on treatment at a mean of 3 months post delivery
Characteristic or view All
Trial group
Placebo Progesterone
Age of baby (days)
Nobs (Nmiss) 612 (614) 317 (293) 295 (321)
Mean (SD) 94.6 (163.3) 100.9 (171.8) 87.8 (153.6)
Median (IQR) 17.0 (7.0–91.0) 21.0 (7.0–112.0) 14.0 (7.0–70.0)
Range 0.0–805.0 0.0–805.0 0.0–751.0
Preferred treatment mode
Nobs (Nmiss) 613 (613) 314 (296) 299 (317)
Vaginal pessary, n (%) 434 (70.8) 222 (70.7) 212 (70.9)
Rectal pessary, n (%) 17 (2.8) 8 (2.5) 9 (3.0)
Injection, n (%) 158 (25.8) 82 (26.1) 76 (25.4)
Any, n (%) 2 (0.3) 0 (0.0) 2 (0.7)
Pessaries, n (%) 2 (0.3) 2 (0.6) 0 (0.0)
Enough information about trial participation
Nobs (Nmiss) 639 (587) 330 (280) 309 (307)
Yes, n (%) 624 (97.7) 322 (97.6) 302 (97.7)
No, n (%) 15 (2.3) 8 (2.4) 7 (2.3)
Enough information about treatment
Nobs (Nmiss) 640 (586) 331 (279) 309 (307)
Yes, n (%) 626 (97.8) 324 (97.9) 302 (97.7)
No, n (%) 14 (2.2) 7 (2.1) 7 (2.3)
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TABLE 8 Women’s views on treatment at a mean of 3 months post delivery (continued )
Characteristic or view All
Trial group
Placebo Progesterone
Satisfaction with treatment
Nobs (Nmiss) 634 (592) 327 (283) 307 (309)
Extremely satisfied, n (%) 445 (70.2) 244 (74.6) 201 (65.5)
Fairly satisfied, n (%) 163 (25.7) 70 (21.4) 93 (30.3)
Somewhat dissatisfied, n (%) 22 (3.5) 10 (3.1) 12 (3.9)
Extremely dissatisfied, n (%) 4 (0.6) 3 (0.9) 1 (0.3)
The treatment was messy
Nobs (Nmiss) 628 (598) 325 (285) 303 (313)
Strongly agree and would not repeat treatment, n (%) 35 (5.6) 14 (4.3) 21 (6.9)
Agree but would still repeat treatment, n (%) 223 (35.5) 110 (33.8) 113 (37.3)
Neither agree nor disagree, n (%) 94 (15.0) 48 (14.8) 46 (15.2)
Disagree, n (%) 276 (43.9) 153 (47.1) 123 (40.6)
The treatment smelled unpleasant
Nobs (Nmiss) 620 (606) 322 (288) 298 (318)
Strongly agree and would not repeat treatment, n (%) 19 (3.1) 9 (2.8) 10 (3.4)
Agree but would still repeat treatment, n (%) 40 (6.5) 18 (5.6) 22 (7.4)
Neither agree nor disagree, n (%) 75 (12.1) 43 (13.4) 32 (10.7)
Disagree, n (%) 486 (78.4) 252 (78.3) 234 (78.5)
The application of treatment was uncomfortable
Nobs (Nmiss) 624 (602) 323 (287) 301 (315)
Strongly agree and would not repeat treatment, n (%) 37 (5.9) 19 (5.9) 18 (6.0)
Agree but would still repeat treatment, n (%) 125 (20.0) 64 (19.8) 61 (20.3)
Neither agree nor disagree, n (%) 121 (19.4) 62 (19.2) 59 (19.6)
Disagree, n (%) 341 (54.6) 178 (55.1) 163 (54.2)
The treatment interfered with sexual activity
Nobs (Nmiss) 619 (607) 320 (290) 299 (317)
Strongly agree and would not repeat treatment, n (%) 33 (5.3) 16 (5.0) 17 (5.7)
Agree but would still repeat treatment, n (%) 154 (24.9) 68 (21.2) 86 (28.8)
Neither agree nor disagree, n (%) 145 (23.4) 90 (28.1) 55 (18.4)
Disagree, n (%) 287 (46.4) 146 (45.6) 141 (47.2)
The treatment stopped me working
Nobs (Nmiss) 625 (601) 324 (286) 301 (315)
Strongly agree and would not repeat treatment, n (%) 17 (2.7) 12 (3.7) 5 (1.7)
Agree but would still repeat treatment, n (%) 11 (1.8) 8 (2.5) 3 (1.0)
Neither agree nor disagree, n (%) 28 (4.5) 16 (4.9) 12 (4.0)
Disagree, n (%) 569 (91.0) 288 (88.9) 281 (93.4)
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TABLE 8 Women’s views on treatment at a mean of 3 months post delivery (continued )
Characteristic or view All
Trial group
Placebo Progesterone
The treatment made me feel dirty
Nobs (Nmiss) 624 (602) 324 (286) 300 (316)
Strongly agree and would not repeat treatment, n (%) 22 (3.5) 11 (3.4) 11 (3.7)
Agree but would still repeat treatment, n (%) 70 (11.2) 32 (9.9) 38 (12.7)
Neither agree nor disagree, n (%) 65 (10.4) 34 (10.5) 31 (10.3)
Disagree, n (%) 467 (74.8) 247 (76.2) 220 (73.3)
The treatment caused irritation
Nobs (Nmiss) 625 (601) 322 (288) 303 (313)
Strongly agree and would not repeat treatment, n (%) 27 (4.3) 14 (4.3) 13 (4.3)
Agree but would still repeat treatment, n (%) 69 (11.0) 32 (9.9) 37 (12.2)
Neither agree nor disagree, n (%) 67 (10.7) 33 (10.2) 34 (11.2)
Disagree, n (%) 462 (73.9) 243 (75.5) 219 (72.3)
The treatment made me feel constipated
Nobs (Nmiss) 625 (601) 323 (287) 302 (314)
Strongly agree and would not repeat treatment, n (%) 16 (2.6) 10 (3.1) 6 (2.0)
Agree but would still repeat treatment, n (%) 26 (4.2) 13 (4.0) 13 (4.3)
Neither agree nor disagree, n (%) 47 (7.5) 21 (6.5) 26 (8.6)
Disagree, n (%) 536 (85.8) 279 (86.4) 257 (85.1)
The treatment gave me backache
Nobs (Nmiss) 624 (602) 324 (286) 300 (316)
Strongly agree and would not repeat treatment, n (%) 15 (2.4) 9 (2.8) 6 (2.0)
Agree but would still repeat treatment, n (%) 11 (1.8) 6 (1.9) 5 (1.7)
Neither agree nor disagree, n (%) 42 (6.7) 22 (6.8) 20 (6.7)
Disagree, n (%) 556 (89.1) 287 (88.6) 269 (89.7)
Panty liners or sanitary towels used?
Nobs (Nmiss) 630 (596) 327 (283) 303 (313)
Yes, n (%) 412 (65.4) 212 (64.8) 200 (66.0)
No, n (%) 218 (34.6) 115 (35.2) 103 (34.0)
Number of towels used per day
Nobs (Nmiss) 391 (835) 197 (413) 194 (422)
Mean (SD) 2.3 (1.4) 2.3 (1.4) 2.3 (1.3)
Median (IQR) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0)
Range 0.0–10.0 0.0–10.0 0.0–7.0
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TABLE 8 Women’s views on treatment at a mean of 3 months post delivery (continued )
Characteristic or view All
Trial group
Placebo Progesterone
Did treatment interfere with daily activities?
Nobs (Nmiss) 629 (597) 324 (286) 305 (311)
Yes, n (%) 11 (1.7) 8 (2.5) 3 (1.0)
No, n (%) 618 (98.3) 316 (97.5) 302 (99.0)
Was the frequency of appointment with health professional . . .
Nobs (Nmiss) 608 (618) 311 (299) 297 (319)
Too often, n (%) 3 (0.5) 1 (0.3) 2 (0.7)
Enough, n (%) 583 (95.9) 302 (97.1) 281 (94.6)
Not enough, n (%) 22 (3.6) 8 (2.6) 14 (4.7)
How would you feel if treatment became normal practice?
Nobs (Nmiss) 623 (603) 320 (290) 303 (313)
Disappointed, n (%) 6 (1.0) 3 (0.9) 3 (1.0)
Not sure, n (%) 168 (27.0) 89 (27.8) 79 (26.1)
Pleased, n (%) 449 (72.1) 228 (71.2) 221 (72.9)
If time went backwards, would you take part again?
Nobs (Nmiss) 635 (591) 327 (283) 308 (308)
Definitely not, n (%) 6 (0.9) 4 (1.2) 2 (0.6)
Probably not, n (%) 21 (3.3) 9 (2.8) 12 (3.9)
Not sure, n (%) 37 (5.8) 19 (5.8) 18 (5.8)
Probably yes, n (%) 159 (25.0) 85 (26.0) 74 (24.0)
Definitely yes, n (%) 412 (64.9) 210 (64.2) 202 (65.6)
Did you have access to a health professional for medical support?
Nobs (Nmiss) 632 (594) 325 (285) 307 (309)
Yes, n (%) 618 (97.8) 319 (98.2) 299 (97.4)
No, n (%) 14 (2.2) 6 (1.8) 8 (2.6)
Did you have access to a health professional for emotional support?
Nobs (Nmiss) 623 (603) 321 (289) 302 (314)
Yes, n (%) 566 (90.9) 294 (91.6) 272 (90.1)
No, n (%) 57 (9.1) 27 (8.4) 30 (9.9)
Did partner have adequate support from care providers?
Nobs (Nmiss) 611 (615) 315 (295) 296 (320)
Yes, n (%) 543 (88.9) 281 (89.2) 262 (88.5)
No, n (%) 68 (11.1) 34 (10.8) 34 (11.5)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
TABLE 9 Women’s views on treatment at 6 months post delivery
Woman’s view All
Trial group
Placebo Progesterone
Enough information about treatment
Nobs (Nmiss) 79 (1147) 45 (565) 34 (582)
Yes, n (%) 77 (97.5) 44 (97.8) 33 (97.1)
No, n (%) 2 (2.5) 1 (2.2) 1 (2.9)
Satisfaction with treatment
Nobs (Nmiss) 78 (1148) 44 (566) 34 (582)
Extremely satisfied, n (%) 60 (76.9) 33 (75.0) 27 (79.4)
Fairly satisfied, n (%) 18 (23.1) 11 (25.0) 7 (20.6)
Somewhat dissatisfied, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Extremely dissatisfied, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
How would you feel if treatment became normal practice?
Nobs (Nmiss) 78 (1148) 44 (566) 34 (582)
Disappointed, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Not sure, n (%) 10 (12.8) 7 (15.9) 3 (8.8)
Pleased, n (%) 68 (87.2) 37 (84.1) 31 (91.2)
If time went backwards, would you take part again?
Nobs (Nmiss) 79 (1147) 45 (565) 34 (582)
Definitely not, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Probably not, n (%) 1 (1.3) 1 (2.2) 0 (0.0)
Not sure, n (%) 4 (5.1) 1 (2.2) 3 (8.8)
Probably yes, n (%) 11 (13.9) 5 (11.1) 6 (17.6)
Definitely yes, n (%) 63 (79.7) 38 (84.4) 25 (73.5)
Did you have access to health professional for medical support?
Nobs (Nmiss) 79 (1147) 45 (565) 34 (582)
Yes, n (%) 76 (96.2) 44 (97.8) 32 (94.1)
No, n (%) 3 (3.8) 1 (2.2) 2 (5.9)
Did you have access to health professional for emotional support?
Nobs (Nmiss) 76 (1150) 43 (567) 33 (583)
Yes, n (%) 70 (92.1) 41 (95.3) 29 (87.9)
No, n (%) 6 (7.9) 2 (4.7) 4 (12.1)
Did partner have adequate support from care providers?
Nobs (Nmiss) 77 (1149) 44 (566) 33 (583)
Yes, n (%) 67 (87.0) 41 (93.2) 26 (78.8)
No, n (%) 10 (13.0) 3 (6.8) 7 (21.2)
Willing participate in interview
Nobs (Nmiss) 377 (849) 200 (410) 177 (439)
Yes, n (%) 301 (79.8) 164 (82.0) 137 (77.4)
No, n (%) 76 (20.2) 36 (18.0) 40 (22.6)
Nmiss, number of women with missing data; Nobs, number of observations.
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TABLE 10 EuroQol-5 Dimensions health utility scores
EQ-5D scores and time
point of measurements All
Trial group
Placebo Progesterone
Randomisation
Nobs (Nmiss) 1056 (170) 524 (86) 532 (84)
Mean (SD) 0.876 (0.190) 0.874 (0.190) 0.879 (0.190)
Median (IQR) 1.000 (0.796–1.000) 1.000 (0.796–1.000) 1.000 (0.796–1.000)
Range –0.349 to 1.000 –0.349 to 1.000 –0.074 to 1.000
Birth
Nobs (Nmiss) 394 (832) 202 (408) 192 (424)
Mean (SD) 0.867 (0.198) 0.866 (0.203) 0.868 (0.194)
Median (IQR) 1.000 (0.796–1.000) 1.000 (0.796–1.000) 1.000 (0.796–1.000)
Range –0.184 to 1.000 –0.184 to 1.000 –0.016 to 1.000
12-month follow-up
Nobs (Nmiss) 616 (610) 307 (303) 309 (307)
Mean (SD) 0.875 (0.194) 0.872 (0.202) 0.878 (0.186)
Median (IQR) 0.883 (0.848–1.000) 0.883 (0.848–1.000) 0.883 (0.848–1.000)
Range –0.135 to 1.000 –0.135 to 1.000 –0.135 to 1.000
24-month follow-up
Nobs (Nmiss) 5 (1221) 2 (608) 3 (613)
Mean (SD) 0.940 (0.083) 0.925 (0.106) 0.949 (0.088)
Median (IQR) 1.000 (0.850–1.000) 0.925 (0.888–0.962) 1.000 (0.924–1.000)
Range 0.848 to 1.000 0.850 to 1.000 0.848 to 1.000
Change from baseline
Birth
Nobs (Nmiss) 390 (836) 199 (411) 191 (425)
Mean (SD) –0.022 (0.214) –0.023 (0.220) –0.021 (0.207)
Median (IQR) 0.000 (–0.152 to 0.036) 0.000 (–0.152 to 0.061) 0.000 (–0.114 to 0.000)
Range –1.032 to 0.970 –1.032 to 0.807 –0.787 to 0.970
12-month follow-up
Nobs (Nmiss) 553 (673) 274 (336) 279 (337)
Mean (SD) –0.012 (0.217) –0.015 (0.221) –0.009 (0.213)
Median (IQR) 0.000 (–0.117 to 0.035) 0.000 (–0.117 to 0.064) 0.000 (–0.117 to 0.000)
Range –1.135 to 1.128 –1.135 to 1.128 –0.841 to 0.829
24-month follow-up
Nobs (Nmiss) 4 (1222) 1 (609) 3 (613)
Mean (SD) 0.068 (0.136) 0.000 (–) 0.091 (0.158)
Median (IQR) 0.000 (0.000–0.068) 0.000 (0.000–0.000) 0.000 (0.000–0.136)
Range 0.000–0.273 0.000–0.000 0.000–0.273
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
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Chapter 4 Safety evaluation
T reatment compliance (assessed according to the criteria described above) is shown in Table 11. Weassessed compliance by looking at medication pack returns, patient diaries and asking patients what
they had been taking. Prior to unblinding, we defined adequate compliance as women in whom the
proportion of actual doses of study medication were 80% of those of expected doses.
Compliance was calculated from the expected number of doses taken and the assumed number of doses
taken, based on the number of doses issued (usually 84) and the number returned or reportedly lost. If the
number returned or lost was not recorded, this were taken as zero. In some cases, this yields implausibly
large values for compliance.
Six women had a derived compliance value of > 120%:
1. compliance = 2100% – expected four doses; number of doses returned or lost not recorded; doses
taken calculated as 84
2. compliance = 158% – expected 53 doses; number of doses returned or lost both zero; doses taken
calculated as 84
3. compliance = 156% – expected 53 doses; number of doses returned = 1, lost = 0; doses taken
calculated as 83
4. compliance = 138% – expected 26 doses; number of doses returned = 48, lost = 0; doses taken
calculated as 36
5. compliance = 135% – expected 17 doses; number of doses returned = 61, lost = 0; doses taken
calculated as 23
6. compliance = 133% – expected nine doses; number of doses returned = 0, lost = 72; doses taken
calculated as 12.
TABLE 11 Treatment compliance in the ITT population
Treatment compliance All
Trial group
Placebo Progesterone
Percentage of medication taken
Nobs (Nmiss) 1011 (215) 509 (101) 502 (114)
Mean (SD) 78.6 (72.0) 77.9 (32.8) 79.3 (96.7)
Median (IQR) 92.7 (65.0–98.7) 92.3 (71.6–98.7) 92.9 (59.0–98.6)
Range 0.0–2100.0 0.0–138.5 0.0–2100.0
Expected number of doses
Nobs (Nmiss) 1197 (29) 597 (13) 600 (16)
Mean (SD) 71.0 (17.4) 70.6 (17.3) 71.4 (17.6)
Median (IQR) 76.0 (72.0–81.0) 76.0 (72.0–80.0) 76.0 (72.0–81.0)
Range 1.0–86.0 1.0–85.0 2.0–86.0
Compliant
Nobs (Nmiss) 1011 (215) 509 (101) 502 (114)
No, n (%) 317 (31.4) 148 (29.1) 169 (33.7)
Yes, n (%) 694 (68.6) 361 (70.9) 333 (66.3)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
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The compliance value for subject 1, listed above, is clearly erroneous, as the participant could not have
taken all 84 doses within 4 days. This subject withdrew from study treatment very soon after randomisation,
delivered shortly afterwards – at approximately 25 weeks’ gestation – and withdrew from the study. The
child died within 2 weeks of birth. However, there is no information that indicates that the participant was
not compliant with treatment during the time that she was supposedly taking the medication.
Compliance (excluding data from subjects who had missing compliance data) is shown in Table 12.
Of the individuals indicated below, the following remain (only the 2100% is removed):
1. compliance = 158% – expected 53 doses; number of doses returned or lost both zero; doses taken
calculated as 84
2. compliance = 156% – expected 53 doses; number of doses returned = 1, lost = 0; doses taken
calculated as 83
3. compliance = 138% – expected 26 doses; number of doses returned = 48, lost = 0; doses taken
calculated as 36
4. compliance = 135% – expected 17 doses; number of doses returned = 61, lost = 0; doses taken
calculated as 23
5. compliance = 133% – expected nine doses; number of doses returned = 0, lost = 72; doses taken
calculated as 12.
Premature treatment withdrawal is shown in Table 13.
Serious adverse events (SAEs) known to occur in the safety population in the reporting window (maximum
of end of treatment date + 28 days and date of delivery + 30 days) or where it is unclear whether or not
they are in the reporting window are listed in Table 14.
Serious adverse events known to occur outside the reporting window and those in which the timing was
uncertain are also reported separately in Appendix 3.
Other prespecified safety outcomes are shown in Tables 15–17.
TABLE 12 Treatment compliance in the ITT population (missing data removed)
Treatment compliance All
Trial group
Placebo Progesterone
Percentage of medication taken
Nobs (Nmiss) 878 (348) 438 (172) 440 (176)
Mean (SD) 77.2 (33.1) 78.7 (32.1) 75.8 (33.9)
Median (IQR) 92.8 (66.7–98.7) 92.3 (74.7–98.7) 93.2 (59.9–98.6)
Range 0.0–158.5 0.0–138.5 0.0–158.5
Compliant
Nobs (Nmiss) 878 (348) 438 (101) 502 (114)
No, n (%) 272 (31.0) 125 (28.5) 147 (33.4)
Yes, n (%) 606 (69.0) 313 (71.5) 293 (66.6)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
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TABLE 13 Premature treatment withdrawal in the ITT population
Trial participation or withdrawal and numbers All
Trial group
Placebo Progesterone
Trial completed
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 374 (30.5) 176 (28.9) 198 (32.1)
Yes, n (%) 852 (69.5) 434 (71.1) 418 (67.9)
Reason for trial termination
Nobs (Nmiss) 374 (852) 176 (434) 198 (418)
Woman unwilling to continue, n (%) 56 (15.0) 25 (14.2) 31 (15.7)
Adverse event, n (%) 1 (0.3) 1 (0.6) 0 (0.0)
Serious adverse event, n (%) 1 (0.3) 1 (0.6) 0 (0.0)
Detection of significant structural chromosomal
anomalies after randomisation, n (%)
0 (0.0) 0 (0.0) 0 (0.0)
Other, n (%) 207 (55.3) 101 (57.4) 106 (53.5)
Physician recommended withdrawal, n (%) 1 (0.3) 1 (0.6) 0 (0.0)
Lost to follow-up, n (%) 72 (19.3) 31 (17.6) 41 (20.7)
Death, n (%) 36 (9.6) 16 (9.1) 20 (10.1)
Nmiss, number of women with missing data; Nobs, number of observations.
TABLE 14 Patients with at least one SAE by System Organ Class and preferred term
Type of SAE All patients, n (%)
Trial group, n (%)
Placebo Progesterone
Number of patients, N 1183 590 593
Blood and lymphatic system disorders 1 (0.1) 1 (0.2) 0 (0.0)
Thrombocytopenia 1 (0.1) 1 (0.2) 0 (0.0)
Congenital, familial and genetic disorders 19 (1.6) 8 (1.4) 11 (1.9)
Cardiac septal defect 1 (0.1) 1 (0.2) 0 (0.0)
Cleft lip and palate 1 (0.1) 0 (0.0) 1 (0.2)
Congenital central nervous system anomaly 1 (0.1) 0 (0.0) 1 (0.2)
Congenital oesophageal anomaly 1 (0.1) 0 (0.0) 1 (0.2)
Cryptorchism 1 (0.1) 0 (0.0) 1 (0.2)
Cystic fibrosis 1 (0.1) 1 (0.2) 0 (0.0)
Congenital dacryostenosis 1 (0.1) 0 (0.0) 1 (0.2)
Hip dysplasia 1 (0.1) 1 (0.2) 0 (0.0)
Holoprosencephaly 1 (0.1) 0 (0.0) 1 (0.2)
Hydrocele 1 (0.1) 1 (0.2) 0 (0.0)
Hypospadias 2 (0.2) 0 (0.0) 2 (0.3)
Kidney malformation 1 (0.1) 0 (0.0) 1 (0.2)
Oculoauriculovertebral dysplasia 1 (0.1) 1 (0.2) 0 (0.0)
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TABLE 14 Patients with at least one SAE by System Organ Class and preferred term (continued )
Type of SAE All patients, n (%)
Trial group, n (%)
Placebo Progesterone
Patent ductus arteriosus 2 (0.2) 2 (0.3) 0 (0.0)
Polydactyly 2 (0.2) 0 (0.0) 2 (0.3)
Congenital pulmonary artery stenosis 1 (0.1) 1 (0.2) 0 (0.0)
Gastrointestinal disorders 8 (0.7) 8 (1.4) 0 (0.0)
Abdominal pain 2 (0.2) 2 (0.3) 0 (0.01)
Ileus paralytic 1 (0.1) 1 (0.2) 0 (0.0)
Inguinal hernia 1 (0.2) 1 (0.2) 0 (0.0)
Necrotising colitis 2 (0.2) 2 (0.3) 0 (0.0)
Neonatal necrotising enterocolitis 3 (0.3) 3 (0.5) 0 (0.0)
General disorders and administration site conditions 4 (0.3) 2 (0.3) 2 (0.3)
Adverse drug reaction 1 (0.1) 1 (0.2) 0 (0.0)
Death neonatal 3 (0.3) 1 (0.2) 2 (0.3)
Infections and infestations 17 (1.4) 8 (1.4) 9 (1.5)
Appendicitis 1 (0.1) 1 (0.2) 0 (0.0)
Bacterial sepsis 2 (0.2) 0 (0.0) 2 (0.3)
Bronchiolitis 1 (0.1) 0 (0.0) 1 (0.2)
Bronchopneumonia 1 (0.1) 0 (0.0) 1 (0.2)
Infection 1 (0.1) 1 (0.2) 0 (0.0)
Lower respiratory tract infection 1 (0.1) 1 (0.2) 0 (0.0)
Meningitis 1 (0.1) 1 (0.2) 0 (0.0)
Meningitis bacterial 1 (0.1) 1 (0.2) 0 (0.0)
Rash pustular 2 (0.2) 1 (0.2) 1 (0.2)
Sepsis 4 (0.3) 2 (0.3) 2 (0.3)
Urinary tract infection 3 (0.3) 1 (0.2) 2 (0.3)
Wound infection 1 (0.1) 0 (0.0) 1 (0.2)
Injury, poisoning and procedural complications 4 (0.3) 1 (0.2) 3 (0.5)
Post-lumbar puncture syndrome 2 (0.2) 0 (0.0) 2 (0.3)
Post-procedural complication 1 (0.1) 1 (0.2) 0 (0.0)
Uterine rupture 1 (0.1) 0 (0.0) 1 (0.2)
Investigations 5 (0.4) 2 (0.3) 3 (0.5)
Echocardiogram abnormal 1 (0.1) 0 (0.0) 1 (0.2)
Echogram abnormal 1 (0.1) 1 (0.2) 0 (0.0)
Fetal heart rate abnormal 1 (0.1) 0 (0.0) 1 (0.2)
Weight decreased 2 (0.2) 1 (0.2) 1 (0.2)
Metabolism and nutrition disorders 4 (0.3) 3 (0.5) 1 (0.2)
Gestational diabetes 1 (0.1) 1 (0.2) 0 (0.0)
Hypoglycaemia 3 (0.3) 2 (0.3) 1 (0.2)
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TABLE 14 Patients with at least one SAE by System Organ Class and preferred term (continued )
Type of SAE All patients, n (%)
Trial group, n (%)
Placebo Progesterone
Neoplasms benign, malignant and unspecified
(including cysts and polyps)
3 (0.3) 1 (0.2) 2 (0.3)
Breast cancer 1 (0.1) 1 (0.2) 0 (0.0)
Haemangioma of skin 1 (0.1) 0 (0.0) 1 (0.2)
Teratoma 1 (0.1) 0 (0.0) 1 (0.2)
Nervous system disorders 4 (0.3) 4 (0.7) 0 (0.0)
Cerebral ventricle dilatation 2 (0.2) 2 (0.3) 0 (0.0)
Hydrocephalus 1 (0.1) 1 (0.2) 0 (0.0)
Migraine 1 (0.1) 1 (0.2) 0 (0.0)
Pregnancy, puerperium and perinatal conditions 83 (7.0) 44 (7.5) 39 (6.6)
Amniorrhexis 3 (0.3) 3 (0.5) 0 (0.0)
Antepartum haemorrhage 9 (0.8) 5 (0.8) 4 (0.7)
Complication of pregnancy 1 (0.1) 1 (0.2) 0 (0.0)
Eclampsia 1 (0.1) 1 (0.2) 0 (0.0)
Fetal growth restriction 1 (0.1) 1 (0.2) 0 (0.0)
Fetal hypokinesia 2 (0.2) 1 (0.2) 1 (0.2)
Intrauterine death 9 (0.8) 4 (0.7) 5 (0.8)
Jaundice neonatal 1 (0.1) 1 (0.2) 0 (0.0)
Oligohydramnios 1 (0.1) 0 (0.0) 1 (0.2)
Placenta praevia haemorrhage 1 (0.1) 0 (0.0) 1 (0.2)
Post-partum haemorrhage 33 (2.8) 17 (2.9) 16 (2.7)
Pre-eclampsia 1 (0.1) 1 (0.2) 0 (0.0)
Premature baby 13 (1.1) 7 (1.2) 6 (1.0)
Premature labour 4 (0.3) 3 (0.5) 1 (0.2)
Premature rupture of membranes 3 (0.3) 1 (0.2) 2 (0.3)
Premature separation of placenta 4 (0.3) 3 (0.5) 1 (0.2)
Retained placenta or membranes 1 (0.1) 0 (0.0) 1 (0.2)
Stillbirth 2 (0.2) 0 (0.0) 2 (0.3)
Threatened labour 4 (0.3) 1 (0.2) 3 (0.5)
Uterine contractions during pregnancy 2 (0.2) 1 (0.2) 1 (0.2)
Renal and urinary disorders 1 (0.1) 1 (0.2) 0 (0.0)
Pyelocaliectasis 1 (0.1) 1 (0.2) 0 (0.0)
Reproductive system and breast disorders 10 (0.8) 6 (1.0) 4 (0.7)
Chordee 1 (0.1) 0 (0.0) 1 (0.2)
Coital bleeding 1 (0.1) 1 (0.2) 0 (0.0)
Uterine atony 1 (0.1) 0 (0.0) 1 (0.2)
Vaginal haemorrhage 7 (0.6) 5 (0.8) 2 (0.3)
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TABLE 14 Patients with at least one SAE by System Organ Class and preferred term (continued )
Type of SAE All patients, n (%)
Trial group, n (%)
Placebo Progesterone
Respiratory, thoracic and mediastinal disorders 6 (0.5) 2 (0.3) 4 (0.7)
Bronchopulmonary dysplasia 1 (0.1) 0 (0.0) 1 (0.2)
Cyanosis neonatal 1 (0.1) 1 (0.2) 0 (0.0)
Grunting 1 (0.1) 0 (0.0) 1 (0.2)
Neonatal asphyxia 1 (0.1) 0 (0.0) 1 (0.2)
Pneumothorax 1 (0.1) 0 (0.0) 1 (0.2)
Transient tachypnoea of the newborn 1 (0.1) 1 (0.2) 0 (0.0)
Skin and subcutaneous tissue disorders 1 (0.1) 1 (0.2) 0 (0.0)
Rash 1 (0.1) 1 (0.2) 0 (0.0)
Surgical and medical procedures 6 (0.5) 5 (0.8) 1 (0.2)
Caesarean section 1 (0.1) 1 (0.2) 0 (0.0)
Mechanical ventilation 1 (0.1) 1 (0.2) 0 (0.0)
Patent ductus arteriosus repair 1 (0.1) 0 (0.0) 1 (0.2)
Spinal decompression 1 (0.1) 1 (0.2) 0 (0.0)
Steroid therapy 1 (0.1) 1 (0.2) 0 (0.0)
Surgery 1 (0.1) 1 (0.2) 0 (0.0)
Vascular disorders 2 (0.2) 1 (0.2) 1 (0.2)
Deep-vein thrombosis 1 (0.1) 1 (0.2) 0 (0.0)
Essential hypertension 1 (0.1) 0 (0.0) 1 (0.2)
TABLE 15 Other preplanned safety outcomes: maternal complications
Maternal complications All
Trial group
Placebo Progesterone
Obstetric cholestasis
Nobs (Nmiss) 1182 (1) 589 (1) 593 (0)
No, n (%) 1172 (99.2) 583 (99.0) 589 (99.3)
Yes, n (%) 10 (0.8) 6 (1.0) 4 (0.7)
Hypertension
Nobs (Nmiss) 1183 (0) 590 (0) 593 (0)
No, n (%) 1136 (96.0) 566 (95.9) 570 (96.1)
Yes, n (%) 47 (4.0) 24 (4.1) 23 (3.9)
Pre-eclampsia
Nobs (Nmiss) 1183 (0) 590 (0) 593 (0)
No, n (%) 1162 (98.2) 579 (98.1) 583 (98.3)
Yes, n (%) 21 (1.8) 11 (1.9) 10 (1.7)
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TABLE 15 Other preplanned safety outcomes: maternal complications (continued )
Maternal complications All
Trial group
Placebo Progesterone
Eclampsia
Nobs (Nmiss) 1183 (0) 590 (0) 593 (0)
No, n (%) 1182 (99.9) 589 (99.8) 593 (100.0)
Yes, n (%) 1 (0.1) 1 (0.2) 0 (0.0)
Preterm membrane rupture
Nobs (Nmiss) 1183 (0) 590 (0) 593 (0)
No, n (%) 1046 (88.4) 518 (87.8) 528 (89.0)
Yes, n (%) 137 (11.6) 72 (12.2) 65 (11.0)
Antepartum haemorrhage
Nobs (Nmiss) 1183 (0) 590 (0) 593 (0)
No, n (%) 1110 (93.8) 554 (93.9) 556 (93.8)
Yes, n (%) 73 (6.2) 36 (6.1) 37 (6.2)
Confirmed deep-vein thrombosis
Nobs (Nmiss) 1183 (0) 590 (0) 593 (0)
No, n (%) 1181 (99.8) 588 (99.7) 593 (100.0)
Yes, n (%) 2 (0.2) 2 (0.3) 0 (0.0)
Gestational diabetes
Nobs (Nmiss) 1183 (0) 590 (0) 593 (0)
No, n (%) 1119 (94.6) 553 (93.7) 566 (95.4)
Yes, n (%) 64 (5.4) 37 (6.3) 27 (4.6)
Cerclage
Nobs (Nmiss) 728 (455) 360 (230) 368 (225)
No, n (%) 648 (89.0) 321 (89.2) 327 (88.9)
Yes, n (%) 80 (11.0) 39 (10.8) 41 (11.1)
Other maternal complication
Nobs (Nmiss) 1183 (0) 590 (0) 593 (0)
No, n (%) 853 (72.1) 426 (72.2) 427 (72.0)
Yes, n (%) 330 (27.9) 164 (27.8) 166 (28.0)
Nmiss, number of women with missing data; Nobs, number of observations.
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TABLE 16 Other preplanned safety outcomes: fetal and neonatal complications
Fetal and neonatal complications All
Trial group
Placebo Progesterone
Other fetal complication
Nobs (Nmiss) 1183 (0) 590 (0) 593 (0)
No, n (%) 1146 (96.9) 572 (96.9) 574 (96.8)
Yes, n (%) 37 (3.1) 18 (3.1) 19 (3.2)
Abdominal circumference of < 5th centile
Nobs (Nmiss) 37 (0) 18 (0) 19 (0)
No, n (%) 27 (73.0) 14 (77.8) 13 (68.4)
Yes, n (%) 10 (27.0) 4 (22.2) 6 (31.6)
Liquor volume reduced
Nobs (Nmiss) 37 (0) 18 (0) 19 (0)
No, n (%) 25 (67.6) 12 (66.7) 13 (68.4)
Yes, n (%) 12 (32.4) 6 (33.3) 6 (31.6)
Doppler > 95th centile (umbilical artery)
Nobs (Nmiss) 37 (0) 18 (0) 19 (0)
No, n (%) 35 (94.6) 17 (94.4) 18 (94.7)
Yes, n (%) 2 (5.4) 1 (5.6) 1 (5.3)
Absent end-diastolic flow (umbilical artery)
Nobs (Nmiss) 37 (0) 18 (0) 19 (0)
No, n (%) 36 (97.3) 18 (100.0) 18 (94.7)
Yes, n (%) 1 (2.7) 0 (0.0) 1 (5.3)
Reversed end-diastolic flow (umbilical artery)
Nobs (Nmiss) 37 (0) 18 (0) 19 (0)
No, n (%) 35 (94.6) 17 (94.4) 18 (94.7)
Yes, n (%) 2 (5.4) 1 (5.6) 1 (5.3)
Abnormal cardiotocogram
Nobs (Nmiss) 37 (0) 18 (0) 19 (0)
No, n (%) 27 (73.0) 11 (61.1) 16 (84.2)
Yes, n (%) 10 (27.0) 7 (38.9) 3 (15.8)
Nmiss, number of women with missing data; Nobs, number of observations.
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TABLE 17 Further preplanned safety outcomes
Safety outcomes All
Trial group
Placebo Progesterone
Hospital admissions
Number of antenatal hospital admissions (per woman)
Nobs (Nmiss) 1160 (23) 581 (9) 579 (14)
Mean (SD) 0.7 (1.2) 0.7 (1.3) 0.6 (1.1)
Median (IQR) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0)
Range 0.0–10.0 0.0–10.0 0.0–8.0
Number of antenatal hospital admissions for threatened preterm labour
Nobs (Nmiss) 1160 (23) 581 (9) 579 (14)
Mean (SD) 0.3 (0.8) 0.4 (0.9) 0.3 (0.7)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Range 0.0–9.0 0.0–9.0 0.0–5.0
Number of antenatal hospital admissions for other reasons
Nobs (Nmiss) 1160 (23) 581 (9) 579 (14)
Mean (SD) 0.3 (0.8) 0.4 (0.8) 0.3 (0.8)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Range 0.0–7.0 0.0–7.0 0.0–6.0
Total number of days in hospital antenatally (per woman)
Nobs (Nmiss) 1153 (30) 576 (14) 577 (16)
Mean (SD) 2.9 (7.6) 3.0 (7.6) 2.7 (7.7)
Median (IQR) 0.0 (0.0–2.0) 0.0 (0.0–3.0) 0.0 (0.0–2.0)
Range 0.0–97.0 0.0–97.0 0.0–84.0
Total number of days in hospital for threatened preterm labour
Nobs (Nmiss) 1156 (27) 579 (11) 577 (16)
Mean (SD) 1.7 (5.8) 1.8 (6.2) 1.6 (5.3)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Range 0.0–97.0 0.0–97.0 0.0–56.0
Total number of days in hospital for other reasons
Nobs (Nmiss) 1157 (26) 578 (12) 579 (14)
Mean (SD) 1.2 (5.0) 1.2 (4.3) 1.1 (5.6)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Range 0.0–84.0 0.0–39.0 0.0–84.0
Antenatal hospital admissions: other details of hospital admissions
Number of hospital admissions with tocolysis, n (%) 33 (8.5) 18 (8.1) 15 (8.9)
Type of tocolysis, Nobs (Nmiss) 33 (0) 18 (0) 15 (0)
Nifedipine, n (%) 17 (51.5) 8 (44.4) 9 (60.0)
Indomethacine, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Atosiban, n (%) 15 (45.5) 9 (50.0) 6 (40.0)
Other, n (%) 1 (3.0) 1 (5.6) 0 (0.0)
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TABLE 17 Further preplanned safety outcomes (continued )
Safety outcomes All
Trial group
Placebo Progesterone
Number of hospital admissions with steroids, n (%) 160 (41.0) 77 (34.8) 83 (49.1)
Number of hospital admissions with antibiotics, n (%) 94 (24.1) 54 (24.4) 40 (23.7)
Number of hospital admissions with sutures, n (%) 18 (4.6) 10 (4.5) 8 (4.7)
Number of hospital admissions with magnesium,
n (%)
0 (0.0) 0 (0.0) 0 (0.0)
Labour outcomes
Duration of first stage (hours)
Nobs (Nmiss) 933 (250) 463 (127) 470 (123)
Mean (SD) 4.2 (5.2) 4.1 (5.1) 4.3 (5.3)
Median (IQR) 3.0 (1.2–5.4) 2.8 (1.2–5.3) 3.2 (1.3–5.5)
Range 0.0–70.0 [0.0–56.0 0.0–70.0
Duration of second stage (minutes)
Nobs (Nmiss) 933 (250) 462 (128) 471 (122)
Mean (SD) 44.1 (113.9) 47.0 (132.8) 41.2 (91.6)
Median (IQR) 16.0 (6.0–40.0) 16.0 (6.0–42.8) 16.0 (5.0–39.0)
Range 0.0–1800.0 0.0–1800.0 0.0–1383.0
Duration of third stage (minutes)
Nobs (Nmiss) 942 (241) 465 (125) 477 (116)
Mean (SD) 16.6 (49.0) 17.0 (46.2) 16.1 (51.6)
Median (IQR) 7.0 (4.0–11.0) 6.0 (4.0–11.0) 7.0 (5.0–10.0)
Range 0.0–900.0 0.0–600.0 0.0–900.0
Membranes ruptured
Nobs (Nmiss) 1149 (34) 575 (15) 574 (19)
No, n (%) 235 (20.5) 109 (19.0) 126 (22.0)
Yes, n (%) 914 (79.5) 466 (81.0) 448 (78.0)
Type of membrane rupture
Nobs (Nmiss) 916 (267) 468 (122) 448 (145)
Artificial, n (%) 253 (27.6) 131 (28.0) 122 (27.2)
Spontaneous, n (%) 663 (72.4) 337 (72.0) 326 (72.8)
Analgesic
Nobs (Nmiss) 1150 (33) 576 (14) 574 (19)
No, n (%) 217 (18.9) 121 (21.0) 96 (16.7)
Yes, n (%) 933 (81.1) 455 (79.0) 478 (83.3)
Analgesics used, n (%)
General anaesthetic 28 (2.4) 16 (2.7) 12 (2.0)
Epidural 388 (32.8) 191 (32.4) 197 (33.2)
Opiates 176 (14.9) 88 (14.9) 88 (14.8)
Entonox 572 (48.4) 269 (45.6) 303 (51.1)
Other 65 (5.5) 34 (5.8) 31 (5.2)
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TABLE 17 Further preplanned safety outcomes (continued )
Safety outcomes All
Trial group
Placebo Progesterone
Delivery outcomes
Delivery method, Nobs (Nmiss) 1154 (29) 578 (12) 576 (17)
Spontaneous vaginal delivery, n (%) 755 (65.4) 380 (65.7) 375 (65.1)
Lower segment caesarean section in labour,
n (%)
115 (10.0) 58 (10.0) 57 (9.9)
Lower segment caesarean section pre labour,
n (%)
176 (15.3) 92 (15.9) 84 (14.6)
Forceps, n (%) 48 (4.2) 21 (3.6) 27 (4.7)
Ventouse, n (%) 38 (3.3) 18 (3.1) 20 (3.5)
Vaginal breech (spontaneous or assisted), n (%) 22 (1.9) 9 (1.6) 13 (2.3)
Reason for assisted delivery, n (%)
Abnormal cardiotocogram 89 (7.5) 45 (7.6) 44 (7.4)
Abnormal pH on fetal scalp sampling 1 (0.1) 0 (0.0) 1 (0.2)
Slow stage 1 14 (1.2) 4 (0.7) 10 (1.7)
Slow stage 2 64 (5.4) 29 (4.9) 35 (5.9)
Malpresentation 54 (4.6) 30 (5.1) 24 (4.0)
Suspected maternal compromise 29 (2.5) 18 (3.1) 11 (1.9)
Suspected fetal compromise 60 (5.1) 33 (5.6) 27 (4.6)
Obstetric history 85 (7.2) 39 (6.6) 46 (7.8)
Other 76 (6.4) 37 (6.3) 39 (6.6)
Blood loss (ml)
Nobs (Nmiss) 1144 (39) 572 (18) 572 (21)
Mean (SD) 405.5 (375.8) 387.4 (356.4) 423.7 (393.8)
Median (IQR) 300.0 (200.0–500.0) 300.0 (200.0–450.0) 300.0 (200.0–500.0)
Range 0.0–4000.0 0.0–4000.0 0.0–4000.0
Suture
Nobs (Nmiss) 1151 (32) 578 (12) 573 (20)
No, n (%) 793 (68.9) 413 (71.5) 380 (66.3)
Yes, n (%) 358 (31.1) 165 (28.5) 193 (33.7)
Reason for suture, n (%)
Episiotomy 98 (8.3) 48 (8.1) 50 (8.4)
Degree 1 tear 46 (3.9) 21 (3.6) 25 (4.2)
Degree 2 tear 201 (17.0) 91 (15.4) 110 (18.5)
Degree 3 tear 23 (1.9) 11 (1.9) 12 (2.0)
Blood transfusion
Nobs (Nmiss) 1152 (31) 578 (12) 574 (19)
No, n (%) 1124 (97.6) 568 (98.3) 556 (96.9)
Yes, n (%) 28 (2.4) 10 (1.7) 18 (3.1)
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TABLE 17 Further preplanned safety outcomes (continued )
Safety outcomes All
Trial group
Placebo Progesterone
Antibiotics during labour and delivery
Nobs (Nmiss) 1151 (32) 578 (12) 573 (20)
No, n (%) 963 (83.7) 482 (83.4) 481 (83.9)
Yes, n (%) 188 (16.3) 96 (16.6) 92 (16.1)
Surgical procedure required
Nobs (Nmiss) 1153 (30) 578 (12) 575 (18)
No, n (%) 1120 (97.1) 563 (97.4) 557 (96.9)
Yes, n (%) 33 (2.9) 15 (2.6) 18 (3.1)
Duration of hospital stay (days)
Nobs (Nmiss) 1144 (39) 577 (13) 567 (26)
Mean (SD) 3.3 (3.3) 3.2 (2.2) 3.3 (4.1)
Median (IQR) 3.0 (2.0–4.0) 3.0 (2.0–4.0) 3.0 (2.0–4.0)
Range 1.0–86.0 1.0–19.0 1.0–86.0
Placental examination
Result of placental examination
Nobs (Nmiss) 167 (1016) 84 (506) 83 (510)
None, n (%) 113 (67.7) 57 (67.9) 56 (67.5)
Chorioamnionitis, n (%) 19 (11.4) 10 (11.9) 9 (10.8)
Chorioamnionitis and funisitis, n (%) 35 (21.0) 17 (20.2) 18 (21.7)
Post-partum complications
Thrombophlebitis
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1155 (99.8) 579 (99.8) 576 (99.8)
Yes, n (%) 2 (0.2) 1 (0.2) 1 (0.2)
Deep-vein thrombosis
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1157 (100.0) 580 (100.0) 577 (100.0)
Wound infection
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1144 (98.9) 574 (99.0) 570 (98.8)
Yes, n (%) 13 (1.1) 6 (1.0) 7 (1.2)
Urine infection
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1150 (99.4) 574 (99.0) 576 (99.8)
Yes, n (%) 7 (0.6) 6 (1.0) 1 (0.2)
Wound breakdown
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1154 (99.7) 579 (99.8) 575 (99.7)
Yes, n (%) 3 (0.3) 1 (0.2) 2 (0.3)
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TABLE 17 Further preplanned safety outcomes (continued )
Safety outcomes All
Trial group
Placebo Progesterone
Mastitis
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1155 (99.8) 579 (99.8) 576 (99.8)
Yes, n (%) 2 (0.2) 1 (0.2) 1 (0.2)
Unknown infection
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1145 (99.0) 574 (99.0) 571 (99.0)
Yes, n (%) 12 (1.0) 6 (1.0) 6 (1.0)
Post-partum haemorrhage
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1070 (92.5) 539 (92.9) 531 (92.0)
Yes, n (%) 87 (7.5) 41 (7.1) 46 (8.0)
Depression
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1155 (99.8) 579 (99.8) 576 (99.8)
Yes, n (%) 2 (0.2) 1 (0.2) 1 (0.2)
Other complication
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1099 (95.0) 553 (95.3) 546 (94.6)
Yes, n (%) 58 (5.0) 27 (4.7) 31 (5.4)
No complication
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 173 (15.0) 83 (14.3) 90 (15.6)
Yes, n (%) 984 (85.0) 497 (85.7) 487 (84.4)
Child assessments at birth
Sex
Nobs (Nmiss) 1156 (27) 578 (12) 578 (15)
Male, n (%) 582 (50.3) 289 (50.0) 293 (50.7)
Female, n (%) 573 (49.6) 289 (50.0) 284 (49.1)
Indeterminate, n (%) 1 (0.1) 0 (0.0) 1 (0.2)
Birthweight (g)
Nobs (Nmiss) 1154 (29) 577 (13) 577 (16)
Mean (SD) 2849 (866) 2822 (884) 2875 (847)
Median (IQR) 3000 (2470–3448) 2960 (2350–3420) 3040 (2550–3450)
Range 380–6400 455–6400 380–5025
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TABLE 17 Further preplanned safety outcomes (continued )
Safety outcomes All
Trial group
Placebo Progesterone
Apgar score at 1 minute
Nobs (Nmiss) 1110 (73) 553 (37) 557 (36)
Mean (SD) 8.1 (1.9) 8.1 (1.8) 8.1 (1.9)
Median (IQR) 9.0 (8.0–9.0) 9.0 (8.0–9.0) 9.0 (8.0–9.0)
Range 0.0, 10.0 0.0, 10.0 0.0, 10.0
Apgar score at 5 minutes
Nobs (Nmiss) 1115 (68) 555 (35) 560 (33)
Mean (SD) 9.1 (1.4) 9.1 (1.3) 9.0 (1.4)
Median (IQR) 9.0 (9.0–10.0) 9.0 (9.0–10.0) 9.0 (9.0–10.0)
Range 0.0, 10.0 0.0, 10.0 0.0, 10.0
Length of hospital stay (days)
Nobs (Nmiss) 1118 (65) 556 (34) 562 (31)
Mean (SD) 9.1 (20.6) 9.8 (20.9) 8.4 (20.2)
Median (IQR) 2.0 (1.0–5.0) 2.0 (1.0–6.0) 2.0 (1.0–4.0)
Range 0.0–220.0 0.0–152.0 0.0–220.0
Child assessments at 2 years
Weight (kg)
Nobs (Nmiss) 687 (496) 355 (235) 332 (261)
Mean (SD) 13.3 (2.7) 13.2 (2.6) 13.4 (2.7)
Median (IQR) 13.0 (12.0–14.2) 13.0 (11.9–14.2) 13.1 (12.0–14.2)
Range 7.0–45.4 7.0–39.3 9.0–45.4
Height (cm)
Nobs (Nmiss) 716 (467) 369 (221) 347 (246)
Mean (SD) 87.3 (9.5) 87.2 (10.7) 87.4 (7.9)
Median (IQR) 88.0 (85.0–91.0) 88.0 (84.1–91.4) 87.6 (85.0–91.0)
Range 0.9–111.0 0.9–111.0 0.9–109.0
Head circumference (cm)
Nobs (Nmiss) 686 (497) 354 (236) 332 (261)
Mean (SD) 49.2 (5.7) 48.9 (4.6) 49.6 (6.7)
Median (IQR) 49.0 (48.0–50.4) 49.0 (48.0–50.3) 49.1 (48.0–50.5)
Range 0.5–98.0 0.5–84.9 0.5–98.0
Respiration rate (breaths per minute)
Nobs (Nmiss) 76 (1107) 38 (552) 38 (555)
Mean (SD) 23.6 (11.3) 25.2 (14.1) 21.9 (7.3)
Median (IQR) 23.0 (16.0–28.0) 24.0 (20.0–28.0) 22.0 (16.0–27.5)
Range 12.0–98.0 12.0–98.0 12.0–38.0
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TABLE 17 Further preplanned safety outcomes (continued )
Safety outcomes All
Trial group
Placebo Progesterone
Heart rate (beats per minute)
Nobs (Nmiss) 73 (1110) 36 (554) 37 (556)
Mean (SD) 109.7 (18.3) 111.4 (17.3) 108.1 (19.3)
Median (IQR) 110.0 (100.0–119.0) 111.0 (102.2–118.0) 110.0 (100.0–120.0)
Range 40.0–170.0 68.0–170.0 40.0–160.0
Systolic blood pressure (mmHg)
Nobs (Nmiss) 46 (1137) 24 (566) 22 (571)
Mean (SD) 98.7 (14.0) 96.6 (13.2) 100.9 (14.7)
Median (IQR) 98.5 (90.2–107.8) 97.0 (89.2–103.5) 103.5 (91.8–108.0)
Range 59.0–128.0 64.0–123.0 59.0–128.0
Diastolic blood pressure (mmHg)
Nobs (Nmiss) 37 (1146) 20 (570) 17 (576)
Mean (SD) 64.2 (12.3) 66.0 (12.9) 62.1 (11.7)
Median (IQR) 64.0 (54.0–70.0) 65.5 (58.5–72.5) 63.0 (54.0–68.0)
Range 42.0–90.0 42.0–90.0 44.0–85.0
Nmiss, number of women with missing data; Nobs, number of observations.
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Chapter 5 Subgroup analyses
Subgroup analyses for the subgroups fibronectin positive (yes/no), short cervix (yes/no; ≤ 25 mm and< 15 mm), previous preterm birth and chorioamnionitis are shown in Tables 18–22.
TABLE 18 Logistic regression model for the effect of treatment adjusted for previous pregnancy of ≥ 14 weeks’
gestation and site as a random effect in subgroups according to risk group (fibronectin status)
Risk group OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
Primary obstetric outcome (death or delivery before 34 weeks’ gestation). Interaction model (n= 1197)
Low, negative fFN (n= 859) 0.88 0.58 to 1.33 0.542 0.907
High, positive fFN (n= 338) 0.91 0.57 to 1.46 0.707
Primary neonatal outcome (death, brain injury or severe chronic lung disease). Interaction model (n= 1176)
Low, negative fFN (n= 847) 0.65 0.37 to 1.13 0.129 0.957
High, positive fFN (n= 329) 0.64 0.34 to 1.20 0.162
Risk group
Expected mean difference
(progesterone vs. placebo) 95% CI p-value
p-value for
interaction
Primary childhood outcome (Bayley-III cognitive composite score adjusted for previous pregnancy). Interaction model
(n = 869)
Low, negative fFN (n= 628) –0.63 –3.28 to 2.03 0.644 0.858
High, positive fFN (n= 241) –1.09 –5.41 to 3.23 0.621
TABLE 19 Logistic regression model for the effect of treatment adjusted for previous pregnancy of ≥ 14 weeks’
gestation and site as a random effect in subgroups according to cervical length (≤ 25mm) at baseline
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
Primary obstetric outcome (death or delivery before 34 weeks’ gestation). Interaction model (n= 696)
> 25 (n= 445) 0.88 0.50 to 1.57 0.672 0.542
≤ 25 (n= 251) 0.69 0.39 to 1.20 0.191
Primary neonatal outcome (death, brain injury or severe chronic lung disease). Interaction model (n= 682)
> 25 (n= 436) 0.74 0.35 to 1.56 0.432 0.564
≤ 25 (n= 246) 0.54 0.25 to 1.16 0.113
Cervical length at baseline (mm)
Expected mean difference
(progesterone vs. placebo) 95% CI p-value
p-value for
interaction
Primary childhood outcome (Bayley-III cognitive composite score adjusted for previous pregnancy). Interaction model
(n = 496)
> 25 (n= 317) –2.27 –6.10 to 1.56 0.247 0.971
≤ 25 (n= 179) –2.15 –7.23 to 2.93 0.408
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TABLE 20 Logistic regression model for the effect of treatment adjusted for previous pregnancy of ≥ 14 weeks’
gestation and site as a random effect in subgroups according to cervical length (< 15mm) at baseline
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
Primary obstetric outcome (death or delivery before 34 weeks’ gestation). Interaction model (n= 696)
> 15 (n= 599) 0.77 0.48 to 1.23 0.274 0.727
≤ 15 (n= 97) 0.91 0.41 to 2.04 0.819
Primary neonatal outcome (death, brain injury or severe chronic lung disease). Interaction model (n= 682)
> 15 (n= 588) 0.73 0.39 to 1.38 0.334 0.503
≤ 15 (n= 94) 0.49 0.18 to 1.31 0.156
Cervical length at baseline (mm)
Expected mean difference
(progesterone vs. placebo) 95% CI p-value
p-value for
interaction
Primary childhood outcome (Bayley-III cognitive composite score adjusted for previous pregnancy). Interaction model (n= 496)
> 15 (n= 423) –2.49 –5.77 to 0.78 0.137 0.680
≤ 15 (n= 73) –0.69 –8.60 to 7.22 0.865
TABLE 21 Logistic regression model for the effect of treatment adjusted for previous pregnancy of ≥ 14 weeks’
gestation and site as a random effect in subgroups according to history of spontaneous preterm birth
History of spontaneous preterm birth OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
Primary obstetric outcome (death or delivery before 34 weeks’ gestation). Interaction model (n= 1176)
No (n= 273) 0.99 0.51 to 1.92 0.972 0.62
Yes (n = 903) 0.82 0.58 to 1.16 0.254
Primary neonatal outcome (death, brain injury or severe chronic lung disease). Interaction model (n= 1156)
No (n= 270) 1.22 0.55 to 2.71 0.620 0.053
Yes (n = 886) 0.48 0.29 to 0.79 0.004
History of spontaneous preterm birth
Expected mean difference
(progesterone vs. placebo) 95% CI p-value
p-value for
interaction
Primary childhood outcome (Bayley-III cognitive composite score adjusted for previous pregnancy). Interaction model (n= 857)
No (n= 201) –1.11 –5.96 to 3.73 0.653 0.73
Yes (n = 656) –0.14 –2.79 to 2.52 0.919
SUBGROUP ANALYSES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
46
TABLE 22 Logistic regression model for the effect of treatment adjusted for previous pregnancy of ≥ 14 weeks’
gestation and site as a random effect in subgroups according to chorioamnionitis diagnosed on pathology
Chorioamnionitis diagnosed
on pathology OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
Primary obstetric outcome (death or delivery before 34 weeks’ gestation). Interaction model (n= 172)
No 1.38 0.55 to 3.45 0.497 0.547
Yes (n = 57) 2.17 0.68 to 6.85 0.190
Primary neonatal outcome (death, brain injury or severe chronic lung disease). Interaction model (n= 171)
No 0.81 0.22 to 2.96 0.752 0.244
Yes (n = 56) 2.21 0.76 to 6.40 0.148
Chorioamnionitis diagnosed
on pathology
Expected mean difference
(progesterone vs. placebo) 95% CI p-value
p-value for
interaction
Primary childhood outcome (Bayley-III cognitive composite score adjusted for previous pregnancy). Interaction model
(n = 124)
No (n= 81) –2.30 –10.30 to 5.70 0.575 0.859
Yes (n = 43) –1.08 –11.91 to 9.76 0.846
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Chapter 6 Further analysis of factors influencing
the childhood outcome
As a further post hoc analysis, we investigated the influence of gestational age at birth and other factorsat birth on the childhood outcome.
Figure 1 shows a scatterplot of gestational age at delivery and Bayley-III cognitive composite scores
(with deaths imputed).
These data show that, at gestational ages of < 34 weeks, there is a linear relationship between gestation
at delivery and the Bayley-III cognitive composite score. The shape of the Lowess line suggests that a
quadratic model might fit best, which was confirmed by comparing the quadratic fit to thinplate regression
splines and finding a very similar shape.
Table 23 shows the results for unadjusted and adjusted models predicting Bayley-III cognitive composite
scores from gestational age as a linear and a quadratic term.
The predicted scores in Figure 2 are for a woman of average age, education and body mass index (BMI),
who has had no previous pregnancy of ≤ 14 weeks, does not smoke and is at a low risk of preterm birth.
Gestational age at delivery has a significant effect on the cognitive outcome. Adjustment alters the effect
estimates only slightly. Other significant predictors are maternal age, BMI, the number of previous
pregnancies and whether the woman was in the high- or the low-risk group; with higher maternal age,
lower BMI, lower number of previous pregnancies and being of a low risk predicting higher Bayley-III
cognitive composite scores.
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FIGURE 1 Scatterplot of raw values of gestational age at delivery and Bayley-III cognitive composite scores, with a
Lowess line.
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TABLE 23 Linear regression model predicting Bayley-III cognitive composite score from gestational age at delivery
as a linear and a quadratic term
Characteristic adjusted for Effect 95% CI p-value
Unadjusted
Gestational age at delivery (linear term) 11.503 8.351 to 14.654 < 0.001
Gestational age at delivery (quadratic term) –0.140 –0.187 to –0.093 < 0.001
Adjusted
Gestational age at delivery (linear term) 10.398 7.155 to 13.640 < 0.001
Gestational age at delivery (quadratic term) –0.126 –0.174 to –0.078 < 0.001
Mother’s age 0.283 0.090 to 0.477 0.004
Time in full-time education 0.288 –0.047 to 0.623 0.092
Mother’s BMI –0.212 –0.365 to –0.059 0.007
Smoking –2.024 –5.025 to 0.976 0.186
Number of previous pregnancies of ≤ 14 weeks –1.863 –2.638 to –1.089 < 0.001
High risk –3.150 –5.477 to –0.824 0.008
BMI, body mass index.
Note
The adjusted model adjusts for mother’s age, years in full-time education, BMI, smoking, previous pregnancies of ≥ 14 weeks
and high/low risk.
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FIGURE 2 Unadjusted and adjusted models predicting Bayley-III cognitive composite scores from gestational age as
a linear and a quadratic term.
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In addition, the relation between gestational age and Bayley-III cognitive composite scores has been
analysed including gestational age as a categorical variable (gestational ages rounded to weeks), with
40 weeks as the reference group. Figure 3 shows the estimated regression coefficients for each week.
Those results suggest that the lower gestational age, the higher the gain from each additional week of
gestation. From week 34 or 36 (weeks 34 and 35 results are unclear) onwards, there seems to be little
additional gain from longer gestation.
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FIGURE 3 Regression coefficients for gestational age at delivery from a linear model predicting Bayley-III cognitive
composite scores from gestational age at delivery as a categorical variable, with 95% CIs. Gestational ages of 22
and 23 weeks have been grouped together, as well as gestational ages of 42 and 43 weeks. The reference category
is 40 weeks. The adjusted model adjusts for mother’s age, years in full-time education, BMI, smoking, previous
pregnancies of ≥ 14 weeks and high/low risk.
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Chapter 7 Discussion and overall conclusions
The OPPTIMUM study aimed to test the hypotheses that progesterone:
l improves obstetric outcome by lengthening pregnancy and reducing the incidence of preterm delivery
(before 34 weeks’ gestation)
l improves neonatal outcome by reducing a composite of death and major morbidity
l leads to improved childhood cognitive and neurosensory outcomes at age 2 years.
In the OPPTIMUM study, the CI of the OR of treatment effect crossed unity for each of the obstetric,
neonatal or childhood outcomes, suggesting that progesterone had no effect on any of these outcomes.
These data contrast with the meta-analyses6,7 on preterm birth prevention (the obstetric outcome) detailed
in Chapter 1, which found that progesterone prevents preterm birth. The literature is less consistent on
whether or not progesterone improves neonatal outcomes. For women with a short cervix, two major
meta-analyses6,7 come to different conclusions for the neonatal outcome, with one7 showing that progesterone
reduces adverse outcomes and the other6 finding no benefit. For women with a previous preterm birth, the
Cochrane meta-analysis6 suggests that progesterone reduces perinatal death and other adverse neonatal
outcomes. OPPTIMUM, the largest single randomised trial, found no effect of progesterone on the composite
neonatal outcome. In subgroup analyses, all of the ORs crossed unity and none of the p-values of any of
the interaction terms approached statistical significance; in other words, we found no evidence that
progesterone is any more effective in any subgroup.
The study benefited from participation of PPI in the conduct of the study. Having PPI representatives on the
trial steering committee was useful in focusing on what patients would find helpful. Our PPI representatives
faced the challenge that many ‘pregnancy’ PPI representatives face, that of little time to contribute to the
study because of the competing demands of their young family.
Reported compliance was 68.6% (95% CI 65.8% to 71.5%). This rate is similar to or better than
compliance rates seen when drugs are taken for clinical indications; hence, we believe that efficacy is as
good or better as would be achieved in ‘real-world’ situations.21 Although other studies11 have reported
higher compliance, this is based on counting returned unused medication, a strategy likely to overestimate
compliance.
Some commentators have noted that the ORs for the obstetric and neonatal outcome are in the direction of
benefit, and have suggested that OPPTIMUM was underpowered to show benefit. We powered the study
carefully as described in the protocol and in the statistical analysis plan (see Appendix 2), and we ultimately
recruited to the planned sample size. Post hoc, we compared the planned with the actual event rate for the
obstetric outcome in the placebo group. In planning our sample size, we calculated that the obstetric
outcome event rate would be 40% for those in the fFN-positive group and 10% for those in the fFN-negative
group for a study power of 81% (see power calculation in Appendix 2 and published).17 We anticipated
recruiting 375 women in the fFN-positive group and 750 women in the fFN-negative group in the study as
whole. Assuming half of these women were randomised to the placebo group, the number of outcome
events in the placebo group would be 0.5 × [(0.4 × 375)+ (0.1 × 750)]= 112.5. Once OPPTIMUM was
complete, the event rate in the fFN-positive group was a little lower and the event rate in the fFN-negative
group was a little higher than expected, with the actual number of obstetric outcome events in the placebo
group being 108. The failure to show an effect of progesterone (at least for the obstetric outcome) was not
because the sample size was too small, but because the effect size (an OR of 0.86 for the obstetric outcome)
was less than anticipated; in other words, because progesterone was much less effective than anticipated.
Hence, OPPTIMUM’s failure to demonstrate benefit (at least for the obstetric outcome) is not because it
is underpowered.
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Others have noted that, in OPPTIMUM, the risk of neonatal death (one of the secondary outcomes) was
reduced from 6 out of 597 in the placebo group to 1 out of 600 in the progesterone group: OR for the
effect of progesterone of 0.17 (95% CI 0.06 to 0.49). Although this reduction is superficially attractive, the
total number of deaths from trial entry to the end of the study was greater in the progesterone group, 16
out of 598 (placebo) and 20 out of 600 (progesterone): OR for the effect of progesterone of 1.26 (95% CI
0.65 to 2.42). Hence, we do not believe that the reduction in neonatal death in the progesterone group is
likely to be clinically useful.
Progesterone is endorsed for preterm birth prevention in women with a short cervix by several expert
guideline groups including the Society for Maternal Fetal Medicine in the USA (that recommend its use in
women with a cervical length of ≤ 20 mm)20 and the National Institute for Health and Care Excellence in
the UK (that endorse its use in women with a cervical length of ≤ 25 mm).21 Both of these guidelines
(generated before the publication of OPPTIMUM) are likely to be revisited to take into account the data
described here. We believe that a comprehensive individual patient-level data meta-analysis, evaluating
the effect of progesterone in a variety of ‘at-risk’ subgroups, is likely to be helpful in determining the
appropriate role of progesterone for preterm birth prevention.
DISCUSSION AND OVERALL CONCLUSIONS
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Appendix 1 Study drugs
Two SmPCs are shown. The first with arachis oil as the excipient and the second with sunflower oil asthe excipient.
(a) (Arachis) 
Utrogestan 200mg Capsules 
Summary of Product Characteristics 
1. NAME OF MEDICINAL PRODUCT 
Utrogestan 200mg capsules 
2. QUALITATIVE AND QUANTITATIVE COMPOSITION 
Each capsule contains 200 mg micronised progesterone (INN). For excipients, 
see 6.1. 
3. PHARMACEUTICAL FORM 
Capsules, soft 
White 
4. CLINICAL PARTICULARS 
4.1. Therapeutic Indications 
Adjunctive use with estrogen in post-menopausal women with an intact uterus. 
(HRT) 
4.2. Posology and method of administration 
Posology 
In women receiving estrogen replacement therapy there is an increased risk of 
endometrial cancer which can be countered by progesterone administration. 
The recommended dose is 200 mg daily at bedtime, for twelve days in the last 
half of each therapeutic cycle (beginning on day 15 of the cycle and ending on 
day 26). Withdrawal bleeding may occur in the following week. 
Alternatively 100 mg can be given at bedtime from day 1 to day 25 of each 
therapeutic cycle, withdrawal bleeding being less with this treatment schedule. 
Children: Not applicable. 
Elderly: As for adults 
Method of Administration: Oral. Utrogestan 200mg Capsules should not be 
taken with food 
4.3. Contraindications 
Known allergy or hypersensitivity to progesterone or to any of the excipients. 
The capsules contain arachis oil (peanut oil) and should never be used by 
patients allergic to peanuts. Severe hepatic dysfunction. Undiagnosed vaginal 
bleeding. Mammary or genital tract carcinoma. Thrombophlebitis. 
Thromboembolic disorders. Cerebral haemorrhage. Porphyria. 
4.4. Special warning and precautions for use 
Warnings: 
Utrogestan 200mg Capsules are not a treatment for premature labour. 
Prescription of progesterone beyond the first trimester of pregnancy may 
reveal gravidic cholestasis. 
Utrogestan 200mg Capsules are not suitable for use as a contraceptive. 
If unexplained, sudden or gradual, partial or complete loss of vision, proptosis 
or diplopia, papilloedema, retinal vascular lesions or migraine occur during 
therapy, the drug should be discontinued and appropriate diagnostic and 
therapeutic measures instituted. 
Utrogestan 200mg Capsules are intended to be co-prescribed with an estrogen 
product as HRT. Epidemiological evidence suggests that the use of HRT is 
associated with an increased risk of developing deep vein thrombosis (DVT) 
or pulmonary embolism. The prescribing information for the co-prescribed 
estrogen product should be referred to for information about the risks of 
venous thromboembolism. 
There is suggestive evidence of a small increased risk of breast cancer with 
estrogen replacement therapy. It is not known whether concurrent 
progesterone influences the risk of cancer in post-menopausal women taking 
hormone replacement therapy. The prescribing information for the coprescribed 
estrogen product should be referred to for information about the 
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risks of breast cancer. 
Precautions 
Prior to taking hormone replacement therapy (and at regular intervals 
thereafter) each woman should be assessed. A personal and family medical 
history should be taken and physical examination should be guided by this and 
by the contraindications and warnings for this product. 
Utrogestan 200mg Capsules should not be taken with food and should be 
taken at bedtime. Concomitant food ingestion increases the bioavailability of 
Utrogestan 100mg Capsules. 
Utrogestan 200mg Capsules should be used cautiously in patients with 
conditions that might be aggravated by fluid retention (e.g. hypertension, 
cardiac disease, renal disease, epilepsy, migraine, asthma); in patients with a 
history of depression, diabetes, mild to moderate hepatic dysfunction, 
migraine or photosensitivity and in breast-feeding mothers. 
Clinical examination of the breasts and pelvic examination should be 
performed where clinically indicated rather than as a routine procedure. 
Women should be encouraged to participate in the national breast cancer 
screening programme (mammography) and the national cervical cancer 
screening programme (cervical cytology) as appropriate for their age. Breast 
awareness should also be encouraged and women advised to report any 
changes in their breasts to their doctor or nurse. 
4.5. Interaction with other medicinal products and other forms of interaction 
Utrogestan 200mg Capsules may interfere with the effects of bromocriptine 
and may raise the plasma concentration of cyclosporine. Utrogestan 200mg 
Capsules may affect the results of laboratory tests of hepatic and/or endocrine 
functions. 
Metabolism of Utrogestan 200mg Capsules is accelerated by rifamycin an 
antibacterial agent. 
The metabolism of progesterone by human liver microsomes was inhibited by 
ketoconazole (IC50 <0.1 M Ketoconazole is a known inhibitor of cytochrome 
P450 3A4. These data therefore suggest that ketoconazole may increase the 
bioavailability of progesterone. The clinical relevance of the in vitro findings 
is unknown. 
4.6. Pregnancy and lactation 
Pregnancy 
Utrogestan 200mg Capsules are not indicated during pregnancy. If pregnancy 
occurs during medication, Utrogestan 200mg Capsules should be withdrawn 
immediately. 
Lactation 
Detectable amounts of progesterone enter the breast milk. There is no 
indication for prescribing HRT during lactation. 
4.7. Effects on ability to drive and use machines 
Utrogestan 200mg Capsules may cause drowsiness and/or dizziness in a 
minority of patients; therefore caution is advised in drivers and users of 
machines. Taking the capsules at bedtime should reduce these effects during 
the day. 
4.8. Undesirable effects 
Somnolence or transient dizziness may occur 1 to 3 hours after intake of the 
drug. Bedtime dosing and reduction of the dose may reduce these effects. 
Shortening of the cycle or breakthrough bleeding may occur. If this occurs, 
the dose of Utrogestan 200mg Capsules can be reduced and taken at bedtime 
from day 1 to day 26 of each therapeutic cycle. 
Acne, urticaria, rashes, fluid retention, weight changes, gastro-intestinal 
disturbances, changes in libido, breast discomfort, premenstrual symptoms, 
menstrual disturbances; also chloasma, depression, pyrexia, insomnia, 
alopecia, hirsutism; rarely jaundice. 
Venous thromboembolism, i.e. deep leg or pelvic venous thrombosis and 
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pulmonary embolism, is more frequent among hormone replacement therapy 
users than among non-users. 
4.9. Overdose 
Symptoms of overdosage may include somnolence, dizziness, euphoria or 
dysmenorrhoea. Treatment is observation and, if necessary, symptomatic and 
supportive measures should be provided. 
5. PHARMACOLOGICAL PROPERTIES 
5.1. Pharmacodynamic properties 
Pharmacotherapeutic group (ATC code: G03D) 
Progesterone is a natural progestogen, the main hormone of the corpus luteum 
and the placenta. It acts on the endometrium by converting the proliferating 
phase to the secretory phase. Utrogestan 200mg Capsules have all the 
properties of endogenous progesterone with induction of a full secretory 
endometrium and in particular gestagenic, antiestrogenic, slightly antiandrogenic 
and antialdosterone effects. 
5.2. Pharmacokinetic properties 
Absorption 
Micronised progesterone is absorbed by the digestive tract. Pharmacokinetic 
studies conducted in healthy volunteers have shown that after oral 
administration of 2 capsules (200mg), plasma progesterone levels increased to 
reach the Cmax of 13.8ng/ml +/- 2.9ng/ml in 2.2 +/- 1.4 hours. The 
elimination half-life observed was 16.8+/- 2.3 hours. 
Although there were inter-individual variations, the individual 
pharmacokinetic characteristics were maintained over several months, 
indicating predictable responses to the drug. 
Distribution 
Progesterone is approximately 96%-99% bound to serum proteins, primarily to 
serum albumin (50%-54%) and transcortin (43%-48%). 
Elimination 
Urinary elimination is observed for 95% in the form of glycuroconjugated 
metabolites, mainly 3 α, 5 β –pregnanediol (pregnandiol). 
Metabolism 
Progesterone is metabolised primarily by the liver. The main plasma 
metabolites are 20 α hydroxy- ∆ 4 α- prenolone and 5 α-dihydroprogesterone. 
Some progesterone metabolites are excreted in the bile and these may be 
deconjugated and further metabolised in the gut via reduction, 
dehydroxylation and epimerisation. The main plasma and urinary metabolites 
are similar to those found during the physiological secretion of the corpus 
luteum. 
5.3. Preclinical safety data 
Preclinical data revealed no special hazard for humans based on conventional 
studies of safety pharmacology and toxicity. 
6. PHARMACEUTICAL PARTICULARS 
6.1. List of excipients 
Arachis oil 
Soya lecithin 
Gelatin 
Glycerol 
Titanium dioxide 
6.2. Incompatibilities 
None. 
6.3. Shelf-life 
3 years. 
6.4. Special precautions for storage 
No special precautions for storage. 
6.5. Nature and contents of container 
The product is supplied in PVC/Aluminium blisters contained in cartons. 
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Pack size: 15 capsules per carton 
6.6. Instructions for use and handling 
Not applicable. 
7. MARKETING AUTHORISATION HOLDER 
Laboratoires BESINS INTERNATIONAL 
3, rue du Bourg l’Abbé 
75003 
Paris 
France 
8. MARKETING AUTHORISATION NUMBER 
PL 16468/0007 
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE 
AUTHORISATION 
23rd February 2006 
10. DATE OF REVISION OF THE TEXT 
Supprimé : 5 
Supprimé : 6 
Supprimé : January 
Supprimé : 5 
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(b) (Sunflower) 
ANNEXE I 
SUMMARY OF THE PRODUCT’S CHARACTERISTICS 
1. NAME OF THE MEDICINAL PRODUCT 
UTROGESTAN 200 mg, oral or vaginal soft capsules. 
2. QUALITATIVE AND QUANTITATIVE COMPOSITION 
Progesterone…………………………………………………………………..200-mg 
For one soft capsule 
For a full list of excipients, see section 6.1 
3. PHARMACEUTICAL FORM 
Oral or vaginal soft capsule. 
4. CLINICAL PARTICULARS 
4.1 Therapeutic indications 
Oral route 
• Pre-menstrual syndrome, 
• Menstrual irregularities due to ovulation disorders or anovulation, 
• Benign mastopathy, 
• Premenopause, 
• Hormone replacement therapy for menopause (as an oestrogen complement). 
Vaginal route 
• Progesterone support during ovarian insufficiency or complete ovarian failure in 
women lacking ovarian function (oocyte donation). 
• Luteal phase supplementation during in vitro fertilization (IVF) cycles, 
• Luteal phase supplementation during spontaneous or induced cycles, in cases of 
hypofertility, in primary or secondary sterility and in particular due to dysovulation, 
• Risk of miscarriage or prevention of repeated miscarriage due to luteal phase 
insufficiency up until the 12th week of pregnancy. 
• For all other progesterone indications, the vaginal route represents an alternative to the 
oral route, in cases of: 
• Adverse events due to progesterone (somnolence after absorption by the oral route). 
4.2 Posology and method of administration 
As in all therapeutic indications, it is important to strictly respect the recommended 
dose. 
Regardless of the indication or the administration route (oral or vaginal), the dosage 
should not exceed 200-mg per dose. 
Oral route 
For progesterone insufficiency, the average dosage is 200 to 300-mg of micronized 
progesterone per day. 
It is not recommended to take the medicine close to mealtimes; preferably, it should be 
taken in the evening before going to bed. 
• In cases of luteal insufficiency (premenstrual syndrome, benign mastopathies, 
menstrual irregularities, premenopause) the usual therapeutic programme is 200 
to 300-mg per day: 
• either 200-mg taken in one dose before bedtime, 
• or 300-mg taken in two doses, 10 days per cycle, normally from the 17th to 
the 26th day inclusive. 
• In replacement treatment for the menopause, oestrogen therapy is not 
recommended on its own (risk of endometrial hyperplasia): progesterone should 
be added at a dosage of 200-mg per day: 
• 100-mg taken twice a day, 
• or in a single dose of 200-mg in the evening before going to bed, either for 
12 to 14 days per month or during the last two weeks of each therapeutic 
sequence. 
This treatment should be followed by an interruption of any substitutive treatment for 
roughly one week during which it is normal to experience a deprivation haemorrhage. 
For these indications, the vaginal route should be used at the same dosage as the oral 
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route in the case of side effects due to the progesterone (drowsiness after oral 
absorption). 
Vaginal route 
Each capsule should be inserted as far as possible into the vagina. 
• Progesterone substitution for ovarian insufficiency or complete deficiency in 
women without ovaries (oocyte donation). 
The therapeutic programme (in complement to an appropriate oestrogenic treatment) is 
as follows: 
• 100-mg of micronized progesterone per day on the 13th and 14th day of the 
transfer cycle then, 
• 200-mg of micronized progesterone per day from the 15th to the 25th day of the 
cycle, spread over one or two daily doses, then, 
• From the 26th day of the cycle and, in the case of the start of pregnancy, this 
dose can be increased to a maximum of 600-mg/day spread over three doses. 
This posology can be followed until the 60th day, or at the latest, until the 12th week of 
pregnancy. 
• Supplementation of the luteal phase during IVF cycles: 
The recommended posology is 400 to 600-mg per day in two or three doses each 
day starting from the hCG injection and until the 12th week of pregnancy. 
• Supplementation of the luteal phase during spontaneous or induced 
cycles, in cases of hypofertility or primary or secondary sterility, especially by 
dysovulation: the recommended posology is 200 to 300-mg per day in two doses 
starting from the 17th day of the cycle for 10 days. The treatment should be 
started again rapidly should menstruation not occur or pregnancy is diagnosed 
until the 12th week of pregnancy. 
• Risk of miscarriage or prevention of repeated miscarriages due to luteal 
insufficiency: the recommended posology is 200 to 400-mg per day taken in two 
doses until the 12th week of pregnancy. 
4.3 Contraindications 
This medicine is contraindicated in the case of serious alterations to the hepatic 
function. 
4.4 Special warnings and precautions for use 
Special warnings: 
• More than half of all early miscarriages are due to genetic accidents. 
Furthermore, infectious phenomena and mechanical problems can be 
responsible for miscarriages. Therefore, the only effect of the administration of 
progesterone would be to slow down the expulsion of a dead ovum (or the 
interruption of a non-evolutional pregnancy). 
• The use of progesterone should only be reserved to cases where the secretion of 
the corpus luteum in insufficient. 
• Under the recommended conditions of use, this treatment is not contraceptive. 
• The use of UTROGESTAN 200-mg during a pregnancy is reserved to the first 
three months and for the vaginal route. UTROGESTAN 200-mg is not a 
treatment against the risk of premature birth. 
• Cytolytic-type cases of hepatic attack and cases of gravidic cholestase have 
been reported on extremely rare occasions during the administration of 
micronized progesterone during 2nd and 3rd thirds of pregnancy. 
4.5 Interaction with other medicinal products and other forms of interaction 
Not applicable. 
4.6 Pregnancy and breast feeding 
Numerous epidemiological studies on over one thousand patients have not shown any 
association between progesterone and foetal malformations. 
4.7 Effects on ability to drive and use machines 
Attention should be paid, especially for drivers of vehicles and those using machinery of 
the risks of drowsiness and/or dizziness attached to the use of this medicine when 
taking it by the oral route. 
4.8 Undesirable effects 
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Oral route 
• Drowsiness of transitory dizziness occurring 1 to 3 hours after ingestion of the 
product. In this case: 
• Decrease the posology of each dose, 
• Or modify the rhythm of the doses (i.e. for a dosage of 200-mg/day, take 
the 200-mg in the evening before bedtime in a single dose not close to 
mealtimes). 
• Or adopt the vaginal route. 
• Shortening of the menstrual cycle or intercurrent bleeding. Move the start of 
treatment to later on in the cycle (for example, start on the 19th day of the cycle in 
stead of the 17th). 
In most cases, these effects indicate overdose. 
Due to the presence of soya lecithin there is a risk of hypersensitive reactions occurring 
(anaphylactic shock, urticaria). 
Vaginal route 
• No local intolerance (burning, pruritus or fatty discharge) has been observed 
during the different clinical trials. 
• No general side effect, in particular, drowsiness or dizziness has been reported 
during clinical studies at the recommended dosages. 
4.9 Overdose 
See part 4.8. 
5. PHARMACOLOGICAL PROPERTIES 
5.1 Pharmacodynamic properties 
PROGESTERONE 
(G03DA04: genito-urinary system and sexual hormones). 
The properties of UTROGESTAN are comparable to those of natural progesterone, in 
particular, gestagen, anti-oestrogen, slightly anti-androgen and anti-aldosterone. 
5.2 Pharmacokinetic properties 
Oral route 
Absorption 
Micronized progesterone is absorbed by the digestive route. 
Progesterone blood level rises during the first hour and the highest plasmatic levels are 
reached 1 to 3 hours after taking the medicine. 
Pharmacokinetic studies carried out on volunteers have shown that after the 
simultaneous ingestion of two capsules of UTROGESTAN 100-mg, the progesterone 
blood level on average goes from 0.13-ng/ml to 4.25-ng/ml after one hour, 11.75-ng/ml 
after 2 hours, 8.37-ng/ml after 4 hours, 2-ng/ml after 6 hours and 1.64-ng/ml after 8 
hours. 
Given the tissue retention time of the hormone, it would appear necessary in order to 
obtain an impregnation the length of the nychthemeron, to spread the dosage over two 
doses roughly 12 hours apart. 
There are noticeable individual variations, however, the same individual conserves the 
same pharmacokinetic characteristics for several months which leads to good individual 
adaptation to the posology. 
Metabolism 
In the plasma, the principle metabolites are 20α-hydroxy, _4-pregnanolone and 5α- 
dihydroprogesterone. 
Urinary elimination is 95 % in the form of glycuroconjugated metabolites the principal of 
which is 3α-5β-pregnandiol. These plasmatic and urinary metabolites are identical to 
those found during the physiological secretion of the ovarian corpus luteum. 
Vaginal route 
Absorption 
After vaginal insertion, the absorption of the progesterone by the vaginal mucous is 
rapid, as witnessed by the increase in the plasma progesterone levels one hour after its 
administration. 
The maximum plasmatic concentration is attained 2 to 6 hours after insertion and is 
maintained at an average concentration over 24 hours of 9.7-ng/ml after administration 
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of 100-mg in the morning and evening. Therefore, this recommended average dosage 
brings about stable and physiological plasmatic concentrations of progesterone similar 
to those observed during the luteal phase of a normal ovulatory menstrual cycle. The 
low interpersonal variations in the levels of progesterone permit a precise forecast of the 
effect expected with a standard posology. 
At doses above 200-mg per day, the concentrations of progesterone obtained are 
comparable to those described during the first three months of pregnancy. 
Metabolism 
The concentration of 5β-pregnanolone is not augmented in the plasma. 
Urinary elimination is mainly in the form of 3α, 5β-pregnandiol as is witnessed by the 
progressive increase in its concentration (until it attains the maximum concentration of 
142-ng/ml by the 6th hour). 
5.3 Preclinical safety data 
Not applicable 
6. PHARMACEUTICAL PARTICULARS 
6.1 List of excipients 
Sunflower oil, soya lecithin 
Capsule shell: gelatine, glycerine and titanium dioxide (E171) 
6.2 Incompatibilities 
Not applicable 
6.3 Shelf life 
3 years. 
6.4 Special precautions for storage 
There are no special precautions for storage. 
6.5 Nature and contents of container 
14, 15, 30 or 60 capsules in blister packs (PVC/aluminium) 
6.6 Special precautions for disposal and other handling 
No particular requirements. 
7. MARKETING AUTHORIZATION HOLDER 
LABORATOIRES BESINS INTERNATIONAL 
3, rue du Bourg l’Abbé 
75003 PARIS – FRANCE 
8. MARKETING AUTHORIZATION NUMBERS 
• 361 988-1: 14 capsules in a blister pack (PVC/aluminium). 
• 348 399-6: 15 capsules in a blister pack (PVC/aluminium). 
• 348 400-4: 30 capsules in a blister pack (PVC/aluminium). 
• 348 401-0: 60 capsules in a blister pack (PVC/aluminium). 
9. DATE OF FIRST AUTHORIZATION / RENEWAL OF THE AUTHORIZATION 
(To be completed by the authorization holder) 
10. DATE OF REVISION OF THE TEXT 
(To be completed by the authorization holder) 
11. DOSIMETRY 
Not applicable. 
12. INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS 
Not applicable. 
CONDITIONS FOR PRESCRIPTION AND ISSUE 
List I 
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 3 
 
08/09/2015 
1. INTRODUCTION 
 
1.1. STUDY 
BACKGROUND 
 
(This paragraph on the background to the study was updated in Spring 2015, to summarise the 
current literature). 
 
Spontaneous preterm birth (PTB) is associated with high morbidity, mortality and high health costs. 
A systematic review 4has shown that, in women with a previous history of preterm birth, 
progestogens reduces the risk of perinatal mortality (risk ratio (RR) 0.50, 95% confidence 
interval (CI) 0.33 to 0.75), and preterm birth less than 34 weeks (RR 0.31, 95% CI 0.14 to 0.69). 
Progestogens also reduce the risk of preterm birth before 34 weeks in women with a short cervix 
(RR 0.64, 95% CI 0.45 to 0.90) . In women with “other” risk factors for preterm birth, progestogens 
reduce the risk of infant birthweight less than 2500 g (RR 0.48, 95% CI 0.25 to 0.91), but not 
preterm birth (RR 0.69, 95% CI 0.16 to 3.01). There is no significant effect of different routes of 
progesterone  (a  surrogate  for  different  progestogens,  since  progesterone  is  normally  given 
vaginally,  and  17  hydroxyprogesterone  caproate  is  given  intramuscularly)  for  the  majority  of 
outcomes examined. An individual patient level data meta-analysis of vaginal progesterone given to 
women with a short cervix demonstrates that progesterone reduced the risk of preterm birth before 
33 weeks (relative risk  0.58, 95% CI 0.42 to 0.80) and a composite of neonatal mortality and 
morbidity (relative risk 0.57, 95% CI 0.40 to 0.81. 7 
 
Despite the overwhelming evidence for the efficacy of progesterone in preterm birth prevention, 
there is very limited evidence on longer term infant and childhood effects, with the most recent 
Cochrane review indicating that “the assessment of which remains a priority”. OPPTIMUM aims to 
address this issue. 
 
1.2. STUDY 
OBJECTIVES 
 
The objective of the study is to  assess whether  a  prophylactic vaginal  treatment with natural 
progesterone (200 mg/day) from 22 to 34 weeks gestation in women at high risk for PTB does, 
compared to placebo: 
 
-    improve  obstetric  outcome  by  lengthening  pregnancy  and  thus  reducing  the  incidence  
of preterm delivery (before 34 weeks gestation)? (Obstetric outcome) 
 
-    improve neonatal outcome by reducing a composite of death and major morbidity?  
(Neonatal outcome) 
 
-    lead to improved childhood cognitive and neurosensory outcomes at two years of age?  
(Early childhood outcome) 
 
1.3. STUDY 
DESIGN 
 
The study is designed as a UK multicentre double blind, randomised, placebo controlled trial. There 
are two parallel groups, one treated daily with 200mg vaginal progesterone, the other with an 
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identical looking placebo from their inclusion between 22 and 24 weeks gestation until week 34 or 
earlier  delivery,  elective  (preterm)  delivery,  fetal  membrane  rupture  or  low-lying  placenta 
(symptomatic placenta praevia). 
 
Women with singleton pregnancy are invited to a screening visit if they are identified to be at risk 
of PTB (having either a history in a previous pregnancy of PTB, second trimester loss or premature 
fetal membrane rupture in a previous pregnancy, a current cervical length <25mm or any cervical 
procedure to treat abnormal smears) at a routine antenatal appointment between 22+0  and 24+0 
weeks gestation. If they consent, a fetal fibronectin (fFN) test is carried out. Those with a positive 
result are invited to participate in the study, and comprise the “high risk” group. Those with a 
negative result are invited to participate if they have had a previous spontaneous preterm birth 
before 34+0  weeks gestation or a cervical length of 25mm or less between 18+0  and 24+0  weeks 
gestation in the current pregnancy and together comprise the “low risk” group. Women giving 
further  consent  are  randomised  to  receive  either  200mg/day  vaginal  progesterone  or  identical 
looking placebo. 
 
A  baseline  examination  is  carried  out  and  a  formal  follow  up  visit  at  34  weeks  gestation. 
Information on labour and delivery is recorded, as well as information on contacts with social care 
or health professionals from a patient diary. 
 
The women’s satisfaction is assessed through two questionnaires, one at one week and one at six 
months after delivery, and through focus group interviews in a subset of randomised women. 
 
For the babies a neonatal examination is carried out. A cranial ultrasound is performed within one 
month of birth. At two years of age, the development of the child is assessed in a follow up visit. 
 
1.4. SAMPLE SIZE AND 
POWER 
 
The study was originally designed to have a sample size of 750 (375 per group). Due to slow 
recruitment, the inclusion criteria were modified to allow women at lower risk of preterm birth (but 
still with potential to benefit from the intervention) into the study. This required an increase in 
sample size. Both sample size calculations are described below. 
 
1.4.1. ORIGINAL CALCULATION 
 
A sample size of 750 (375 per group) gives adequate statistical power to detect clinically important 
and plausible differences in the three primary measures of outcome. All these power calculations 
allow for loss to follow up rates (5% at delivery and 10% at 2 years) and suboptimal compliance. 
 
Primary  Obstetric  Outcome:  The  primary  obstetric  outcome  is  delivery  before  34+0   weeks 
gestation. On placebo, this is expected to be 40% (data from an untreated high risk UK population 
with a positive fFN test at 22 weeks22) and 27% on progesterone consistent with the odds ratio of 
0.45 for the overall PTB with any progestational agent.23 With 750 randomised, the study will have 
95% power at a 5% level of significance to detect such a reduction from 40% to 27% using a two-
sided binomial test. For a more modest reduction from 40% to 30% (odds ratio 0.64) the study 
would still have 80% power. 
 
Primary  Neonatal Outcome:  The primary neonatal outcome is  a composite of death, severe 
chronic lung disease, and intraventricular haemorrhage and also includes non-haemorrhagic brain 
injuries. With n=750 randomised, the OPPTIMUM study would have 80% power at a 5% level of 
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significance to detect a difference in this composite outcome of death, brain damage, or chronic 
lung disease from 20 to 12%, using a binomial test. 
 
Primary Childhood Outcome: The primary childhood outcome is the Bayley III Cognitive Scale 
at 2 years. With 750 randomised, the study will have 93% power at a 5% level of significance to 
detect a difference in means equivalent to 0.25 of a standard deviation, using a two sample two 
sided t-test. Based on previous work24, we estimate the standard deviation will be
about 15 points, enabling us to detect a difference of 4 points in the Bayley Score. In clinical terms, 
a difference of 4 points is small, thus the power of the study to detect larger, more clinically 
significant differences, is high. 
 
1.4.2. REVISED CALCULATION 
 
The following calculations are based on recruiting 1250 women, where 400 are classified as high 
risk (i.e. meet the original entry criteria of having a positive fFN test at 22+0-24+0 weeks gestation, 
plus satisfying the screening phase entry criteria), and 850 are classified as low risk (i.e. a previous 
spontaneous preterm birth before 34+0 weeks gestation or a cervical length of 25mm or less between 
18+0 and 24+0 weeks gestation in the current pregnancy, with a negative fFN test  at 22 weeks). 
 
Primary  Obstetric  Outcome:  The  following  table  gives  the  estimated  power  for  different 
combinations of sample sizes, all assuming that the proportion of high risk women will be one third 
of the study population and assuming a relative treatment effect of 32.5%. 
 
Event rate Power for total number of subjects of 
High risk Low risk  1125 1200 1275 
40% 10%  81% 83% 85% 
45% 13%  88% 90% 92% 
      50%        15%        93%       94%        95%         
 
The assumed outcome rates in the placebo group were conservative estimates, based on a blinded 
data review. 
 
Primary Neonatal Outcome: Assuming that in the placebo group, the primary neonatal outcome 
(neonatal death, severe chronic lung disease, intraventricular haemorrhage) rate is 25% in the high 
risk group and 8% in the low risk group, then the overall outcome rate will be 13.67%. A sample 
size of 1125 women will have 81% power to detect a reduction in this rate to 8.2% (a relative risk 
of 0.6, as per the original calculation). Under the same assumptions, a sample size of 1200 women 
will have 83% power and a sample size of 1275 will  have 86% power. The assumed outcome rates 
in the placebo group were also based on a blinded data review, though the data at the time were less 
mature than for the primary obstetric outcome. 
 
Primary Childhood Outcome: At the time the power calculation was revised there was no data 
mature on this outcome within OPPTIMUM, as the first babies born had not yet reached two years 
of age. It is more difficult to assess the power convincingly with a mixture of high and low risk 
women on a continuous outcome such as the Bayley Score, since the power calculation requires 
assumptions about not just the anticipated treatment effect but also the assumed variability via the 
standard deviation. If we assume the same 4 unit difference in the high risk and a 4/3 unit difference 
in the low risk group (consistent with the pro-rata rate of delivery <34 weeks), with the same 15 
unit standard deviation, then the study will have 71%, 73% or 76% power if 1125, 1200 or 1275 
women are randomised. However, this is for an unadjusted analysis, and in practice we will adjust 
Table 1 Study power for a variety of sample sizes, and a variety of proporons of women at high and low risk
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for high and low risk group, and a limited number of other baseline covariates strongly related to 
Bayley Score at 2 years (eg gender) as specified in the statistical analysis plan, and this will reduce 
the variability and hence increase the power. For example, if the underlying variability in the lower 
risk group is lower – say halved, at 7.5 units, consistent with a higher proportion having uniformly 
high Bayley Scores since they have no disability – then the approximate power would be 93%, 94% 
or 95%. In practice the reduction in variability by adjusting for both this design variate (high and 
low risk) and additional baseline covariates may be considerably greater, so we are confident that 
the original power on the childhood development outcome will be protected at or above the original 
90% level by randomising at least 1125 subjects. 
 
 
1.5. STUDY POPULATION 
 
The study population are pregnant women who meet all inclusion and none of the exclusion criteria 
listed below and who give written informed consent to participate in the study. 
 
1.5.1. INCLUSION CRITERIA 
 
-    Screening phase: 
 
o At least one of 
    History of PTB or second trimester loss. 
    History of previous preterm premature fetal membrane rupture. 
    Cervical length < 25mm on ultrasound at 18+0-24+0 weeks gestation. 
    Any cervical procedure to treat abnormal smears. 
o Gestation established by scan at 16+0 weeks or earlier. 
o Signed consent form. 
o Aged 16 years or older. 
 
-    Main study: At least one of 
 
o Positive fetal fibronectin (fFN) test at 22+0-24+0 weeks gestation. 
o Previous spontaneous preterm birth before 34+0 weeks gestation. 
o Cervical length < 25mm on ultrasound at 18+0-24+0 weeks gestation. 
 
Depending on which inclusion criteria are met patients are classified as high or low risk as follows: 
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1.5.2. EXCLUSION CRITERIA 
 
-    Known significant structural or chromosomal fetal anomaly. 
-    Known sensitivity, contraindication or intolerance to progesterone (initially including 
peanut allergy, but this criterion has been removed later). 
-    Suspected or proven rupture of the fetal membranes at the time of recruitment. 
-    Multiple pregnancy.
-    Prescription or ingestion of medications known to interact with progesterone. 
-    Women currently prescribed progesterone or who have taken progesterone beyond 18 
weeks gestation. 
 
1.6. STATISTICAL ANALYSIS PLAN 
(SAP) 
 
1.6.1. SAP OBJECTIVES 
 
The objective of this SAP is to describe the statistical analyses to be carried out for the final 
analysis of the OPPTIMUM Study. 
 
Earlier draft versions of the SAP only included analyses relating to birth and neonatal outcomes. It 
has then been decided to have only one SAP for all efficacy and safety analyses. 
 
1.6.2. CURRENT PROTOCOL 
 
The current study protocol at the time of writing is version 15.1, dated 1st  April 2015. Future 
amendments to the protocol will be reviewed for their impact on this SAP, which will be updated 
only if necessary. If no changes are required to this SAP following future amendments to the study 
protocol,  this  will  be  documented  as  part  of  Robertson  Centre  Change  Impact  Assessment 
processes. 
 
Figure 1 Screening inclusion criteria, and risk allocaon according to fFN status
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1.6.3. GENERAL PRINCIPLES 
 
For all variables summarised, the number of available measurements and the number of missing 
values  will  be  given.  Continuous  variables  will  be  summarised  as  mean,  standard  deviation, 
minimum, 1st  quartile, median, 3rd  quartile and maximum. For categorical variables, numbers and 
percentages for all categories will be given. 
 
Baseline  characteristics  will  be  compared  between  patients  with  and  patients  without  missing 
primary outcome variables. 
 
The number of observations used and number of missing values will be reported for all analyses. 
Main analyses will not impute missing values, but multiple imputation strategies will be considered 
as sensitivity analyses. The following predictors will be considered: 
 
Primary obstetric and neonatal outcomes: Previous pregnancy of at least 14 weeks, high/low 
risk, maternal age, sex. Gestational age will not be used to predict the primary neonatal outcome 
since it is assumed to be too closely related. 
 
Primary Childhood outcome: Gestational age, birth weight, Chronic Lung Disease, brain 
injury, previous pregnancy of at least 14 weeks, high/low risk, maternal age, sex. Multiple 
imputation will be repeated not using gestational age, since gestational age is likely to be a 
predictor of the other variables in the model. 
 
As results of generalised linear models, type 3 p-values, effect estimates (in case of a binomially 
distributed outcome odds ratios) and 95% confidence intervals for the effect estimates will be 
reported for each variable in the model. For all generalised linear models the canonical link function 
will be used. 
 
Regression analyses will adjust for previous pregnancy of at least 14 weeks and study centre as a 
random effect. Continuous variables may be transformed to enhance model fit. 
 
In addition, regression analyses adjusting for baseline covariates that are significantly related to the 
outcome in question will be carried out as major secondary analyses. All baseline variables will 
considered for this. The subset of variables related to each outcome will be determined prior to 
unblinding through LASSO retaining all variables with non-zero coefficients. The results of this 
blinded analysis and the resulting sets of adjustment variables will be documented and agreed prior 
to the final unblinded analysis. 
 
The  global  level  of  significance  is  0.05.  The  statistical  report  will  present  p-values  without 
adjustment for multiple comparisons. Given that more than one primary outcome will be analysed, 
the results will also be interpreted with adjustment by the Bonferroni-Holm method [Holm 1979]. 
The analyses of secondary and exploratory outcomes are exploratory, therefore no adjustment will 
be  done.  P-values  other  than  for  the  primary  outcomes  have  to  be  considered  as  descriptive 
measures. 
 
1.6.4. DEVIATIONS TO THE ANALYSES SPECIFIED IN STUDY PROTOCOL 
 
The primary neonatal outcome was defined as death OR (brain injury AND severe chronic lung 
disease) in the study protocol. It has been agreed that the primary neonatal outcome to be analysed 
is death OR brain injury OR severe chronic lung disease. 
 
The protocol states that in the subgroup analyses the significance level will be 0.01. This will not be 
done, as all subgroup analyses are now exploratory. 
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In the protocol it was planned to use two part models for the analysis of the primary childhood 
outcome, the Bayley III scale. Over the course of the study it has been decided to analyse death and 
Bayley III scores separately for the primary analysis, since the interpretation of a combined analysis 
might be difficult. In addition, analyses of each primary outcome will be carried out using multiple 
imputation to account for missing values; in these analyses, Bayley III scores of children who died 
will be imputed as the lowest possible score -1, which is 49. 
 
The protocol mentions that the Child Behavior Check List will be part of the childhood outcomes. 
However, the Child Behavior Check List is not used and therefore not part of the outcomes in this 
SAP. 
 
1.6.5. ADDITIONAL ANALYSES TO THOSE SPECIFIED IN STUDY PROTOCOL 
 
Additional analyses are detailed in section 
2.7. 
 
1.6.6. SOFTWARE 
 
Statistical analyses will be carried out with S-Plus for Windows v8.1, SAS v9.3 or R v3.0.1
or higher versions of those programs. 
 
2. ANALYSIS 
 
2.1. STUDY 
POPULATIONS 
 
All efficacy analyses will be carried out on the intention to treat population. Safety analyses will be 
carried out on the safety population. Primary analyses will be repeated exploratorily on the per 
protocol population. 
 
2.1.1. POPULATION DEFINITIONS 
 
Screening population: All women who have been screened for the trial and consented to the 
fFN test. 
 
Safety population: All women and children who were randomised and have been exposed to the 
study drug at least once according to the patient diary or the number of doses returned. The women 
will be grouped according to treatment received for the safety analyses. 
 
Intention to treat (ITT) population: All women and children who were randomised and did not 
fail any inclusion/exclusion criteria. 
 
Per protocol (PP) population: All members of the ITT population without any major protocol 
violations  and  for  whom  there  is  sufficient  evidence  of  adequate  treatment  compliance.  The 
following predefined protocol violations will be considered: 
 
-    Structural or chromosomal fetal anomaly discovered after inclusion. 
-    Multiple pregnancy discovered after inclusion. 
-    Patient has ingested medications known to interact with progesterone. 
-    Any other reported potential protocol violations. 
 
Other protocol violations may be identified during blinded data reviews prior to the final analyses. 
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2.1.2. SUBGROUPS 
 
In order to determine whether a reduced or improved response to progesterone can be predicted, 
subgroups of the ITT population will be formed according to the following factors (ordered from 
most important to least important): 
 
1.  Risk group (high risk / low risk). 
 
2.  Cervical length at 18-24 weeks gestation (≤25mm / >25mm and ≤15mm / >15mm). 
 
3.  Reason for risk of preterm delivery. 
 
a.   Spontaneous preterm birth (yes / no). 
b.  Any preterm birth (yes / no). 
4.  Chorioamnionitis diagnosed on pathology (yes / no). 
 
5.  Previous pregnancy of at least 14 weeks (yes / no). 
 
2.1.3. PATIENT NUMBERS 
 
The number of women in the following groups will be reported for the whole study and separately 
for each study site: 
 
-    Screened women. 
-    Women in the safety population. 
-    Women in the ITT population. 
-    Women in the PP population. 
 
Further, the number of women excluded in each step will be reported according to the different 
reasons for exclusion. 
 
2.2. INCLUSION 
CRITERIA 
 
The following inclusion criteria will be summarised for all patients, for subgroups according to 
treatment groups and for subgroups according to missingness of primary outcome variables for each 
outcome: 
 
-    History of delivery / pregnancy loss at 16 or more and less than 37 weeks gestation. 
 
-    Previous preterm premature rupture of fetal membranes before or at 37 weeks gestation. 
 
-    Cervical length <25mm on ultrasound at 18+0 to 24+0 gestation. 
 
-    Any cervical procedure to treat abnormal smears. 
 
-    Positive fetal fibronectin test at 22–24 weeks gestation. 
 
-    Negative fetal fibronectin test at 22+0 to 24+0 weeks gestation and previous 
spontaneous preterm birth before or at 34 weeks gestation. 
 
-    Negative fetal fibronectin test at 22+0 to 24+0 weeks gestation and cervical length ≤ 
25mm between 18 and 24 weeks gestation in index pregnancy. 
 
All other inclusion criteria have to be met by all women in the ITT population and will therefore not 
be summarised. 
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2.3. BASELINE 
CHARACTERISTICS 
 
The following baseline variables will be summarised for all patients, for subgroups according to 
treatment groups and for subgroups according to missingness of primary outcome variables for each 
outcome: 
 
-    Age at trial entry as (date of trial entry – date of birth)/365.25 
-    Height 
-    Weight (earliest recorded during this pregnancy) 
-    BMI=weight [kg]/(height[m])2 
-    Smoking at baseline (yes/no) 
-    Alcohol at baseline (yes/no) 
-    Drug use at baseline (yes/no) 
-    Level of education 
-    Ethnic group (White / Asian / Afro-Caribbean / Oriental / Mixed / other) 
-    Systolic blood pressure 
-    Diastolic blood pressure 
-    Week of gestation at inclusion calculated from EDD from scan 
-    Result of fetal anomaly scan (normal / defined abnormality / uncertain abnormality /  
not done) 
-    Amniocentesis (normal / not normal / not done) 
-    CVS (normal / not normal / not done) 
-    Cervical length at 18-24 weeks gestation 
-    Number of live births 
-    Total number of pregnancies 
-    History of induced labour or elective caesarean. 
-    History of miscarriage. 
-    History of ectopic pregnancy. 
-    History of TOP before 14 weeks gestation. 
-    History of TOP at or after 14 weeks gestation. 
-    History of still birth. 
 
-    History of live birth followed by neonatal death. 
-    History of spontaneous preterm birth with premature membrane rupture. 
-    History of spontaneous preterm birth without premature membrane rupture. 
-    History of elective or induced preterm birth. 
-    EQ-5D 
 
2.4. EFFICACY 
OUTCOMES 
 
All outcome variables will be summarised for all patients and according to treatment groups. 
 
2.4.1. PRIMARY OUTCOME 
 
OBSTETRIC OUTCOME 
 
The primary obstetric outcome is delivery or fetal death before 34 completed weeks of gestation 
based on ultrasound (based on the projected date of delivery estimated from scan in the first 
trimester). 
 
DOI: 10.3310/hta22350 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 35
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Norman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
77
 12 
The following null hypothesis will be tested: 
 
There is no difference in the incidence of delivery or fetal death before 34 completed weeks of 
gestation between the group treated with 200mg / day progesterone and the group treated with 
placebo from week 22-24 to week 34 of gestation or earlier delivery. 
 
The outcome will be compared between the treatment groups using a logistic regression model 
including treatment and previous pregnancy of at least 14 weeks. The hypothesis will be tested with 
a likelihood ratio test. 
 
NEONATAL OUTCOME 
 
The primary neonatal outcome is a binary outcome indicating whether one of the following has 
occurred: 
 
-    Death at any time point, i.e. miscarriage, stillbirth or neonatal death. 
 
-    Brain  injury  (defined  as  any  intraventricular  haemorrhage  (IVH)  (excludes  
subependymal haemorrhages), parenchymal cystic or haemorrhagic lesion or persistent 
ventriculomegaly (VI 
>97th percentile). If no scan has been carried out, it is assumed that there is no brain injury. 
 
-    Severe  chronic  lung  disease  (defined  as  need  for  ≥30%  oxygen  and/or  positive  
pressure (positive pressure ventilation or nasal continuous positive airway pressure) at 36  
weeks post menstrual age or discharge, which ever comes first). 
 
The following null hypothesis will be tested: 
 
There is no difference in the combined incidence of neonatal death, brain injury or severe chronic 
lung disease between the group treated with 200mg / day progesterone and the group treated with 
placebo from week 22-24 to week 34 or earlier delivery. 
 
This outcome will also be compared between the treatment groups using a logistic regression model 
including treatment and previous pregnancy of at least 14 weeks. The hypothesis will be tested with 
a likelihood ratio test. 
 
CHILDHOOD OUTCOME 
 
The primary childhood outcome is the Bayley III Cognitive Scale standardised score at 2 years  (22 
to 26 months) of age. As the number of deaths at any point between randomisation and 2 years of 
age is expected to be sufficiently large as not to be negligible, survival up to 2 years will also be an 
outcome. 
 
The following null hypotheses will be tested: 
 
There is no difference in Bayley III cognitive scale standardised scores at 2 years of age between 
the group treated with 200mg / day progesterone and the group treated with placebo from week 22- 
24 to week 34 or earlier delivery. 
 
There is no difference in survival up to 2 years between the group treated with 200mg / day 
progesterone and the group treated with placebo from week 22-24 to week 34 or earlier delivery.  
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The first outcome will be compared between the treatment groups using a linear regression model 
including treatment and previous pregnancy of at least 14 weeks. The hypothesis will be tested with 
a likelihood ratio test. 
 
The second outcome will be compared between the treatment groups using a logistic regression 
model including treatment and previous pregnancy of at least 14 weeks. The hypothesis will be 
tested with a likelihood ratio test. 
 
2.4.2. SECONDARY OUTCOMES 
 
Secondary outcomes  are: 
 
-    Obstetric: 
 
o Fetal death, i.e. miscarriage or stillbirth 
o Delivery before 34 completed weeks of pregnancy 
 
-    Birth and neonatal: 
 
o Gestational age at delivery. 
o Neonatal death 
o Incidence of the individual components of the primary neonatal outcome (death, 
brain injury, severe chronic lung disease). 
o Need for surfactant administration. 
o Incidence of necrosing entercolitis (no and suspected vs. yes, medical treatment only 
and yes, required drain or laparotomy). 
o Number of discrete episodes of bloodstream or CNS infection (e.g. positive blood or 
CSF culture). 
o Daily level of care after delivery room (normal / special / level 2 / level 1). 
o Maternal and child serious adverse events during pregnancy and birth. (Yes if either 
mother or child had at least one serious adverse event, else no) 
 
-    Childhood (2 years of age) 
 
o Composite outcome of death or moderate/severe neurodevelopmental impairment 
(as defined by BAPM/RCPCH working group, Jan 2008). 
 
o Moderate/severe  neurodevelopmental  impairment  (as  defined  by  BAPM/RCPCH 
working group, Jan 2008). 
o Individual components of disability (motor, cognitive function, hearing, speech 
and language, vision, respiratory, gastrointestinal, renal, as defined by  
BAPM/RCPCH working group, Jan 2008). 
o Medical events during follow-up 
o Behavioural outcome at 2 years assessed in parent questionnaire 
 
-    Change in EQ-5D from baseline 
-    Women’s perception of treatment. 
 
All secondary outcomes will be compared between treatment groups through generalised mixed 
linear regression analyses including treatment and adjusting for previous pregnancy of at least 14 
weeks and a random effect for centre. 
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2.5. SAFETY 
OUTCOMES 
 
2.5.1. TREATMENT COMPLIANCE 
 
Patients are supposed to record on what days they took the study medication in the patient diary. In 
addition, medication packs will be reviewed. The number of doses of study medication taken will 
be recorded by the midwife in an interview with the patient, based on the information in the diary 
and the returned medication packs. 
 
One dose of study medication should be taken daily from the date of randomisation until the start of 
labour or 6 weeks prior to the expected date of delivery (EDD), which ever comes first. The 
expected number of doses of study medication is then 
 
min( Date of membrane rupture, EDD - 6 weeks ) - Date of randomisation 
 
Compliance will be calculated as the ratio of the number of doses of study medication used, divided 
by the expected number of doses for each patient, expressed as a percentage. Compliance will be 
summarised for all women and separately for both treatment groups. 
 
Patients are considered to be adequately compliant if they have taken the medication on at least 
80% of the days they should have taken it. 
 
2.5.2. PREMATURE WITHDRAWAL 
 
The following details on premature withdrawals will be summarised according to treatment groups: 
 
-    Number of women who stopped treatment 
-    Main reason for discontinuation. 
o Woman unwilling to continue 
o Severe adverse event 
o Detection of significant structural chromosomal anomalies after randomisation 
o Woman violated protocol 
o Sponsor terminated participation 
o Investigator terminated participation 
o Woman withdrawn consent for use of outcome data 
o Elective (preterm) delivery 
o Fetal membrane rupture
o Symptomatic placenta praevia 
o Other reason 
 
2.5.3. ADVERSE EVENTS 
 
All serious adverse events, including intrauterine infections or chorioamnionitis, occurring during 
the study will be listed individually. Listings will include the system organ class and preferred term 
according to the MedDRA system, the date of onset, the date the adverse event ended, the intensity 
of the adverse event, relationship to study medication, medication taken in relation to the serious 
adverse event (for details see section on concomitant medications), and the outcome. 
 
Serious adverse events will be summarised as the number and percentage of subjects reporting at 
least  one  event  by  system  organ  class,  preferred  term,  intensity,  and  relationship  to  study 
medication for each treatment group. 
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The same serious adverse event recorded by a patient at different visits will count as one event for 
that patient, with the strongest reported intensity and relationship to study medication. 
 
Data on non-serious adverse events is not collected in this study. 
 
2.5.4. CONCOMITANT MEDICATIONS 
 
Only  medications  in  relation  with  serious  adverse  events  are  recorded.  These  will  be  listed 
individually, including drug name, start date, stop date, dose, frequency and the SAE they’re linked 
to. 
 
2.5.5. OTHER SAFETY OUTCOMES 
 
The following safety outcomes will be summarised according to treatment groups: 
Pregnancy complications 
Hospital admissions before Delivery: 
-    Indication 
-    Diagnosis 
-    Duration of hospital stay 
-    Tocolysis and details thereof 
-    Steroid therapy 
-    Antibiotic therapy 
-    Treatment with magnesium sulphate 
 
Labour 
-    Type of labour (Spontaneous / Induced) or Elective CS 
-    Duration of stages of labour 
-    Details of membrane rupture 
-    Analgesics 
 
Delivery 
-    Delivery method 
-    Reason for assisted delivery 
-    Blood loss 
-    Suture 
-    Reason for suture 
-    Blood transfusion 
-    Antibiotics 
-    Surgical procedure required 
-    Duration of hospital stay 
 
Results  of  the  placental  examination  (classified  as  “normal”,  “ascending  infection”  or  “other 
pathology”) 
 
Post partum complications 
 
Child assessment at birth 
-    Sex 
-    Weight 
-    Apgar score at 1 minute 
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-    Apgar score at 5 minutes 
-    Duration of hospital stay 
 
Child assessment at 2 years 
-    Weight 
-    Height 
-    Head circumference 
-    Respiratory rate 
-    Heart rate 
-    Blood pressure 
 
2.6. SUBGROUP 
ANALYSES 
 
The analyses of the primary outcomes will be repeated on the subgroups of patients defined in 
section 2.1 in an exploratory manner. 
 
In addition, the effect of the subgroup variables on outcome will be analysed through logistic 
regression models. Logistic regression will be carried out in one model including the subgroup 
variable  and  treatment  and  a  second  model  additionally including  the  interaction  term  of  the 
subgroup variable and treatment. 
 
2.7. ADDITIONAL 
ANALYSES 
 
Additional analyses to those specified in this SAP based on the results of the primary and secondary 
analyses may be carried out at a later stage where appropriate. Any additional analyses will be 
documented separately as appropriate. The following additional analyses are planned at this stage. 
 
2.7.1. SURVIVAL ANALYSIS 
 
The possibility of analysing survival from randomisation up to two years using proportional hazards 
regression as a supplemental analysis to the primary childhood outcome will be explored. 
 
2.7.2. RISK FACTOR MODEL 
 
The possibility of creating a  risk  prediction  model  for the primary obstetric outcome  will  be 
explored. Variables considered for the risk prediction model will be those related to the primary 
obstetric outcome identified as explained in section 1.6.3. Logistic regression will be used in the 
first place to derive a risk score, but the use of other methods may be explored. The predictive 
performance of the resulting risk score will be assessed. 
 
3. DOCUMENT HISTORY 
 
This is version 1.1 of the SAP for the OPPTIMUM study, dated 16th  November 2011, replacing 
v1.0, dated 01st  September 2010. It is based on version 13 of the study protocol. The following 
changes have been made: 
 
inclusion criteria have been modified to allow inclusion of women with a negative fFN test 
at 22 weeks gestation (Section 1.5.1). 
Added definition of high/low risk group to inclusion criteria section. 
sample size calculations for the modified study have been added (Section 1.4). 
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more explicit reference has been made to the current protocol version (Section 1.6.2). 
Details about adjusted analyses of the primary outcomes added (Section 1.6.3). 
Details about imputation of missing values added (Section 1.6.3). 
Change of primary neonatal outcome added to deviations section (Section 1.6.4). 
Section about primary childhood analysis added to deviations section (Section 1.6.4). 
Population definitions updated (Section 2.1.1). 
Added hierarchy to subgroup analyses (Section 2.1.2). 
 
Added list of inclusion criteria that will be summarised, i.e. those where not all of them 
need to be met (section 2.2). 
Lists of outcomes updated (Sections 2.4 and 2.5). 
Section about additional analyses added (Section 2.7). 
Risk factor model has been moved into the additional analyses section. 
Sample tables have been removed (Section 4). 
Introduction updated to reflect current literature. 
 
4. TABLES 
 
The layout of the tables will be agreed based on tables created using dummy treatment codes prior 
to database lock. 
 
5. LISTINGS 
Listing 1: Serious Adverse Events. 
Listing 2: Listing of 
coconcomitant 
medications in relation 
to serious adverse 
events.
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Appendix 3 Statistical analysis output
Part 1: patient numbers
Does progesterone prophylaxis to prevent preterm labour improve outcome?
OPPTIMUM
Final report tables
Part 1: patient numbers
v1.1
20 November 2015
Martina Messow
Robertson Centre for Biostatistics
EudraCT number 2007-007950-77
CTA number 22931/0009/001-0001 revised by MHRA to 01384/0208/001
MREC number 08/MRE00/6
ISRCTN ISRCTN14568373
Co-sponsors University of Edinburgh/NHS Lothian
Funder Medical Research Council/NIHR EME
Funding reference number G0700452, Grant No: 84982 – 09/800/27
Protocol version 15.1 (1 April 2015)
SAP version 1.1 (8 September 2015)
CTA, Clinical Trial Authorisation; EudraCT, European Union Drug Regulating Authorities Clinical Trials; MREC, Multicentre
Research Ethics Committee; SAP, statistical analysis plan.
TABLE 24 Number of patients in each population (screening, ITT, safety and PP), overall and by treatment group
Population All Placebo Progesterone
Screening, n 15,132 – –
Randomised (% of screened), n (%) 1228 (8.1) 610 618
ITT (% of randomised), n (%) 1226 (99.8) 610 (100.0) 616 (99.7)
Safety (% of randomised), n (%) 1183 (96.3) 590 (96.7) 593 (96.0)
PP (% of ITT), n (%) 687 (56.0) 360 (59.0) 327 (53.1)
Note
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TABLE 25 Number of patients in each population (screening, ITT, PP and safety), by study site
Site
Population (n)
Screening ITT PP Safety
Ealing Hospital 77 3 2 3
University Hospital of Coventry, Warwickshire 448 20 5 20
Guy’s & St Thomas’ Hospital (KCL), London 959 165 71 149
Queen Charlotte’s Maternity, London 212 35 11 34
Birmingham Women’s Hospital 324 60 32 59
City Hospital, Nottingham 253 23 12 20
St Mary’s Hospital, London 138 32 18 29
Wansbeck General Hospital 149 10 4 10
Ninewell’s Hospital, Dundee 101 0 0 0
St Mary’s Hospital, Manchester 227 14 12 13
Liverpool Women’s Hospital 382 23 11 23
Royal Derby Hospital 130 9 5 9
Warrington Hospital 193 14 9 13
Princess Anne Hospital, Southampton 57 16 6 14
Edinburgh Royal Infirmary 259 41 15 41
Pilgrim Hospital 62 7 2 7
Royal Victoria Hospital, Newcastle 558 50 30 49
Aberdeen Maternity Hospital 63 11 7 9
Bradford Royal Infirmary 256 21 14 19
Worcester Royal Hospital 190 14 7 14
Royal Devon and Exeter 303 6 3 5
Pembury Hospital 3 1 1 1
University Hospital Wales/Llandough Hospital, Cardiff 261 23 13 23
University College Hospital, London 587 51 27 48
North Staffordshire Hospital 251 14 7 14
Wirral Hospital Trust 184 31 24 30
Cumberland Infirmary, Carlisle 27 0 0 0
Queen’s Medical Centre, Nottingham 357 21 12 21
Brighton & Sussex University Hospitals NHS Trust 12 6 5 6
Heart of England Hospital 122 24 12 23
Lincoln County Hospital 97 2 0 2
Forth Park Hospital, Fife 34 7 5 7
South Tyneside NHS Foundation Trust 115 6 1 6
Royal Preston Hospital 604 44 31 44
Isle of Wight NHS Trust 261 21 17 21
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TABLE 25 Number of patients in each population (screening, ITT, PP and safety), by study site (continued )
Site
Population (n)
Screening ITT PP Safety
Calderdale Royal Hospital 50 0 0 0
Royal Hospital 52 7 4 7
Blackpool Victoria Hospital 393 13 10 13
Southport & Ormskirk NHS Trust 355 9 5 9
Burnley General Hospital 615 25 13 25
Queen Elizabeth Hospital, Gateshead 171 3 2 3
Royal Blackburn Hospital 924 9 5 8
Southern General Hospital 185 5 5 5
Derriford Hospital, Plymouth 284 12 6 12
The Ulster Hospital 10 1 0 1
West Cumberland Infirmary 49 6 3 6
Basingstoke & North Hampshire Foundation Trust 70 15 2 14
Lancaster, Morecambe and Furness 245 21 13 21
Chesterfield Royal Hospital 441 10 7 10
Chelsea & Westminster Hospital 53 14 8 14
Royal Cornwall 53 12 10 12
Royal Bolton Hospital 106 7 4 7
Royal Shrewsbury Hospital 182 3 2 3
Wishaw General Hospital 91 18 16 18
Basildon & Thurrock University Hospital 57 12 8 12
St George’s Hospital London 177 12 9 11
South Warwickshire NHS Trust 317 5 2 5
West Middlesex University Hospital 172 25 12 25
The Dudley Group of Hospitals 340 14 9 14
Burton Hospitals NHS Foundation Trust 407 35 29 36
Norfolk & Norwich University Hospitals 86 24 15 24
Newham Hospital 14 6 3 5
City Hospitals Sunderland NHS Foundation Trust 663 58 36 57
Leighton Hospital, Mid-Cheshire 306 13 12 13
Sahlgrenska University 8 7 6 7
KCL, King’s College London.
Note
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Part 2: baseline characteristics
Does progesterone prophylaxis to prevent preterm labour improve outcome?
OPPTIMUM
Final report tables
Part 2: baseline characteristics
v1.0
2 October 2015
Martina Messow
Robertson Centre for Biostatistics
EudraCT number 2007-007950-77
CTA number 22931/0009/001-0001 revised by MHRA to 01384/0208/001
MREC number 08/MRE00/6
ISRCTN ISRCTN14568373
Co-sponsors University of Edinburgh/NHS Lothian
Funder Medical Research Council/NIHR EME
Funding reference number G0700452, Grant No: 84982 – 09/800/27
Protocol version 15.1 (1 April 2015)
SAP version 1.1 (8 September 2015)
CTA, Clinical Trial Authorisation; EudraCT, European Union Drug Regulating Authorities Clinical Trials; MREC, Multicentre
Research Ethics Committee; SAP, statistical analysis plan.
TABLE 26 Inclusion criteria at randomisation: ITT population
Inclusion criteria at randomisation All
Trial group
Placebo Progesterone
History of delivery/pregnancy loss at ≥ 16 and < 37 weeks’ gestation
Nobs (Nmiss) 1225 (1) 610 (0) 615 (1)
No, n (%) 118 (9.6) 61 (10.0) 57 (9.3)
Yes, n (%) 1107 (90.4) 549 (90.0) 558 (90.7)
Previous preterm premature rupture of fetal membranes ≤ 37 weeks’ gestation
Nobs (Nmiss) 1225 (1) 610 (0) 615 (1)
No, n (%) 581 (47.4) 312 (51.1) 269 (43.7)
Yes, n (%) 644 (52.6) 298 (48.9) 346 (56.3)
Cervical length of ≤ 25mm on ultrasound at 18+0–24+0 weeks’ gestation
Nobs (Nmiss) 1225 (1) 610 (0) 615 (1)
No, n (%) 1000 (81.6) 506 (83.0) 494 (80.3)
Yes, n (%) 225 (18.4) 104 (17.0) 121 (19.7)
Any cervical procedure to treat abnormal smears
Nobs (Nmiss) 1196 (30) 594 (16) 602 (14)
No, n (%) 1000 (83.6) 502 (84.5) 498 (82.7)
Yes, n (%) 196 (16.4) 92 (15.5) 104 (17.3)
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TABLE 26 Inclusion criteria at randomisation: ITT population (continued )
Inclusion criteria at randomisation All
Trial group
Placebo Progesterone
Positive fFN test at 22–24 weeks’ gestation
Nobs (Nmiss) 1225 (1) 610 (0) 615 (1)
No, n (%) 882 (72.0) 430 (70.5) 452 (73.5)
Yes, n (%) 343 (28.0) 180 (29.5) 163 (26.5)
Negative fFN test at 22–24 weeks’ gestation and previous spontaneous preterm birth before ≤ 34 weeks’ gestation
Nobs (Nmiss) 1175 (51) 585 (25) 590 (26)
No, n (%) 337 (28.7) 179 (30.6) 158 (26.8)
Yes, n (%) 838 (71.3) 406 (69.4) 432 (73.2)
Negative fFN test at 22–24 weeks’ gestation and cervical length of ≤ 25mm between 18 and 24 weeks’ gestation in index
pregnancy
Nobs (Nmiss) 1175 (51) 585 (25) 590 (26)
No, n (%) 1057 (90.0) 532 (90.9) 525 (89.0)
Yes, n (%) 118 (10.0) 53 (9.1) 65 (11.0)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 02 14:33:54 2015.
TABLE 27 Baseline characteristics (part 1). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by treatment
Parameter All
Trial group
Placebo Progesterone
Age (years)
Nobs (Nmiss) 1225 (1) 610 (0) 615 (1)
Mean (SD) 31.4 (5.7) 31.4 (5.8) 31.5 (5.6)
Median (IQR) 31.5 (27.4–35.7) 31.4 (27.2–35.7) 31.5 (27.6–35.6)
Range 16.8–49.2 17.5–49.2 16.8–45.9
Height (cm)
Nobs (Nmiss) 1221 (5) 607 (3) 614 (2)
Mean (SD) 163.5 (6.6) 163.6 (6.4) 163.5 (6.7)
Median (IQR) 163.0 (159.0–168.0) 163.0 (159.0–168.0) 164.0 (159.0–168.0)
Range 144.0–183.0 144.0–183.0 147.0–183.0
Weight (kg)
Nobs (Nmiss) 1221 (5) 607 (3) 614 (2)
Mean (SD) 71.6 (17.1) 71.4 (16.7) 71.9 (17.5)
Median (IQR) 68.0 (60.0–81.0) 68.0 (59.0–82.0) 68.0 (60.0–80.0)
Range 41.0–186.0 43.0–145.0 41.0–186.0
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TABLE 27 Baseline characteristics (part 1). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by treatment (continued )
Parameter All
Trial group
Placebo Progesterone
BMI (kg/m2)
Nobs (Nmiss) 1221 (5) 607 (3) 614 (2)
Mean (SD) 26.8 (6.3) 26.7 (6.1) 26.9 (6.4)
Median (IQR) 25.5 (22.3–29.8) 25.4 (22.2–29.7) 25.6 (22.5–29.8)
Range 15.2–80.5 15.6–54.4 15.2–80.5
Systolic blood pressure (mmHg)
Nobs (Nmiss) 1219 (7) 608 (2) 611 (5)
Mean (SD) 111.9 (12.4) 112.4 (12.2) 111.3 (12.5)
Median (IQR) 110.0 (102.0–120.0) 110.0 (104.0–120.0) 110.0 (100.0–120.0)
Range 78.0–189.0 78.0–159.0 82.0–189.0
Diastolic blood pressure (mmHg)
Nobs (Nmiss) 1219 (7) 608 (2) 611 (5)
Mean (SD) 66.0 (8.6) 66.2 (8.6) 65.7 (8.5)
Median (IQR) 65.0 (60.0–71.0) 66.0 (60.0–71.0) 64.0 (60.0–70.0)
Range 40.0–104.0 41.0–104.0 40.0–98.0
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; O Level, ordinary level;
PG, postgraduate; SD, standard deviation.
Note
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TABLE 28 Baseline characteristics (part 2). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by treatment
Parameter All
Trial group
Placebo Progesterone
Smoking
Nobs (Nmiss) 1220 (6) 607 (3) 613 (3)
No, n (%) 984 (80.7) 482 (79.4) 502 (81.9)
Yes, n (%) 236 (19.3) 125 (20.6) 111 (18.1)
Alcohol consumption
Nobs (Nmiss) 1223 (3) 609 (1) 614 (2)
No, n (%) 1160 (94.8) 575 (94.4) 585 (95.3)
Yes, n (%) 63 (5.2) 34 (5.6) 29 (4.7)
Drug use
Nobs (Nmiss) 1223 (3) 609 (1) 614 (2)
No, n (%) 1206 (98.6) 600 (98.5) 606 (98.7)
Yes, n (%) 17 (1.4) 9 (1.5) 8 (1.3)
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TABLE 28 Baseline characteristics (part 2). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by treatment (continued )
Parameter All
Trial group
Placebo Progesterone
In full-time education
Nobs (Nmiss) 1216 (10) 607 (3) 609 (7)
No, n (%) 1175 (96.6) 590 (97.2) 585 (96.1)
Yes, n (%) 41 (3.4) 17 (2.8) 24 (3.9)
Years in full-time education
Nobs (Nmiss) 1122 (53) 568 (22) 554 (31)
Mean (SD) 13.5 (3.1) 13.5 (3.0) 13.5 (3.1)
Median (IQR) 13.0 (11.0–16.0) 13.0 (11.0–16.0) 13.0 (11.0–16.0)
Range 1.0–31.0 1.0–31.0 1.0–31.0
Educated in the UK
Nobs (Nmiss) 1206 (20) 602 (8) 604 (12)
No, n (%) 211 (17.5) 109 (18.1) 102 (16.9)
Yes, n (%) 995 (82.5) 493 (81.9) 502 (83.1)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 29 Baseline characteristics (part 3). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by treatment
Parameter All
Trial group
Placebo Progesterone
Highest level of education if in the UK
Nobs (Nmiss) 975 (20) 488 (5) 487 (15)
No formal qualifications, n (%) 99 (10.2) 56 (11.5) 43 (8.8)
Entry Level Certificate/Foundation
Diploma, n (%)
13 (1.3) 6 (1.2) 7 (1.4)
GCSE/Standard/O Level, n (%) 327 (33.5) 164 (33.6) 163 (33.5)
A Level, AS Level, Highers or BTEC
Diploma/Certificate, n (%)
137 (14.1) 70 (14.3) 67 (13.8)
Certificate of Higher Education/
City & Guilds, n (%)
53 (5.4) 25 (5.1) 28 (5.7)
Diploma HE/FE or HND/HNC, n (%) 69 (7.1) 33 (6.8) 36 (7.4)
Graduate certificate or diploma,
n (%)
14 (1.4) 10 (2.0) 4 (0.8)
Degree, n (%) 158 (16.2) 72 (14.8) 86 (17.7)
continued
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TABLE 29 Baseline characteristics (part 3). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by treatment (continued )
Parameter All
Trial group
Placebo Progesterone
Professional qualifications, n (%) 40 (4.1) 19 (3.9) 21 (4.3)
PG certificate, diploma, masters,
doctorate, n (%)
65 (6.7) 33 (6.8) 32 (6.6)
Ethnic group
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
White, n (%) 895 (73.1) 446 (73.2) 449 (73.0)
Chinese, n (%) 1 (0.1) 1 (0.2) 0 (0.0)
Other ethnic group, n (%) 17 (1.4) 5 (0.8) 12 (2.0)
Mixed
White and black Caribbean, n (%) 17 (1.4) 8 (1.3) 9 (1.5)
White and black African, n (%) 3 (0.2) 0 (0.0) 3 (0.5)
White and Asian, n (%) 2 (0.2) 1 (0.2) 1 (0.2)
Other mixed background, n (%) 6 (0.5) 3 (0.5) 3 (0.5)
Asian
Indian, n (%) 30 (2.5) 16 (2.6) 14 (2.3)
Pakistani, n (%) 45 (3.7) 23 (3.8) 22 (3.6)
Bangladeshi, n (%) 5 (0.4) 4 (0.7) 1 (0.2)
Other Asian background, n (%) 23 (1.9) 7 (1.1) 16 (2.6)
Black
Caribbean, n (%) 47 (3.8) 27 (4.4) 20 (3.3)
African, n (%) 119 (9.7) 59 (9.7) 60 (9.8)
Other black background, n (%) 14 (1.1) 9 (1.5) 5 (0.8)
Ethnic group
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
White, n (%) 895 (73.1) 446 (73.2) 449 (73.0)
Black, n (%) 180 (14.7) 95 (15.6) 85 (13.8)
Asian, n (%) 104 (8.5) 51 (8.4) 53 (8.6)
Mixed, n (%) 28 (2.3) 12 (2.0) 16 (2.6)
Other, n (%) 17 (1.4) 5 (0.8) 12 (2.0)
A Level, Advanced Level; AS Level, Advanced Subsidiary Level; BTEC, Business and Technology Education Council;
FE, Further Education; GCSE, General Certificate of Secondary Education; HE, Higher Education; HNC, Higher National
Certificate; HND, Higher National Diploma; Nmiss, number of women with missing data; Nobs, number of observations;
O Level, ordinary level; PG, postgraduate.
Note
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TABLE 30 Baseline characteristics (part 4): this pregnancy. Number of observed values, number of missing values,
number and percentage per category or mean, standard deviation, median and quartiles, minimum and maximum
for all patients and by treatment
Parameter All
Trial group
Placebo Progesterone
Gestation (weeks) at fFN test
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
Mean (SD) 22.9 (0.6) 22.9 (0.6) 22.9 (0.6)
Median (IQR) 22.9 (22.4–23.4) 22.9 (22.4–23.4) 22.9 (22.4–23.4)
Range 21.7–27.1 22.0–27.1 21.7–26.6
Fetal anomaly scan done
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 63 (5.1) 34 (5.6) 29 (4.7)
Yes, n (%) 1163 (94.9) 576 (94.4) 587 (95.3)
Fetal anomaly scan result
Nobs (Nmiss) 1163 (0) 576 (0) 587 (0)
Normal, n (%) 1150 (98.9) 569 (98.8) 581 (99.0)
Defined abnormality, n (%) 7 (0.6) 4 (0.7) 3 (0.5)
Uncertain abnormality, n (%) 6 (0.5) 3 (0.5) 3 (0.5)
Amniocentesis done
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 1218 (99.3) 607 (99.5) 611 (99.2)
Yes, n (%) 8 (0.7) 3 (0.5) 5 (0.8)
Results of amniocentesis
Nobs (Nmiss) 8 (0) 3 (0) 5 (0)
Normal, n (%) 8 (100.0) 3 (100.0) 5 (100.0)
Other, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Chorionic villus sampling done
Nobs (Nmiss) 1225 (1) 610 (0) 615 (1)
No, n (%) 1216 (99.3) 607 (99.5) 609 (99.0)
Yes, n (%) 9 (0.7) 3 (0.5) 6 (1.0)
Results of chorionic villus sampling
Nobs (Nmiss) 9 (0) 3 (0) 6 (0)
Normal, n (%) 9 (100.0) 3 (100.0) 6 (100.0)
Other, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
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TABLE 30 Baseline characteristics (part 4): this pregnancy. Number of observed values, number of missing values,
number and percentage per category or mean, standard deviation, median and quartiles, minimum and maximum
for all patients and by treatment (continued )
Parameter All
Trial group
Placebo Progesterone
Cervical length (mm)
Nobs (Nmiss) 712 (514) 351 (259) 361 (255)
Mean (SD) 28.5 (10.8) 28.8 (11.1) 28.2 (10.6)
Median (IQR) 30.0 (22.0–36.0) 30.0 (22.5–36.0) 30.0 (22.0–36.0)
Range 0.0–84.0 0.0–84.0 0.0–58.0
Risk
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
Low, n (%) 882 (71.9) 429 (70.3) 453 (73.5)
High, n (%) 344 (28.1) 181 (29.7) 163 (26.5)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 02 14:33:55 2015.
TABLE 31 Previous pregnancies (part 1). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by treatment
Parameter All
Trial group
Placebo Progesterone
Any previous pregnancy
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 52 (4.2) 28 (4.6) 24 (3.9)
Yes, n (%) 1172 (95.8) 581 (95.4) 591 (96.1)
Number of previous pregnancies
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
Mean (SD) 2.6 (2.0) 2.7 (1.9) 2.6 (2.0)
Median (IQR) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0)
Range 0.0–14.0 0.0–12.0 0.0–14.0
Any previous pregnancy of ≥ 14 weeks’ gestation
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 75 (6.1) 38 (6.2) 37 (6.0)
Yes, n (%) 1149 (93.9) 571 (93.8) 578 (94.0)
Number of previous pregnancies of ≥ 14 weeks’ gestation
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
Mean (SD) 1.9 (1.4) 1.9 (1.4) 1.9 (1.4)
Median (IQR) 2.0 (1.0–2.0) 2.0 (1.0–3.0) 2.0 (1.0–2.0)
Range 0.0–13.0 0.0–10.0 0.0–13.0
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TABLE 31 Previous pregnancies (part 1). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by treatment (continued )
Parameter All
Trial group
Placebo Progesterone
Any previous live birth
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 197 (16.1) 97 (15.9) 100 (16.3)
Yes, n (%) 1027 (83.9) 512 (84.1) 515 (83.7)
Number of previous live births
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
Mean (SD) 1.5 (1.3) 1.6 (1.3) 1.5 (1.3)
Median (IQR) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0)
Range 0.0–13.0 0.0–10.0 0.0–13.0
Any previous pregnancy that ended with baby alive and well
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 646 (52.8) 321 (52.7) 325 (52.8)
Yes, n (%) 578 (47.2) 288 (47.3) 290 (47.2)
Number of previous pregnancies that ended with baby alive and well
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
Mean (SD) 0.8 (1.2) 0.8 (1.2) 0.8 (1.2)
Median (IQR) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0)
Range 0.0–13.0 0.0–10.0 0.0–13.0
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 02 14:33:56 2015.
TABLE 32 Previous pregnancies (part 2). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by treatment
Parameter All
Trial group
Placebo Progesterone
History of induced labour or elective caesarean section
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 1065 (87.0) 524 (86.0) 541 (88.0)
Yes, n (%) 159 (13.0) 85 (14.0) 74 (12.0)
History of miscarriage
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 701 (57.3) 335 (55.0) 366 (59.5)
Yes, n (%) 523 (42.7) 274 (45.0) 249 (40.5)
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TABLE 32 Previous pregnancies (part 2). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by treatment (continued )
Parameter All
Trial group
Placebo Progesterone
History of ectopic pregnancy
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 1193 (97.5) 600 (98.5) 593 (96.4)
Yes, n (%) 31 (2.5) 9 (1.5) 22 (3.6)
History of termination of pregnancy
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 1085 (88.6) 542 (89.0) 543 (88.3)
Yes, n (%) 139 (11.4) 67 (11.0) 72 (11.7)
History of termination of pregnancy before 14 weeks’ gestation
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 1106 (90.2) 554 (90.8) 552 (89.6)
Yes, n (%) 120 (9.8) 56 (9.2) 64 (10.4)
History of termination of pregnancy at ≥ 14 weeks’ gestation
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 1201 (98.0) 596 (97.7) 605 (98.2)
Yes, n (%) 25 (2.0) 14 (2.3) 11 (1.8)
History of live birth followed by neonatal death
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 1059 (86.5) 524 (86.0) 535 (87.0)
Yes, n (%) 165 (13.5) 85 (14.0) 80 (13.0)
History of live birth followed by death other than neonatal
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 1208 (98.7) 604 (99.2) 604 (98.2)
Yes, n (%) 16 (1.3) 5 (0.8%) 11 (1.8)
History of stillbirth
Nobs (Nmiss) 1224 (2) 609 (1) 615 (1)
No, n (%) 1129 (92.2) 561 (92.1) 568 (92.4)
Yes, n (%) 95 (7.8) 48 (7.9) 47 (7.6)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 02 14:33:56 2015.
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TABLE 33 Baseline characteristics (part 1). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of obstetric outcome
Parameter All
Obstetric outcome available
No Yes
Age (years)
Nobs (Nmiss) 1225 (1) 28 (1) 1197 (0)
Mean (SD) 31.4 (5.7) 32.4 (5.2) 31.4 (5.7)
Median (IQR) 31.5 (27.4–35.7) 32.8 (29.1–34.9) 31.4 (27.3–35.7)
Range 16.8–49.2 22.7–41.0 16.8–49.2
Height (cm)
Nobs (Nmiss) 1221 (5) 28 (1) 1193 (4)
Mean (SD) 163.5 (6.6) 165.4 (8.1) 163.5 (6.5)
Median (IQR) 163.0 (159.0–168.0) 166.0 (160.0–170.5) 163.0 (159.0–168.0)
Range 144.0–183.0 147.0–181.0 144.0–183.0
Weight (kg)
Nobs (Nmiss) 1221 (5) 28 (1) 1193 (4)
Mean (SD) 71.6 (17.1) 73.2 (14.5) 71.6 (17.2)
Median (IQR) 68.0 (60.0–81.0) 71.0 (63.5–80.2) 68.0 (59.0–81.0)
Range 41.0–186.0 51.0–113.0 41.0–186.0
BMI (kg/m2)
Nobs (Nmiss) 1221 (5) 28 (1) 1193 (4)
Mean (SD) 26.8 (6.3) 26.8 (5.2) 26.8 (6.3)
Median (IQR) 25.5 (22.3–29.8) 27.1 (22.4–28.8) 25.5 (22.3–29.8)
Range 15.2–80.5 19.9–45.3 15.2–80.5
Systolic blood pressure (mmHg)
Nobs (Nmiss) 1219 (7) 28 (1) 1191 (6)
Mean (SD) 111.9 (12.4) 113.1 (12.8) 111.8 (12.4)
Median (IQR) 110.0 (102.0–120.0) 110.0 (102.0–119.2) 110.0 (102.0–120.0)
Range 78.0–189.0 92.0–150.0 78.0–189.0
Diastolic blood pressure (mmHg)
Nobs (Nmiss) 1219 (7) 28 (1) 1191 (6)
Mean (SD) 66.0 (8.6) 65.9 (10.6) 66.0 (8.5)
Median (IQR) 65.0 (60.0–71.0) 62.0 (60.0–70.5) 65.0 (60.0–71.0)
Range 40.0–104.0 50.0–98.0 40.0–104.0
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 34 Baseline characteristics (part 2). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of obstetric outcome
Parameter All
Obstetric outcome available
No Yes
Smoking
Nobs (Nmiss) 1220 (6) 28 (1) 1192 (5)
No, n (%) 984 (80.7) 21 (75.0) 963 (80.8)
Yes, n (%) 236 (19.3) 7 (25.0) 229 (19.2)
Alcohol consumption
Nobs (Nmiss) 1223 (3) 28 (1) 1195 (2)
No, n (%) 1160 (94.8) 26 (92.9) 1134 (94.9)
Yes, n (%) 63 (5.2) 2 (7.1) 61 (5.1)
Drug use
Nobs (Nmiss) 1223 (3) 28 (1) 1195 (2)
No, n (%) 1206 (98.6) 28 (100.0) 1178 (98.6)
Yes, n (%) 17 (1.4) 0 (0.0) 17 (1.4)
In full-time education
Nobs (Nmiss) 1216 (10) 28 (1) 1188 (9)
No, n (%) 1175 (96.6) 28 (100.0) 1147 (96.5)
Yes, n (%) 41 (3.4) 0 (0.0) 41 (3.5)
Years in full-time education
Nobs (Nmiss) 1122 (53) 28 (0) 1094 (53)
Mean (SD) 13.5 (3.1) 13.5 (3.1) 13.5 (3.1)
Median (IQR) 13.0 (11.0–16.0) 13.0 (11.0–16.2) 13.0 (11.0–16.0)
Range 1.0–31.0 7.0–19.0 1.0–31.0
Educated in the UK
Nobs (Nmiss) 1206 (20) 28 (1) 1178 (19)
No, n (%) 211 (17.5) 8 (28.6) 203 (17.2)
Yes, n (%) 995 (82.5) 20 (71.4) 975 (82.8)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 35 Baseline characteristics (part 3). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of obstetric outcome
Parameter All
Obstetric outcome available
No Yes
Highest level of education if in UK
Nobs (Nmiss) 975 (20) 20 (0) 955 (20)
No formal qualifications, n (%) 99 (10.2) 5 (25.0) 94 (9.8)
Entry Level Certificate/Foundation Diploma,
n (%)
13 (1.3) 0 (0.0) 13 (1.4)
GCSE/Standard/O Level, n (%) 327 (33.5) 8 (40.0) 319 (33.4)
A Level, AS Level, Highers or BTEC
Diploma/Certificate, n (%)
137 (14.1) 1 (5.0) 136 (14.2)
Certificate of Higher Education/City &
Guilds, n (%)
53 (5.4) 0 (0.0) 53 (5.5)
Diploma HE/FE or HND/HNC, n (%) 69 (7.1) 2 (10.0) 67 (7.0)
Graduate certificate or diploma, n (%) 14 (1.4) 0 (0.0) 14 (1.5)
Degree, n (%) 158 (16.2) 4 (20.0) 154 (16.1)
Professional qualifications, n (%) 40 (4.1) 0 (0.0) 40 (4.2)
PG certificate, diploma, masters, doctorate,
n (%)
65 (6.7) 0 (0.0) 65 (6.8)
Ethnic group
Nobs (Nmiss) 1224 (2) 28 (1) 1196 (1)
White, n (%) 895 (73.1) 22 (78.6) 873 (73.0)
Chinese, n (%) 1 (0.1) 0 (0.0) 1 (0.1)
Other ethnic group, n (%) 17 (1.4) 0 (0.0) 17 (1.4)
Mixed
White and black Caribbean, n (%) 17 (1.4) 0 (0.0) 17 (1.4)
White and black African, n (%) 3 (0.2) 0 (0.0) 3 (0.3)
White and Asian, n (%) 2 (0.2) 0 (0.0) 2 (0.2)
Other mixed background, n (%) 6 (0.5) 1 (3.6) 5 (0.4)
Asian
Indian, n (%) 30 (2.5) 1 (3.6) 29 (2.4)
Pakistani, n (%) 45 (3.7) 1 (3.6) 44 (3.7)
Bangladeshi, n (%) 5 (0.4) 0 (0.0) 5 (0.4)
Other Asian background, n (%) 23 (1.9) 0 (0.0) 23 (1.9)
Black
Caribbean, n (%) 47 (3.8) 0 (0.0) 47 (3.9)
African, n (%) 119 (9.7) 3 (10.7) 116 (9.7)
Other black background, n (%) 14 (1.1) 0 (0.0) 14 (1.2)
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TABLE 36 Baseline characteristics (part 4): this pregnancy. Number of observed values, number of missing values,
number and percentage per category or mean, standard deviation, median and quartiles, minimum and maximum
for all patients and by availability of obstetric outcome
Parameter All
Obstetric outcome available
No Yes
Gestation (weeks) at fFN test
Nobs (Nmiss) 1226 (0) 29 (0) 1197 (0)
Mean (SD) 22.9 (0.6) 22.8 (0.6) 22.9 (0.6)
Median (IQR) 22.9 (22.4–23.4) 22.7 (22.3–23.4) 22.9 (22.4–23.4)
Range 21.7–27.1 22.0–23.9 21.7–27.1
Fetal anomaly scan done
Nobs (Nmiss) 1226 (0) 29 (0) 1197 (0)
No, n (%) 63 (5.1) 1 (3.4) 62 (5.2)
Yes, n (%) 1163 (94.9) 28 (96.6) 1135 (94.8)
Fetal anomaly scan result
Nobs (Nmiss) 1163 (0) 28 (0) 1135 (0)
Normal, n (%) 1150 (98.9) 28 (100.0) 1122 (98.9)
Defined abnormality, n (%) 7 (0.6) 0 (0.0) 7 (0.6)
Uncertain abnormality, n (%) 6 (0.5) 0 (0.0) 6 (0.5)
Amniocentesis done
Nobs (Nmiss) 1226 (0) 29 (0) 1197 (0)
No, n (%) 1218 (99.3) 28 (96.6) 1190 (99.4)
Yes, n (%) 8 (0.7) 1 (3.4) 7 (0.6)
TABLE 35 Baseline characteristics (part 3). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of obstetric outcome (continued )
Parameter All
Obstetric outcome available
No Yes
Ethnic group
Nobs (Nmiss) 1224 (2) 28 (1) 1196 (1)
White, n (%) 895 (73.1) 22 (78.6) 873 (73.0)
Black, n (%) 180 (14.7) 3 (10.7) 177 (14.8)
Asian, n (%) 104 (8.5) 2 (7.1) 102 (8.5)
Mixed, n (%) 28 (2.3) 1 (3.6) 27 (2.3)
Other, n (%) 17 (1.4) 0 (0.0) 17 (1.4)
A Level, Advanced Level; AS Level, Advanced Subsidiary Level; BTEC, Business and Technology Education Council;
FE, Further Education; GCSE, General Certificate of Secondary Education; HE, Higher Education; HNC, Higher National
Certificate; HND, Higher National Diploma; Nmiss, number of women with missing data; Nobs, number of observations;
O Level, ordinary level; PG, postgraduate.
Note
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TABLE 36 Baseline characteristics (part 4): this pregnancy. Number of observed values, number of missing values,
number and percentage per category or mean, standard deviation, median and quartiles, minimum and maximum
for all patients and by availability of obstetric outcome (continued )
Parameter All
Obstetric outcome available
No Yes
Results of amniocentesis
Nobs (Nmiss) 8 (0) 1 (0) 7 (0)
Normal, n (%) 8 (100.0) 1 (100.0) 7 (100.0)
Other, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Chorionic villus sampling done
Nobs (Nmiss) 1225 (1) 29 (0) 1196 (1)
No, n (%) 1216 (99.3) 29 (100.0) 1187 (99.2)
Yes, n (%) 9 (0.7) 0 (0.0) 9 (0.8)
Results of chorionic villus sampling
Nobs (Nmiss) 9 (0) 0 (0) 9 (0)
No, n (%) 9 (100.0) 0 (–) 9 (100.0)
Yes, n (%) 0 (0.0) 0 (–) 0 (0.0)
Cervical length (mm)
Nobs (Nmiss) 712 (514) 16 (13) 696 (501)
Mean (SD) 28.5 (10.8) 31.2 (10.4) 28.5 (10.9)
Median (IQR) 30.0 (22.0–36.0) 32.0 (23.5–38.8) 30.0 (22.0–36.0)
Range 0.0–84.0 12.0–50.0 0.0–84.0
Risk
Nobs (Nmiss) 1226 (0) 29 (0) 1197 (0)
Low, n (%) 882 (71.9) 23 (79.3) 859 (71.8)
High, n (%) 344 (28.1) 6 (20.7) 338 (28.2)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 02 14:33:57 2015.
TABLE 37 Previous pregnancies (part 1). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of obstetric outcome
Parameter All
Obstetric outcome available
No Yes
Any previous pregnancy
Nobs (Nmiss) 1224 (2) 27 (2) 1197 (0)
No, n (%) 52 (4.2) 0 (0.0) 52 (4.3)
Yes, n (%) 1172 (95.8) 27 (100.0) 1145 (95.7)
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TABLE 37 Previous pregnancies (part 1). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of obstetric outcome (continued )
Parameter All
Obstetric outcome available
No Yes
Number of previous pregnancies
Nobs (Nmiss) 1224 (2) 27 (2) 1197 (0)
Mean (SD) 2.6 (2.0) 2.7 (1.7) 2.6 (2.0)
Median (IQR) 2.0 (1.0–3.0) 3.0 (1.0–3.5) 2.0 (1.0–3.0)
Range 0.0–14.0 1.0–6.0 0.0–14.0
Any previous pregnancy of ≥ 14 weeks’ gestation
Nobs (Nmiss) 1224 (2) 27 (2) 1197 (0)
No, n (%) 75 (6.1) 2 (7.4) 73 (6.1)
Yes, n (%) 1149 (93.9) 25 (92.6) 1124 (93.9)
Number of previous pregnancies of ≥ 14 weeks’ gestation
Nobs (Nmiss) 1224 (2) 27 (2) 1197 (0)
Mean (SD) 1.9 (1.4) 2.0 (1.5) 1.9 (1.4)
Median (IQR) 2.0 (1.0–2.0) 2.0 (1.0–2.5) 2.0 (1.0–2.0)
Range 0.0–13.0 0.0–6.0 0.0–13.0
Any previous live birth
Nobs (Nmiss) 1224 (2) 27 (2) 1197 (0)
No, n (%) 197 (16.1) 5 (18.5) 192 (16.0)
Yes, n (%) 1027 (83.9) 22 (81.5) 1005 (84.0)
Number of previous live births
Nobs (Nmiss) 1224 (2) 27 (2) 1197 (0)
Mean (SD) 1.5 (1.3) 1.6 (1.3) 1.5 (1.3)
Median (IQR) 1.0 (1.0–2.0) 2.0 (1.0–2.0) 1.0 (1.0–2.0)
Range 0.0–13.0 0.0–6.0 0.0–13.0
Any previous pregnancy that ended with baby alive and well
Nobs (Nmiss) 1224 (2) 27 (2) 1197 (0)
No, n (%) 646 (52.8) 12 (44.4) 634 (53.0)
Yes, n (%) 578 (47.2) 15 (55.6) 563 (47.0)
Number of previous pregnancies that ended with baby alive and well
Nobs (Nmiss) 1224 (2) 27 (2) 1197 (0)
Mean (SD) 0.8 (1.2) 1.1 (1.3) 0.8 (1.2)
Median (IQR) 0.0 (0.0–1.0) 1.0 (0.0–2.0) 0.0 (0.0–1.0)
Range 0.0–13.0 0.0–5.0 0.0–13.0
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 38 Previous pregnancies (part 2). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of obstetric outcome
Parameter All
Obstetric outcome available
No Yes
History of induced labour or elective caesarean section
Nobs (Nmiss) 1224 (2) 27 (2) 1197 (0)
No, n (%) 1065 (87.0) 21 (77.8) 1044 (87.2)
Yes, n (%) 159 (13.0) 6 (22.2) 153 (12.8)
History of miscarriage
Nobs (Nmiss) 1224 (2) 27 (2) 1197 (0)
No, n (%) 701 (57.3) 13 (48.1) 688 (57.5)
Yes, n (%) 523 (42.7) 14 (51.9) 509 (42.5)
History of ectopic pregnancy
Nobs (Nmiss) 1224 (2) 27 (2) 1197 (0)
No, n (%) 1193 (97.5) 26 (96.3) 1167 (97.5)
Yes, n (%) 31 (2.5) 1 (3.7) 30 (2.5)
History of termination of pregnancy
Nobs (Nmiss) 1224 (2) 27 (2) 1197 (0)
No, n (%) 1085 (88.6) 24 (88.9) 1061 (88.6)
Yes, n (%) 139 (11.4) 3 (11.1) 136 (11.4)
History of termination of pregnancy before 14 weeks’ gestation
Nobs (Nmiss) 1226 (0) 29 (0) 1197 (0)
No, n (%) 1106 (90.2) 26 (89.7) 1080 (90.2)
Yes, n (%) 120 (9.8) 3 (10.3) 117 (9.8)
History of termination of pregnancy at ≥ 14 weeks’ gestation
Nobs (Nmiss) 1226 (0) 29 (0) 1197 (0)
No, n (%) 1201 (98.0) 29 (100.0) 1172 (97.9)
Yes, n (%) 25 (2.0) 0 (0.0) 25 (2.1)
History of live birth followed by neonatal death
Nobs (Nmiss) 1224 (2) 27 (2) 1197 (0)
No, n (%) 1059 (86.5) 26 (96.3) 1033 (86.3)
Yes, n (%) 165 (13.5) 1 (3.7) 164 (13.7)
History of live birth followed by death other than neonatal
Nobs (Nmiss) 1224 (2) 27 (2) 1197 (0)
No, n (%) 1208 (98.7) 26 (96.3) 1182 (98.7)
Yes, n (%) 16 (1.3) 1 (3.7) 15 (1.3)
History of stillbirth
Nobs (Nmiss) 1224 (2) 27 (2) 1197 (0)
No, n (%) 1129 (92.2) 25 (92.6) 1104 (92.2)
Yes, n (%) 95 (7.8) 2 (7.4) 93 (7.8)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 39 Baseline characteristics (part 1). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of neonatal outcome
Parameter All
Neonatal outcome available
No Yes
Age (years)
Nobs (Nmiss) 1225 (1) 49 (1) 1176 (0)
Mean (SD) 31.4 (5.7) 31.5 (5.3) 31.4 (5.7)
Median (IQR) 31.5 (27.4–35.7) 31.9 (27.6–35.0) 31.4 (27.4–35.7)
Range 16.8–49.2 20.8–41.0 16.8–49.2
Height (cm)
Nobs (Nmiss) 1221 (5) 48 (2) 1173 (3)
Mean (SD) 163.5 (6.6) 165.1 (7.3) 163.5 (6.6)
Median (IQR) 163.0 (159.0–168.0) 166.0 (160.0–170.0) 163.0 (159.0–168.0)
Range 144.0–183.0 147.0–181.0 144.0–183.0
Weight (kg)
Nobs (Nmiss) 1221 (5) 48 (2) 1173 (3)
Mean (SD) 71.6 (17.1) 75.5 (19.5) 71.5 (17.0)
Median (IQR) 68.0 (60.0–81.0) 71.0 (63.0–84.0) 68.0 (59.0–81.0)
Range 41.0–186.0 51.0–130.0 41.0–186.0
BMI (kg/m2)
Nobs (Nmiss) 1221 (5) 48 (2) 1173 (3)
Mean (SD) 26.8 (6.3) 27.7 (7.1) 26.8 (6.2)
Median (IQR) 25.5 (22.3–29.8) 26.2 (22.5–30.2) 25.5 (22.3–29.8)
Range 15.2–80.5 18.0–49.5 15.2–80.5
Systolic blood pressure (mmHg)
Nobs (Nmiss) 1219 (7) 49 (1) 1170 (6)
Mean (SD) 111.9 (12.4) 115.9 (13.7) 111.7 (12.3)
Median (IQR) 110.0 (102.0–120.0) 110.0 (109.0–122.0) 110.0 (102.0–120.0)
Range 78.0–189.0 92.0–159.0 78.0–189.0
Diastolic blood pressure (mmHg)
Nobs (Nmiss) 1219 (7) 49 (1) 1170 (6)
Mean (SD) 66.0 (8.6) 66.8 (9.6) 65.9 (8.5)
Median (IQR) 65.0 (60.0–71.0) 67.0 (60.0–70.0) 65.0 (60.0–71.0)
Range 40.0–104.0 50.0–98.0 40.0–104.0
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 40 Baseline characteristics (part 2). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of neonatal outcome
Parameter All
Neonatal outcome available
No Yes
Smoking
Nobs (Nmiss) 1220 (6) 48 (2) 1172 (4)
No, n (%) 984 (80.7) 38 (79.2) 946 (80.7)
Yes, n (%) 236 (19.3) 10 (20.8) 226 (19.3)
Alcohol consumption
Nobs (Nmiss) 1223 (3) 49 (1) 1174 (2)
No, n (%) 1160 (94.8) 47 (95.9) 1113 (94.8)
Yes, n (%) 63 (5.2) 2 (4.1) 61 (5.2)
Drug use
Nobs (Nmiss) 1223 (3) 49 (1) 1174 (2)
No, n (%) 1206 (98.6) 49 (100.0) 1157 (98.6)
Yes, n (%) 17 (1.4) 0 (0.0) 17 (1.4)
In full-time education
Nobs (Nmiss) 1216 (10) 49 (1) 1167 (9)
No, n (%) 1175 (96.6) 47 (95.9) 1128 (96.7)
Yes, n (%) 41 (3.4) 2 (4.1) 39 (3.3)
Years in full-time education
Nobs (Nmiss) 1122 (53) 44 (3) 1078 (50)
Mean (SD) 13.5 (3.1) 13.4 (2.9) 13.5 (3.1)
Median (IQR) 13.0 (11.0–16.0) 13.0 (11.0–15.2) 13.0 (11.0–16.0)
Range 1.0–31.0 7.0–19.0 1.0–31.0
Educated in the UK
Nobs (Nmiss) 1206 (20) 49 (1) 1157 (19)
No, n (%) 211 (17.5) 14 (28.6) 197 (17.0)
Yes, n (%) 995 (82.5) 35 (71.4) 960 (83.0)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 41 Baseline characteristics (part 3). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of neonatal outcome
Parameter All
Neonatal outcome available
No Yes
Highest level of education if in UK
Nobs (Nmiss) 975 (20) 33 (2) 942 (18)
No formal qualifications, n (%) 99 (10.2) 8 (24.2) 91 (9.7)
Entry Level Certificate/Foundation Diploma, n (%) 13 (1.3) 0 (0.0) 13 (1.4)
GCSE/Standard/O Level, n (%) 327 (33.5) 11 (33.3) 316 (33.5)
A Level, AS Level, Highers or BTEC
Diploma/Certificate, n (%)
137 (14.1) 2 (6.1) 135 (14.3)
Certificate of Higher Education/City & Guilds, n (%) 53 (5.4) 2 (6.1) 51 (5.4)
Diploma HE/FE or HND/HNC, n (%) 69 (7.1) 2 (6.1) 67 (7.1)
Graduate certificate or diploma, n (%) 14 (1.4) 1 (3.0) 13 (1.4)
Degree, n (%) 158 (16.2) 4 (12.1) 154 (16.3)
Professional qualifications, n (%) 40 (4.1) 2 (6.1) 38 (4.0)
PG certificate, diploma, masters, doctorate, n (%) 65 (6.7) 1 (3.0) 64 (6.8)
Ethnic group
Nobs (Nmiss) 1224 (2) 49 (1) 1175 (1)
White, n (%) 895 (73.1) 34 (69.4) 861 (73.3)
Chinese, n (%) 1 (0.1) 0 (0.0) 1 (0.1)
Other ethnic group, n (%) 17 (1.4) 0 (0.0) 17 (1.4)
Mixed
White and black Caribbean, n (%) 17 (1.4) 0 (0.0) 17 (1.4)
White and black African, n (%) 3 (0.2) 0 (0.0) 3 (0.3)
White and Asian, n (%) 2 (0.2) 1 (2.0) 1 (0.1)
Other mixed background, n (%) 6 (0.5) 1 (2.0) 5 (0.4)
Asian
Indian, n (%) 30 (2.5) 1 (2.0) 29 (2.5)
Pakistani, n (%) 45 (3.7) 1 (2.0) 44 (3.7)
Bangladeshi, n (%) 5 (0.4) 0 (0.0) 5 (0.4)
Other Asian background, n (%) 23 (1.9) 1 (2.0) 22 (1.9)
Black
Caribbean, n (%) 47 (3.8) 0 (0.0) 47 (4.0)
African, n (%) 119 (9.7) 9 (18.4) 110 (9.4)
Other black background, n (%) 14 (1.1) 1 (2.0) 13 (1.1)
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TABLE 41 Baseline characteristics (part 3). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of neonatal outcome (continued )
Parameter All
Neonatal outcome available
No Yes
Ethnic group
Nobs (Nmiss) 1224 (2) 49 (1) 1175 (1)
White, n (%) 895 (73.1) 34 (69.4) 861 (73.3)
Black, n (%) 180 (14.7) 10 (20.4) 170 (14.5)
Asian, n (%) 104 (8.5) 3 (6.1) 101 (8.6)
Mixed, n (%) 28 (2.3) 2 (4.1) 26 (2.2)
Other, n (%) 17 (1.4) 0 (0.0) 17 (1.4)
A Level, Advanced Level; AS Level, Advanced Subsidiary Level; BTEC, Business and Technology Education Council;
FE, Further Education; GCSE, General Certificate of Secondary Education; HE, Higher Education; HNC, Higher National
Certificate; HND, Higher National Diploma; Nmiss, number of women with missing data; Nobs, number of observations;
O Level, ordinary level; PG, postgraduate.
Note
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TABLE 42 Baseline characteristics (part 4): this pregnancy. Number of observed values, number of missing values,
number and percentage per category or mean, standard deviation, median and quartiles, minimum and maximum
for all patients and by availability of neonatal outcome
Parameter All
Neonatal outcome available
No Yes
Gestation (weeks) at fFN test
Nobs (Nmiss) 1226 (0) 50 (0) 1176 (0)
Mean (SD) 22.9 (0.6) 22.9 (0.6) 22.9 (0.6)
Median (IQR) 22.9 (22.4–23.4) 22.7 (22.4–23.4) 22.9 (22.4–23.4)
Range 21.7–27.1 22.0–23.9 21.7–27.1
Fetal anomaly scan done
Nobs (Nmiss) 1226 (0) 50 (0) 1176 (0)
No, n (%) 63 (5.1) 2 (4.0) 61 (5.2)
Yes, n (%) 1163 (94.9) 48 (96.0) 1115 (94.8)
Fetal anomaly scan result
Nobs (Nmiss) 1163 (0) 48 (0) 1115 (0)
Normal, n (%) 1150 (98.9) 48 (100.0) 1102 (98.8)
Defined abnormality, n (%) 7 (0.6) 0 (0.0) 7 (0.6)
Uncertain abnormality, n (%) 6 (0.5) 0 (0.0) 6 (0.5)
Amniocentesis done
Nobs (Nmiss) 1226 (0) 50 (0) 1176 (0)
No, n (%) 1218 (99.3) 49 (98.0) 1169 (99.4)
Yes, n (%) 8 (0.7) 1 (2.0) 7 (0.6)
continued
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TABLE 42 Baseline characteristics (part 4): this pregnancy. Number of observed values, number of missing values,
number and percentage per category or mean, standard deviation, median and quartiles, minimum and maximum
for all patients and by availability of neonatal outcome (continued )
Parameter All
Neonatal outcome available
No Yes
Results of amniocentesis
Nobs (Nmiss) 8 (0) 1 (0) 7 (0)
Normal, n (%) 8 (100.0) 1 (100.0) 7 (100.0)
Other, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Chorionic villus sampling done
Nobs (Nmiss) 1225 (1) 50 (0) 1175 (1)
No, n (%) 1216 (99.3) 50 (100.0) 1166 (99.2)
Yes, n (%) 9 (0.7) 0 (0.0) 9 (0.8)
Results of chorionic villus sampling
Nobs (Nmiss) 9 (0) 0 (0) 9 (0)
Normal, n (%) 9 (100.0) 0 (–) 9 (100.0)
Other, n (%) 0 (0.0) 0 (–) 0 (0.0)
Cervical length (mm)
Nobs (Nmiss) 712 (514) 30 (20) 682 (494)
Mean (SD) 28.5 (10.8) 31.0 (11.4) 28.4 (10.8)
Median (IQR) 30.0 (22.0–36.0) 32.0 (22.2–37.8) 30.0 (22.0–36.0)
Range 0.0–84.0 12.0–58.0 0.0–84.0
Risk
Nobs (Nmiss) 1226 (0) 50 (0) 1176 (0)
Low, n (%) 882 (71.9) 35 (70.0) 847 (72.0)
High, n (%) 344 (28.1) 15 (30.0) 329 (28.0)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 43 Previous pregnancies (part 1). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of neonatal outcome
Parameter All
Neonatal outcome available
No Yes
Any previous pregnancy
Nobs (Nmiss) 1224 (2) 48 (2) 1176 (0)
No, n (%) 52 (4.2) 0 (0.0) 52 (4.4)
Yes, n (%) 1172 (95.8) 48 (100.0) 1124 (95.6)
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TABLE 43 Previous pregnancies (part 1). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of neonatal outcome (continued )
Parameter All
Neonatal outcome available
No Yes
Number of previous pregnancies
Nobs (Nmiss) 1224 (2) 48 (2) 1176 (0)
Mean (SD) 2.6 (2.0) 2.8 (1.6) 2.6 (2.0)
Median (IQR) 2.0 (1.0–3.0) 3.0 (1.8– 4.0) 2.0 (1.0–3.0)
Range 0.0–14.0 1.0–7.0 0.0–14.0
Any previous pregnancy of ≥ 14 weeks’ gestation
Nobs (Nmiss) 1224 (2) 48 (2) 1176 (0)
No, n (%) 75 (6.1) 2 (4.2) 73 (6.2)
Yes, n (%) 1149 (93.9) 46 (95.8) 1103 (93.8)
Number of previous pregnancies of ≥ 14 weeks’ gestation
Nobs (Nmiss) 1224 (2) 48 (2) 1176 (0)
Mean (SD) 1.9 (1.4) 2.0 (1.3) 1.9 (1.4)
Median (IQR) 2.0 (1.0–2.0) 2.0 (1.0–3.0) 2.0 (1.0–2.0)
Range 0.0–13.0 0.0–6.0 0.0–13.0
Any previous live birth
Nobs (Nmiss) 1224 (2) 48 (2) 1176 (0)
No, n (%) 197 (16.1) 7 (14.6) 190 (16.2)
Yes, n (%) 1027 (83.9) 41 (85.4) 986 (83.8)
Number of previous live births
Nobs (Nmiss) 1224 (2) 48 (2) 1176 (0)
Mean (SD) 1.5 (1.3) 1.5 (1.1) 1.6 (1.3)
Median (IQR) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0)
Range 0.0–13.0 0.0–6.0 0.0–13.0
Any previous pregnancy that ended with baby alive and well
Nobs (Nmiss) 1224 (2) 48 (2) 1176 (0)
No, n (%) 646 (52.8) 26 (54.2) 620 (52.7)
Yes, n (%) 578 (47.2) 22 (45.8) 556 (47.3)
Number of previous pregnancies that ended with baby alive and well
Nobs (Nmiss) 1224 (2) 48 (2) 1176 (0)
Mean (SD) 0.8 (1.2) 0.8 (1.2) 0.8 (1.2)
Median (IQR) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0)
Range 0.0–13.0 0.0–5.0 0.0–13.0
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 44 Previous pregnancies (part 2). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of neonatal outcome
Parameter All
Neonatal outcome available
No Yes
History of induced labour or elective caesarean section
Nobs (Nmiss) 1224 (2) 48 (2) 1176 (0)
No, n (%) 1065 (87.0) 38 (79.2) 1027 (87.3)
Yes, n (%) 159 (13.0) 10 (20.8) 149 (12.7)
History of miscarriage
Nobs (Nmiss) 1224 (2) 48 (2) 1176 (0)
No, n (%) 701 (57.3) 24 (50.0) 677 (57.6)
Yes, n (%) 523 (42.7) 24 (50.0) 499 (42.4)
History of ectopic pregnancy
Nobs (Nmiss) 1224 (2) 48 (2) 1176 (0)
No, n (%) 1193 (97.5) 45 (93.8) 1148 (97.6)
Yes, n (%) 31 (2.5) 3 (6.2) 28 (2.4)
History of termination of pregnancy
Nobs (Nmiss) 1224 (2) 48 (2) 1176 (0)
No, n (%) 1085 (88.6) 42 (87.5) 1043 (88.7)
Yes, n (%) 139 (11.4) 6 (12.5) 133 (11.3)
History of termination of pregnancy before 14 weeks’ gestation
Nobs (Nmiss) 1226 (0) 50 (0) 1176 (0)
No, n (%) 1106 (90.2) 44 (88.0) 1062 (90.3)
Yes, n (%) 120 (9.8) 6 (12.0) 114 (9.7)
History of termination of pregnancy at ≥ 14 weeks’ gestation
Nobs (Nmiss) 1226 (0) 50 (0) 1176 (0)
No, n (%) 1201 (98.0) 49 (98.0) 1152 (98.0)
Yes, n (%) 25 (2.0) 1 (2.0) 24 (2.0)
History of live birth followed by neonatal death
Nobs (Nmiss) 1224 (2) 48 (2) 1176 (0)
No, n (%) 1059 (86.5) 45 (93.8) 1014 (86.2)
Yes, n (%) 165 (13.5) 3 (6.2) 162 (13.8)
History of live birth followed by death other than neonatal
Nobs (Nmiss) 1224 (2) 48 (2) 1176 (0)
No, n (%) 1208 (98.7) 47 (97.9) 1161 (98.7)
Yes, n (%) 16 (1.3) 1 (2.1) 15 (1.3)
History of stillbirth
Nobs (Nmiss) 1224 (2) 48 (2) 1176 (0)
No, n (%) 1129 (92.2) 44 (91.7) 1085 (92.3)
Yes, n (%) 95 (7.8) 4 (8.3) 91 (7.7)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 45 Baseline characteristics (part 1). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of Bayley-III cognitive composite score at 2 years
Parameter All
Bayley-III cognitive composite score at 2 years available
No Yes
Age (years)
Nobs (Nmiss) 1225 (1) 392 (1) 833 (0)
Mean (SD) 31.4 (5.7) 29.8 (5.7) 32.2 (5.5)
Median (IQR) 31.5 (27.4–35.7) 29.4 (26.1–33.8) 32.3 (28.2–36.2)
Range 16.8–49.2 16.8–45.3 17.5–49.2
Height (cm)
Nobs (Nmiss) 1221 (5) 390 (3) 831 (2)
Mean (SD) 163.5 (6.6) 163.5 (6.6) 163.5 (6.6)
Median (IQR) 163.0 (159.0–168.0) 163.0 (159.0–168.0) 164.0 (159.0–168.0)
Range 144.0–183.0 147.0–183.0 144.0–183.0
Weight (kg)
Nobs (Nmiss) 1221 (5) 390 (3) 831 (2)
Mean (SD) 71.6 (17.1) 70.4 (15.8) 72.2 (17.6)
Median (IQR) 68.0 (60.0–81.0) 67.0 (58.0–80.0) 68.0 (60.0–81.0)
Range 41.0–186.0 43.0–130.0 41.0–186.0
BMI (kg/m2)
Nobs (Nmiss) 1221 (5) 390 (3) 831 (2)
Mean (SD) 26.8 (6.3) 26.3 (5.6) 27.0 (6.5)
Median (IQR) 25.5 (22.3–29.8) 25.2 (22.2–29.6) 25.6 (22.4–30.1)
Range 15.2–80.5 15.2–49.5 15.6–80.5
Systolic blood pressure (mmHg)
Nobs (Nmiss) 1219 (7) 392 (1) 827 (6)
Mean (SD) 111.9 (12.4) 111.2 (12.0) 112.2 (12.5)
Median (IQR) 110.0 (102.0–120.0) 110.0 (102.0–120.0) 110.0 (102.5–120.0)
Range 78.0–189.0 78.0–159.0 80.0–189.0
Diastolic blood pressure (mmHg)
Nobs (Nmiss) 1219 (7) 392 (1) 827 (6)
Mean (SD) 66.0 (8.6) 65.6 (8.9) 66.1 (8.4)
Median (IQR) 65.0 (60.0–71.0) 65.0 (60.0–70.0) 65.0 (60.0–71.0)
Range 40.0–104.0 44.0–98.0 40.0–104.0
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 46 Baseline characteristics (part 2). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of Bayley-III cognitive composite score at 2 years
Parameter All
Bayley-III cognitive composite score at 2 years available
No Yes
Smoking
Nobs (Nmiss) 1220 (6) 391 (2) 829 (4)
No, n (%) 984 (80.7) 277 (70.8) 707 (85.3)
Yes, n (%) 236 (19.3) 114 (29.2) 122 (14.7)
Alcohol consumption
Nobs (Nmiss) 1223 (3) 392 (1) 831 (2)
No, n (%) 1160 (94.8) 369 (94.1) 791 (95.2)
Yes, n (%) 63 (5.2) 23 (5.9) 40 (4.8)
Drug use
Nobs (Nmiss) 1223 (3) 392 (1) 831 (2)
No, n (%) 1206 (98.6) 384 (98.0) 822 (98.9)
Yes, n (%) 17 (1.4) 8 (2.0) 9 (1.1)
In full-time education
Nobs (Nmiss) 1216 (10) 388 (5) 828 (5)
No, n (%) 1175 (96.6) 371 (95.6) 804 (97.1)
Yes, n (%) 41 (3.4) 17 (4.4) 24 (2.9)
Years in full-time education
Nobs (Nmiss) 1122 (53) 345 (26) 777 (27)
Mean (SD) 13.5 (3.1) 12.8 (3.1) 13.8 (3.0)
Median (IQR) 13.0 (11.0–16.0) 12.0 (11.0–14.0) 13.0 (11.0–16.0)
Range 1.0–31.0 1.0–31.0 3.0–24.0
Educated in the UK
Nobs (Nmiss) 1206 (20) 382 (11) 824 (9)
No, n (%) 211 (17.5) 69 (18.1) 142 (17.2)
Yes, n (%) 995 (82.5) 313 (81.9) 682 (82.8)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 47 Baseline characteristics (part 3). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of Bayley-III cognitive composite score at 2 years
Parameter All
Bayley-III cognitive composite score
at 2 years available
No Yes
Highest level of education if in UK
Nobs (Nmiss) 975 (20) 303 (10) 672 (10)
No formal qualifications, n (%) 99 (10.2) 58 (19.1) 41 (6.1)
Entry Level Certificate/Foundation Diploma, n (%) 13 (1.3) 2 (0.7) 11 (1.6)
GCSE/Standard/O Level, n (%) 327 (33.5) 129 (42.6) 198 (29.5)
A Level, AS Level, Highers or BTEC
Diploma/Certificate, n (%)
137 (14.1) 34 (11.2) 103 (15.3)
Certificate of Higher Education/City & Guilds, n (%) 53 (5.4) 10 (3.3) 43 (6.4)
Diploma HE/FE or HND/HNC, n (%) 69 (7.1) 21 (6.9) 48 (7.1)
Graduate certificate or diploma, n (%) 14 (1.4) 4 (1.3) 10 (1.5)
Degree, n (%) 158 (16.2) 29 (9.6) 129 (19.2)
Professional qualifications, n (%) 40 (4.1) 7 (2.3) 33 (4.9)
PG certificate, diploma, masters, doctorate, n (%) 65 (6.7) 9 (3.0) 56 (8.3)
Ethnic group
Nobs (Nmiss) 1224 (2) 392 (1) 832 (1)
White, n (%) 895 (73.1) 276 (70.4) 619 (74.4)
Chinese, n (%) 1 (0.1) 0 (0.0) 1 (0.1)
Other ethnic group, n (%) 17 (1.4) 7 (1.8) 10 (1.2)
Mixed
White and black Caribbean, n (%) 17 (1.4) 5 (1.3) 12 (1.4)
White and black African, n (%) 3 (0.2) 1 (0.3) 2 (0.2)
White and Asian, n (%) 2 (0.2) 0 (0.0) 2 (0.2)
Other mixed background, n (%) 6 (0.5) 2 (0.5) 4 (0.5)
Asian
Indian, n (%) 30 (2.5) 7 (1.8) 23 (2.8)
Pakistani, n (%) 45 (3.7) 13 (3.3) 32 (3.8)
Bangladeshi, n (%) 5 (0.4) 3 (0.8) 2 (0.2)
Other Asian background, n (%) 23 (1.9) 8 (2.0) 15 (1.8)
Black
Caribbean, n (%) 47 (3.8) 17 (4.3) 30 (3.6)
African, n (%) 119 (9.7) 46 (11.7) 73 (8.8)
Other black background, n (%) 14 (1.1) 7 (1.8) 7 (0.8)
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TABLE 47 Baseline characteristics (part 3). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of Bayley-III cognitive composite score at 2 years (continued )
Parameter All
Bayley-III cognitive composite score
at 2 years available
No Yes
Ethnic group
Nobs (Nmiss) 1224 (2) 392 (1) 832 (1)
White, n (%) 895 (73.1) 276 (70.4) 619 (74.4)
Black, n (%) 180 (14.7) 70 (17.9) 110 (13.2)
Asian, n (%) 104 (8.5) 31 (7.9) 73 (8.8)
Mixed, n (%) 28 (2.3) 8 (2.0) 20 (2.4)
Other, n (%) 17 (1.4) 7 (1.8) 10 (1.2)
A Level, Advanced Level; AS Level, Advanced Subsidiary Level; BTEC, Business and Technology Education Council;
FE, Further Education; GCSE, General Certificate of Secondary Education; HE, Higher Education; HNC, Higher National
Certificate; HND, Higher National Diploma; Nmiss, number of women with missing data; Nobs, number of observations;
O Level, ordinary level; PG, postgraduate.
Note
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TABLE 48 Baseline characteristics (part 4): this pregnancy. Number of observed values, number of missing values,
number and percentage per category or mean, standard deviation, median and quartiles, minimum and maximum
for all patients and by availability of Bayley-III cognitive composite score at 2 years
Parameter All
Bayley-III cognitive composite score
at 2 years available
No Yes
Gestation (weeks) at fFN test
Nobs (Nmiss) 1226 (0) 393 (0) 833 (0)
Mean (SD) 22.9 (0.6) 22.9 (0.6) 22.9 (0.6)
Median (IQR) 22.9 (22.4–23.4) 22.9 (22.4–23.4) 22.9 (22.4–23.4)
Range 21.7–27.1 22.0–24.1 21.7–27.1
Fetal anomaly scan done
Nobs (Nmiss) 1226 (0) 393 (0) 833 (0)
No, n (%) 63 (5.1) 25 (6.4) 38 (4.6)
Yes, n (%) 1163 (94.9) 368 (93.6) 795 (95.4)
Fetal anomaly scan result
Nobs (Nmiss) 1163 (0) 368 (0) 795 (0)
Normal, n (%) 1150 (98.9) 365 (99.2) 785 (98.7)
Defined abnormality, n (%) 7 (0.6) 0 (0.0) 7 (0.9)
Uncertain abnormality, n (%) 6 (0.5) 3 (0.8) 3 (0.4)
Amniocentesis done
Nobs (Nmiss) 1226 (0) 393 (0) 833 (0)
No, n (%) 1218 (99.3) 392 (99.7) 826 (99.2)
Yes, n (%) 8 (0.7) 1 (0.3) 7 (0.8)
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
114
TABLE 48 Baseline characteristics (part 4): this pregnancy. Number of observed values, number of missing values,
number and percentage per category or mean, standard deviation, median and quartiles, minimum and maximum
for all patients and by availability of Bayley-III cognitive composite score at 2 years (continued )
Parameter All
Bayley-III cognitive composite score
at 2 years available
No Yes
Results of amniocentesis
Nobs (Nmiss) 8 (0) 1 (0) 7 (0)
Normal, n (%) 8 (100.0) 1 (100.0) 7 (100.0)
Other, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Chorionic villus sampling done
Nobs (Nmiss) 1225 (1) 393 (0) 832 (1)
No, n (%) 1216 (99.3) 390 (99.2) 826 (99.3)
Yes, n (%) 9 (0.7) 3 (0.8) 6 (0.7)
Results of chorionic villus sampling
Nobs (Nmiss) 9 (0) 3 (0) 6 (0)
Normal, n (%) 9 (100.0) 3 (100.0) 6 (100.0)
Other, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Cervical length (mm)
Nobs (Nmiss) 712 (514) 234 (159) 478 (355)
Mean (SD) 28.5 (10.8) 28.4 (10.6) 28.6 (11.0)
Median (IQR) 30.0 (22.0–36.0) 30.0 (22.0–36.0) 30.0 (22.0–36.0)
Range 0.0–84.0 0.0–50.0 0.0–84.0
Risk
Nobs (Nmiss) 1226 (0) 393 (0) 833 (0)
Low, n (%) 882 (71.9) 268 (68.2) 614 (73.7)
High, n (%) 344 (28.1) 125 (31.8) 219 (26.3)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 49 Previous pregnancies (part 1). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of Bayley-III cognitive composite score at 2 years
Parameter All
Bayley-III cognitive composite score
at 2 years available
No Yes
Any previous pregnancy
Nobs (Nmiss) 1224 (2) 391 (2) 833 (0)
No, n (%) 52 (4.2) 10 (2.6) 42 (5.0)
Yes, n (%) 1172 (95.8) 381 (97.4) 791 (95.0)
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TABLE 49 Previous pregnancies (part 1). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of Bayley-III cognitive composite score at 2 years (continued )
Parameter All
Bayley-III cognitive composite score
at 2 years available
No Yes
Number of previous pregnancies
Nobs (Nmiss) 1224 (2) 391 (2) 833 (0)
Mean (SD) 2.6 (2.0) 2.9 (2.2) 2.5 (1.9)
Median (IQR) 2.0 (1.0–3.0) 2.0 (1.0–4.0) 2.0 (1.0–3.0)
Range 0.0–14.0 0.0–13.0 0.0–14.0
Any previous pregnancy of ≥ 14 weeks’ gestation
Nobs (Nmiss) 1224 (2) 391 (2) 833 (0)
No, n (%) 75 (6.1) 19 (4.9) 56 (6.7)
Yes, n (%) 1149 (93.9) 372 (95.1) 777 (93.3)
Number of previous pregnancies of ≥ 14 weeks’ gestation
Nobs (Nmiss) 1224 (2) 391 (2) 833 (0)
Mean (SD) 1.9 (1.4) 2.1 (1.6) 1.8 (1.3)
Median (IQR) 2.0 (1.0–2.0) 2.0 (1.0–3.0) 1.0 (1.0–2.0)
Range 0.0–13.0 0.0–13.0 0.0–10.0
Any previous live birth
Nobs (Nmiss) 1224 (2) 391 (2) 833 (0)
No, n (%) 197 (16.1) 61 (15.6) 136 (16.3)
Yes, n (%) 1027 (83.9) 330 (84.4) 697 (83.7)
Number of previous live births
Nobs (Nmiss) 1224 (2) 391 (2) 833 (0)
Mean (SD) 1.5 (1.3) 1.7 (1.5) 1.5 (1.2)
Median (IQR) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0)
Range 0.0–13.0 0.0–13.0 0.0–10.0
Any previous pregnancy that ended with baby alive and well
Nobs (Nmiss) 1224 (2) 391 (2) 833 (0)
No, n (%) 646 (52.8) 210 (53.7) 436 (52.3)
Yes, n (%) 578 (47.2) 181 (46.3) 397 (47.7)
Number of previous pregnancies that ended with baby alive and well
Nobs (Nmiss) 1224 (2) 391 (2) 833 (0)
Mean (SD) 0.8 (1.2) 0.9 (1.4) 0.8 (1.1)
Median (IQR) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0)
Range 0.0–13.0 0.0–13.0 0.0–10.0
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 50 Previous pregnancies (part 2). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of Bayley-III cognitive composite score at 2 years
Parameter All
Bayley-III cognitive composite score at 2 years available
No Yes
History of induced labour or elective caesarean section
Nobs (Nmiss) 1224 (2) 391 (2) 833 (0)
No, n (%) 1065 (87.0%) 334 (85.4) 731 (87.8)
Yes, n (%) 159 (13.0%) 57 (14.6) 102 (12.2)
History of miscarriage
Nobs (Nmiss) 1224 (2) 391 (2) 833 (0)
No, n (%) 701 (57.3) 212 (54.2) 489 (58.7)
Yes, n (%) 523 (42.7) 179 (45.8) 344 (41.3)
History of ectopic pregnancy
Nobs (Nmiss) 1224 (2) 391 (2) 833 (0)
No, n (%) 1193 (97.5) 380 (97.2) 813 (97.6)
Yes, n (%) 31 (2.5) 11 (2.8) 20 (2.4)
History of termination of pregnancy
Nobs (Nmiss) 1224 (2) 391 (2) 833 (0)
No, n (%) 1085 (88.6) 338 (86.4) 747 (89.7)
Yes, n (%) 139 (11.4) 53 (13.6) 86 (10.3)
History of termination of pregnancy before 14 weeks’ gestation
Nobs (Nmiss) 1226 (0) 393 (0) 833 (0)
No, n (%) 1106 (90.2) 348 (88.5) 758 (91.0)
Yes, n (%) 120 (9.8) 45 (11.5) 75 (9.0)
History of termination of pregnancy at ≥ 14 weeks’ gestation
Nobs (Nmiss) 1226 (0) 393 (0) 833 (0)
No, n (%) 1201 (98.0) 382 (97.2) 819 (98.3)
Yes, n (%) 25 (2.0) 11 (2.8) 14 (1.7)
History of live birth followed by neonatal death
Nobs (Nmiss) 1224 (2) 391 (2) 833 (0)
No, n (%) 1059 (86.5) 338 (86.4) 721 (86.6)
Yes, n (%) 165 (13.5) 53 (13.6) 112 (13.4)
History of live birth followed by death other than neonatal
Nobs (Nmiss) 1224 (2) 391 (2) 833 (0)
No, n (%) 1208 (98.7) 383 (98.0) 825 (99.0)
Yes, n (%) 16 (1.3) 8 (2.0) 8 (1.0)
History of stillbirth
Nobs (Nmiss) 1224 (2) 391 (2) 833 (0)
No, n (%) 1129 (92.2) 359 (91.8) 770 (92.4)
Yes, n (%) 95 (7.8) 32 (8.2) 63 (7.6)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 51 Baseline characteristics (part 1). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability survival at 2 years
Parameter All
Survival at 2 years available
No Yes
Age (years)
Nobs (Nmiss) 1225 (1) 216 (1) 1009 (0)
Mean (SD) 31.4 (5.7) 29.4 (5.6) 31.9 (5.6)
Median (IQR) 31.5 (27.4–35.7) 29.2 (25.6–33.0) 32.0 (28.0–36.0)
Range 16.8–49.2 17.6–45.3 16.8–49.2
Height (cm)
Nobs (Nmiss) 1221 (5) 216 (1) 1005 (4)
Mean (SD) 163.5 (6.6) 163.9 (6.9) 163.4 (6.5)
Median (IQR) 163.0 (159.0–168.0) 163.0 (159.0–168.0) 163.0 (159.0–168.0)
Range 144.0–183.0 147.0–182.0 144.0–183.0
Weight (kg)
Nobs (Nmiss) 1221 (5) 216 (1) 1005 (4)
Mean (SD) 71.6 (17.1) 71.5 (16.4) 71.7 (17.2)
Median (IQR) 68.0 (60.0–81.0) 68.0 (59.0–81.0) 68.0 (60.0–81.0)
Range 41.0–186.0 43.0–130.0 41.0–186.0
BMI (kg/m2)
Nobs (Nmiss) 1221 (5) 216 (1) 1005 (4)
Mean (SD) 26.8 (6.3) 26.6 (5.8) 26.8 (6.3)
Median (IQR) 25.5 (22.3–29.8) 25.5 (22.4–29.7) 25.6 (22.3–29.8)
Range 15.2–80.5 16.4–49.5 15.2–80.5
Systolic blood pressure (mmHg)
Nobs (Nmiss) 1219 (7) 216 (1) 1003 (6)
Mean (SD) 111.9 (12.4) 110.9 (12.1) 112.1 (12.4)
Median (IQR) 110.0 (102.0–120.0) 110.0 (100.8–120.0) 110.0 (103.0–120.0)
Range 78.0–189.0 78.0–159.0 80.0–189.0
Diastolic blood pressure (mmHg)
Nobs (Nmiss) 1219 (7) 216 (1) 1003 (6)
Mean (SD) 66.0 (8.6) 65.2 (8.7) 66.1 (8.5)
Median (IQR) 65.0 (60.0–71.0) 64.0 (60.0–70.0) 65.0 (60.0–71.0)
Range 40.0–104.0 44.0–98.0 40.0–104.0
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 52 Baseline characteristics (part 2). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of survival at 2 years
Parameter All
Survival at 2 years available
No Yes
Smoking
Nobs (Nmiss) 1220 (6) 216 (1) 1004 (5)
No, n (%) 984 (80.7) 137 (63.4) 847 (84.4)
Yes, n (%) 236 (19.3) 79 (36.6) 157 (15.6)
Alcohol consumption
Nobs (Nmiss) 1223 (3) 216 (1) 1007 (2)
No, n (%) 1160 (94.8) 201 (93.1) 959 (95.2)
Yes, n (%) 63 (5.2) 15 (6.9) 48 (4.8)
Drug use
Nobs (Nmiss) 1223 (3) 216 (1) 1007 (2)
No, n (%) 1206 (98.6) 211 (97.7) 995 (98.8)
Yes, n (%) 17 (1.4) 5 (2.3) 12 (1.2)
In full-time education
Nobs (Nmiss) 1216 (10) 215 (2) 1001 (8)
No, n (%) 1175 (96.6) 206 (95.8) 969 (96.8)
Yes, n (%) 41 (3.4) 9 (4.2) 32 (3.2)
Years in full-time education
Nobs (Nmiss) 1122 (53) 196 (10) 926 (43)
Mean (SD) 13.5 (3.1) 12.7 (2.7) 13.7 (3.1)
Median (IQR) 13.0 (11.0–16.0) 12.0 (11.0–14.0) 13.0 (11.0–16.0)
Range 1.0–31.0 5.0–23.0 1.0–31.0
Educated in the UK
Nobs (Nmiss) 1206 (20) 213 (4) 993 (16)
No, n (%) 211 (17.5) 30 (14.1) 181 (18.2)
Yes, n (%) 995 (82.5) 183 (85.9) 812 (81.8)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 02 14:34:01 2015.
DOI: 10.3310/hta22350 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 35
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Norman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
119
TABLE 53 Baseline characteristics (part 3). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of survival at 2 years
Parameter All
Survival at 2 years available
No Yes
Highest level of education if in UK
Nobs (Nmiss) 975 (20) 176 (7) 799 (13)
No formal qualifications, n (%) 99 (10.2) 40 (22.7) 59 (7.4)
Entry Level Certificate/Foundation Diploma, n (%) 13 (1.3) 1 (0.6) 12 (1.5)
GCSE/Standard/O Level, n (%) 327 (33.5) 74 (42.0) 253 (31.7)
A Level, AS Level, Highers or BTEC
Diploma/Certificate, n (%)
137 (14.1) 21 (11.9) 116 (14.5)
Certificate of Higher Education/City & Guilds, n (%) 53 (5.4) 8 (4.5) 45 (5.6)
Diploma HE/FE or HND/HNC, n (%) 69 (7.1) 7 (4.0) 62 (7.8)
Graduate certificate or diploma, n (%) 14 (1.4) 3 (1.7) 11 (1.4)
Degree, n (%) 158 (16.2) 15 (8.5) 143 (17.9)
Professional qualifications, n (%) 40 (4.1) 4 (2.3) 36 (4.5)
PG certificate, diploma, masters, doctorate, n (%) 65 (6.7) 3 (1.7) 62 (7.8)
Ethnic group
Nobs (Nmiss) 1224 (2) 216 (1) 1008 (1)
White, n (%) 895 (73.1) 154 (71.3) 741 (73.5)
Chinese, n (%) 1 (0.1) 0 (0.0) 1 (0.1)
Other ethnic group, n (%) 17 (1.4) 2 (0.9) 15 (1.5)
Mixed
White and black Caribbean, n (%) 17 (1.4) 4 (1.9) 13 (1.3)
White and black African, n (%) 3 (0.2) 1 (0.5) 2 (0.2)
White and Asian, n (%) 2 (0.2) 0 (0.0) 2 (0.2)
Other mixed background, n (%) 6 (0.5) 1 (0.5) 5 (0.5)
Asian
Indian, n (%) 30 (2.5) 5 (2.3) 25 (2.5)
Pakistani, n (%) 45 (3.7) 7 (3.2) 38 (3.8)
Bangladeshi, n (%) 5 (0.4) 2 (0.9) 3 (0.3)
Other Asian background, n (%) 23 (1.9) 2 (0.9) 21 (2.1)
Black
Caribbean, n (%) 47 (3.8) 11 (5.1) 36 (3.6)
African, n (%) 119 (9.7) 23 (10.6) 96 (9.5)
Other black background, n (%) 14 (1.1) 4 (1.9) 10 (1.0)
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TABLE 53 Baseline characteristics (part 3). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of survival at 2 years (continued )
Parameter All
Survival at 2 years available
No Yes
Ethnic group
Nobs (Nmiss) 1224 (2) 216 (1) 1008 (1)
White, n (%) 895 (73.1) 154 (71.3) 741 (73.5)
Black, n (%) 180 (14.7) 38 (17.6) 142 (14.1)
Asian, n (%) 104 (8.5) 16 (7.4) 88 (8.7)
Mixed, n (%) 28 (2.3) 6 (2.8) 22 (2.2)
Other, n (%) 17 (1.4) 2 (0.9) 15 (1.5)
A Level, Advanced Level; AS Level, Advanced Subsidiary Level; BTEC, Business and Technology Education Council;
FE, Further Education; GCSE, General Certificate of Secondary Education; HE, Higher Education; HNC, Higher National
Certificate; HND, Higher National Diploma; Nmiss, number of women with missing data; Nobs, number of observations;
O Level, ordinary level; PG, postgraduate.
Note
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TABLE 54 Baseline characteristics (part 4): this pregnancy. Number of observed values, number of missing values,
number and percentage per category or mean, standard deviation, median and quartiles, minimum and maximum
for all patients and by availability of survival at 2 years
Parameter All
Survival at 2 years available
No Yes
Gestation (weeks) at fFN test
Nobs (Nmiss) 1226 (0) 217 (0) 1009 (0)
Mean (SD) 22.9 (0.6) 22.9 (0.6) 22.9 (0.6)
Median (IQR) 22.9 (22.4–23.4) 22.9 (22.4–23.6) 22.9 (22.4–23.3)
Range 21.7–27.1 22.0–24.1 21.7–27.1
Fetal anomaly scan done
Nobs (Nmiss) 1226 (0) 217 (0) 1009 (0)
No, n (%) 63 (5.1) 12 (5.5) 51 (5.1)
Yes, n (%) 1163 (94.9) 205 (94.5) 958 (94.9)
Fetal anomaly scan result
Nobs (Nmiss) 1163 (0) 205 (0) 958 (0)
Normal, n (%) 1150 (98.9) 205 (100.0) 945 (98.6)
Defined abnormality, n (%) 7 (0.6) 0 (0.0) 7 (0.7)
Uncertain abnormality, n (%) 6 (0.5) 0 (0.0) 6 (0.6)
Amniocentesis done
Nobs (Nmiss) 1226 (0) 217 (0) 1009 (0)
No, n (%) 1218 (99.3) 216 (99.5) 1002 (99.3)
Yes, n (%) 8 (0.7) 1 (0.5) 7 (0.7)
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TABLE 54 Baseline characteristics (part 4): this pregnancy. Number of observed values, number of missing values,
number and percentage per category or mean, standard deviation, median and quartiles, minimum and maximum
for all patients and by availability of survival at 2 years (continued )
Parameter All
Survival at 2 years available
No Yes
Results of amniocentesis
Nobs (Nmiss) 8 (0) 1 (0) 7 (0)
Normal, n (%) 8 (100.0) 1 (100.0) 7 (100.0)
Other, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Chorionic villus sampling done
Nobs (Nmiss) 1225 (1) 217 (0) 1008 (1)
No, n (%) 1216 (99.3) 214 (98.6) 1002 (99.4)
Yes, n (%) 9 (0.7) 3 (1.4) 6 (0.6)
Results of chorionic villus sampling
Nobs (Nmiss) 9 (0) 3 (0) 6 (0)
Normal, n (%) 9 (100.0) 3 (100.0) 6 (100.0)
Other, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Cervical length (mm)
Nobs (Nmiss) 712 (514) 129 (88) 583 (426)
Mean (SD) 28.5 (10.8) 29.9 (10.0) 28.2 (11.0)
Median (IQR) 30.0 (22.0–36.0) 32.0 (23.0–37.0) 30.0 (22.0–36.0)
Range 0.0–84.0 4.0–50.0 0.0–84.0
Risk
Nobs (Nmiss) 1226 (0) 217 (0) 1009 (0)
Low, n (%) 882 (71.9) 157 (72.4) 725 (71.9)
High, n (%) 344 (28.1) 60 (27.6) 284 (28.1)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 55 Previous pregnancies (part 1). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of survival at 2 years
Parameter All
Survival at 2 years available
No Yes
Any previous pregnancy
Nobs (Nmiss) 1224 (2) 215 (2) 1009 (0)
No, n (%) 52 (4.2) 2 (0.9) 50 (5.0)
Yes, n (%) 1172 (95.8) 213 (99.1) 959 (95.0)
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TABLE 55 Previous pregnancies (part 1). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of survival at 2 years (continued )
Parameter All
Survival at 2 years available
No Yes
Number of previous pregnancies
Nobs (Nmiss) 1224 (2) 215 (2) 1009 (0)
Mean (SD) 2.6 (2.0) 3.1 (2.2) 2.5 (1.9)
Median (IQR) 2.0 (1.0–3.0) 3.0 (1.0–4.0) 2.0 (1.0–3.0)
Range 0.0–14.0 0.0–12.0 0.0–14.0
Any previous pregnancy of ≥ 14 weeks’ gestation
Nobs (Nmiss) 1224 (2) 215 (2) 1009 (0)
No, n (%) 75 (6.1) 6 (2.8) 69 (6.8)
Yes, n (%) 1149 (93.9) 209 (97.2) 940 (93.2)
Number of previous pregnancies of ≥ 14 weeks’ gestation
Nobs (Nmiss) 1224 (2) 215 (2) 1009 (0)
Mean (SD) 1.9 (1.4) 2.3 (1.5) 1.8 (1.4)
Median (IQR) 2.0 (1.0–2.0) 2.0 (1.0–3.0) 1.0 (1.0–2.0)
Range 0.0–13.0 0.0–8.0 0.0–13.0
Any previous live birth
Nobs (Nmiss) 1224 (2) 215 (2) 1009 (0)
No, n (%) 197 (16.1) 26 (12.1) 171 (16.9)
Yes, n (%) 1027 (83.9) 189 (87.9) 838 (83.1)
Number of previous live births
Nobs (Nmiss) 1224 (2) 215 (2) 1009 (0)
Mean (SD) 1.5 (1.3) 1.8 (1.4) 1.5 (1.3)
Median (IQR) 1.0 (1.0–2.0) 2.0 (1.0–2.0) 1.0 (1.0–2.0)
Range 0.0–13.0 0.0–8.0 0.0–13.0
Any previous pregnancy that ended with baby alive and well
Nobs (Nmiss) 1224 (2) 215 (2) 1009 (0)
No, n (%) 646 (52.8) 109 (50.7) 537 (53.2)
Yes, n (%) 578 (47.2) 106 (49.3) 472 (46.8)
Number of previous pregnancies that ended with baby alive and well
Nobs (Nmiss) 1224 (2) 215 (2) 1009 (0)
Mean (SD) 0.8 (1.2) 0.9 (1.2) 0.8 (1.2)
Median (IQR) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0)
Range 0.0–13.0 0.0–6.0 0.0–13.0
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 56 Previous pregnancies (part 2). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of survival at 2 years
Parameter All
Survival at 2 years available
No Yes
History of induced labour or elective caesarean section
Nobs (Nmiss) 1224 (2) 215 (2) 1009 (0)
No, n (%) 1065 (87.0) 178 (82.8) 887 (87.9)
Yes, n (%) 159 (13.0) 37 (17.2) 122 (12.1)
History of miscarriage
Nobs (Nmiss) 1224 (2) 215 (2) 1009 (0)
No, n (%) 701 (57.3) 114 (53.0) 587 (58.2)
Yes, n (%) 523 (42.7) 101 (47.0) 422 (41.8)
History of ectopic pregnancy
Nobs (Nmiss) 1224 (2) 215 (2) 1009 (0)
No, n (%) 1193 (97.5) 209 (97.2) 984 (97.5)
Yes, n (%) 31 (2.5) 6 (2.8) 25 (2.5)
History of termination of pregnancy
Nobs (Nmiss) 1224 (2) 215 (2) 1009 (0)
No, n (%) 1085 (88.6) 183 (85.1) 902 (89.4)
Yes, n (%) 139 (11.4) 32 (14.9) 107 (10.6)
History of termination of pregnancy before 14 weeks’ gestation
Nobs (Nmiss) 1226 (0) 217 (0) 1009 (0)
No, n (%) 1106 (90.2) 190 (87.6) 916 (90.8)
Yes, n (%) 120 (9.8) 27 (12.4) 93 (9.2)
History of termination of pregnancy at ≥ 14 weeks’ gestation
Nobs (Nmiss) 1226 (0) 217 (0) 1009 (0)
No, n (%) 1201 (98.0) 210 (96.8) 991 (98.2)
Yes, n (%) 25 (2.0) 7 (3.2) 18 (1.8)
History of live birth followed by neonatal death
Nobs (Nmiss) 1224 (2) 215 (2) 1009 (0)
No, n (%) 1059 (86.5) 186 (86.5) 873 (86.5)
Yes, n (%) 165 (13.5) 29 (13.5) 136 (13.5)
History of live birth followed by death other than neonatal
Nobs (Nmiss) 1224 (2) 215 (2) 1009 (0)
No, n (%) 1208 (98.7) 210 (97.7) 998 (98.9)
Yes, n (%) 16 (1.3) 5 (2.3) 11 (1.1)
History of stillbirth
Nobs (Nmiss) 1224 (2) 215 (2) 1009 (0)
No, n (%) 1129 (92.2) 195 (90.7) 934 (92.6)
Yes, n (%) 95 (7.8) 20 (9.3) 75 (7.4)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 57 Summaries of primary outcome measures for all patients and according to treatment groups
Parameter All
Trial group
Placebo Progesterone
Death or delivery before 34 weeks’ gestation
Nobs (Nmiss) 1197 (29) 597 (13) 600 (16)
No, n (%) 993 (83.0) 489 (81.9) 504 (84.0)
Yes, n (%) 204 (17.0) 108 (18.1) 96 (16.0)
Death, brain injury or severe chronic lung disease
Nobs (Nmiss) 1176 (50) 587 (23) 589 (27)
No, n (%) 1077 (91.6) 527 (89.8) 550 (93.4)
Yes, n (%) 99 (8.4) 60 (10.2) 39 (6.6)
Bayley-III cognitive composite score at 2 years
Nobs (Nmiss) 833 (393) 423 (187) 410 (206)
Mean (SD) 99.6 (14.9) 99.5 (15.0) 99.7 (14.7)
Median (IQR) 100.0
(90.0–105.0)
100.0
(90.0–105.0)
100.0
(90.0–110.0)
Range 55.0–149.0 55.0–149.0 55.0–145.0
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TABLE 57 Summaries of primary outcome measures for all patients and according to treatment groups (continued )
Parameter All
Trial group
Placebo Progesterone
Bayley-III cognitive composite score at 2 years (imputed)
Nobs (Nmiss) 869 (357) 439 (171) 430 (186)
Mean (SD) 97.5 (17.7) 97.7 (17.5) 97.3 (17.9)
Median (IQR) 100.0
(90.0–105.0)
100.0
(90.0–105.0)
100.0
(90.0–105.0)
Range 49.0–149.0 49.0–149.0 49.0–145.0
Alive at 2 years
Nobs (Nmiss) 1009 (217) 509 (101) 500 (116)
No, n (%) 36 (3.6) 16 (3.1) 20 (4.0)
Yes, n (%) 973 (96.4) 493 (96.9) 480 (96.0)
Survival (days)
Nobs (Nmiss) 1198 (28) 598 (12) 600 (16)
Deaths, median time 36,756.00 16,759.00 20,751.00
Range 1–1335 1–1331 1–1335
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 58 Summaries of secondary outcome measures at delivery/neonatal for all patients and according to
treatment groups (part 1)
All
Trial group
Placebo Progesterone
Gestational age at delivery (weeks)
Nobs (Nmiss) 1197 (29) 597 (13) 600 (16)
Mean (SD) 36.9 (4.2) 36.8 (4.2) 36.9 (4.1)
Median (IQR) 38.3 (35.7–39.6) 38.3 (35.4–39.7) 38.1 (36.0–39.4)
Range 22.4–42.7 22.4–42.7 23.0–42.1
Delivery before 34 weeks’ gestation
Nobs (Nmiss) 1197 (29) 597 (13) 600 (16)
No, n (%) 993 (83.0) 489 (81.9) 504 (84.0)
Yes, n (%) 204 (17.0) 108 (18.1) 96 (16.0)
Fetal death (miscarriage or stillbirth)
Nobs (Nmiss) 1197 (29) 597 (13) 600 (16)
No, n (%) 1182 (98.7) 590 (98.8) 592 (98.7)
Yes, n (%) 15 (1.3) 7 (1.2) 8 (1.3)
Neonatal death
Nobs (Nmiss) 1197 (29) 597 (13) 600 (16)
No, n (%) 1190 (99.4) 591 (99.0) 599 (99.8)
Yes, n (%) 7 (0.6) 6 (1.0) 1 (0.2)
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TABLE 58 Summaries of secondary outcome measures at delivery/neonatal for all patients and according to
treatment groups (part 1) (continued )
All
Trial group
Placebo Progesterone
Brain injury
Nobs (Nmiss) 1158 (68) 574 (36) 584 (32)
No, n (%) 1106 (95.5) 540 (94.1) 566 (96.9)
Yes, n (%) 52 (4.5) 34 (5.9) 18 (3.1)
Severe chronic lung disease
Nobs (Nmiss) 1154 (72) 574 (36) 580 (36)
No, n (%) 1119 (97.0) 556 (96.9) 563 (97.1)
Yes, n (%) 35 (3.0) 18 (3.1) 17 (2.9)
Need for surfactant administration
Nobs (Nmiss) 1156 (70) 573 (37) 583 (33)
No, n (%) 1064 (92.0) 528 (92.1) 536 (91.9)
Yes, n (%) 92 (8.0) 45 (7.9) 47 (8.1)
Necrotising enterocolitis
Nobs (Nmiss) 1155 (71) 574 (36) 581 (35)
No, n (%) 1124 (97.3) 561 (97.7) 563 (96.9)
Yes suspected, n (%) 16 (1.4) 5 (0.9) 11 (1.9)
Yes medical treatment only, n (%) 10 (0.9) 4 (0.7) 6 (1.0)
Yes required drain or laparotomy, n (%) 5 (0.4) 4 (0.7) 1 (0.2)
Infection
Nobs (Nmiss) 1154 (72) 573 (37) 581 (35)
No, n (%) 1074 (93.1) 537 (93.7) 537 (92.4)
Yes, n (%) 80 (6.9) 36 (6.3) 44 (7.6)
Number of discrete episodes with positive blood culture in those with infection
Nobs (Nmiss) 73 (7) 33 (3) 40 (4)
0, n (%) 37 (50.7) 14 (42.4) 23 (57.5)
1, n (%) 28 (38.4) 16 (48.5) 12 (30.0)
2, n (%) 7 (9.6) 3 (9.1) 4 (10.0)
4, n (%) 1 (1.4) 0 (0.0) 1 (2.5)
Number of discrete episodes with positive cerebrospinal fluid culture in those with infection
Nobs (Nmiss) 74 (6) 34 (2) 40 (4)
0, n (%) 71 (95.9) 34 (100.0) 37 (92.5)
1, n (%) 2 (2.7) 0 (0.0) 2 (5.0)
2, n (%) 1 (1.4) 0 (0.0) 1 (2.5)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 59 Summaries of secondary outcome measures at delivery/neonatal for all patients and according to
treatment groups (part 2)
All
Trial group
Placebo Progesterone
Highest level of care in delivery room
Nobs (Nmiss) 1165 (61) 584 (26) 581 (35)
Minimal (none required or tactile stimulation), n (%) 924 (79.3) 456 (78.1) 468 (80.6)
Intubation plus chest compressions and/or adrenaline, n (%) 3 (0.3) 0 (0.0) 3 (0.5)
Suction, n (%) 7 (0.6) 4 (0.7) 3 (0.5)
Suction and facial O2 only, n (%) 39 (3.3) 19 (3.3) 20 (3.4)
Mask ventilation only, n (%) 100 (8.6) 56 (9.6) 44 (7.6)
Intubation, n (%) 86 (7.4) 47 (8.0) 39 (6.7)
Intubation plus chest compressions, n (%) 6 (0.5) 2 (0.3) 4 (0.7)
Number of days of normal care
Nobs (Nmiss) 1151 (75) 570 (40) 581 (35)
Mean (SD) 1.7 (2.0) 1.7 (2.3) 1.7 (1.6)
Median (IQR) 1.0 (1.0–2.0) 1.0 (0.0–2.0) 1.0 (1.0–2.0)
Range 0.0–28.0 0.0–28.0 0.0–12.0
Number of days of special care
Nobs (Nmiss) 1151 (75) 570 (40) 581 (35)
Mean (SD) 3.5 (9.6) 4.2 (10.6) 2.9 (8.3)
Median (IQR) (0.0–0.0) 0.0 (0.0–1.0) 0.0 (0.0–0.0)
Range 0.0–92.0 0.0–85.0 0.0–92.0
Number of days of level 2 care
Nobs (Nmiss) 1149 (77) 569 (41) 580 (36)
Mean (SD) 2.2 (9.5) 2.2 (8.4) 2.1 (10.4)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Range 0.0–137.0 0.0–74.0 0.0–137.0
Number of days of level 1 care
Nobs (Nmiss) 1149 (77) 569 (41) 580 (36)
Mean (SD) 1.9 (7.7) 1.8 (7.3) 1.9 (8.1)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Range 0.0–75.0 0.0–75.0 0.0–64.0
Maternal or child SAEs during pregnancy and birtha
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 1097 (89.5) 540 (88.5) 557 (90.4)
Yes, n (%) 129 (10.5) 70 (11.5) 59 (9.6)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
a Up to and including day 1 after birth.
Note
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TABLE 60 Summaries of secondary outcome measures at 2-year follow-up for all patients and according to
treatment groups (part 1)
All
Trial group
Placebo Progesterone
Death or moderate/severe neurodevelopmental impairment
Nobs (Nmiss) 818 (408) 419 (191) 399 (217)
No, n (%) 700 (85.6) 368 (87.8) 332 (83.2)
Yes, n (%) 118 (14.4) 51 (12.2) 67 (16.8)
Moderate/severe neurodevelopmental impairment
Nobs (Nmiss) 782 (444) 403 (207) 379 (237)
No, n (%) 700 (89.5) 368 (91.3) 332 (87.6)
Yes, n (%) 82 (10.5) 35 (8.7) 47 (12.4)
Components of neurodevelopmental disability
Motor
Nobs (Nmiss) 917 (309) 456 (154) 461 (155)
No, n (%) 909 (99.1) 452 (99.1) 457 (99.1)
Yes, n (%) 8 (0.9) 4 (0.9) 4 (0.9)
Cognitive function
Nobs (Nmiss) 913 (313) 452 (158) 461 (155)
No, n (%) 876 (95.9) 434 (96.0) 442 (95.9)
Yes, n (%) 37 (4.1) 18 (4.0) 19 (4.1)
Hearing
Nobs (Nmiss) 931 (295) 465 (145) 466 (150)
No, n (%) 928 (99.7) 463 (99.6) 465 (99.8)
Yes, n (%) 3 (0.3) 2 (0.4) 1 (0.2)
Speech and language
Nobs (Nmiss) 891 (335) 446 (164) 445 (171)
No, n (%) 859 (96.4) 432 (96.9) 427 (96.0)
Yes, n (%) 32 (3.6) 14 (3.1) 18 (4.0)
Vision
Nobs (Nmiss) 913 (313) 466 (144) 447 (169)
No, n (%) 909 (99.6) 462 (99.1) 447 (100.0)
Yes, n (%) 4 (0.4) 4 (0.9) 0 (0.0)
Respiratory
Nobs (Nmiss) 847 (379) 434 (176) 413 (203)
No, n (%) 837 (98.8) 431 (99.3) 406 (98.3)
Yes, n (%) 10 (1.2) 3 (0.7) 7 (1.7)
Gastrointestinal
Nobs (Nmiss) 844 (382) 432 (178) 412 (204)
No, n (%) 831 (98.5) 428 (99.1) 403 (97.8)
Yes, n (%) 13 (1.5) 4 (0.9) 9 (2.2)
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TABLE 60 Summaries of secondary outcome measures at 2-year follow-up for all patients and according to
treatment groups (part 1) (continued )
All
Trial group
Placebo Progesterone
Renal
Nobs (Nmiss) 848 (378) 434 (176) 414 (202)
No, n (%) 844 (99.5) 433 (99.8) 411 (99.3)
Yes, n (%) 4 (0.5) 1 (0.2) 3 (0.7)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 61 Summaries of secondary outcome measures at 2-year follow-up for all patients and according to
treatment groups (part 2): hospitalisations
All
Trial group
Placebo Progesterone
Admitted to hospital
Nobs (Nmiss) 850 (376) 434 (176) 416 (200)
No, n (%) 751 (88.4) 383 (88.2) 368 (88.5)
Yes, n (%) 99 (11.6) 51 (11.8) 48 (11.5)
Admitted to hospital for respiratory reason
Nobs (Nmiss) 127 (1099) 63 (547) 64 (552)
No, n (%) 79 (62.2) 39 (61.9) 40 (62.5)
Yes, n (%) 48 (37.8) 24 (38.1) 24 (37.5)
Admitted to hospital for surgery
Nobs (Nmiss) 118 (1108) 56 (554) 62 (554)
No, n (%) 96 (81.4) 49 (87.5) 47 (75.8)
Yes, n (%) 22 (18.6) 7 (12.5) 15 (24.2)
Admitted to hospital for other reason
Nobs (Nmiss) 119 (1107) 56 (554) 63 (553)
No, n (%) 92 (77.3) 43 (76.8) 49 (77.8)
Yes, n (%) 27 (22.7) 13 (23.2) 14 (22.2)
Number of hospitalisations
Nobs (Nmiss) 858 (368) 437 (173) 421 (195)
0, n (%) 750 (87.4) 386 (88.3) 364 (86.5)
1, n (%) 87 (10.1) 42 (9.6) 45 (10.7)
2, n (%) 15 (1.7) 5 (1.1) 10 (2.4)
3, n (%) 2 (0.2) 2 (0.5) 0 (0.0)
4, n (%) 2 (0.2) 1 (0.2) 1 (0.2)
7, n (%) 1 (0.1) 1 (0.2) 0 (0.0)
11, n (%) 1 (0.1) 0 (0.0) 1 (0.2)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 62 Summaries of secondary outcome measures at 2-year follow-up for all patients and according to
treatment groups (part 3): Strengths and Difficulties Questionnaire
All
Trial group
Placebo Progesterone
Emotional problems scale
Nobs (Nmiss) 669 (557) 341 (269) 328 (288)
Mean (SD) 1.1 (1.2) 1.1 (1.2) 1.1 (1.2)
Median (IQR) 1.0 (0.0–2.0) 1.0 (0.0–1.0) 1.0 (0.0–2.0)
Range 0.0–10.0 0.0–10.0 0.0–7.0
Conduct problems scale
Nobs (Nmiss) 668 (558) 342 (268) 326 (290)
Mean (SD) 2.6 (1.8) 2.7 (1.8) 2.6 (1.8)
Median (IQR) 2.0 (1.0–4.0) 2.0 (1.0–4.0) 2.0 (1.0–3.8)
Range 0.0–10.0 0.0–10.0 0.0–8.0
Hyperactivity scale
Nobs (Nmiss) 649 (577) 334 (276) 315 (301)
Mean (SD) 4.3 (2.3) 4.2 (2.4) 4.5 (2.3)
Median (IQR) 4.0 (3.0–6.0) 4.0 (2.0–6.0) 4.0 (3.0–6.0)
Range 0.0–10.0 0.0–10.0 0.0–10.0
Peer problems scale
Nobs (Nmiss) 663 (563) 345 (265) 318 (298)
Mean (SD) 2.0 (1.6) 2.0 (1.7) 2.1 (1.6)
Median (IQR) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0)
Range 0.0–7.0 0.0–7.0 0.0–7.0
Prosocial scale
Nobs (Nmiss) 659 (567) 339 (271) 320 (296)
Mean (SD) 6.1 (2.2) 6.3 (2.2) 5.9 (2.3)
Median (IQR) 6.0 (5.0–8.0) 6.0 (5.0–8.0) 6.0 (4.0–8.0)
Range 0.0–10.0 0.0–10.0 0.0–10.0
Total difficulties scale
Nobs (Nmiss) 597 (629) 302 (308) 295 (321)
Mean (SD) 10.0 (4.9) 9.8 (4.9) 10.2 (4.9)
Median (IQR) 9.0 (7.0–12.0) 9.0 (6.0–12.0) 9.0 (7.0–13.0)
Range 0.0–30.0 0.0–30.0 0.0–25.0
Impact scale
Nobs (Nmiss) 828 (398) 424 (186) 404 (212)
Mean (SD) 0.2 (1.1) 0.2 (1.0) 0.2 (1.2)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Range 0.0–10.0 0.0–10.0 0.0–10.0
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 63 Summaries of secondary outcome measures for all patients and according to treatment groups: women’s
views at 1 month post delivery (part 1)
All
Trial group
Placebo Progesterone
Age of baby (days)
Nobs (Nmiss) 612 (614) 317 (293) 295 (321)
Mean (SD) 94.6 (163.3) 100.9 (171.8) 87.8 (153.6)
Median (IQR) 17.0 (7.0–91.0) 21.0 (7.0–112.0) 14.0 (7.0–70.0)
Range 0.0–805.0 0.0–805.0 0.0–751.0
Treatment received to prevent preterm labor
Nobs (Nmiss) 643 (583) 332 (278) 311 (305)
None, n (%) 389 (60.5) 197 (59.3) 192 (61.7)
Aspirin, n (%) 66 (10.3) 34 (10.2) 32 (10.3)
Antibiotics, n (%) 41 (6.4) 22 (6.6) 19 (6.1)
Stitch, n (%) 93 (14.5) 51 (15.4) 42 (13.5)
Other, n (%) 54 (8.4) 28 (8.4) 26 (8.4)
Progesterone in previous pregnancy
Nobs (Nmiss) 632 (594) 325 (285) 307 (309)
Yes, n (%) 67 (10.6) 45 (13.8) 22 (7.2)
No, n (%) 565 (89.4) 280 (86.2) 285 (92.8)
Relationship status
Nobs (Nmiss) 639 (587) 331 (279) 308 (308)
Married, n (%) 356 (55.7) 181 (54.7) 175 (56.8)
Living with partner, n (%) 213 (33.3) 105 (31.7) 108 (35.1)
Single, n (%) 70 (11.0) 45 (13.6) 25 (8.1)
Widowed, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Preferred treatment mode
Nobs (Nmiss) 613 (613) 314 (296) 299 (317)
Vaginal pessary, n (%) 434 (70.8) 222 (70.7) 212 (70.9)
Rectal pessary, n (%) 17 (2.8) 8 (2.5) 9 (3.0)
Injection, n (%) 158 (25.8) 82 (26.1) 76 (25.4)
Any, n (%) 2 (0.3) 0 (0.0) 2 (0.7)
Pessaries, n (%) 2 (0.3) 2 (0.6) 0 (0.0)
Enough information about trial participation
Nobs (Nmiss) 639 (587) 330 (280) 309 (307)
Yes, n (%) 624 (97.7) 322 (97.6) 302 (97.7)
No, n (%) 15 (2.3) 8 (2.4) 7 (2.3)
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TABLE 63 Summaries of secondary outcome measures for all patients and according to treatment groups: women’s
views at 1 month post delivery (part 1) (continued )
All
Trial group
Placebo Progesterone
Enough information about treatment
Nobs (Nmiss) 640 (586) 331 (279) 309 (307)
Yes, n (%) 626 (97.8) 324 (97.9) 302 (97.7)
No, n (%) 14 (2.2) 7 (2.1) 7 (2.3)
Satisfaction with treatment
Nobs (Nmiss) 634 (592) 327 (283) 307 (309)
Extremely satisfied, n (%) 445 (70.2) 244 (74.6) 201 (65.5)
Fairly satisfied, n (%) 163 (25.7) 70 (21.4) 93 (30.3)
Somewhat dissatisfied, n (%) 22 (3.5) 10 (3.1) 12 (3.9)
Extremely dissatisfied, n (%) 4 (0.6) 3 (0.9) 1 (0.3)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 02 14:34:04 2015.
TABLE 64 Summaries of secondary outcome measures for all patients and according to treatment groups: women’s
views at 1 month post delivery (part 2)
All
Trial group
Placebo Progesterone
The treatment was messy
Nobs (Nmiss) 628 (598) 325 (285) 303 (313)
Strongly agree and would not repeat treatment, n (%) 35 (5.6) 14 (4.3) 21 (6.9)
Agree but would still repeat treatment, n (%) 223 (35.5) 110 (33.8) 113 (37.3)
Neither agree nor disagree, n (%) 94 (15.0) 48 (14.8) 46 (15.2)
Disagree, n (%) 276 (43.9) 153 (47.1) 123 (40.6)
The treatment smelt unpleasant
Nobs (Nmiss) 620 (606) 322 (288) 298 (318)
Strongly agree and would not repeat treatment, n (%) 19 (3.1) 9 (2.8) 10 (3.4)
Agree but would still repeat treatment, n (%) 40 (6.5) 18 (5.6) 22 (7.4)
Neither agree nor disagree, n (%) 75 (12.1) 43 (13.4) 32 (10.7)
Disagree, n (%) 486 (78.4) 252 (78.3) 234 (78.5)
The application of treatment was uncomfortable
Nobs (Nmiss) 624 (602) 323 (287) 301 (315)
Strongly agree and would not repeat treatment, n (%) 37 (5.9) 19 (5.9) 18 (6.0)
Agree but would still repeat treatment, n (%) 125 (20.0) 64 (19.8) 61 (20.3)
Neither agree nor disagree, n (%) 121 (19.4) 62 (19.2) 59 (19.6)
Disagree, n (%) 341 (54.6) 178 (55.1) 163 (54.2)
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TABLE 64 Summaries of secondary outcome measures for all patients and according to treatment groups: women’s
views at 1 month post delivery (part 2) (continued )
All
Trial group
Placebo Progesterone
The treatment interfered with sexual activity
Nobs (Nmiss) 619 (607) 320 (290) 299 (317)
Strongly agree and would not repeat treatment, n (%) 33 (5.3) 16 (5.0) 17 (5.7)
Agree but would still repeat treatment, n (%) 154 (24.9) 68 (21.2) 86 (28.8)
Neither agree nor disagree, n (%) 145 (23.4) 90 (28.1) 55 (18.4)
Disagree, n (%) 287 (46.4) 146 (45.6) 141 (47.2)
The treatment stopped me working
Nobs (Nmiss) 625 (601) 324 (286) 301 (315)
Strongly agree and would not repeat treatment, n (%) 17 (2.7) 12 (3.7) 5 (1.7)
Agree but would still repeat treatment, n (%) 11 (1.8) 8 (2.5) 3 (1.0)
Neither agree nor disagree, n (%) 28 (4.5) 16 (4.9) 12 (4.0)
Disagree, n (%) 569 (91.0) 288 (88.9) 281 (93.4)
The treatment made me feel dirty
Nobs (Nmiss) 624 (602) 324 (286) 300 (316)
Strongly agree and would not repeat treatment, n (%) 22 (3.5) 11 (3.4) 11 (3.7)
Agree but would still repeat treatment, n (%) 70 (11.2) 32 (9.9) 38 (12.7)
Neither agree nor disagree, n (%) 65 (10.4) 34 (10.5) 31 (10.3)
Disagree, n (%) 467 (74.8) 247 (76.2) 220 (73.3)
The treatment caused irritation
Nobs (Nmiss) 625 (601) 322 (288) 303 (313)
Strongly agree and would not repeat treatment, n (%) 27 (4.3) 14 (4.3) 13 (4.3)
Agree but would still repeat treatment, n (%) 69 (11.0) 32 (9.9) 37 (12.2)
Neither agree nor disagree, n (%) 67 (10.7) 33 (10.2) 34 (11.2)
Disagree, n (%) 462 (73.9) 243 (75.5) 219 (72.3)
The treatment made me feel constipated
Nobs (Nmiss) 625 (601) 323 (287) 302 (314)
Strongly agree and would not repeat treatment, n (%) 16 (2.6) 10 (3.1) 6 (2.0)
Agree but would still repeat treatment, n (%) 26 (4.2) 13 (4.0) 13 (4.3)
Neither agree nor disagree, n (%) 47 (7.5) 21 (6.5) 26 (8.6)
Disagree, n (%) 536 (85.8) 279 (86.4) 257 (85.1)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 65 Summaries of secondary outcome measures for all patients and according to treatment groups: women’s
views at 1 month post delivery (part 3)
All
Trial group
Placebo Progesterone
The treatment gave me backache
Nobs (Nmiss) 624 (602) 324 (286) 300 (316)
Strongly agree and would not repeat treatment, n (%) 15 (2.4) 9 (2.8) 6 (2.0)
Agree but would still repeat treatment, n (%) 11 (1.8) 6 (1.9) 5 (1.7)
Neither agree nor disagree, n (%) 42 (6.7) 22 (6.8) 20 (6.7)
Disagree, n (%) 556 (89.1) 287 (88.6) 269 (89.7)
Panty liners or sanitary towels used?
Nobs (Nmiss) 630 (596) 327 (283) 303 (313)
Yes, n (%) 412 (65.4) 212 (64.8) 200 (66.0)
No, n (%) 218 (34.6) 115 (35.2) 103 (34.0)
Number of towels used per day
Nobs (Nmiss) 391 (835) 197 (413) 194 (422)
Mean (SD) 2.3 (1.4) 2.3 (1.4) 2.3 (1.3)
Median (IQR) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0)
Range 0.0–10.0 0.0–10.0 0.0–7.0
Did treatment interfere with daily activities?
Nobs (Nmiss) 629 (597) 324 (286) 305 (311)
Yes, n (%) 11 (1.7) 8 (2.5) 3 (1.0)
No, n (%) 618 (98.3) 316 (97.5) 302 (99.0)
Was the frequency of appointment with health professional . . .
Nobs (Nmiss) 608 (618) 311 (299) 297 (319)
Too often, n (%) 3 (0.5) 1 (0.3) 2 (0.7)
Enough, n (%) 583 (95.9) 302 (97.1) 281 (94.6)
Not enough, n (%) 22 (3.6) 8 (2.6) 14 (4.7)
How would you feel if treatment became normal practice?
Nobs (Nmiss) 623 (603) 320 (290) 303 (313)
Disappointed, n (%) 6 (1.0) 3 (0.9) 3 (1.0)
Not sure, n (%) 168 (27.0) 89 (27.8) 79 (26.1)
Pleased, n (%) 449 (72.1) 228 (71.2) 221 (72.9)
If time went backwards would you take part again?
Nobs (Nmiss) 635 (591) 327 (283) 308 (308)
Definitely not, n (%) 6 (0.9) 4 (1.2) 2 (0.6)
Probably not, n (%) 21 (3.3) 9 (2.8) 12 (3.9)
Not sure, n (%) 37 (5.8) 19 (5.8) 18 (5.8)
Probably yes, n (%) 159 (25.0) 85 (26.0) 74 (24.0)
Definitely yes, n (%) 412 (64.9) 210 (64.2) 202 (65.6)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 66 Summaries of secondary outcome measures for all patients and according to treatment groups: women’s
views at 1 month post delivery (part 4)
All
Trial group
Placebo Progesterone
Did you have access to health professional for medical support?
Nobs (Nmiss) 632 (594) 325 (285) 307 (309)
Yes, n (%) 618 (97.8) 319 (98.2) 299 (97.4)
No, n (%) 14 (2.2) 6 (1.8) 8 (2.6)
Did you have access to a health professional for emotional support?
Nobs (Nmiss) 623 (603) 321 (289) 302 (314)
Yes, n (%) 566 (90.9) 294 (91.6) 272 (90.1)
No, n (%) 57 (9.1) 27 (8.4) 30 (9.9)
Did partner have adequate support from care providers?
Nobs (Nmiss) 611 (615) 315 (295) 296 (320)
Yes, n (%) 543 (88.9) 281 (89.2) 262 (88.5)
No, n (%) 68 (11.1) 34 (10.8) 34 (11.5)
Willing to complete 6-month questionnaire?
Nobs (Nmiss) 222 (1004) 119 (491) 103 (513)
Yes, n (%) 205 (92.3) 112 (94.1) 93 (90.3)
No, n (%) 17 (7.7) 7 (5.9) 10 (9.7)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 67 Summaries of secondary outcome measures for all patients and according to treatment groups: women’s
views at 6 months post delivery
All
Trial group
Placebo Progesterone
Enough information about treatment
Nobs (Nmiss) 79 (1147) 45 (565) 34 (582)
Yes, n (%) 77 (97.5) 44 (97.8) 33 (97.1)
No, n (%) 2 (2.5) 1 (2.2) 1 (2.9)
Satisfaction with treatment
Nobs (Nmiss) 78 (1148) 44 (566) 34 (582)
Extremely satisfied, n (%) 60 (76.9) 33 (75.0) 27 (79.4)
Fairly satisfied, n (%) 18 (23.1) 11 (25.0) 7 (20.6)
Somewhat dissatisfied, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Extremely dissatisfied, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
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TABLE 67 Summaries of secondary outcome measures for all patients and according to treatment groups: women’s
views at 6 months post delivery (continued )
All
Trial group
Placebo Progesterone
How would you feel if treatment became normal practice?
Nobs (Nmiss) 78 (1148) 44 (566) 34 (582)
Disappointed, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Not sure, n (%) 10 (12.8) 7 (15.9) 3 (8.8)
Pleased, n (%) 68 (87.2) 37 (84.1) 31 (91.2)
If time went backwards would you take part again?
Nobs (Nmiss) 79 (1147) 45 (565) 34 (582)
Definitely not, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Probably not, n (%) 1 (1.3) 1 (2.2) 0 (0.0)
Not sure, n (%) 4 (5.1) 1 (2.2) 3 (8.8)
Probably yes, n (%) 11 (13.9) 5 (11.1) 6 (17.6)
Definitely yes, n (%) 63 (79.7) 38 (84.4) 25 (73.5)
Did you have access to a health professional for medical support?
Nobs (Nmiss) 79 (1147) 45 (565) 34 (582)
Yes, n (%) 76 (96.2) 44 (97.8) 32 (94.1)
No, n (%) 3 (3.8) 1 (2.2) 2 (5.9)
Did you have access to a health professional for emotional support?
Nobs (Nmiss) 76 (1150) 43 (567) 33 (583)
Yes, n (%) 70 (92.1) 41 (95.3) 29 (87.9)
No, n (%) 6 (7.9) 2 (4.7) 4 (12.1)
Did partner have adequate support from care providers?
Nobs (Nmiss) 77 (1149) 44 (566) 33 (583)
Yes, n (%) 67 (87.0) 41 (93.2) 26 (78.8)
No, n (%) 10 (13.0) 3 (6.8) 7 (21.2)
Willing participate in interview
Nobs (Nmiss) 377 (849) 200 (410) 177 (439)
Yes, n (%) 301 (79.8) 164 (82.0) 137 (77.4)
No, n (%) 76 (20.2) 36 (18.0) 40 (22.6)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 68 Summaries of EQ-5D health utility scores
All
Trial group
Placebo Progesterone
Randomisation
Nobs (Nmiss) 1056 (170) 524 (86) 532 (84)
Mean (SD) 0.876 (0.190) 0.874 (0.190) 0.879 (0.190)
Median (IQR) 1.000 (0.796–1.000) 1.000 (0.796–1.000) 1.000 (0.796–1.000)
Range –0.349 to 1.000 –0.349 to 1.000 –0.074 to 1.000
Birth
Nobs (Nmiss) 394 (832) 202 (408) 192 (424)
Mean (SD) 0.867 (0.198) 0.866 (0.203) 0.868 (0.194)
Median (IQR) 1.000 (0.796–1.000) 1.000 (0.796–1.000) 1.000 (0.796–1.000)
Range –0.184 to 1.000 –0.184 to 1.000 –0.016 to 1.000
12-month follow-up
Nobs (Nmiss) 616 (610) 307 (303) 309 (307)
Mean (SD) 0.875 (0.194) 0.872 (0.202) 0.878 (0.186)
Median (IQR) 0.883 (0.848–1.000) 0.883 (0.848–1.000) 0.883 (0.848–1.000)
Range –0.135 to 1.000 –0.135 to 1.000 –0.135 to 1.000
24-month follow-up
Nobs (Nmiss) 5 (1221) 2 (608) 3 (613)
Mean (SD) 0.940 (0.083) 0.925 (0.106) 0.949 (0.088)
Median (IQR) 1.000 (0.850–1.000) 0.925 (0.888–0.962) 1.000 (0.924–1.000)
Range 0.848–1.000 0.850–1.000 0.848–1.000
Change from baseline
Birth
Nobs (Nmiss) 390 (836) 199 (411) 191 (425)
Mean (SD) –0.022 (0.214) –0.023 (0.220) –0.021 (0.207)
Median (IQR) 0.000 (–0.152 to 0.036) 0.000 (–0.152 to 0.061) 0.000 (–0.114 to 0.000)
Range –1.032 to 0.970 –1.032 to 0.807 –0.787 to 0.970
12-month follow-up
Nobs (Nmiss) 553 (673) 274 (336) 279 (337)
Mean (SD) –0.012 (0.217) –0.015 (0.221) –0.009 (0.213)
Median (IQR) 0.000 (–0.117 to 0.035) 0.000 (–0.117 to 0.064) 0.000 (–0.117 to 0.000)
Range –1.135 to 1.128 –1.135 to 1.128 –0.841 to 0.829
24-month follow-up
Nobs (Nmiss) 4 (1222) 1 (609) 3 (613)
Mean (SD) 0.068 (0.136) 0.000 (–) 0.091 (0.158)
Median (IQR) 0.000 (0.000–0.068) 0.000 (0.000–0.000) 0.000 (0.000–0.136)
Range 0.000–0.273 0.000–0.000 0.000–0.273
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 69 Mixed effects logistic regression model for the effect of treatment on the primary obstetric outcome
death or delivery before 34 weeks’ gestation adjusted for previous pregnancy of ≥ 14 weeks’ gestation and study
centre as a random effect
Parameter OR 95% CI p-value
Treatment (progesterone vs. placebo) 0.86 0.64 to 1.17 0.336
Previous pregnancy of ≥ 14 weeks’ gestation 1.05 0.55 to 1.99 0.879
n= 1197
Note
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TABLE 70 Mixed effects logistic regression model for the effect of treatment on the primary neonatal outcome
death, brain injury or severe chronic lung disease adjusted for previous pregnancy of ≥ 14 weeks’ gestation and
study centre as a random effect
Parameter OR 95% CI p-value
Treatment (progesterone vs. placebo) 0.62 0.41 to 0.94 0.024
Previous pregnancy of ≥ 14 weeks’ gestation 1.05 0.45 to 2.44 0.913
n= 1176
Note
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TABLE 71 Mixed effects logistic regression model for the effect of treatment on the primary neonatal outcome
death, brain injury or severe chronic lung disease adjusted for previous pregnancy of ≥ 14 weeks’ gestation and
study centre as a random effect
Parameter OR 95% CI p-value
Treatment (progesterone vs. placebo) –0.48 –2.77 to 1.81 0.680
Previous pregnancy of ≥ 14 weeks’ gestation –6.37 –11.12 to –1.61 0.009
n= 869
Note
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TABLE 73 Mixed effects proportional hazards regression model for the effect of treatment on the primary childhood
outcome survival adjusted for previous pregnancy of ≥ 14 weeks’ gestation and study centre as a random effect
Parameter Hazard ratio 95% CI p-value
Treatment (progesterone vs. placebo) 1.26 0.65 to 2.42 0.497
Previous pregnancy of ≥ 14 weeks’ gestation 2.38 0.33 to 17.36 0.393
n= 1198
Note
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TABLE 74 Mixed effects proportional hazards regression model for the effect of treatment on the secondary birth
outcome gestational age at delivery adjusted for previous pregnancy of ≥ 14 weeks’ gestation and study centre as a
random effect
Parameter Hazard ratio 95% CI p-value
Treatment (progesterone vs. placebo) 1.03 0.92 to 1.15 0.616
Previous pregnancy of ≥ 14 weeks’ gestation 1.13 0.89 to 1.43 0.330
n= 1197
Note
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TABLE 72 Mixed effects logistic regression model for the effect of treatment on the primary childhood outcome
survival adjusted for previous pregnancy of ≥ 14 weeks’ gestation and study centre as a random effect
Parameter OR 95% CI p-value
Treatment (progesterone vs. placebo) 0.78 0.40 to 1.52 0.465
Previous pregnancy of ≥ 14 weeks’ gestation 0.38 0.05 to 2.81 0.344
n= 1009
Note
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TABLE 76 Logistic regression models for the effect of treatment on secondary neonatal outcomes adjusted for
previous pregnancies of ≥ 14 weeks’ gestation
Outcome n OR 95% CI p-value
Brain injury 1158 0.50 0.31 to 0.84 0.008
Severe chronic lung disease 1154 0.94 0.49 to 1.78 0.843
Need for surfactant administration 1156 1.03 0.68 to 1.55 0.903
Infection 1154 1.22 0.79 to 1.88 0.364
Mother or child suffering a SAE during pregnancy and
birth
1224 0.83 0.58 to 1.16 0.274
Note
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TABLE 77 Poisson or binomial regression models for the effect of treatment on secondary neonatal outcomes
adjusted for previous pregnancies of ≥ 14 weeks’ gestation
Outcome n
Expected
mean ratio 95% CI p-value
Number of discrete episodes of bloodstream infection 73 0.73 0.42 to 1.27 0.269
Outcome n OR 95% CI p-value
Number of days of level 1 care > 0 1149 0.75 0.53 to 1.06 0.104
Number of days of level 1 care > 5 1149 0.90 0.56 to 1.43 0.643
Number of days of level 1 or 2 care > 0 1149 0.84 0.61 to 1.16 0.299
Number of days of level 1 or 2 care > 5 1149 0.77 0.52 to 1.13 0.185
Number of days of special or higher level of care > 0 1149 0.86 0.66 to 1.12 0.268
Number of days of special or higher level of care > 5 1149 0.80 0.60 to 1.08 0.145
Number of days of special or higher level of care > 14 1149 0.74 0.53 to 1.05 0.092
Number of days of normal or higher level of care > 3 1148 0.81 0.64 to 1.04 0.101
Number of days of normal or higher level of care > 7 1148 0.80 0.60 to 1.08 0.142
Number of days of normal or higher level of care > 14 1148 0.70 0.50 to 0.99 0.044
Note
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TABLE 75 Mixed effects logistic regression model for the effect of treatment on the secondary birth outcome fetal
death after trial entry adjusted for previous pregnancy of ≥ 14 weeks’ gestation and study centre as a random effect
Parameter OR 95% CI p-value
Treatment (progesterone vs. placebo) 1.14 0.41 to 3.17 0.802
Previous pregnancy of ≥ 14 weeks’ gestation 0.91 0.12 to 7.00 0.924
n= 1197
Note
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TABLE 79 Regression models for the effect of treatment on secondary childhood outcomes adjusted for previous
pregnancies of ≥ 14 weeks’ gestation and centre as a random effect. Scores analysed as binary variable (raised vs.
normal score). Scores analysed as continuous variables where approximately normally distributed
Outcome n OR 95% CI p-value
SDQ emotional problems score above normal 669 1.01 0.61 to 1.67 0.958
SDQ conduct problems score above normal 668 0.92 0.65 to 1.31 0.656
SDQ hyperactivity score above normal 649 1.10 0.79 to 1.55 0.570
SDQ peer problems score above normal 663 1.22 0.88 to 1.69 0.223
SDQ total difficulties score above normal 597 1.23 0.85 to 1.78 0.282
SDQ prosocial score below normal 659 1.20 0.88 to 1.63 0.254
SDQ impact score above normal 828 1.31 0.73 to 2.35 0.368
Outcome n
Parameter
estimate 95% CI p-value
SDQ hyperactivity score (continuous) 649 0.32 –0.03 to 0.68 0.074
SDQ total difficulties score (continuous) 597 0.41 –0.36 to 1.18 0.301
SDQ prosocial score (continuous) 659 –0.38 –0.72 to –0.03 0.032
SDQ, Strengths and Difficulties Questionnaire.
Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 02 14:34:21 2015.
TABLE 78 Logistic regression models for the effect of treatment on secondary childhood outcomes adjusted for
previous pregnancies of ≥ 14 weeks’ gestation and centre as a random effect
Outcome n OR 95% CI p-value
Death or moderate/severe neurodevelopmental impairment 818 1.45 0.98 to 2.15 0.064
Moderate/severe neurodevelopmental impairment 782 1.48 0.95 to 2.33 0.087
Any hospitalisation 850 0.98 0.65 to 1.47 0.919
Any hospitalisation for respiratory reason 127 0.97 0.47 to 2.02 0.944
Any hospitalisation for surgery 118 2.48 1.01 to 6.09 0.049
Any hospitalisation for other reason 119 0.99 0.42 to 2.30 0.977
Note
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TABLE 80 Treatment compliance (ITT population)
Compliance All
Trial group
Placebo Progesterone
Percentage of medication taken
Nobs (Nmiss) 1011 (215) 509 (101) 502 (114)
Mean (SD) 78.6 (72.0) 77.9 (32.8) 79.3 (96.7)
Median (IQR) 92.7 (65.0–98.7) 92.3 (71.6–98.7) 92.9 (59.0–98.6)
Range 0.0–2100.0 0.0–138.5 0.0–2100.0
Expected number of doses
Nobs (Nmiss) 1197 (29) 597 (13) 600 (16)
Mean (SD) 71.0 (17.4) 70.6 (17.3) 71.4 (17.6)
Median (IQR) 76.0 (72.0–81.0) 76.0 (72.0–80.0) 76.0 (72.0–81.0)
Range 1.0–86.0 1.0–85.0 2.0–86.0
Compliant
Nobs (Nmiss) 1011 (215) 509 (101) 502 (114)
No, n (%) 317 (31.4) 148 (29.1) 169 (33.7)
Yes, n (%) 694 (68.6) 361 (70.9) 333 (66.3)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 82 Consent withdrawal (ITT population)
Outcome All
Trial group
Placebo Progesterone
Withdrawn consent from any part of the study
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 1113 (90.8) 558 (91.5) 555 (90.1)
Yes, n (%) 113 (9.2) 52 (8.5) 61 (9.9)
Withdrawn consent for future evaluation of mother and child
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 1124 (91.7) 561 (92.0) 563 (91.4)
Yes, n (%) 102 (8.3) 49 (8.0) 53 (8.6)
Withdrawn consent for future evaluation of health records
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 1170 (95.4) 587 (96.2) 583 (94.6)
Yes, n (%) 56 (4.6) 23 (3.8) 33 (5.4)
TABLE 81 Trial termination (ITT population)
Outcome All
Trial group
Placebo Progesterone
Trial completed
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 374 (30.5) 176 (28.9) 198 (32.1)
Yes, n (%) 852 (69.5) 434 (71.1) 418 (67.9)
Reason for trial termination
Nobs (Nmiss) 374 (852) 176 (434) 198 (418)
Woman unwilling to continue, n (%) 56 (15.0) 25 (14.2) 31 (15.7)
Adverse event, n (%) 1 (0.3) 1 (0.6) 0 (0.0)
SAE, n (%) 1 (0.3) 1 (0.6) 0 (0.0)
Detection of significant structural chromosomal
anomalies after randomisation, n (%)
0 (0.0) 0 (0.0) 0 (0.0)
Other, n (%) 207 (55.3) 101 (57.4) 106 (53.5)
Physician recommended withdrawal, n (%) 1 (0.3) 1 (0.6) 0 (0.0)
Lost to follow-up, n (%) 72 (19.3) 31 (17.6) 41 (20.7)
Death, n (%) 36 (9.6) 16 (9.1) 20 (10.1)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 82 Consent withdrawal (ITT population) (continued )
Outcome All
Trial group
Placebo Progesterone
Withdrawn consent for neonatal head scan
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 1217 (99.3) 607 (99.5) 610 (99.0)
Yes, n (%) 9 (0.7) 3 (0.5) 6 (1.0)
Withdrawn consent for use of placental tissue
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 1224 (99.8) 610 (100.0) 614 (99.7)
Yes, n (%) 2 (0.2) 0 (0.0) 2 (0.3)
Withdrawn consent for completing the 2-year follow-up questionnaire
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 1223 (99.8) 609 (99.8) 614 (99.7)
Yes, n (%) 3 (0.2) 1 (0.2) 2 (0.3)
Withdrawn consent for completing the 2-year follow-up visit
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 1223 (99.8) 609 (99.8) 614 (99.7)
Yes, n (%) 3 (0.2) 1 (0.2) 2 (0.3)
Withdrawn consent for health economics questionnaire
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 1223 (99.8) 609 (99.8) 614 (99.7)
Yes, n (%) 3 (0.2) 1 (0.2) 2 (0.3)
Withdrawn consent for women’s views questionnaire
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 1223 (99.8) 609 (99.8) 614 (99.7)
Yes, n (%) 3 (0.2) 1 (0.2) 2 (0.3)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 83 Availability of information at different stages (ITT population)
Outcome All
Trial group
Placebo Progesterone
Information available from end of treatment visit
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
No, n (%) 20 (1.6) 10 (1.6) 10 (1.6)
Yes, n (%) 1206 (98.4) 600 (98.4) 606 (98.4)
Information on labour
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
Available, n (%) 1197 (97.6) 597 (97.9) 600 (97.4)
Missing, n (%) 1 (0.1) 1 (0.2) 0 (0.0)
Lost, n (%) 28 (2.3) 12 (2.0) 16 (2.6)
Information on birth in those not lost
Nobs (Nmiss) 1198 (0) 598 (0) 600 (0)
Available, n (%) 1197 (99.9) 597 (99.8) 600 (100.0)
Missing, n (%) 1 (0.1) 1 (0.2) 0 (0.0)
Lost, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Information on neonatal outcomes in those not lost
Nobs (Nmiss) 1198 (0) 598 (0) 600 (0)
Available, n (%) 1158 (96.7) 574 (96.0) 584 (97.3)
Died, n (%) 23 (1.9) 13 (2.2) 10 (1.7)
Missing, n (%) 5 (0.4) 2 (0.3) 3 (0.5)
Lost, n (%) 12 (1.0) 9 (1.5) 3 (0.5)
Paediatric assessment available in those not lost at neonatal stage
Nobs (Nmiss) 1186 (0) 589 (0) 597 (0)
No, n (%) 292 (24.6) 136 (23.1) 156 (26.1)
Yes, n (%) 858 (72.3) 437 (74.2) 421 (70.5)
Died, n (%) 36 (3.0) 16 (2.7) 20 (3.4)
Parent questionnaire available in those not lost at neonatal stage
Nobs (Nmiss) 1186 (0) 589 (0) 597 (0)
No, n (%) 300 (25.3) 141 (23.9) 159 (26.6)
Yes, n (%) 850 (71.7) 432 (73.3) 418 (70.0)
Died, n (%) 36 (3.0) 16 (2.7) 20 (3.4)
Womens’ views questionnaire available in those not lost at neonatal stage
Nobs (Nmiss) 1186 (0) 589 (0) 597 (0)
No, n (%) 515 (43.4) 245 (41.6) 270 (45.2)
Yes, n (%) 642 (54.1) 331 (56.2) 311 (52.1)
Died, n (%) 29 (2.4) 13 (2.2) 16 (2.7)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 84 Patients with at least one SAE by System Organ Class and Preferred Term for all SAEs in reporting
window (maximum of end of treatment date + 28 days and date of delivery + 30 days) or where it is unclear
whether or not they are in the reporting window
Outcome All patients, n (%)
Trial group, n (%)
Placebo Progesterone
Number of patients, n 1183 590 593
Blood and lymphatic system disorders 1 (0.1) 1 (0.2) 0 (0.0)
Thrombocytopenia 1 (0.1) 1 (0.2) 0 (0.0)
Congenital, familial and genetic disorders 19 (1.6) 8 (1.4) 11 (1.9)
Cardiac septal defect 1 (0.1) 1 (0.2) 0 (0.0)
Cleft lip and palate 1 (0.1) 0 (0.0) 1 (0.2)
Congenital central nervous system anomaly 1 (0.1) 0 (0.0) 1 (0.2)
Congenital oesophageal anomaly 1 (0.1) 0 (0.0) 1 (0.2)
Cryptorchism 1 (0.1) 0 (0.0) 1 (0.2)
Cystic fibrosis 1 (0.1) 1 (0.2) 0 (0.0)
Congenital dacryostenosis 1 (0.1) 0 (0.0) 1 (0.2)
Hip dysplasia 1 (0.1) 1 (0.2) 0 (0.0)
Holoprosencephaly 1 (0.1) 0 (0.0) 1 (0.2)
Hydrocele 1 (0.1) 1 (0.2) 0 (0.0)
continued
DOI: 10.3310/hta22350 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 35
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Norman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
147
TABLE 84 Patients with at least one SAE by System Organ Class and Preferred Term for all SAEs in reporting
window (maximum of end of treatment date + 28 days and date of delivery + 30 days) or where it is unclear
whether or not they are in the reporting window (continued )
Outcome All patients, n (%)
Trial group, n (%)
Placebo Progesterone
Hypospadias 2 (0.2) 0 (0.0) 2 (0.3)
Kidney malformation 1 (0.1) 0 (0.0) 1 (0.2)
Oculoauriculovertebral dysplasia 1 (0.1) 1 (0.2) 0 (0.0)
Patent ductus arteriosus 2 (0.2) 2 (0.3) 0 (0.0)
Polydactyly 2 (0.2) 0 (0.0) 2 (0.3)
Congenital pulmonary artery stenosis 1 (0.1) 1 (0.2) 0 (0.0)
Gastrointestinal disorders 8 (0.7) 8 (1.4) 0 (0.0)
Abdominal pain 2 (0.2) 2 (0.3) 0 (0.0)
Ileus paralytic 1 (0.1) 1 (0.2) 0 (0.0)
Inguinal hernia 1 (0.1) 1 (0.2) 0 (0.0)
Necrotising colitis 2 (0.2) 2 (0.3) 0 (0.0)
Neonatal necrotising enterocolitis 3 (0.3) 3 (0.5) 0 (0.0)
General disorders and administration site conditions 4 (0.3) 2 (0.3) 2 (0.3)
Adverse drug reaction 1 (0.1) 1 (0.2) 0 (0.0)
Death neonatal 3 (0.3) 1 (0.2) 2 (0.3)
Infections and infestations 17 (1.4) 8 (1.4) 9 (1.5)
Appendicitis 1 (0.1) 1 (0.2) 0 (0.0)
Bacterial sepsis 2 (0.2) 0 (0.0) 2 (0.3)
Bronchiolitis 1 (0.1) 0 (0.0) 1 (0.2)
Bronchopneumonia 1 (0.1) 0 (0.0) 1 (0.2)
Infection 1 (0.1) 1 (0.2) 0 (0.0)
Lower respiratory tract infection 1 (0.1) 1 (0.2) 0 (0.0)
Meningitis 1 (0.1) 1 (0.2) 0 (0.0)
Meningitis bacterial 1 (0.1) 1 (0.2) 0 (0.0)
Rash pustular 2 (0.2) 1 (0.2) 1 (0.2)
Sepsis 4 (0.3) 2 (0.3) 2 (0.3)
Urinary tract infection 3 (0.3) 1 (0.2) 2 (0.3)
Wound infection 1 (0.1) 0 (0.0) 1 (0.2)
Injury, poisoning and procedural complications 4 (0.3) 1 (0.2) 3 (0.5)
Post-lumbar puncture 2 (0.2) 0 (0.0) 2 (0.3)
Syndrome post-procedural complication 1 (0.1) 1 (0.2) 0 (0.0)
Uterine rupture 1 (0.1) 0 (0.0) 1 (0.2)
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TABLE 84 Patients with at least one SAE by System Organ Class and Preferred Term for all SAEs in reporting
window (maximum of end of treatment date + 28 days and date of delivery + 30 days) or where it is unclear
whether or not they are in the reporting window (continued )
Outcome All patients, n (%)
Trial group, n (%)
Placebo Progesterone
Investigations 5 (0.4) 2 (0.3) 3 (0.5)
Echocardiogram abnormal 1 (0.1) 0 (0.0) 1 (0.2)
Echography abnormal 1 (0.1) 1 (0.2) 0 (0.0)
Fetal heart rate abnormal 1 (0.1) 0 (0.0) 1 (0.2)
Weight decreased 2 (0.2) 1 (0.2) 1 (0.2)
Metabolism and nutrition disorders 4 (0.3) 3 (0.5) 1 (0.2)
Gestational diabetes 1 (0.1) 1 (0.2) 0 (0.0)
Hypoglycaemia 3 (0.3) 2 (0.3) 1 (0.2)
Neoplasms benign, malignant and unspecified
(including cysts and polyps)
3 (0.3) 1 (0.2) 2 (0.3)
Breast cancer 1 (0.1) 1 (0.2) 0 (0.0)
Haemangioma of skin 1 (0.1) 0 (0.0) 1 (0.2)
Teratoma 1 (0.1) 0 (0.0) 1 (0.2)
Nervous system disorders 4 (0.3) 4 (0.7) 0 (0.0)
Cerebral ventricle dilatation 2 (0.2) 2 (0.3) 0 (0.0)
Hydrocephalus 1 (0.1) 1 (0.2) 0 (0.0)
Migraine 1 (0.1) 1 (0.2) 0 (0.0)
Pregnancy, puerperium and perinatal conditions 83 (7.0) 44 (7.5) 39 (6.6)
Amniorrhexis 3 (0.3) 3 (0.5) 0 (0.0)
Antepartum haemorrhage 9 (0.8) 5 (0.8) 4 (0.7)
Complication of pregnancy 1 (0.1) 1 (0.2) 0 (0.0)
Eclampsia 1 (0.1) 1 (0.2) 0 (0.0)
Fetal growth restriction 1 (0.1) 1 (0.2) 0 (0.0)
Fetal hypokinesia 2 (0.2) 1 (0.2) 1 (0.2)
Intrauterine death 9 (0.8) 4 (0.7) 5 (0.8)
Jaundice neonatal 1 (0.1) 1 (0.2) 0 (0.0)
Oligohydramnios 1 (0.1) 0 (0.0) 1 (0.2)
Placenta praevia haemorrhage 1 (0.1) 0 (0.0) 1 (0.2)
Post-partum haemorrhage 33 (2.8) 17 (2.9) 16 (2.7)
Pre-eclampsia 1 (0.1) 1 (0.2) 0 (0.0)
Premature baby 13 (1.1) 7 (1.2) 6 (1.0)
Premature labour 4 (0.3) 3 (0.5) 1 (0.2)
Premature rupture of membranes 3 (0.3) 1 (0.2) 2 (0.3)
Premature separation of placenta 4 (0.3) 3 (0.5) 1 (0.2)
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TABLE 84 Patients with at least one SAE by System Organ Class and Preferred Term for all SAEs in reporting
window (maximum of end of treatment date + 28 days and date of delivery + 30 days) or where it is unclear
whether or not they are in the reporting window (continued )
Outcome All patients, n (%)
Trial group, n (%)
Placebo Progesterone
Retained placenta or membranes 1 (0.1) 0 (0.0) 1 (0.2)
Stillbirth 2 (0.2) 0 (0.0) 2 (0.3)
Threatened labour 4 (0.3) 1 (0.2) 3 (0.5)
Uterine contractions during pregnancy 2 (0.2) 1 (0.2) 1 (0.2)
Renal and urinary disorders 1 (0.1) 1 (0.2) 0 (0.0)
Pyelocaliectasis 1 (0.1) 1 (0.2) 0 (0.0)
Reproductive system and breast disorders 10 (0.8) 6 (1.0) 4 (0.7)
Chordee 1 (0.1) 0 (0.0) 1 (0.2)
Coital bleeding 1 (0.1) 1 (0.2) 0 (0.0)
Cterine atony 1 (0.1) 0 (0.0) 1 (0.2)
Vaginal haemorrhage 7 (0.6) 5 (0.8) 2 (0.3)
Respiratory, thoracic and mediastinal disorders 6 (0.5) 2 (0.3) 4 (0.7)
Bronchopulmonary dysplasia 1 (0.1) 0 (0.0) 1 (0.2)
Cyanosis neonatal 1 (0.1) 1 (0.2) 0 (0.0)
Grunting 1 (0.1) 0 (0.0) 1 (0.2)
Neonatal asphyxia 1 (0.1) 0 (0.0) 1 (0.2)
Pneumothorax 1 (0.1) 0 (0.0) 1 (0.2)
Transient tachypnoea of the newborn 1 (0.1) 1 (0.2) 0 (0.0)
Skin and subcutaneous tissue disorders 1 (0.1) 1 (0.2) 0 (0.0)
Rash 1 (0.1) 1 (0.2) 0 (0.0)
Surgical and medical procedures 6 (0.5) 5 (0.8) 1 (0.2)
Caesarean section 1 (0.1) 1 (0.2) 0 (0.0)
Mechanical ventilation 1 (0.1) 1 (0.2) 0 (0.0)
Patent ductus arteriosus repair 1 (0.1) 0 (0.0) 1 (0.2)
Spinal decompression 1 (0.1) 1 (0.2) 0 (0.0)
Steroid therapy 1 (0.1) 1 (0.2) 0 (0.0)
Surgery 1 (0.1) 1 (0.2) 0 (0.0)
Vascular disorders 2 (0.2) 1 (0.2) 1 (0.2)
Deep-vein thrombosis 1 (0.1) 1 (0.2) 0 (0.0)
Essential hypertension 1 (0.1) 0 (0.0) 1 (0.2)
Note
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TABLE 86 Patients with at least one SAE of at least moderate severity or missing severity by System Organ Class
and Preferred Term for all SAEs in reporting window (maximum of end of treatment date + 28 days and date of
delivery + 30 days) or where it is unclear whether or not they are in the reporting window
Outcome All patients, n (%)
Trial group, n (%)
Placebo Progesterone
Number of patients, n 1183 590 593
Congenital, familial and genetic disorders 10 (0.8) 4 (0.7) 6 (1.0)
Cleft lip and palate 1 (0.1) 0 (0.0) 1 (0.2)
Congenital central nervous system anomaly 1 (0.1) 0 (0.0) 1 (0.2)
Congenital oesophageal anomaly 1 (0.1) 0 (0.0) 1 (0.2)
Cystic fibrosis 1 (0.1) 1 (0.2) 0 (0.0)
Congenital dacryostenosis 1 (0.1) 0 (0.0) 1 (0.2)
Holoprosencephaly 1 (0.1) 0 (0.0) 1 (0.2)
Kidney malformation 1 (0.1) 0 (0.0) 1 (0.2)
Patent ductus arteriosus 2 (0.2) 2 (0.3) 0 (0.0)
Congenital pulmonary artery stenosis 1 (0.1) 1 (0.2) 0 (0.0)
continued
TABLE 85 Patients with at least one SAE by System Organ Class and Preferred Term for all SAEs definitely outside
reporting window (maximum of end of treatment date + 28 days and date of delivery + 30 days)
Outcome All patients, n (%)
Trial group, n (%)
Placebo Progesterone
Number of patients, n 1183 590 593
Congenital, familial and genetic disorders 2 (0.2) 1 (0.2) 1 (0.2)
Multiple congenital abnormalities 1 (0.1) 0 (0.0) 1 (0.2)
Pyloric stenosis 1 (0.1) 1 (0.2) 0 (0.0)
Eye disorders 1 (0.1) 0 (0.0) 1 (0.2)
Retinopathy of prematurity 1 (0.1) 0 (0.0) 1 (0.2)
Gastrointestinal disorders 1 (0.1) 0 (0.0) 1 (0.2)
Neonatal necrotising enterocolitis 1 (0.1) 0 (0.0) 1 (0.2)
General disorders and administration site conditions 1 (0.1) 1 (0.2) 0 (0.0)
Drowning 1 (0.1) 1 (0.2) 0 (0.0)
Nervous system disorders 1 (0.1) 0 (0.0) 1 (0.2)
Convulsion 1 (0.1) 0 (0.0) 1 (0.2)
Pregnancy, puerperium and perinatal conditions 1 (0.1) 0 (0.0) 1 (0.2)
Premature baby 1 (0.1) 0 (0.0) 1 (0.2)
Surgical and medical procedures 1 (0.1) 1 (0.2) 0 (0.0)
Inguinal hernia repair 1 (0.1) 1 (0.2) 0 (0.0)
Note
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TABLE 86 Patients with at least one SAE of at least moderate severity or missing severity by System Organ Class
and Preferred Term for all SAEs in reporting window (maximum of end of treatment date + 28 days and date of
delivery + 30 days) or where it is unclear whether or not they are in the reporting window (continued )
Outcome All patients, n (%)
Trial group, n (%)
Placebo Progesterone
Gastrointestinal disorders 5 (0.4) 5 (0.8) 0 (0.0)
Inguinal hernia 1 (0.1) 1 (0.2) 0 (0.0)
Necrotising colitis 2 (0.2) 2 (0.3) 0 (0.0)
Neonatal necrotising enterocolitis 3 (0.3) 3 (0.5) 0 (0.0)
General disorders and administration site conditions 4 (0.3) 2 (0.3) 2 (0.3)
Adverse drug reaction 1 (0.1) 1 (0.2) 0 (0.0)
Death neonatal 3 (0.3) 1 (0.2) 2 (0.3)
Infections and infestations 11 (0.9) 6 (1.0) 5 (0.8)
Appendicitis 1 (0.1) 1 (0.2) 0 (0.0)
Bronchopneumonia 1 (0.1) 0 (0.0) 1 (0.2)
Infection 1 (0.1) 1 (0.2) 0 (0.0)
Lower respiratory tract infection 1 (0.1) 1 (0.2) 0 (0.0)
Meningitis 1 (0.1) 1 (0.2) 0 (0.0)
Meningitis bacterial 1 (0.1) 1 (0.2) 0 (0.0)
Rash pustular 1 (0.1) 1 (0.2) 0 (0.0)
Sepsis 3 (0.3) 1 (0.2) 2 (0.3)
Urinary tract infection 1 (0.1) 0 (0.0) 1 (0.2)
Wound infection 1 (0.1) 0 (0.0) 1 (0.2)
Injury, poisoning and procedural complications 2 (0.2) 0 (0.0) 2 (0.3)
Post-lumbar puncture syndrome 1 (0.1) 0 (0.0) 1 (0.2)
Uterine rupture 1 (0.1) 0 (0.0) 1 (0.2)
Investigations 2 (0.2) 1 (0.2) 1 (0.2)
Fetal heart rate abnormal 1 (0.1) 0 (0.0) 1 (0.2)
Weight decreased 1 (0.1) 1 (0.2) 0 (0.0)
Neoplasms benign, malignant and unspecified
(including cysts and polyps)
2 (0.2) 1 (0.2) 1 (0.2)
Breast cancer 1 (0.1) 1 (0.2) 0 (0.0)
Teratoma 1 (0.1) 0 (0.0) 1 (0.2)
Nervous system disorders 3 (0.3) 3 (0.5) 0 (0.0)
Cerebral ventricle dilatation 2 (0.2) 2 (0.3) 0 (0.0)
Hydrocephalus 1 (0.1) 1 (0.2) 0 (0.0)
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TABLE 86 Patients with at least one SAE of at least moderate severity or missing severity by System Organ Class
and Preferred Term for all SAEs in reporting window (maximum of end of treatment date + 28 days and date of
delivery + 30 days) or where it is unclear whether or not they are in the reporting window (continued )
Outcome All patients, n (%)
Trial group, n (%)
Placebo Progesterone
Pregnancy, puerperium and perinatal conditions 56 (4.7) 27 (4.6) 29 (4.9)
Amniorrhexis 1 (0.1) 1 (0.2) 0 (0.0)
Antepartum haemorrhage 6 (0.5) 3 (0.5) 3 (0.5)
Eclampsia 1 (0.1) 1 (0.2) 0 (0.0)
Fetal hypokinesia 1 (0.1) 0 (0.0) 1 (0.2)
Intrauterine death 8 (0.7) 4 (0.7) 4 (0.7)
Jaundice neonatal 1 (0.1) 1 (0.2) 0 (0.0)
Oligohydramnios 1 (0.1) 0 (0.0) 1 (0.2)
Placenta praevia haemorrhage 1 (0.1) 0 (0.0) 1 (0.2)
Post-partum haemorrhage 20 (1.7) 9 (1.5) 11 (1.9)
Premature baby 13 (1.1) 7 (1.2) 6 (1.0)
Premature labour 3 (0.3) 2 (0.3) 1 (0.2)
Premature rupture of membranes 3 (0.3) 1 (0.2) 2 (0.3)
Premature separation of placenta 4 (0.3) 3 (0.5) 1 (0.2)
Retained placenta or membranes 1 (0.1) 0 (0.0) 1 (0.2)
Stillbirth 2 (0.2) 0 (0.0) 2 (0.3)
Threatened labour 1 (0.1) 0 (0.0) 1 (0.2)
Reproductive system and breast disorders 2 (0.2) 0 (0.0) 2 (0.3)
Uterine atony 1 (0.1) 0 (0.0) 1 (0.2)
Vaginal haemorrhage 1 (0.1) 0 (0.0) 1 (0.2)
Respiratory, thoracic and mediastinal disorders 4 (0.3) 1 (0.2) 3 (0.5)
Bronchopulmonary dysplasia 1 (0.1) 0 (0.0) 1 (0.2)
Neonatal asphyxia 1 (0.1) 0 (0.0) 1 (0.2)
Pneumothorax 1 (0.1) 0 (0.0) 1 (0.2)
Transient tachypnoea of the newborn 1 (0.1) 1 (0.2) 0 (0.0)
Surgical and medical procedures 5 (0.4) 4 (0.7) 1 (0.2)
Caesarean section 1 (0.1) 1 (0.2) 0 (0.0)
Mechanical ventilation 1 (0.1) 1 (0.2) 0 (0.0)
Patent ductus arteriosus repair 1 (0.1) 0 (0.0) 1 (0.2)
Spinal decompression 1 (0.1) 1 (0.2) 0 (0.0)
Surgery 1 (0.1) 1 (0.2) 0 (0.0)
Vascular disorders 2 (0.2) 1 (0.2) 1 (0.2)
Deep-vein thrombosis 1 (0.1) 1 (0.2) 0 (0.0)
Essential hypertension 1 (0.1) 0 (0.0) 1 (0.2)
Note
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TABLE 87 Patients with at least one severe SAE or an SAE with missing severity by System Organ Class and
Preferred Term for all SAEs in reporting window (maximum of end of treatment date + 28 days and date of
delivery + 30 days) or where it is unclear whether or not they are in the reporting window
Outcome All patients, n (%)
Trial group, n (%)
Placebo Progesterone
Number of patients, n 1183 590 593
Congenital, familial and genetic disorders 5 (0.4) 0 (0.0) 5 (0.8)
Cleft lip and palate 1 (0.1) 0 (0.0) 1 (0.2)
Congenital central nervous system anomaly 1 (0.1) 0 (0.0) 1 (0.2)
Congenital oesophageal anomaly 1 (0.1) 0 (0.0) 1 (0.2)
Holoprosencephaly 1 (0.1) 0 (0.0) 1 (0.2)
Kidney malformation 1 (0.1) 0 (0.0) 1 (0.2)
Gastrointestinal disorders 3 (0.3) 3 (0.5) 0 (0.0)
Necrotising colitis 2 (0.2) 2 (0.3) 0 (0.0)
Neonatal necrotising enterocolitis 2 (0.2) 2 (0.3) 0 (0.0)
General disorders and administration site conditions 3 (0.3) 1 (0.2) 2 (0.3)
Death neonatal 3 (0.3) 1 (0.2) 2 (0.3)
Infections and infestations 3 (0.3) 2 (0.3) 1 (0.2)
Appendicitis 1 (0.1) 1 (0.2) 0 (0.0)
Meningitis 1 (0.1) 1 (0.2) 0 (0.0)
Sepsis 1 (0.1) 0 (0.0) 1 (0.2)
Injury, poisoning and procedural complications 1 (0.1) 0 (0.0) 1 (0.2)
Uterine rupture 1 (0.1) 0 (0.0) 1 (0.2)
Investigations 1 (0.1) 0 (0.0) 1 (0.2)
Fetal heart rate abnormal 1 (0.1) 0 (0.0) 1 (0.2)
Neoplasms benign, malignant and unspecified
(including cysts and polyps)
2 (0.2) 1 (0.2) 1 (0.2)
Breast cancer 1 (0.1) 1 (0.2) 0 (0.0)
Teratoma 1 (0.1) 0 (0.0) 1 (0.2)
Nervous system disorders 1 (0.1) 1 (0.2) 0 (0.0)
Hydrocephalus 1 (0.1) 1 (0.2) 0 (0.0)
Pregnancy, puerperium and perinatal conditions 30 (2.5) 15 (2.5) 15 (2.5)
Amniorrhexis 1 (0.1) 1 (0.2) 0 (0.0)
Antepartum haemorrhage 3 (0.3) 2 (0.3) 1 (0.2)
Eclampsia 1 (0.1) 1 (0.2) 0 (0.0)
Intrauterine death 8 (0.7) 4 (0.7) 4 (0.7)
Oligohydramnios 1 (0.1) 0 (0.0) 1 (0.2)
Post-partum haemorrhage 5 (0.4) 2 (0.3) 3 (0.5)
Premature baby 12 (1.0) 6 (1.0) 6 (1.0)
Premature labour 1 (0.1) 0 (0.0) 1 (0.2)
Premature separation of placenta 2 (0.2) 1 (0.2) 1 (0.2)
Retained placenta or membranes 1 (0.1) 0 (0.0) 1 (0.2)
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TABLE 87 Patients with at least one severe SAE or an SAE with missing severity by System Organ Class and
Preferred Term for all SAEs in reporting window (maximum of end of treatment date + 28 days and date of
delivery + 30 days) or where it is unclear whether or not they are in the reporting window (continued )
Outcome All patients, n (%)
Trial group, n (%)
Placebo Progesterone
Stillbirth 2 (0.2) 0 (0.0) 2 (0.3)
Reproductive system and breast disorders 1 (0.1) 0 (0.0) 1 (0.2)
Uterine atony 1 (0.1) 0 (0.0) 1 (0.2)
Respiratory, thoracic and mediastinal disorders 2 (0.2) 0 (0.0) 2 (0.3)
Bronchopulmonary dysplasia 1 (0.1) 0 (0.0) 1 (0.2)
Pneumothorax 1 (0.1) 0 (0.0) 1 (0.2)
Surgical and medical procedures 1 (0.1) 1 (0.2) 0 (0.0)
Spinal decompression 1 (0.1) 1 (0.2) 0 (0.0)
Vascular disorders 1 (0.1) 0 (0.0) 1 (0.2)
Essential hypertension 1 (0.1) 0 (0.0) 1 (0.2)
Note
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TABLE 88 Patients with at least one SAE that is at least possibly related to treatment or SAE with missing
relationship by System Organ Class and Preferred Term for all SAEs in reporting window (maximum of end of
treatment date + 28 days and date of delivery + 30 days) or where it is unclear whether or not they are in the
reporting window
Outcome All patients, n (%)
Trial group, n (%)
Placebo Progesterone
Number of patients, n 1183 590 593
Blood and lymphatic system disorders 1 (0.1) 1 (0.2) 0 (0.0)
Thrombocytopenia 1 (0.1) 1 (0.2) 0 (0.0)
Congenital, familial and genetic disorders 1 (0.1) 1 (0.2) 0 (0.0)
Hydrocele 1 (0.1) 1 (0.2) 0 (0.0)
General disorders and administration site conditions 1 (0.1) 1 (0.2) 0 (0.0)
Adverse drug reaction 1 (0.1) 1 (0.2) 0 (0.0)
Infections and infestations 1 (0.1) 1 (0.2) 0 (0.0)
Infection 1 (0.1) 1 (0.2) 0 (0.0)
Rash pustular 1 (0.1) 1 (0.2) 0 (0.0)
Investigations 1 (0.1) 0 (0.0) 1 (0.2)
Fetal heart rate abnormal 1 (0.1) 0 (0.0) 1 (0.2)
Metabolism and nutrition disorders 1 (0.1) 1 (0.2) 0 (0.0)
Gestational diabetes 1 (0.1) 1 (0.2) 0 (0.0)
Nervous system disorders 3 (0.3) 3 (0.5) 0 (0.0)
Cerebral ventricle dilatation 2 (0.2) 2 (0.3) 0 (0.0)
Migraine 1 (0.1) 1 (0.2) 0 (0.0)
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TABLE 88 Patients with at least one SAE that is at least possibly related to treatment or SAE with missing
relationship by System Organ Class and Preferred Term for all SAEs in reporting window (maximum of end of
treatment date + 28 days and date of delivery + 30 days) or where it is unclear whether or not they are in the
reporting window (continued )
Outcome All patients, n (%)
Trial group, n (%)
Placebo Progesterone
Pregnancy, puerperium and perinatal conditions 6 (0.5) 5 (0.8) 1 (0.2)
Antepartum haemorrhage 2 (0.2) 2 (0.3) 0 (0.0)
Fetal growth restriction 1 (0.1) 1 (0.2) 0 (0.0)
Post-partum haemorrhage 3 (0.3) 2 (0.3) 1 (0.2)
Premature labour 1 (0.1) 1 (0.2) 0 (0.0)
Premature separation of placenta 1 (0.1) 1 (0.2) 0 (0.0)
Reproductive system and breast disorders 2 (0.2) 2 (0.3) 0 (0.0)
Vaginal haemorrhage 2 (0.2) 2 (0.3) 0 (0.0)
Surgical and medical procedures 1 (0.1) 1 (0.2) 0 (0.0)
Steroid therapy 1 (0.1) 1 (0.2) 0 (0.0)
Note
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TABLE 89 Logistic regression model for the effect of treatment on the primary obstetric outcome death or delivery
before 34 weeks’ gestation adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect
in subgroups according to risk group
Separate models in each subgroup
Risk group OR (progesterone vs. placebo) 95% CI p-value n
Low 0.88 0.58 to 1.32 0.535 859
High 0.91 0.57 to 1.47 0.708 338
Interaction model (n= 1197)
Risk group OR (progesterone vs. placebo) 95% CI p-value p-value for interaction
Low 0.88 0.58 to 1.33 0.542 0.907
High 0.91 0.57 to 1.46 0.707
Note
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TABLE 90 Logistic regression model for the effect of treatment on the primary neonatal outcome death, brain
injury or severe chronic lung disease adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a
random effect in subgroups according to risk group
Separate models in each subgroup
Risk group OR (progesterone vs. placebo) 95% CI p-value n
Low 0.65 0.37 to 1.14 0.136 847
High 0.66 0.36 to 1.24 0.196 329
Interaction model (n= 1176)
Risk group OR (progesterone vs. placebo) 95% CI p-value p-value for interaction
Low 0.65 0.37 to 1.13 0.129 0.957
High 0.64 0.34 to 1.20 0.162
Note
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TABLE 91 Linear regression model for the effect of treatment on the primary childhood outcome Bayley-III
cognitive scale adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect in subgroups
according to risk group
Separate models in each subgroup
Risk group
Expected mean difference
(progesterone vs. placebo) 95% CI p-value n
Low –0.62 –3.14 to 1.90 0.629 628
High –1.12 –5.99 to 3.76 0.654 241
Interaction model (n= 869)
Risk group
Expected mean difference
(progesterone vs. placebo) 95% CI p-value p-value for interaction
Low –0.63 –3.28 to 2.03 0.644 0.858
High –1.09 –5.41 to 3.23 0.621
Note
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TABLE 93 Proportional hazards regression model for the effect of treatment on the primary childhood outcome
survival adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect in subgroups
according to risk group
Separate models in each subgroup
Risk group Hazard ratio (progesterone vs. placebo) 95% CI p-value n
Low 1.74 0.58 to 5.18 0.323 860
High 1.19 0.51 to 2.79 0.692 338
Interaction model (n= 1198)
Risk group Hazard ratio (progesterone vs. placebo) 95% CI p-value p-value for interaction
Low 1.73 0.58 to 5.17 0.325 0.540
High 1.13 0.49 to 2.60 0.778
Note
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TABLE 92 Logistic regression model for the effect of treatment on the primary childhood outcome survival at
2 years adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect in subgroups
according to risk group
Separate models in each subgroup
Risk group OR (progesterone vs. placebo) 95% CI p-value n
Low Regression failed
High 0.87 0.36 to 2.08 0.749 284
Interaction model (n= 1009)
Risk group OR (progesterone vs. placebo) 95% CI p-value p-value for interaction
Low 0.56 0.19 to 1.68 0.305 0.546
High 0.87 0.36 to 2.06 0.744
Model in low risk subgroup not adjusting for previous pregnancy of ≥ 14 weeks
Risk group OR (progesterone vs. placebo) 95% CI p-value n
Low 0.56 0.19 to 1.70 0.309 725
Note
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TABLE 95 Logistic regression model for the effect of treatment on the primary neonatal outcome death, brain
injury or severe chronic lung disease adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a
random effect in subgroups according to cervical length at baseline
Separate models in each subgroup
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value n
> 25 Regression failed
≤ 25 0.57 0.28 to 1.16 0.122 246
Interaction model (n= 682)
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
> 25 0.74 0.35 to 1.56 0.432 0.564
≤ 25 0.54 0.25 to 1.16 0.113
Model in subgroup with a cervical length of > 25mm at baseline, not adjusting for previous pregnancy of
≥ 14 weeks’ gestation
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value n
> 25 0.75 0.36 to 1.57 0.442 436
Note
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TABLE 94 Logistic regression model for the effect of treatment on the primary obstetric outcome death or delivery
before 34 weeks’ gestation adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect
in subgroups according to cervical length at baseline
Separate models in each subgroup
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value n
> 25 Regression failed
≤ 25 0.69 0.39 to 1.20 0.192 251
Interaction model (n= 696)
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
> 25 0.88 0.50 to 1.57 0.672 0.542
≤ 25 0.69 0.39 to 1.20 0.191
Model in subgroup with a cervical length of > 25mm at baseline, not adjusting for previous pregnancy of
≥ 14 weeks’ gestation
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value n
> 25 0.88 0.51 to 1.54 0.658 445
Note
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TABLE 97 Logistic regression model for the effect of treatment on the primary childhood outcome survival
adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect in subgroups according to
cervical length at baseline
Separate models in each subgroup
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value n
> 25 Regression failed
≤ 25 1.10 0.46 to 2.67 0.825 214
Interaction model (n= 583)
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
> 25 1.24 0.27 to 5.62 0.782 0.807
≤ 25 0.97 0.29 to 3.30 0.963
Model in subgroup with a cervical length of > 25 mm at baseline, not adjusting for previous pregnancy of
≥ 14 weeks’ gestation
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value n
> 25 1.31 0.57 to 3.01 0.520 369
Note
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TABLE 96 Linear regression model for the effect of treatment on the primary childhood outcome Bayley-III
cognitive scale adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect in subgroups
according to cervical length at baseline
Separate models in each subgroup
Cervical length at baseline (mm)
Expected mean difference
(progesterone vs. placebo) 95% CI p-value n
> 25 –2.13 –5.79 to 1.54 0.256 317
≤ 25 –2.25 –7.70 to 3.20 0.419 179
Interaction model (n= 496)
Cervical length at baseline (mm)
Expected mean difference
(progesterone vs. placebo) 95% CI p-value
p-value for
interaction
> 25 –2.27 –6.10 to 1.56 0.247 0.971
≤ 25 –2.15 –7.23 to 2.93 0.408
Note
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TABLE 99 Logistic regression model for the effect of treatment on the primary obstetric outcome death or delivery
before 34 weeks’ gestation adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect
in subgroups according to cervical length at baseline
Separate models in each subgroup
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value n
> 15 0.77 0.48 to 1.22 0.262 599
≤ 15 0.91 0.40 to 2.06 0.815 97
Interaction model (n= 696)
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
> 15 0.77 0.48 to 1.23 0.274 0.727
≤ 15 0.91 0.41 to 2.04 0.819
Note
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TABLE 100 Logistic regression model for the effect of treatment on the primary neonatal outcome death, brain
injury or severe chronic lung disease adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a
random effect in subgroups according to cervical length at baseline
Separate models in each subgroup
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value n
> 15 0.73 0.38 to 1.38 0.329 588
≤ 15 0.49 0.18 to 1.31 0.158 94
Interaction model (n= 682)
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
> 15 0.73 0.39 to 1.38 0.334 0.503
≤ 15 0.49 0.18 to 1.31 0.156
Note
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TABLE 98 Proportional hazards regression model for the effect of treatment on the primary childhood outcome
survival adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect in subgroups
according to cervical length at baseline
Separate models in each subgroup
Cervical length at baseline (mm)
Hazard ratio
(progesterone vs. placebo) 95% CI p-value n
> 25 0.78 0.17 to 3.49 0.747 445
≤ 25 0.97 0.29 to 3.20 0.957 252
Interaction model (n= 697)
Cervical length at baseline (mm)
Hazard ratio
(progesterone vs. placebo) 95% CI p-value
p-value for
interaction
> 25 0.79 0.18 to 3.51 0.752 0.766
≤ 25 1.05 0.32 to 3.44 0.937
Note
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TABLE 101 Linear regression model for the effect of treatment on the primary childhood outcome Bayley-III
cognitive composite score adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect in
subgroups according to cervical length at baseline
Separate models in each subgroup
Cervical length at baseline (mm)
Expected mean difference
(progesterone vs. placebo) 95% CI p-value n
> 15 –2.55 –5.73 to 0.63 0.116 423
≤ 15 –0.34 –9.75 to 9.08 0.944 73
Interaction model (n= 496)
Cervical length at baseline (mm)
Expected mean difference
(progesterone vs. placebo) 95% CI p-value
p-value for
interaction
> 15 –2.49 –5.77 to 0.78 0.137 0.680
≤ 15 –0.69 –8.60 to 7.22 0.865
Note
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TABLE 102 Logistic regression model for the effect of treatment on the primary childhood outcome survival
adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect in subgroups according to
cervical length at baseline
Separate models in each subgroup
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value n
> 1 Regression failed
≤ 15 1.88 0.40 to 8.74 0.424 85
Interaction model (n= 583)
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
> 15 0.66 0.19 to 2.33 0.515 0.304
≤ 15 1.83 0.41 to 8.12 0.426
Model in subgroup with a cervical length of > 15mm at baseline, not adjusting for previous pregnancy of
≥ 14 weeks’ gestation
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value n
> 15 0.66 0.18 to 2.36 0.519 498
Note
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TABLE 104 Logistic regression model for the effect of treatment on the primary obstetric outcome death or
delivery before 34 weeks’ gestation adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random
effect in subgroups according to history of spontaneous preterm birth
Separate models in each subgroup
History of spontaneous preterm birth OR (progesterone vs. placebo) 95% CI p-value n
No 0.99 0.51 to 1.92 0.972 273
Yes Regression failed
Interaction model (n= 1176)
History of spontaneous preterm birth OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
No 0.99 0.51 to 1.92 0.972 0.618
Yes 0.82 0.58 to 1.16 0.254
Model in subgroup with a history of spontaneous preterm birth, not adjusting for previous pregnancy of
≥ 14 weeks’ gestation
History of spontaneous preterm birth OR (progesterone vs. placebo) 95% CI p-value n
Yes 0.82 0.58 to 1.15 0.253 903
Note
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TABLE 103 Proportional hazards regression model for the effect of treatment on the primary childhood outcome
survival adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect in subgroups
according to cervical length at baseline
Separate models in each subgroup
Cervical length at baseline (mm)
Hazard ratio
(progesterone vs. placebo) 95% CI p-value n
> 15 1.49 0.42 to 5.28 0.536 600
≤ 15 0.53 0.13 to 2.25 0.391 97
Interaction model (n= 697)
Cervical length at baseline (mm)
Hazard ratio
(progesterone vs. placebo) 95% CI p-value
p-value for
interaction
> 15 1.50 0.42 to 5.32 0.530 0.292
≤ 15 0.55 0.13 to 2.28 0.406
Note
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TABLE 105 Logistic regression model for the effect of treatment on the primary neonatal outcome death, brain
injury or severe chronic lung disease adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a
random effect in subgroups according to history of spontaneous preterm birth
Separate models in each subgroup
Cervical length at baseline (mm) OR (progesterone vs. placebo) 95% CI p-value n
No 1.26 0.58 to 2.72 0.557 270
Yes Regression failed
Interaction model (n= 1156)
History of spontaneous preterm birth OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
No 1.22 0.55 to 2.71 0.620 0.053
Yes 0.48 0.29 to 0.79 0.004
Model in subgroup with a history of spontaneous preterm birth, not adjusting for previous pregnancy of
≥ 14 weeks’ gestation
History of spontaneous preterm birth OR (progesterone vs. placebo) 95% CI p-value n
Yes 0.48 0.30 to 0.78 0.003 886
Note
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TABLE 106 Linear regression model for the effect of treatment on the primary childhood outcome Bayley-III
cognitive composite score adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect in
subgroups according to history of spontaneous preterm birth
Separate models in each subgroup
History of spontaneous preterm birth
Expected mean difference
(progesterone vs. placebo) 95% CI p-value n
No –1.05 –5.89 to 3.79 0.672 201
Yes Regression failed
Interaction model (n= 857)
History of spontaneous preterm birth
Expected mean difference
(progesterone vs. placebo) 95% CI p-value
p-value for
interaction
No –1.11 –5.96 to 3.73 0.653 0.730
Yes –0.14 –2.79 to 2.52 0.919
Model in subgroup with a history of spontaneous preterm birth, not adjusting for previous pregnancy of
≥ 14 weeks’ gestation
History of spontaneous preterm birth Parameter estimate 95% CI p-value n
Yes –0.22 –2.89 to 2.44 0.870 656
Note
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TABLE 107 Logistic regression model for the effect of treatment on the primary childhood outcome survival
adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect in subgroups according to
history of spontaneous preterm birth
Separate models in each subgroup
History of spontaneous preterm birth OR (progesterone vs. placebo) 95% CI p-value n
No 0.64 0.17 to 2.40 0.506 243
Yes Regression failed
Interaction model (n= 993)
History of spontaneous preterm birth OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
No 0.64 0.17 to 2.44 0.510 0.754
Yes 0.82 0.38 to 1.76 0.605
Model in subgroup with a history of spontaneous preterm birth, not adjusting for previous pregnancy of
≥ 14 weeks’ gestation
History of spontaneous preterm birth OR 95% CI p-value n
Yes 0.82 0.38 to 1.77 0.606 750
Note
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TABLE 108 Proportional hazards regression model for the effect of treatment on the primary childhood outcome
survival adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect in subgroups
according to history of spontaneous preterm birth
Separate models in each subgroup
History of spontaneous preterm birth
Hazard ratio
(progesterone vs. placebo) 95% CI p-value n
No 1.55 0.42 to 5.78 0.513 273
Yes Regression failed
Interaction model (n= 1177)
History of spontaneous preterm birth
Hazard ratio
(progesterone vs. placebo) 95% CI p-value
p-value for
interaction
No 1.55 0.42 to 5.78 0.513 0.734
Yes 1.19 0.56 to 2.55 0.650
Model in subgroup with a history of spontaneous preterm birth, not adjusting for previous pregnancy of
≥ 14 weeks’ gestation
History of spontaneous preterm birth Hazard ratio 95% CI p-value n
Yes 1.20 0.56 to 2.55 0.645 904
Note
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TABLE 109 Logistic regression model for the effect of treatment on the primary obstetric outcome death or
delivery before 34 weeks’ gestation adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random
effect in subgroups according to history of preterm birth
Separate models in each subgroup
History of preterm birth OR (progesterone vs. placebo) 95% CI p-value n
No 1.06 0.53 to 2.13 0.862 250
Yes Regression failed
Interaction model (n= 1196)
History of preterm birth OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
No 1.06 0.53 to 2.12 0.868 0.497
Yes 0.81 0.58 to 1.14 0.225
Model in subgroup with a history of preterm birth, not adjusting for previous pregnancy of ≥ 14 weeks’ gestation
History of spontaneous preterm birth OR 95% CI p-value n
Yes 0.81 0.58 to 1.14 0.226 946
Note
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TABLE 110 Logistic regression model for the effect of treatment on the primary neonatal outcome death, brain
injury or severe chronic lung disease adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a
random effect in subgroups according to history of preterm birth
Separate models in each subgroup
History of preterm birth OR (progesterone vs. placebo) 95% CI p-value n
No 1.12 0.50 to 2.49 0.781 248
Yes Regression failed
Interaction model (n= 1175)
History of preterm birth OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
No 1.09 0.48 to 2.45 0.836 0.125
Yes 0.52 0.32 to 0.84 0.008
Model in subgroup with a history of preterm birth, not adjusting for previous pregnancy of ≥ 14 weeks’ gestation
History of spontaneous preterm birth OR 95% CI p-value n
Yes 0.52 0.33 to 0.83 0.007 927
Note
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TABLE 111 Linear regression model for the effect of treatment on the primary childhood outcome Bayley-III
cognitive composite score adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect in
subgroups according to history of preterm birth
Separate models in each subgroup
History of preterm birth
Expected mean difference
(progesterone vs. placebo) 95% CI p-value n
No –0.83 –5.96 to 4.29 0.750 187
Yes Regression failed
Interaction model (n= 868)
History of preterm birth
Expected mean difference
(progesterone vs. placebo) 95% CI p-value
p-value for
interaction
No –0.91 –5.92 to 4.11 0.724 0.852
Yes –0.37 –2.96 to 2.23 0.782
Model in subgroup with a history of preterm birth, not adjusting for previous pregnancy of ≥ 14 weeks’ gestation
History of spontaneous preterm birth Parameter estimate 95% CI p-value n
Yes –0.44 –3.02 to 2.14 0.739 681
Note
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TABLE 112 Logistic regression model for the effect of treatment on the primary childhood outcome survival
adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect in subgroups according to
history of preterm birth
Separate models in each subgroup
History of preterm birth OR (progesterone vs. placebo) 95% CI p-value n
No 0.63 0.17 to 2.39 0.500 223
Yes Regression failed
Interaction model (n= 1008)
History of preterm birth OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
No 0.63 0.16 to 2.43 0.505 0.747
Yes 0.82 0.38 to 1.77 0.607
Model in subgroup with a history of preterm birth, not adjusting for previous pregnancy of ≥ 14 weeks’ gestation
History of spontaneous preterm birth OR 95% CI p-value n
Yes 0.82 0.38 to 1.77 0.609 785
Note
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TABLE 113 Proportional hazards regression model for the effect of treatment on the primary childhood outcome
survival adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect in subgroups
according to history of preterm birth
Separate models in each subgroup
History of preterm birth
Hazard ratio
(progesterone vs. placebo) 95% CI p-value n
No 1.52 0.41 to 5.68 0.530 250
Yes Regression failed
Interaction model (n= 1197)
History of preterm birth
Hazard ratio
(progesterone vs. placebo) 95% CI p-value
p-value for
interaction
No 1.52 0.41 to 5.66 0.533 0.762
Yes 1.20 0.56 to 2.57 0.633
Model in subgroup with a history of preterm birth, not adjusting for previous pregnancy of ≥ 14 weeks’ gestation
History of spontaneous
preterm birth Hazard ratio 95% CI p-value n
Yes 1.21 0.56 to 2.58 0.629 947
Note
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TABLE 114 Logistic regression model for the effect of treatment on the primary obstetric outcome death or
delivery before 34 weeks’ gestation adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random
effect in subgroups according to chorioamnionitis diagnosed on pathology
Separate models in each subgroup
Chorioamnionitis diagnosed
on pathology OR (progesterone vs. placebo) 95% CI p-value n
No Regression failed
Yes 2.16 0.69 to 6.83 0.194 57
Interaction model (n= 172)
Chorioamnionitis diagnosed
on pathology OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
No 1.38 0.55 to 3.45 0.497 0.547
Yes 2.17 0.68 to 6.85 0.190
Model in subgroup without chorioamnionitis, not adjusting for previous pregnancy of ≥ 14 weeks’ gestation
Chorioamnionitis diagnosed
on pathology OR (progesterone vs. placebo) 95% CI p-value n
No 1.36 0.55 to 3.41 0.509 115
Note
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TABLE 115 Logistic regression model for the effect of treatment on the primary neonatal outcome death, brain
injury or severe chronic lung disease adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a
random effect in subgroups according to chorioamnionitis diagnosed on pathology
Separate models in each subgroup
Chorioamnionitis diagnosed
on pathology OR (progesterone vs. placebo) 95% CI p-value n
No Regression failed
Yes 2.10 0.65 to 6.77 0.220 56
Interaction model (n= 171)
Chorioamnionitis diagnosed
on pathology OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
No 0.81 0.22 to 2.96 0.752 0.244
Yes 2.21 0.76 to 6.40 0.148
Model in subgroup without chorioamnionitis, not adjusting for previous pregnancy of ≥ 14 weeks’ gestation
Chorioamnionitis diagnosed
on pathology OR (progesterone vs. placebo) 95% CI p-value n
No 0.94 0.39 to 2.29 0.892 115
Note
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TABLE 116 Linear regression model for the effect of treatment on the primary childhood outcome Bayley-III
cognitive composite score adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect in
subgroups according to chorioamnionitis diagnosed on pathology
Separate models in each subgroup
Chorioamnionitis diagnosed
on pathology
Expected mean difference
(progesterone vs. placebo) 95% CI p-value n
No –2.15 –9.80 to 5.49 0.582 81
Yes –2.57 –14.76 to 9.62 0.682 43
Interaction model (n= 124)
Chorioamnionitis diagnosed
on pathology
Expected mean difference
(progesterone vs. placebo) 95% CI p-value
p-value for
interaction
No –2.30 –10.30 to 5.70 0.575 0.859
Yes –1.08 –11.91 to 9.76 0.846
Note
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TABLE 118 Proportional hazards regression model for the effect of treatment on the primary childhood outcome
survival adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect in subgroups
according to chorioamnionitis diagnosed on pathology
Separate models in each subgroup
Chorioamnionitis diagnosed
on pathology
Hazard ratio
(progesterone vs. placebo) 95% CI p-value n
No 3.48 0.36 to 33.47 0.280 115
Yes 5.74 0.67 to 49.18 0.111 57
Interaction model failed
Interaction model not adjusting for previous pregnancy of at least 14 weeks’ gestation (n= 172)
Chorioamnionitis diagnosed
on pathology
Hazard ratio
(progesterone vs. placebo) 95% CI p-value n
No 3.55 0.37 to 34.38 0.274 0.538
Yes 5.40 0.62 to 46.81 0.126
Note
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TABLE 117 Logistic regression model for the effect of treatment on the primary childhood outcome survival
adjusted for previous pregnancy of ≥ 14 weeks’ gestation and site as a random effect in subgroups according to
chorioamnionitis diagnosed on pathology
Separate models in each subgroup
Chorioamnionitis diagnosed
on pathology OR (progesterone vs. placebo) 95% CI p-value n
No Regression failed
Yes Regression failed
Interaction model failed
Fisher’s exact test in subgroups according to history of spontaneous preterm birth
History of spontaneous preterm birth
Treatment
p-valuePlacebo Progesterone
No, Nobs (Nmiss) 52 (6) 49 (8) 0.353
Alive at 2 years
No, n (%) 1 (1.9) 3 (6.1)
Yes, n (%) 51 (98.1) 46 (93.9)
Yes, Nobs (Nmiss) 26 (3) 25 (3) 0.099
Alive at 2 years
No, n (%) 1 (3.8) 5 (20.0)
Yes, n (%) 25 (96.2) 20 (80.0)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 119 Logistic regression model for the effect of treatment on the primary obstetric outcome death or
delivery before 34 weeks’ gestation in subgroups according to previous pregnancy of ≥ 14 weeks’ gestation
Separate models in each subgroup
Previous pregnancy of
≥ 14 weeks’ gestation OR (progesterone vs. placebo) 95% CI p-value n
No 1.65 0.47 to 5.85 0.440 73
Yes 0.83 0.61 to 1.13 0.235 1124
Interaction model (n= 1197)
Previous pregnancy of
≥ 14 weeks’ gestation OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
No 1.65 0.47 to 5.79 0.434 0.296
Yes 0.83 0.61 to 1.13 0.235
Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 09 14:56:07 2015.
TABLE 120 Logistic regression model for the effect of treatment on the primary neonatal outcome death, brain
injury or severe chronic lung disease in subgroups according to previous pregnancy of ≥ 14 weeks’ gestation
Separate models in each subgroup
Previous pregnancy of
≥ 14 weeks’ gestation OR (progesterone vs. placebo) 95% CI p-value n
No 11.02 2.72 to 44.70 0.001 73
Yes 0.54 0.35 to 0.84 0.006 1103
Interaction model (n= 1176)
Previous pregnancy of
≥ 14 weeks’ gestation OR (progesterone vs. placebo) 95% CI p-value
p-value for
interaction
No 6.24 0.73 to 53.04 0.094 0.029
Yes 0.54 0.35 to 0.83 0.005
Note
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TABLE 121 Linear regression model for the effect of treatment on the primary childhood outcome Bayley-III
cognitive composite score in subgroups according to previous pregnancy of ≥ 14 weeks’ gestation
Separate models in each subgroup
Previous pregnancy of
≥ 14 weeks’ gestation
Expected mean difference
(progesterone vs. placebo) 95% CI p-value n
No –3.03 –11.54 to 5.47 0.488 57
Yes –0.40 –2.78 to 1.99 0.745 812
Interaction model (n= 869)
Previous pregnancy of
≥ 14 weeks’ gestation
Expected mean difference
(progesterone vs. placebo) 95% CI p-value
p-value for
interaction
No –1.72 –10.70 to 7.26 0.707 0.780
Yes –0.40 –2.77 to 1.98 0.744
Note
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TABLE 122 Logistic regression model for the effect of treatment on the primary childhood outcome survival in
subgroups according to previous pregnancy of ≥ 14 weeks’ gestation
Separate models in each subgroup
Previous pregnancy of
≥ 14 weeks’ gestation OR (progesterone vs. placebo) 95% CI p-value n
No Regression failed
Yes 0.82 0.42 to 1.62 0.571 940
Interaction model failed
Fisher’s exact test in subgroups according to previous pregnancy of ≥ 14 weeks’ gestation
Previous pregnancy of ≥ 14 weeks’ gestation
Treatment
p-valuePlacebo Progesterone
No, Nobs (Nmiss) 35 (3) 34 (3) 0.493
Alive at 2 years
No, n (%) 0 (0.0) 1 (2.9)
Yes, n (%) 35 (100.0) 33 (97.1)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 123 Proportional hazards regression model for the effect of treatment on the primary childhood outcome
survival in subgroups according to previous pregnancy of ≥ 14 weeks’ gestation
Separate models in each subgroup
Previous pregnancy of
≥ 14 weeks’ gestation
Hazard ratio
(progesterone vs. placebo) 95% CI p-value n
No 4781116004.75 0.00 to Infinity 1.000 73
Yes 1.19 0.61 to 2.32 0.605 1125
Interaction model (n= 1198)
Previous pregnancy of
≥ 14 weeks’ gestation
Hazard ratio
(progesterone vs. placebo) 95% CI p-value
p-value for
interaction
No 60718556.85 0.00 to Infinity 0.998 0.262
Yes 1.19 0.61 to 2.32 0.606
Log-rank test for the effect of treatment (unadjusted) in the group with no previous
pregnancy of ≥ 14 weeks’ gestation
0.297
Note
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TABLE 124 Pregnancy complications
Outcome All
Trial group
Placebo Progesterone
Obstetric cholestasis
Nobs (Nmiss) 1182 (1) 589 (1) 593 (0)
No, n (%) 1172 (99.2) 583 (99.0) 589 (99.3)
Yes, n (%) 10 (0.8) 6 (1.0) 4 (0.7)
Hypertension
Nobs (Nmiss) 1183 (0) 590 (0) 593 (0)
No, n (%) 1136 (96.0) 566 (95.9) 570 (96.1)
Yes, n (%) 47 (4.0) 24 (4.1) 23 (3.9)
Pre-eclampsia
Nobs (Nmiss) 1183 (0) 590 (0) 593 (0)
No, n (%) 1162 (98.2) 579 (98.1) 583 (98.3)
Yes, n (%) 21 (1.8) 11 (1.9) 10 (1.7)
Eclampsia
Nobs (Nmiss) 1183 (0) 590 (0) 593 (0)
No, n (%) 1182 (99.9) 589 (99.8) 593 (100.0)
Yes, n (%) 1 (0.1) 1 (0.2) 0 (0.0)
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TABLE 124 Pregnancy complications (continued )
Outcome All
Trial group
Placebo Progesterone
Preterm membrane rupture
Nobs (Nmiss) 1183 (0) 590 (0) 593 (0)
No, n (%) 1046 (88.4) 518 (87.8) 528 (89.0)
Yes, n (%) 137 (11.6) 72 (12.2) 65 (11.0)
Antepartum haemorrhage
Nobs (Nmiss) 1183 (0) 590 (0) 593 (0)
No, n (%) 1110 (93.8) 554 (93.9) 556 (93.8)
Yes, n (%) 73 (6.2) 36 (6.1) 37 (6.2)
Confirmed deep-vein thrombosis
Nobs (Nmiss) 1183 (0) 590 (0) 593 (0)
No, n (%) 1181 (99.8) 588 (99.7) 593 (100.0)
Yes, n (%) 2 (0.2) 2 (0.3) 0 (0.0)
Gestational diabetes
Nobs (Nmiss) 1183 (0) 590 (0) 593 (0)
No, n (%) 1119 (94.6) 553 (93.7) 566 (95.4)
Yes, n (%) 64 (5.4) 37 (6.3) 27 (4.6)
Cerclage
Nobs (Nmiss) 728 (455) 360 (230) 368 (225)
No, n (%) 648 (89.0) 321 (89.2) 327 (88.9)
Yes, n (%) 80 (11.0) 39 (10.8) 41 (11.1)
Other maternal complication
Nobs (Nmiss) 1183 (0) 590 (0) 593 (0)
No, n (%) 853 (72.1) 426 (72.2) 427 (72.0)
Yes, n (%) 330 (27.9) 164 (27.8) 166 (28.0)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 125 Pregnancy complications: other fetal
Outcome All
Trial group
Placebo Progesterone
Other fetal complication
Nobs (Nmiss) 1183 (0) 590 (0) 593 (0)
No, n (%) 1146 (96.9) 572 (96.9) 574 (96.8)
Yes, n (%) 37 (3.1) 18 (3.1) 19 (3.2)
Abdominal circumference < 5th centile
Nobs (Nmiss) 37 (0) 18 (0) 19 (0)
No, n (%) 27 (73.0) 14 (77.8) 13 (68.4)
Yes, n (%) 10 (27.0) 4 (22.2) 6 (31.6)
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TABLE 125 Pregnancy complications: other fetal (continued )
Outcome All
Trial group
Placebo Progesterone
Liquor volume reduced
Nobs (Nmiss) 37 (0) 18 (0) 19 (0)
No, n (%) 25 (67.6) 12 (66.7) 13 (68.4)
Yes, n (%) 12 (32.4) 6 (33.3) 6 (31.6)
Doppler > 95th centile (umbilical artery)
Nobs (Nmiss) 37 (0) 18 (0) 19 (0)
No, n (%) 35 (94.6) 17 (94.4) 18 (94.7)
Yes, n (%) 2 (5.4) 1 (5.6) 1 (5.3)
Absent end-diastolic flow (umbilical artery)
Nobs (Nmiss) 37 (0) 18 (0) 19 (0)
No, n (%) 36 (97.3) 18 (100.0) 18 (94.7)
Yes, n (%) 1 (2.7) 0 (0.0) 1 (5.3)
Reversed end-diastolic flow (umbilical artery)
Nobs (Nmiss) 37 (0) 18 (0) 19 (0)
No, n (%) 35 (94.6) 17 (94.4) 18 (94.7)
Yes, n (%) 2 (5.4) 1 (5.6) 1 (5.3)
Abnormal cardiotocogram
Nobs (Nmiss) 37 (0) 18 (0) 19 (0)
No, n (%) 27 (73.0) 11 (61.1) 16 (84.2)
Yes, n (%) 10 (27.0) 7 (38.9) 3 (15.8)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 126 Antenatal hospital admissions: number of admissions and number of days in hospital per woman
Outcome All
Trial group
Placebo Progesterone
Number of antenatal hospital admissions (per woman)
Nobs (Nmiss) 1160 (23) 581 (9) 579 (14)
Mean (SD) 0.7 (1.2) 0.7 (1.3) 0.6 (1.1)
Median (IQR) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0)
Range 0.0–10.0 0.0–10.0 0.0–8.0
Number of antenatal hospital admissions for threatened preterm labour
Nobs (Nmiss) 1160 (23) 581 (9) 579 (14)
Mean (SD) 0.3 (0.8) 0.4 (0.9) 0.3 (0.7)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Range 0.0–9.0 0.0–9.0 0.0–5.0
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TABLE 126 Antenatal hospital admissions: number of admissions and number of days in hospital per woman
(continued )
Outcome All
Trial group
Placebo Progesterone
Number of antenatal hospital admissions for other reasons
Nobs (Nmiss) 1160 (23) 581 (9) 579 (14)
Mean (SD) 0.3 (0.8) 0.4 (0.8) 0.3 (0.8)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Range 0.0–7.0 0.0–7.0 0.0–6.0
Total number of days in hospital antenatally (per woman)
Nobs (Nmiss) 1153 (30) 576 (14) 577 (16)
Mean (SD) 2.9 (7.6) 3.0 (7.6) 2.7 (7.7)
Median (IQR) 0.0 (0.0–2.0) 0.0 (0.0–3.0) 0.0 (0.0–2.0)
Range 0.0–97.0 0.0–97.0 0.0–84.0
Total number of days in hospital for threatened preterm labour
Nobs (Nmiss) 1156 (27) 579 (11) 577 (16)
Mean (SD) 1.7 (5.8) 1.8 (6.2) 1.6 (5.3)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Range 0.0–97.0 0.0–97.0 0.0–56.0
Total number of days in hospital for other reasons
Nobs (Nmiss) 1157 (26) 578 (12) 579 (14)
Mean (SD) 1.2 (5.0) 1.2 (4.3) 1.1 (5.6)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Range 0.0–84.0 0.0–39.0 0.0–84.0
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 127 Antenatal hospital admissions: number of admissions per indication on admission and discharge diagnosis
Outcome All, n (%)
Trial group, n (%)
Placebo Progesterone
Number of hospital admissions per indication for admission (multiple indications possible)
Total number of admissions, n 381 206 175
Hypertension 18 (4.7) 11 (5.3) 7 (4.0)
Pre-eclampsia 8 (2.1) 4 (1.9) 4 (2.3)
Eclampsia 0 (0.0) 0 (0.0) 0 (0.0)
Membranes ruptured 18 (4.7) 7 (3.4) 11 (6.3)
Antepartum haemorrhage 39 (10.2) 20 (9.7) 19 (10.9)
Suspected deep-vein thrombosis 1 (0.3) 1 (0.5) 0 (0.0)
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TABLE 127 Antenatal hospital admissions: number of admissions per indication on admission and discharge
diagnosis (continued )
Outcome All, n (%)
Trial group, n (%)
Placebo Progesterone
Diabetes 10 (2.6) 4 (1.9) 6 (3.4)
Abdominal pain 91 (23.9) 44 (21.4) 47 (26.9)
Symphyseal pain 7 (1.8) 3 (1.5) 4 (2.3)
Other maternal 204 (53.5) 113 (54.9) 91 (52.0)
Other fetal 11 (2.9) 8 (3.9) 3 (1.7)
Abdominal circumference 2 (0.5) 1 (0.5) 1 (0.6)
Reduced liquor volume 0 (0.0) 0 (0.0) 0 (0.0)
Abnormal Doppler 0 (0.0) 0 (0.0) 0 (0.0)
Absent end-diastolic flow 0 (0.0) 0 (0.0) 0 (0.0)
Reverse end-diastolic flow 0 (0.0) 0 (0.0) 0 (0.0)
Abnormal cardiotocogram 1 (0.3) 1 (0.5) 0 (0.0)
None 12 (3.1) 7 (3.4) 5 (2.9)
Number of hospital admissions per discharge diagnosis (multiple indications possible)
Hypertension 12 (3.1) 8 (3.9) 4 (2.3)
Pre-eclampsia 6 (1.6) 3 (1.5) 3 (1.7)
Eclampsia 0 (0.0) 0 (0.0) 0 (0.0)
Membranes ruptured 9 (2.4) 3 (1.5) 6 (3.4)
Antepartum haemorrhage 37 (9.7) 17 (8.3) 20 (11.4)
Suspected deep-vein thrombosis 1 (0.3) 1 (0.5) 0 (0.0)
Diabetes 8 (2.1) 3 (1.5) 5 (2.9)
Abdominal pain 63 (16.5) 33 (16.0) 30 (17.1)
Symphyseal pain 8 (2.1) 3 (1.5) 5 (2.9)
Other maternal 214 (56.2) 123 (59.7) 91 (52.0)
Other fetal 9 (2.4) 7 (3.4) 2 (1.1)
Abdominal circumference 0 (0.0) 0 (0.0) 0 (0.0)
Reduced liquor volume 1 (0.3) 1 (0.5) 0 (0.0)
Doppler 0 (0.0) 0 (0.0) 0 (0.0)
Absent end-diastolic flow 0 (0.0) 0 (0.0) 0 (0.0)
Reverse end-diastolic flow 0 (0.0) 0 (0.0) 0 (0.0)
Abnormal cardiotocogram 1 (0.3) 0 (0.0) 1 (0.6)
None 38 (10.0) 18 (8.7) 20 (11.4)
Note
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TABLE 128 Antenatal hospital admissions: number of women with at least one admission for each indication on
admission and discharge diagnosis
Outcome All All, n (%) Placebo, n (%)
Indication for hospitalisation, n 242 135 107
Hypertension 12 (5.0) 7 (5.2) 5 (4.7)
Pre-eclampsia 8 (3.3) 4 (3.0) 4 (3.7)
Eclampsia, 0 (0.0) 0 (0.0) 0 (0.0)
Membranes ruptured 16 (6.6) 7 (5.2) 9 (8.4)
Antepartum haemorrhage 28 (11.6) 16 (11.9) 12 (11.2)
Suspected deep-vein thrombosis 1 (0.4) 1 (0.7) 0 (0.0)
Diabetes 5 (2.1) 3 (2.2) 2 (1.9)
Abdominal pain 73 (30.2) 37 (27.4) 36 (33.6)
Symphyseal pain 7 (2.9) 3 (2.2) 4 (3.7)
Other maternal 142 (58.7) 79 (58.5) 63 (58.9)
Other fetal 9 (3.7) 6 (4.4) 3 (2.8)
Abdominal circumference 2 (0.8) 1 (0.7) 1 (0.9)
Reduced liquor volume 0 (0.0) 0 (0.0) 0 (0.0)
Doppler 0 (0.0) 0 (0.0) 0 (0.0)
Absent end-diastolic flow 0 (0.0) 0 (0.0) 0 (0.0)
Reverse end-diastolic flow 0 (0.0) 0 (0.0) 0 (0.0)
Abnormal cardiotocogram 1 (0.4) 1 (0.7) 0 (0.0)
None 10 (4.1) 7 (5.2) 3 (2.8)
Number of women discharged from hospital at least once per discharge diagnosis (multiple indications possible)
Hypertension 7 (2.9) 5 (3.7) 2 (1.9)
Pre-eclampsia 6 (2.5) 3 (2.2) 3 (2.8)
Eclampsia 0 (0.0) 0 (0.0) 0 (0.0)
Membranes ruptured 9 (3.7) 3 (2.2) 6 (5.6)
Antepartum haemorrhage 23 (9.5) 12 (8.9) 11 (10.3)
Suspected deep-vein thrombosis 1 (0.4) 1 (0.7) 0 (0.0)
Diabetes 4 (1.7) 2 (1.5) 2 (1.9)
Abdominal pain 51 (21.1) 27 (20.0) 24 (22.4)
Symphyseal pain 8 (3.3) 3 (2.2) 5 (4.7)
Other maternal 153 (63.2) 90 (66.7) 63 (58.9)
Other fetal 9 (3.7) 7 (5.2) 2 (1.9)
Abdominal circumference 0 (0.0) 0 (0.0) 0 (0.0)
Reduced liquor volume 1 (0.4) 1 (0.7) 0 (0.0)
Doppler 0 (0.0) 0 (0.0) 0 (0.0)
Absent end-diastolic flow 0 (0.0) 0 (0.0) 0 (0.0)
Reverse end-diastolic flow 0 (0.0) 0 (0.0) 0 (0.0)
Abnormal cardiotocogram 1 (0.4) 0 (0.0) 1 (0.9)
None 31 (12.8) 16 (11.9) 15 (14.0)
Note
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TABLE 129 Antenatal hospital admissions: other details of hospital admissions
Outcome All
Trial group
Placebo Progesterone
Number of hospital admissions with tocolysis, n (%) 33 (8.5) 18 (8.1) 15 (8.9)
Type of tocolysis
Nobs (Nmiss) 33 (0) 18 (0) 15 (0)
Nifedipine, n (%) 17 (51.5) 8 (44.4) 9 (60.0)
Indomethacine, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Atosiban, n (%) 15 (45.5) 9 (50.0) 6 (40.0)
Other, n (%) 1 (3.0) 1 (5.6) 0 (0.0)
Number of hospital admissions with steroid, n (%) 160 (41.0) 77 (34.8) 83 (49.1)
Number of hospital admissions with antibiotic, n (%) 94 (24.1) 54 (24.4) 40 (23.7)
Number of hospital admissions with suture, n (%) 18 (4.6) 10 (4.5) 8 (4.7)
Number of hospital admissions with magnesium, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 130 Labour
Outcome All
Trial group
Placebo Progesterone
Duration of first stage (hours)
Nobs (Nmiss) 933 (250) 463 (127) 470 (123)
Mean (SD) 4.2 (5.2) 4.1 (5.1) 4.3 (5.3)
Median (IQR) 3.0 (1.2–5.4) 2.8 (1.2–5.3) 3.2 (1.3–5.5)
Range 0.0–70.0 0.0–56.0 0.0–70.0
Duration of second stage (minutes)
Nobs (Nmiss) 933 (250) 462 (128) 471 (122)
Mean (SD) 44.1 (113.9) 47.0 (132.8) 41.2 (91.6)
Median (IQR) 16.0 (6.0–40.0) 16.0 (6.0–42.8) 16.0 (5.0–39.0)
Range 0.0–1800.0 0.0–1800.0 0.0–1383.0
Duration of third stage (minutes)
Nobs (Nmiss) 942 (241) 465 (125) 477 (116)
Mean (SD) 16.6 (49.0) 17.0 (46.2) 16.1 (51.6)
Median (IQR) 7.0 (4.0–11.0) 6.0 (4.0–11.0) 7.0 (5.0–10.0)
Range 0.0–900.0 0.0–600.0 0.0–900.0
Membranes ruptured
Nobs (Nmiss) 1149 (34) 575 (15) 574 (19)
No, n (%) 235 (20.5) 109 (19.0) 126 (22.0)
Yes, n (%) 914 (79.5) 466 (81.0) 448 (78.0)
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TABLE 130 Labour (continued )
Outcome All
Trial group
Placebo Progesterone
Type of membrane rupture
Nobs (Nmiss) 916 (267) 468 (122) 448 (145)
Artificial, n (%) 253 (27.6) 131 (28.0) 122 (27.2)
Spontaneous, n (%) 663 (72.4) 337 (72.0) 326 (72.8)
Analgesic
Nobs (Nmiss) 1150 (33) 576 (14) 574 (19)
No, n (%) 217 (18.9) 121 (21.0) 96 (16.7)
Yes, n (%) 933 (81.1) 455 (79.0) 478 (83.3)
Analgesics used
General anaesthetic, n (%) 28 (2.4) 16 (2.7) 12 (2.0)
Epidural, n (%) 388 (32.8) 191 (32.4) 197 (33.2)
Opiates, n (%) 176 (14.9) 88 (14.9) 88 (14.8)
Entonox, n (%) 572 (48.4) 269 (45.6) 303 (51.1)
Other, n (%) 65 (5.5) 34 (5.8) 31 (5.2)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 131 Delivery
Outcome All
Trial group
Placebo Progesterone
Delivery method
Nobs (Nmiss) 1154 (29) 578 (12) 576 (17)
Spontaneous vaginal delivery, n (%) 755 (65.4) 380 (65.7) 375 (65.1)
Lower segment caesarean section in labour,
n (%)
115 (10.0) 58 (10.0) 57 (9.9)
Lower segment caesarean section pre labour,
n (%)
176 (15.3) 92 (15.9) 84 (14.6)
Forceps, n (%) 48 (4.2) 21 (3.6) 27 (4.7)
Ventouse, n (%) 38 (3.3) 18 (3.1) 20 (3.5)
Vaginal breech (spontaneous or assisted), n (%) 22 (1.9) 9 (1.6) 13 (2.3)
Reason for assisted delivery, n (%)
Abnormal cardiotocogram 89 (7.5) 45 (7.6) 44 (7.4)
Abnormal pH 1 (0.1) 0 (0.0) 1 (0.2)
Slow stage 1 14 (1.2) 4 (0.7) 10 (1.7)
Slow stage 2 64 (5.4) 29 (4.9) 35 (5.9)
Malpresentation 54 (4.6) 30 (5.1) 24 (4.0)
Suspected maternal compromise 29 (2.5) 18 (3.1) 11 (1.9)
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TABLE 131 Delivery (continued )
Outcome All
Trial group
Placebo Progesterone
Suspected fetal compromise 60 (5.1) 33 (5.6) 27 (4.6)
Obstetric history 85 (7.2) 39 (6.6) 46 (7.8)
Other 76 (6.4) 37 (6.3) 39 (6.6)
Blood loss, ml
Nobs (Nmiss) 1144 (39) 572 (18) 572 (21)
Mean (SD) 405.5 (375.8) 387.4 (356.4) 423.7 (393.8)
Median (IQR) 300.0 (200.0–500.0) 300.0 (200.0–450.0) 300.0 (200.0–500.0)
Range 0.0–4000.0 0.0–4000.0 0.0–4000.0
Suture
Nobs (Nmiss) 1151 (32) 578 (12) 573 (20)
No, n (%) 793 (68.9) 413 (71.5) 380 (66.3)
Yes, n (%) 358 (31.1) 165 (28.5) 193 (33.7)
Reason for suture
Episiotomy, n (%) 98 (8.3) 48 (8.1) 50 (8.4)
Degree 1 tear, n (%) 46 (3.9) 21 (3.6) 25 (4.2)
Degree 2 tear, n (%) 201 (17.0) 91 (15.4) 110 (18.5)
Degree 3 tear, n (%) 23 (1.9) 11 (1.9) 12 (2.0)
Blood transfusion
Nobs (Nmiss) 1152 (31) 578 (12) 574 (19)
No, n (%) 1124 (97.6) 568 (98.3) 556 (96.9)
Yes, n (%) 28 (2.4) 10 (1.7) 18 (3.1)
Antibiotics during labour and delivery
Nobs (Nmiss) 1151 (32) 578 (12) 573 (20)
No, n (%) 963 (83.7) 482 (83.4) 481 (83.9)
Yes, n (%) 188 (16.3) 96 (16.6) 92 (16.1)
Surgical procedure required
Nobs (Nmiss) 1153 (30) 578 (12) 575 (18)
No, n (%) 1120 (97.1) 563 (97.4) 557 (96.9)
Yes, n (%) 33 (2.9) 15 (2.6) 18 (3.1)
Duration of hospital stay (days)
Nobs (Nmiss) 1144 (39) 577 (13) 567 (26)
Mean (SD) 3.3 (3.3) 3.2 (2.2) 3.3 (4.1)
Median (IQR) 3.0 (2.0–4.0) 3.0 (2.0–4.0) 3.0 (2.0–4.0)
Range 1.0–86.0 1.0–19.0 1.0–86.0
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 132 Placental examination
Result of placental examination All
Trial group
Placebo Progesterone
Nobs (Nmiss) 167 (1016) 84 (506) 83 (510)
None, n (%) 113 (67.7) 57 (67.9) 56 (67.5)
Chorioamnionitis, n (%) 19 (11.4) 10 (11.9) 9 (10.8)
Chorioamnionitis and funisitis, n (%) 35 (21.0) 17 (20.2) 18 (21.7)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 133 Post-partum complications
Outcome All
Trial group
Placebo Progesterone
Thrombophlebitis
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1155 (99.8) 579 (99.8) 576 (99.8)
Yes, n (%) 2 (0.2) 1 (0.2) 1 (0.2)
Deep-vein thrombosis
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1157 (100.0) 580 (100.0) 577 (100.0)
Wound infection
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1144 (98.9) 574 (99.0) 570 (98.8)
Yes, n (%) 13 (1.1) 6 (1.0) 7 (1.2)
Urine infection
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1150 (99.4) 574 (99.0) 576 (99.8)
Yes, n (%) 7 (0.6) 6 (1.0) 1 (0.2)
Wound breakdown
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1154 (99.7) 579 (99.8) 575 (99.7)
Yes, n (%) 3 (0.3) 1 (0.2) 2 (0.3)
Mastitis
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1155 (99.8) 579 (99.8) 576 (99.8)
Yes, n (%) 2 (0.2) 1 (0.2) 1 (0.2)
Unknown infection
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1145 (99.0) 574 (99.0) 571 (99.0)
Yes, n (%) 12 (1.0) 6 (1.0) 6 (1.0)
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TABLE 133 Post-partum complications (continued )
Outcome All
Trial group
Placebo Progesterone
Post-partum haemorrhage
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1070 (92.5) 539 (92.9) 531 (92.0)
Yes, n (%) 87 (7.5) 41 (7.1) 46 (8.0)
Depression
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1155 (99.8) 579 (99.8) 576 (99.8)
Yes, n (%) 2 (0.2) 1 (0.2) 1 (0.2)
Other complication
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 1099 (95.0) 553 (95.3) 546 (94.6)
Yes, n (%) 58 (5.0) 27 (4.7) 31 (5.4)
No complication
Nobs (Nmiss) 1157 (26) 580 (10) 577 (16)
No, n (%) 173 (15.0) 83 (14.3) 90 (15.6)
Yes, n (%) 984 (85.0) 497 (85.7) 487 (84.4)
Nmiss, number of women with missing data; Nobs, number of observations.
Note
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TABLE 134 Child assessment at birth
Outcome All
Trial group
Placebo Progesterone
Sex
Nobs (Nmiss) 1156 (27) 578 (12) 578 (15)
Male, n (%) 582 (50.3) 289 (50.0) 293 (50.7)
Female, n (%) 573 (49.6) 289 (50.0) 284 (49.1)
Indeterminate, n (%) 1 (0.1) 0 (0.0) 1 (0.2)
Birthweight (g)
Nobs (Nmiss) 1154 (29) 577 (13) 577 (16)
Mean (SD) 2849 (866) 2822 (884) 2875 (847)
Median (IQR) 3000 (2470–3448) 2960 (2350–3420) 3040 (2550–3450)
Range 380–6400 455–6400 380–5025
Apgar score at 1 minute
Nobs (Nmiss) 1110 (73) 553 (37) 557 (36)
Mean (SD) 8.1 (1.9) 8.1 (1.8) 8.1 (1.9)
Median (IQR) 9.0 (8.0–9.0) 9.0 (8.0–9.0) 9.0 (8.0–9.0)
Range 0.0–10.0 0.0–10.0 0.0–10.0
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TABLE 134 Child assessment at birth (continued )
Outcome All
Trial group
Placebo Progesterone
Apgar score at 5 minutes
Nobs (Nmiss) 1115 (68) 555 (35) 560 (33)
Mean (SD) 9.1 (1.4) 9.1 (1.3) 9.0 (1.4)
Median (IQR) 9.0 (9.0–10.0) 9.0 (9.0–10.0) 9.0 (9.0–10.0)
Range 0.0–10.0 0.0–10.0 0.0–10.0
Length of hospital stay (days)
Nobs (Nmiss) 1118 (65) 556 (34) 562 (31)
Mean (SD) 9.1 (20.6) 9.8 (20.9) 8.4 (20.2)
Median (IQR) 2.0 (1.0–5.0) 2.0 (1.0–6.0) 2.0 (1.0–4.0)
Range 0.0–220.0 0.0–152.0 0.0–220.0
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 135 Child assessment at 2 years
Outcome All
Trial group
Placebo Progesterone
Weight (kg)
Nobs (Nmiss) 687 (496) 355 (235) 332 (261)
Mean (SD) 13.3 (2.7) 13.2 (2.6) 13.4 (2.7)
Median (IQR) 13.0 (12.0–14.2) 13.0 (11.9–14.2) 13.1 (12.0–14.2)
Range 7.0–45.4 7.0–39.3 9.0–45.4
Height (cm)
Nobs (Nmiss) 716 (467) 369 (221) 347 (246)
Mean (SD) 87.3 (9.5) 87.2 (10.7) 87.4 (7.9)
Median (IQR) 88.0 (85.0–91.0) 88.0 (84.1–91.4) 87.6 (85.0–91.0)
Range 0.9–111.0 0.9–111.0 0.9–109.0
Head circumference (cm)
Nobs (Nmiss) 686 (497) 354 (236) 332 (261)
Mean (SD) 49.2 (5.7) 48.9 (4.6) 49.6 (6.7)
Median (IQR) 49.0 (48.0–50.4) 49.0 (48.0–50.3) 49.1 (48.0–50.5)
Range 0.5–98.0 0.5–84.9 0.5–98.0
Respiration rate (breaths per minute)
Nobs (Nmiss) 76 (1107) 38 (552) 38 (555)
Mean (SD) 23.6 (11.3) 25.2 (14.1) 21.9 (7.3)
Median (IQR) 23.0 (16.0–28.0) 24.0 (20.0–28.0) 22.0 (16.0–27.5)
Range 12.0–98.0 12.0–98.0 12.0–38.0
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TABLE 135 Child assessment at 2 years (continued )
Outcome All
Trial group
Placebo Progesterone
Heart rate (beats per minute)
Nobs (Nmiss) 73 (1110) 36 (554) 37 (556)
Mean (SD) 109.7 (18.3) 111.4 (17.3) 108.1 (19.3)
Median (IQR) 110.0 (100.0–119.0) 111.0 (102.2–118.0) 110.0 (100.0–120.0)
Range 40.0–170.0 68.0–170.0 40.0–160.0
Systolic blood pressure (mmHg)
Nobs (Nmiss) 46 (1137) 24 (566) 22 (571)
Mean (SD) 98.7 (14.0) 96.6 (13.2) 100.9 (14.7)
Median (IQR) 98.5 (90.2–107.8) 97.0 (89.2–103.5) 103.5 (91.8–108.0)
Range 59.0–128.0 64.0–123.0 59.0–128.0
Diastolic blood pressure (mmHg)
Nobs (Nmiss) 37 (1146) 20 (570) 17 (576)
Mean (SD) 64.2 (12.3) 66.0 (12.9) 62.1 (11.7)
Median (IQR) 64.0 (54.0–70.0) 65.5 (58.5–72.5) 63.0 (54.0–68.0)
Range 42.0–90.0 42.0–90.0 44.0–85.0
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Note
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TABLE 136 Mixed effects logistic regression model for the effect of treatment on the primary obstetric outcome
death or delivery before 34 weeks’ gestation adjusted for previous pregnancy of ≥ 14 weeks’ gestation and study
centre as a random effect (PP population)
Parameter OR 95% CI p-value
Treatment (progesterone vs. placebo) 0.86 0.55 to 1.35 0.512
Previous pregnancy of ≥ 14 weeks’ gestation 1.21 0.50 to 2.92 0.675
n= 687
Note
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TABLE 137 Mixed effects logistic regression model for the effect of treatment on the primary neonatal outcome
death, brain injury or severe chronic lung disease adjusted for previous pregnancy of ≥ 14 weeks’ gestation and
study centre as a random effect (PP population)
Parameter OR 95% CI p-value
Treatment (progesterone vs. placebo) 0.55 0.30 to 0.99 0.046
Previous pregnancy of ≥ 14 weeks’ gestation 1.30 0.41 to 4.12 0.652
n= 682
Note
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TABLE 138 Mixed effects linear regression model for the effect of treatment on the primary childhood outcome
Bayley-III cognitive composite score adjusted for previous pregnancy of ≥ 14 weeks’ gestation and study centre as a
random effect (PP population)
Parameter Parameter estimate 95% CI p-value
Treatment (progesterone vs. placebo) 0.49 –2.22 to 3.20 0.725
Previous pregnancy of ≥ 14 weeks’ gestation –7.13 –12.29 to –1.97 0.007
n= 575
Note
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TABLE 139 Mixed effects logistic regression model for the effect of treatment on the primary childhood outcome
survival adjusted for previous pregnancy of ≥ 14 weeks’ gestation and study centre as a random effect
(PP population)
Parameter OR 95% CI p-value
Treatment (progesterone vs. placebo) 0.92 0.43 to 1.97 0.831
Previous pregnancy of ≥ 14 weeks’ gestation 0.00 0.00 to infinity 1.000
n= 638
Note
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TABLE 141 Sensitivity analysis: multiple imputation of primary outcomes
Outcome Parameter estimate or hazard ratio 95% CI p-value
Variables used for predicting outcome: previous pregnancy of ≥ 14 weeks’ gestation, high/low risk, maternal age and sex
Obstetric outcome 0.866 0.640 to 1.170 0.348
Neonatal outcome 0.637 0.418 to 0.971 0.036
Variables used for predicting outcome: gestational age, birth weight, chronic lung disease, brain injury, previous pregnancy
of ≥ 14 weeks’ gestation, high/low risk, maternal age and sex
Alive at 2 years 0.760 0.392 to 1.476 0.418
Bayley-III cognitive composite score –0.019 –0.372 to 0.334 0.908
Variables used for predicting outcome: birth weight, chronic lung disease, brain injury, previous pregnancy of ≥ 14 weeks’
gestation, high/low risk, maternal age and sex
Alive at 2 years 0.744 0.384 to 1.441 0.380
Bayley-III cognitive composite score –0.051 –0.371 to 0.269 0.737
Note
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TABLE 142 Analysis of the obstetric outcome adjusted for previous pregnancy of ≥ 14 weeks’ gestation, cervical
length at baseline and risk group
Variable OR 95% CI p-value
Treatment (progesterone vs. placebo) 0.86 0.57 to 1.31 0.495
Previous pregnancy of ≥ 14 weeks’ gestation 2.01 0.92 to 4.39 0.082
Cervical length at baseline 0.96 0.94 to 0.98 < 0.001
High risk vs. low risk 3.06 1.96 to 4.78 < 0.001
n= 696
Note
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TABLE 140 Mixed effects proportional hazards regression model for the effect of treatment on the primary
childhood outcome survival adjusted for previous pregnancy of ≥ 14 weeks’ gestation and study centre as a
random effect (PP population)
Parameter Hazard ratio 95% CI p-value
Treatment (progesterone vs. placebo) 1.08 0.40 to 2.87 0.884
Previous pregnancy of ≥ 14 weeks’ gestation NA NA to NA NA
n= 687
NA, not appropriate.
Note
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TABLE 143 Analysis of Bayley-III cognitive composite score adjusted for previous pregnancy of ≥ 14 weeks’
gestation, age, time in education, ethnicity (black vs. other ethnicities), height, number of previous live births,
number of previous pregnancies and risk group
Variable Parameter estimate 95% CI p-value
Treatment (progesterone vs. placebo) –0.52 –2.74 to 1.69 0.645
Previous pregnancy of ≥ 14 weeks’ gestation –2.94 –7.94 to 2.05 0.248
Age 0.40 0.18 to 0.62 < 0.001
Time in education 0.52 0.13 to 0.90 0.008
Ethnicity (black vs. all other) –4.31 –7.98 to –0.65 0.021
Height 0.34 0.17 to 0.51 < 0.001
Number of previous live births –1.85 –3.03 to –0.68 0.002
Number of previous pregnancies –0.64 –1.43 to 0.15 0.114
High risk vs. low risk –6.46 –9.07 to –3.86 < 0.001
n= 811
Note
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FIGURE 4 Survival curve for gestational age at delivery. These results have not been independently checked. Every
effort has been made to ensure their accuracy, but the possibility of error remains. OPPTIMUM Output created by
OPPTIMUM_main_v2_0.R. Last run on Friday 23 October 2015 at 13:07:12.
TABLE 144 Age at Bayley-III cognitive composite score assessment (ITT population)
Parameter or outcome All
Trial group
Placebo Progesterone
Age (weeks) at Bayley-III cognitive composite score assessment in those with cognitive composite score available
Nobs (Nmiss) 830 (3) 422 (1) 408 (2)
Mean (SD) 115.7 (17.1) 116.1 (18.3) 115.3 (15.8)
Median (IQR) 111.1 (104.3–122.0) 111.6 (104.6–122.2) 110.4 (104.0–121.5)
Range 2.6–184.4 2.6–180.0 94.0–184.4
Age (weeks) at Bayley-III cognitive composite score assessment in those with cognitive composite score available and in the
22- to 26-month window
Nobs (Nmiss) 446 (0) 221 (0) 225 (0)
Mean (SD) 104.6 (4.5) 104.8 (4.6) 104.5 (4.4)
Median (IQR) 104.7 (101.0–108.3) 104.7 (101.3–108.4) 104.6 (101.0–107.7)
Range 95.6–113.1 95.6–113.1 95.6–113.1
Bayley-III cognitive composite score available for those in the 22- to 26-month window or those who died before
Nobs (Nmiss) 482 (6) 237 (4) 245 (2)
Mean (SD) 95.5 (19.9) 95.1 (19.3) 95.9 (20.4)
Median (IQR) 100.0 (90.0–105.0) 95.0 (85.0–105.0) 100.0 (90.0–110.0)
Range 49.0–149.0 49.0–149.0 49.0–145.0
n Effect estimate 95% CI p-value
Regression analysis for subgroup with age in 22- to 26-month window or those who died before
Treatment 482 0.76 –2.74 to 4.27 0.670
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Notes
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TABLE 145 Number of cases using information from general practitioner letters
In the first step the components of disability have been defined from the paediatric assessment. Only for
patients where there was no, or not enough, information in the paediatric assessment data the GP letters have
been used to try to impute missing values. This has been done for each variable at a time, i.e. there could be
slight differences in the number of imputed items from one variable to the next. Expressed differently, for
patients with both records it is possible that some of the variables come from the paediatric assessment and
others from the GP letters
Number of cases with a record in the disability section of the paediatric assessment questionnaire 857
Number of cases with a GP letter 92
Number with both (included in both rows above) 6
GP, general practitioner.
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Note
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
TABLE 146 Neonatal outcome in the subgroup without previous pregnancy of ≥ 14 weeks’ gestation. Summary and
Fisher’s exact test
Neonatal outcome All
Trial group
Placebo Progesterone
Nobs (Nmiss) 38 (0) 35 (2) p = 0.098
No, n (%) 37 (97.4) 30 (85.7)
Yes, n (%) 1 (2.6) 5 (14.3)
Nmiss, number of women with missing data; Nobs, number of observations.
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 23 13:07:18 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
TABLE 147 Additional sensitivity analyses for brain injury
Parameter or outcome All
Trial group
Placebo Progesterone
Any information on neonatal outcomes
Nobs (Nmiss) 1226 (0) 610 (0) 616 (0)
Available, n (%) 1158 (94.5) 574 (94.1) 584 (94.8)
Died, n (%) 23 (1.9) 13 (2.1) 10 (1.6)
Missing, n (%) 5 (0.4) 2 (0.3) 3 (0.5)
Lost, n (%) 40 (3.3) 21 (3.4) 19 (3.1)
Ultrasonography done
Nobs (Nmiss) 1152 (74) 572 (38) 580 (36)
No, n (%) 376 (32.6) 172 (30.1) 204 (35.2)
Yes, n (%) 776 (67.4) 400 (69.9) 376 (64.8)
Intraventricular haemorrhage
Nobs (Nmiss) 740 (486) 383 (227) 357 (259)
No, n (%) 720 (97.3) 370 (96.6) 350 (98.0)
Yes, n (%) 20 (2.7) 13 (3.4) 7 (2.0)
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TABLE 147 Additional sensitivity analyses for brain injury (continued )
Parameter or outcome All
Trial group
Placebo Progesterone
Parenchymal cystic or haemorrhagic lesion
Nobs (Nmiss) 739 (487) 382 (228) 357 (259)
No, n (%) 708 (95.8) 359 (94.0) 349 (97.8)
Yes, n (%) 31 (4.2) 23 (6.0) 8 (2.2)
Persistent ventriculomegaly (VI > 97th percentile)
Nobs (Nmiss) 721 (505) 372 (238) 349 (267)
No, n (%) 710 (98.5) 364 (97.8) 346 (99.1)
Yes, n (%) 11 (1.5) 8 (2.2) 3 (0.9)
n OR 95% CI p-value
Regression analysis only including those with information on whether or not scan has been done
Treatment 1152 0.51 0.31 to 0.84 0.009
Regression analysis only including those where scan has been done
Treatment 776 0.54 0.32 to 0.88 0.015
Nmiss, number of women with missing data; Nobs, number of observations.
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 23 13:07:24 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
TABLE 148 Follow-up information summarised separately for those with and those without brain injury
Brain injury All
Trial group
Placebo Progesterone
No Bayley-III cognitive composite score
Nobs (Nmiss) 805 (301) 400 (140) 405 (161)
Mean (SD) 99.2 (15.9) 99.9 (15.4) 98.6 (16.3)
Median (IQR) 100.0 (90.0–110.0) 100.0 (90.0–110.0) 100.0 (90.0–110.0)
Range 49.0–149.0 49.0–149.0 49.0–149.0
Yes Bayley-III cognitive composite score
Nobs (Nmiss) 38 (14) 24 (10) 14 (4)
Mean (SD) 89.5 (17.1) 87.3 (14.4) 93.2 (21.0)
Median (IQR) 90.0 (85.0–100.0) 90.0 (85.0–95.0) 95.0 (82.5–100.0)
Range 55.0–145.0 55.0–105.0 55.0–145.0
No Survival status
Nobs (Nmiss) 1106 (0) 540 (0) 566 (0)
0, n (%) 1093 (98.8) 537 (99.4) 556 (98.2)
1, n (%) 13 (1.2) 3 (0.6) 10 (1.8)
Yes Survival status
Nobs (Nmiss) 52 (0) 34 (0) 18 (0)
0, n (%) 52 (100.0) 34 (100.0) 18 (100.0)
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TABLE 148 Follow-up information summarised separately for those with and those without brain injury
(continued )
Brain injury All
Trial group
Placebo Progesterone
No Moderate/severe neurodevelopmental impairment
Nobs (Nmiss) 743 (363) 379 (161) 364 (202)
No, n (%) 672 (90.4) 350 (92.3) 322 (88.5)
Yes, n (%) 71 (9.6) 29 (7.7) 42 (11.5)
Yes Moderate/severe neurodevelopmental impairment
Nobs (Nmiss) 36 (16) 22 (12) 14 (4)
No, n (%) 25 (69.4) 16 (72.7) 9 (64.3)
Yes, n (%) 11 (30.6) 6 (27.3) 5 (35.7)
Nmiss, number of women with missing data; Nobs, number of observations.
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 23 13:07:27 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
TABLE 149 Days of care summaries
Parameter or outcome All
Trial group
Placebo Progesterone
Number of days of level 1 care > 0
Nobs (Nmiss) 1149 (77) 569 (41) 580 (36)
No, n (%) 1002 (87.2) 487 (85.6) 515 (88.8)
Yes, n (%) 147 (12.8) 82 (14.4) 65 (11.2)
Number of days of level 1 care > 5
Nobs (Nmiss) 1149 (77) 569 (41) 580 (36)
No, n (%) 1078 (93.8) 532 (93.5) 546 (94.1)
Yes, n (%) 71 (6.2) 37 (6.5) 34 (5.9)
Number of days of level 1 or 2 care > 0
Nobs (Nmiss) 1149 (77) 569 (41) 580 (36)
No, n (%) 970 (84.4) 474 (83.3) 496 (85.5)
Yes, n (%) 179 (15.6) 95 (16.7) 84 (14.5)
Number of days of level 1 or 2 care > 5
Nobs (Nmiss) 1149 (77) 569 (41) 580 (36)
No, n (%) 1037 (90.3) 507 (89.1) 530 (91.4)
Yes, n (%) 112 (9.7) 62 (10.9) 50 (8.6)
Number of days of special or higher level of care > 0
Nobs (Nmiss) 1149 (77) 569 (41) 580 (36)
No, n (%) 844 (73.5) 410 (72.1) 434 (74.8)
Yes, n (%) 305 (26.5) 159 (27.9) 146 (25.2)
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TABLE 149 Days of care summaries (continued )
Parameter or outcome All
Trial group
Placebo Progesterone
Number of days of special or higher level of care > 5
Nobs (Nmiss) 1149 (77) 569 (41) 580 (36)
No, n (%) 930 (80.9) 451 (79.3) 479 (82.6)
Yes, n (%) 219 (19.1) 118 (20.7) 101 (17.4)
Number of days of special or higher level of care > 14
Nobs (Nmiss) 1149 (77) 569 (41) 580 (36)
No, n (%) 999 (86.9) 485 (85.2) 514 (88.6)
Yes, n (%) 150 (13.1) 84 (14.8) 66 (11.4)
Number of days of normal or higher level of care > 3
Nobs (Nmiss) 1148 (78) 569 (41) 579 (37)
No, n (%) 771 (67.2) 369 (64.9) 402 (69.4)
Yes, n (%) 377 (32.8) 200 (35.1) 177 (30.6)
Number of days of normal or higher level of care > 7
Nobs (Nmiss) 1148 (78) 569 (41) 579 (37)
No, n (%) 922 (80.3) 447 (78.6) 475 (82.0)
Yes, n (%) 226 (19.7) 122 (21.4) 104 (18.0)
Number of days of normal or higher level of care > 14
Nobs (Nmiss) 1148 (78) 569 (41) 579 (37)
No, n (%) 996 (86.8) 482 (84.7) 514 (88.8)
Yes, n (%) 152 (13.2) 87 (15.3) 65 (11.2)
Nmiss, number of women with missing data; Nobs, number of observations.
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 23 13:07:32 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
TABLE 150 Linear mixed effects regression analyses predicting EQ-5D from treatment adjusting for EQ-5D at
baseline, previous pregnancy of ≥ 14 weeks’ gestation and centre as a random effect
Time n Effect estimate 95% CI p-value
Birth 390 0.001 –0.034 to 0.036 0.966
12 months 553 0.003 –0.026 to 0.032 0.833
Nmiss, number of women with missing data; Nobs, number of observations.
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 23 13:07:36 2015
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
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TABLE 151 Cervical length summaries
Parameter or outcome All
Trial group
Placebo Progesterone
Cervical length at baseline (mm)
Nobs (Nmiss) 712 (514) 351 (259) 361 (255)
> 25, n (%) 456 (64.0) 232 (66.1) 224 (62.0)
≤ 25, n (%) 256 (36.0) 119 (33.9) 137 (38.0)
Cervical length at baseline (mm)
Nobs (Nmiss) 712 (514) 351 (259) 361 (255)
> 15, n (%) 614 (86.2) 304 (86.6) 310 (85.9)
≤ 15, n (%) 98 (13.8) 47 (13.4) 51 (14.1)
Nmiss, number of women with missing data; Nobs, number of observations.
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 23 13:07:38 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
TABLE 152 Logistic regression models for the effect of treatment on secondary outcomes adjusted for previous
pregnancies of ≥ 14 weeks’ gestation
Outcome n OR 95% CI p-value
Fetal death 1197 1.14 0.41 to 3.17 0.802
Fetal death before 34 weeks’ gestation 1197 1.16 0.39 to 3.49 0.786
Delivery before 34 weeks’ gestation (excluding deaths before
34 weeks’ gestation)
1184 0.85 0.62 to 1.15 0.292
Neonatal deaths (excluding fetal deaths)a 1182 0.17 0.06 to 0.49 0.001
Neonatal or fetal death 1197 0.69 0.32 to 1.48 0.337
Necrotising enterocolitis (suspected or treated) 1155 1.37 0.76 to 2.45 0.291
Any episode of infection with positive blood culture vs. no
infection or infection without positive blood culture
1147 0.87 0.49 to 1.56 0.642
Any episode of infection with positive blood or cerebrospinal
fluid culture vs. no infection or infection without positive
blood or cerebrospinal fluid culture
1147 0.92 0.52 to 1.65 0.789
a Not adjusted for previous pregnancy of ≥ 14 weeks’ gestation.
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 23 13:07:46 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
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TABLE 153 Logistic regression models for the effect of treatment on components of disability adjusted for previous
pregnancies of ≥ 14 weeks’ gestation and centre as a random effect
Component n OR 95% CI p-value
Components of disability
Motor Regression failed
Cognitive 913 1.03 0.58 to 1.84 0.918
Hearing Regression failed
Speech and language 891 1.32 0.72 to 2.43 0.364
Vision Regression failed
Respiratory Regression failed
Gastrointestinal Regression failed
Renal 848 3.65 1.96 to 6.82 < 0.001
Not adjusted for previous pregnancy of ≥ 14 weeks
Components of disability
Motor 917 0.99 0.25 to 3.98 0.988
Hearing 931 0.56 0.33 to 0.94 0.028
Vision Regression failed
Respiratory 847 3.03 1.56 to 5.88 0.001
Gastrointestinal 844 2.67 1.37 to 5.20 0.004
Fisher’s exact test
Treatment
p-valuePlacebo Progesterone
Components of disability: vision
Nobs (Nmiss) 466 (144) 447 (169) 0.125
No, n (%) 462 (99.1) 447 (100.0)
Yes, n (%) 4 (0.9) 0 (0.0)
Nmiss, number of women with missing data; Nobs, number of observations.
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 23 13:08:05 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
TABLE 154 Logistic regression models for the effect of treatment on treatment satisfaction adjusted for previous
pregnancies of ≥ 14 weeks’ gestation and centre as a random effect
Parameter or outcome n OR 95% CI p-value
Extremely or fairly satisfied 634 0.93 0.42 to 2.04 0.854
Extremely satisfied 634 0.64 0.45 to 0.90 0.011
Extremely satisfied (6 months) 78 1.34 0.46 to 3.88 0.591
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 23 13:08:08 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
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TABLE 155 Summaries of categorical Strengths and Difficulties Questionnaire scores
Parameter or outcome All
Trial group
Placebo Progesterone
SDQ emotional problems score normal (≤ 2)
Nobs (Nmiss) 669 (557) 341 (269) 328 (288)
No, n (%) 69 (10.3) 35 (10.3) 34 (10.4)
Yes, n (%) 600 (89.7) 306 (89.7) 294 (89.6)
SDQ conduct problems score normal (≤ 3)
Nobs (Nmiss) 668 (558) 342 (268) 326 (290)
No, n (%) 174 (26.0) 92 (26.9) 82 (25.2)
Yes, n (%) 494 (74.0) 250 (73.1) 244 (74.8)
SDQ hyperactivity score normal (≤ 5)
Nobs (Nmiss) 649 (577) 334 (276) 315 (301)
No, n (%) 191 (29.4) 95 (28.4) 96 (30.5)
Yes, n (%) 458 (70.6) 239 (71.6) 219 (69.5)
SDQ peer problems score normal (≤ 2)
Nobs (Nmiss) 663 (563) 345 (265) 318 (298)
No, n (%) 225 (33.9) 110 (31.9) 115 (36.2)
Yes, n (%) 438 (66.1) 235 (68.1) 203 (63.8)
SDQ total score normal (≤ 12)
Nobs (Nmiss) 597 (629) 302 (308) 295 (321)
No, n (%) 149 (25.0) 70 (23.2) 79 (26.8)
Yes, n (%) 448 (75.0) 232 (76.8) 216 (73.2)
SDQ prosocial score normal (≥ 7)
Nobs (Nmiss) 659 (567) 339 (271) 320 (296)
No, n (%) 364 (55.2) 180 (53.1) 184 (57.5)
Yes, n (%) 295 (44.8) 159 (46.9) 136 (42.5)
SDQ impact score normal (0)
Nobs (Nmiss) 828 (398) 424 (186) 404 (212)
No, n (%) 49 (5.9) 22 (5.2) 27 (6.7)
Yes, n (%) 779 (94.1) 402 (94.8) 377 (93.3)
Nmiss, number of women with missing data; Nobs, number of observations; SDQ, Strengths and Difficulties Questionnaire.
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Oct 23 13:08:12 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
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TABLE 156 Adjusted CI using Bonferroni–Holm adjustment
Outcome 95% CI
Obstetric 0.61 to 1.22
Neonatal 0.38 to 1.03
Note
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Nov 27 13:41:38 2015.
TABLE 157 Number randomised before change in inclusion criteria (1 September 2010)
84
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Nov 27 13:41:39 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
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TABLE 158 Rates of primary outcome in subgroups
Risk group
Trial group, n/N (%)
Placebo Progesterone
Low/high risk group
Low 54/418 (12.9) 51/442 (11.5)
High 54/179 (30.2) 45/159 (28.3)
Cervical length at baseline (mm)
> 25 29/228 (12.7) 25/217 (11.5)
≤ 25 38/118 (32.2) 33/133 (24.8)
Cervical length at baseline (mm)
> 15 46/299 (15.4) 37/300 (12.3)
≤ 15 21/47 (44.7) 21/50 (42.0)
History of spontaneous preterm birth
No 26/154 (16.9) 22/130 (16.9)
Yes 82/443 (18.5) 74/470 (15.7)
History of any preterm birth
No 23/152 (15.1) 19/131 (14.5)
Yes 84/442 (19.0) 77/469 (16.4)
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Nov 27 13:41:45 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
TABLE 159 Baseline characteristics (part 1). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of Bayley-III cognitive composite score at 2 years
Characteristic All
Bayley-III cognitive composite score at 2 years available
No Yes
Age (years)
Nobs (Nmiss) 1225 (1) 356 (1) 869 (0)
Mean (SD) 31.4 (5.7) 29.6 (5.7) 32.2 (5.5)
Median (IQR) 31.5 (27.4–35.7) 29.3 (25.7–33.3) 32.3 (28.2–36.2)
Range 16.8–49.2 16.8–45.3 17.5–49.2
Height (cm)
Nobs (Nmiss) 1221 (5) 354 (3) 867 (2)
Mean (SD) 163.5 (6.6) 163.6 (6.6) 163.5 (6.6)
Median (IQR) 163.0 (159.0–168.0) 163.0 (159.0–168.0) 164.0 (159.0–168.0)
Range 144.0–183.0 147.0–183.0 144.0–183.0
Weight (kg)
Nobs (Nmiss) 1221 (5) 354 (3) 867 (2)
Mean (SD) 71.6 (17.1) 70.3 (15.7) 72.2 (17.6)
Median (IQR) 68.0 (60.0–81.0) 67.0 (59.0–80.0) 68.0 (60.0–81.0)
Range 41.0–186.0 43.0–130.0 41.0–186.0
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TABLE 159 Baseline characteristics (part 1). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of Bayley-III cognitive composite score at 2 years (continued )
Characteristic All
Bayley-III cognitive composite score at 2 years available
No Yes
BMI (kg/m2)
Nobs (Nmiss) 1221 (5) 354 (3) 867 (2)
Mean (SD) 26.8 (6.3) 26.3 (5.5) 27.0 (6.5)
Median (IQR) 25.5 (22.3–29.8) 25.0 (22.2–29.4) 25.6 (22.4–30.1)
Range 15.2–80.5 16.3–49.5 [5.2–80.5
Systolic blood pressure (mmHg)
Nobs (Nmiss) 1219 (7) 356 (1) 863 (6)
Mean (SD) 111.9 (12.4) 111.1 (12.0) 112.2 (12.5)
Median (IQR) 110.0 (102.0–120.0) 110.0 (102.0–120.0) 110.0 (103.0–120.0)
Range 78.0–189.0 78.0–159.0 80.0–189.0
Diastolic blood pressure (mmHg)
Nobs (Nmiss) 1219 (7) 356 (1) 863 (6)
Mean (SD) 66.0 (8.6) 65.4 (8.8) 66.2 (8.5)
Median (IQR) 65.0 (60.0–71.0) 64.0 (60.0–70.0) 65.0 (60.0–71.0)
Range 40.0–104.0 44.0–98.0 40.0–104.0
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Nov 27 13:41:47 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
TABLE 160 Baseline characteristics (part 2). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of Bayley-III cognitive composite score at 2 years
Characteristic All
Bayley-III cognitive composite score at 2 years available
No Yes
Smoking
Nobs (Nmiss) 1220 (6) 355 (2) 865 (4)
No, n (%) 984 (80.7) 245 (69.0) 739 (85.4)
Yes, n (%) 236 (19.3) 110 (31.0) 126 (14.6)
Alcohol consumption
Nobs (Nmiss) 1223 (3) 356 (1) 867 (2)
No, n (%) 1160 (94.8) 335 (94.1) 825 (95.2)
Yes, n (%) 63 (5.2) 21 (5.9) 42 (4.8)
continued
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TABLE 160 Baseline characteristics (part 2). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of Bayley-III cognitive composite score at 2 years (continued )
Characteristic All
Bayley-III cognitive composite score at 2 years available
No Yes
Drug use
Nobs (Nmiss) 1223 (3) 356 (1) 867 (2)
No, n (%) 1206 (98.6) 348 (97.8) 858 (99.0)
Yes, n (%) 17 (1.4) 8 (2.2) 9 (1.0)
Nmiss, number of women with missing data; Nobs, number of observations.
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Nov 27 13:41:49 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
TABLE 161 Baseline characteristics (part 3). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of Bayley-III cognitive composite score at 2 years
Characteristic All
Bayley-III cognitive composite score at 2 years available
No Yes
In full-time education
Nobs (Nmiss) 1216 (10) 353 (4) 863 (6)
No, n (%) 1175 (96.6) 339 (96.0) 836 (96.9)
Yes, n (%) 41 (3.4) 14 (4.0) 27 (3.1)
Years in full-time education
Nobs (Nmiss) 1122 (53) 315 (24) 807 (29)
Mean (SD) 13.5 (3.1) 12.7 (2.8) 13.8 (3.1)
Median (IQR) 13.0 (11.0–16.0) 12.0 (11.0–14.0) 13.0 (11.0–16.0)
Range 1.0–31.0 1.0–26.0 3.0–31.0
Educated in the UK
Nobs (Nmiss) 1206 (20) 347 (10) 859 (10)
No, n (%) 211 (17.5) 61 (17.6) 150 (17.5)
Yes, n (%) 995 (82.5) 286 (82.4) 709 (82.5)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Nov 27 13:41:49 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
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TABLE 162 Baseline characteristics (part 4): this pregnancy. Number of observed values, number of missing values,
number and percentage per category or mean, standard deviation, median and quartiles, minimum and maximum
for all patients and by availability of Bayley-III cognitive composite score at 2 years
Characteristic All
Bayley-III cognitive composite score at 2 years available
No Yes
Gestation (weeks) at fFN test
Nobs (Nmiss) 1226 (0) 357 (0) 869 (0)
Mean (SD) 22.9 (0.6) 22.9 (0.6) 22.9 (0.6)
Median (IQR) 22.9 (22.4–23.4) 22.9 (22.4–23.4) 22.9 (22.4–23.3)
Range 21.7–27.1 22.0–24.1 21.7–27.1
Fetal anomaly scan done
Nobs (Nmiss) 1226 (0) 357 (0) 869 (0)
No, n (%) 63 (5.1) 22 (6.2) 41 (4.7)
Yes, n (%) 1163 (94.9) 335 (93.8) 828 (95.3)
Fetal anomaly scan result
Nobs (Nmiss) 1163 (0) 335 (0) 828 (0)
Normal, n (%) 1150 (98.9) 333 (99.4) 817 (98.7)
Defined abnormality,
n (%)
7 (0.6) 0 (0.0) 7 (0.8)
Uncertain abnormality,
n (%)
6 (0.5) 2 (0.6) 4 (0.5)
Amniocentesis done
Nobs (Nmiss) 1226 (0) 357 (0) 869 (0)
No, n (%) 1218 (99.3) 356 (99.7) 862 (99.2)
Yes, n (%) 8 (0.7) 1 (0.3) 7 (0.8)
Results of amniocentesis
Nobs (Nmiss) 8 (0) 1 (0) 7 (0)
Normal, n (%) 8 (100.0) 1 (100.0) 7 (100.0)
Other, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Chorionic villus sampling done
Nobs (Nmiss) 1225 (1) 357 (0) 868 (1)
No, n (%) 1216 (99.3) 354 (99.2) 862 (99.3)
Yes, n (%) 9 (0.7) 3 (0.8) 6 (0.7)
Results of chorionic villus sampling
Nobs (Nmiss) 9 (0) 3 (0) 6 (0)
Normal, n (%) 9 (100.0) 3 (100.0) 6 (100.0)
Other, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Cervical length (mm)
Nobs (Nmiss) 712 (514) 216 (141) 496 (373)
Mean (SD) 28.5 (10.8) 29.0 (10.1) 28.3 (11.1)
Median (IQR) 30.0 (22.0–36.0) 30.0 (23.0–36.0) 30.0 (22.0–36.0)
Range 0.0–84.0 0.0–50.0 0.0–84.0
continued
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TABLE 162 Baseline characteristics (part 4): this pregnancy. Number of observed values, number of missing values,
number and percentage per category or mean, standard deviation, median and quartiles, minimum and maximum
for all patients and by availability of Bayley-III cognitive composite score at 2 years (continued )
Characteristic All
Bayley-III cognitive composite score at 2 years available
No Yes
Risk
Nobs (Nmiss) 1226 (0) 357 (0) 869 (0)
Low, n (%) 882 (71.9) 254 (71.1) 628 (72.3)
High, n (%) 344 (28.1) 103 (28.9) 241 (27.7)
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Nov 27 13:41:53 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
TABLE 163 Baseline characteristics (part 5). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of Bayley-III cognitive composite score at 2 years
Characteristic All
Bayley-III cognitive composite score at 2 years available
No Yes
Any previous pregnancy
Nobs (Nmiss) 1224 (2) 355 (2) 869 (0)
No, n (%) 52 (4.2) 10 (2.8) 42 (4.8)
Yes, n (%) 1172 (95.8) 345 (97.2) 827 (95.2)
Number of previous pregnancies
Nobs (Nmiss) 1224 (2) 355 (2) 869 (0)
Mean (SD) 2.6 (2.0) 2.9 (2.1) 2.5 (1.9)
Median (IQR) 2.0 (1.0–3.0) 2.0 (1.0–4.0) 2.0 (1.0–3.0)
Range 0.0–14.0 0.0–12.0 0.0–14.0
Any previous pregnancy of ≥ 14 weeks’ gestation
Nobs (Nmiss) 1224 (2) 355 (2) 869 (0)
No, n (%) 75 (6.1) 18 (5.1) 57 (6.6)
Yes, n (%) 1149 (93.9) 337 (94.9) 812 (93.4)
Number of previous pregnancies of ≥ 14 weeks’ gestation
Nobs (Nmiss) 1224 (2) 355 (2) 869 (0)
Mean (SD) 1.9 (1.4) 2.1 (1.5) 1.8 (1.3)
Median (IQR) 2.0 (1.0–2.0) 2.0 (1.0–3.0) 1.0 (1.0–2.0)
Range 0.0–13.0 0.0–8.0 0.0–13.0
Any previous live birth
Nobs (Nmiss) 1224 (2) 355 (2) 869 (0)
No, n (%) 197 (16.1) 56 (15.8) 141 (16.2)
Yes, n (%) 1027 (83.9) 299 (84.2) 728 (83.8)
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TABLE 163 Baseline characteristics (part 5). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of Bayley-III cognitive composite score at 2 years (continued )
Characteristic All
Bayley-III cognitive composite score at 2 years available
No Yes
Number of previous live births
Nobs (Nmiss) 1224 (2) 355 (2) 869 (0)
Mean (SD) 1.5 (1.3) 1.7 (1.3) 1.5 (1.3)
Median (IQR) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0)
Range 0.0–13.0 0.0–8.0 0.0–13.0
Any previous pregnancy that ended with baby alive and well
Nobs (Nmiss) 1224 (2) 355 (2) 869 (0)
No, n (%) 646 (52.8) 194 (54.6) 452 (52.0)
Yes, n (%) 578 (47.2) 161 (45.4) 417 (48.0)
Number of previous pregnancies that ended with baby alive and well
Nobs (Nmiss) 1224 (2) 355 (2) 869 (0)
Mean (SD) 0.8 (1.2) 0.9 (1.2) 0.8 (1.2)
Median (IQR) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0)
Range 0.0–13.0 0.0–6.0 0.0–13.0
IQR, interquartile range; Nmiss, number of women with missing data; Nobs, number of observations; SD, standard deviation.
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Nov 27 13:41:55 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
TABLE 164 Baseline characteristics (part 6). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of Bayley-III cognitive composite score at 2 years
Characteristic All
Bayley-III cognitive composite score at 2 years available
No Yes
History of induced labour or elective caesarean section
Nobs (Nmiss) 1224 (2) 355 (2) 869 (0)
No, n (%) 1065 (87.0) 304 (85.6) 761 (87.6)
Yes, n (%) 159 (13.0) 51 (14.4) 108 (12.4)
History of miscarriage
Nobs (Nmiss) 1224 (2) 355 (2) 869 (0)
No, n (%) 701 (57.3) 193 (54.4) 508 (58.5)
Yes, n (%) 523 (42.7) 162 (45.6) 361 (41.5)
History of ectopic pregnancy
Nobs (Nmiss) 1224 (2) 355 (2) 869 (0)
No, n (%) 1193 (97.5) 345 (97.2) 848 (97.6)
Yes, n (%) 31 (2.5) 10 (2.8) 21 (2.4)
continued
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TABLE 164 Baseline characteristics (part 6). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of Bayley-III cognitive composite score at 2 years (continued )
Characteristic All
Bayley-III cognitive composite score at 2 years available
No Yes
History of termination of pregnancy
Nobs (Nmiss) 1224 (2) 355 (2) 869 (0)
No, n (%) 1085 (88.6) 308 (86.8) 777 (89.4)
Yes, n (%) 139 (11.4) 47 (13.2) 92 (10.6)
History of termination of pregnancy before 14 weeks’ gestation
Nobs (Nmiss) 1226 (0) 357 (0) 869 (0)
No, n (%) 1106 (90.2) 317 (88.8) 789 (90.8)
Yes, n (%) 120 (9.8) 40 (11.2) 80 (9.2)
History of termination of pregnancy at ≥ 14 weeks’ gestation
Nobs (Nmiss) 1226 (0) 357 (0) 869 (0)
No, n (%) 1201 (98.0) 347 (97.2) 854 (98.3)
Yes, n (%) 25 (2.0) 10 (2.8) 15 (1.7)
History of live birth followed by neonatal death
Nobs (Nmiss) 1224 (2) 355 (2) 869 (0)
No, n (%) 1059 (86.5) 311 (87.6) 748 (86.1)
Yes, n (%) 165 (13.5) 44 (12.4) 121 (13.9)
History of live birth followed by death other than neonatal
Nobs (Nmiss) 1224 (2) 355 (2) 869 (0)
No, n (%) 1208 (98.7) 347 (97.7) 861 (99.1)
Yes, n (%) 16 (1.3) 8 (2.3) 8 (0.9)
History of stillbirth
Nobs (Nmiss) 1224 (2) 355 (2) 869 (0)
No, n (%) 1129 (92.2) 326 (91.8) 803 (92.4)
Yes, n (%) 95 (7.8) 29 (8.2) 66 (7.6)
Nmiss, number of women with missing data; Nobs, number of observations.
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Nov 27 13:41:57 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
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TABLE 165 Baseline characteristics (part 7). Number of observed values, number of missing values, number and
percentage per category or mean, standard deviation, median and quartiles, minimum and maximum for all
patients and by availability of Bayley-III cognitive composite score at 2 years
Characteristic All
Bayley-III cognitive composite score at 2 years available
No Yes
Ethnic group
Nobs (Nmiss) 1224 (2) 356 (1) 868 (1)
White, n (%) 895 (73.1) 254 (71.3) 641 (73.8)
Black, n (%) 180 (14.7) 62 (17.4) 118 (13.6)
Asian, n (%) 104 (8.5) 27 (7.6) 77 (8.9)
Mixed, n (%) 28 (2.3) 8 (2.2) 20 (2.3)
Other, n (%) 17 (1.4) 5 (1.4) 12 (1.4)
Nmiss, number of women with missing data; Nobs, number of observations.
Notes
OPPTIMUM Output created by OPPTIMUM_main_v2_0.R Last run on Fri Nov 27 13:47:03 2015.
These results have not been independently checked. Every effort has been made to ensure their accuracy, but the possibility
of error remains.
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Appendix 4 Patient information sheet
A patient information sheet for each of the main and screening phases of the study is attached.
a) 
 
 
 
PARTICIPANT INFORMATION LEAFLET  FIBRONECTIN 
TESTING 
 
Helping you decide whether or not to 
join our study 
 
 
1. Study Title  
Does progesterone prophylaxis to prevent preterm labour improve outcome? 
– A randomised double blind placebo controlled trial. “OPPTIMUM”.  
  
Short title: Does progesterone to prevent preterm labour improve outcome? 
  
2. Invitation Paragraph  
You are being invited to take part in a research study, as you have been 
identified by your doctor or midwife as someone who may be suitable.  Before 
you decide it is important for you to understand why the research is being 
done and what it will involve.  Please take time to read the following 
information carefully. Talk to others about the study if you wish. Ask us if there 
is anything that is not clear or if you would like more information.  Take time to 
decide whether or not you wish to take part.  
 
3. What is the purpose of the study?  
The purpose of the study is to see if progesterone given to women at high risk 
of preterm delivery is good for mother’s and baby’s health. However in order 
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to know if you are suitable to enter the study we need to do a fibronectin test. 
This information leaflet is to tell you about fibronectin testing.  
 
Fibronectin is a substance made naturally by the body in pregnancy, and 
binds the fetal membranes (around the amniotic fluid) to the lining of the 
womb. If it is found in high quantities in your vagina in pregnancy, you are 
more likely to deliver preterm. The fibronectin test measures the amount of 
fibronectin in the vagina.  
 
If you are fibronectin positive you will be eligible for the main study to see if 
giving progesterone to women at high risk of preterm delivery is good for both 
the mother’s and baby’s health. Regardless of the fFN result, you will also be 
eligible if you had a previous spontaneous labour resulting in a preterm birth ≤ 
34 weeks gestation or short cervix in index pregnancy, defined as cervical 
length ≤ 25mm, but we would like to find out whether the fibronectin test is 
positive, as this will help us determine the group of women that progesterone 
works best in. 
 
Information on the main study is available in a separate sheet and will be 
given to you if you are eligible, or would like further information before 
deciding whether or not to participate in the screening.  
  
4. Why have I been chosen?  
You have been chosen because we believe you might be at higher than 
average risk of preterm delivery. This may be because of what happened in a 
previous pregnancy, or because you have been found to have a short cervix 
on ultrasound. We would like now to do a fibronectin test to check whether 
you really are at high risk of preterm delivery. If the fibronectin test is positive, 
then we believe your risk of having a preterm delivery is around 4 in 10. We 
will then ask if you would like to participate in the main study.  
 
If your fibronectin test is negative, this means that you are at lower risk of 
preterm delivery, and you will not be eligible for participation in the main study 
unless you have a spontaneous labour resulting in a preterm birth ≤ 34 weeks 
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gestation in a previous pregnancy or a short cervix in index pregnancy, 
defined as cervical length ≤ 25mm in this pregnancy. 
. 
5. Do I have to take part?  
No.  It is up to you to decide whether or not to take part.  If you do, you will be 
given this information sheet to keep and be asked to sign a consent form. You 
are still free to withdraw at any time and without giving a reason.  A decision 
to withdraw at any time, or a decision not to take part, will not affect the 
standard of care you receive.   
  
6. What will happen to me if I take part?  
If you agree to take part we will take a swab from your vagina. The swab will 
then be tested for “fibronectin”. You will be informed of the results and, if 
appropriate, you will be invited to participate in the main study looking at a 
treatment that we hope will reduce the risk of having your baby early. 
Whatever the result of your fibronectin test, we will follow you up to see how 
many weeks pregnant you are when you have the baby, how your baby is 
delivered, and your own and your baby’s health details at delivery.  
 
7. What do I have to do?  
We ask that you agree to a vaginal swab for the fibronectin test to be 
performed. Once the fibronectin test is completed, you will be informed of the 
results and, if appropriate, you will be invited to participate in the main study 
and given further information.    
 
Women who are not randomised to progesterone or placebo will be provided 
with a (pre paid) postcard to let us know when they have delivered their baby. 
The local care team will then collect information from your hospital notes 
about you and your baby’s, delivery; such as the date and type of delivery.  
Information collected will help us to evaluate the outcomes for all women who 
were considered at risk of preterm delivery and will contribute towards the 
understanding we have about preterm labour. 
  
8. What is the drug, device or procedure that is being tested?  
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The drug that is being tested in the main study is called progesterone. There 
is some evidence to suggest that it might be helpful in preventing preterm 
delivery but further research is needed to understand its long term effects. 
This information form is for the fibronectin testing part of the study only.  
  
9. What are the alternatives for diagnosis or treatment?  
At present, there are no licensed or recommended treatments for the 
prevention of preterm delivery in women at high risk in the UK.   
  
10. What are the side effects of any treatment received when taking 
part?  
At this stage you will not be given any treatment with medication but 
information is available in the leaflet about the main study. You can request 
the leaflet from your doctor or view it on our website, www.opptimum.org.uk 
  
11. What are the other possible disadvantages and risks of taking part?  
A vaginal swab can be a little uncomfortable.  
  
12. What are the possible benefits of taking part?  
We will be able to give you a clearer idea of how likely you are to have a 
preterm delivery. In the event that you are at high risk of preterm birth, you 
would be eligible for participation in the main study.  
  
13. What happens when the research study stops?  
At the end of the study in 2015, the results will be published on the study 
website and in medical journals.  
 
14.   What if there is a problem?  
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. Please direct complaints to 
the local research doctor in the first instance.  
  
15.   What will happen if I don’t want to carry on with the study?  
You can withdraw from treatment at any time. The information collected up 
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until the point you decide not to continue will be used.  
  
16.    What if there is a problem?  
If you have a concern about any aspect of this study, you should ask to speak 
with the researchers who will do their best to answer your questions.  If you 
remain unhappy and wish to complain formally, you can do this through the 
NHS Complaints Procedure.  Details can be obtained from the hospital.  
  
In the event that something does go wrong and you are harmed during the 
research study there are no special compensation arrangements.  If you are 
harmed and this is due to someone’s negligence then you may have grounds 
for a legal action for compensation against  (the local Hospital or the Study 
Sponsors: University of Edinburgh/NHS Lothian) but you may have to pay 
your legal costs.  The normal National Health Service complaints mechanisms 
will still be available to you (if appropriate).  
  
17. Will my taking part in this study be kept confidential?  
All information that is collected about you during the course of the research 
will be kept strictly confidential.   
  
With your consent we will notify your own GP of your participation in the 
study. We may also ask your GP how you and your baby are getting on in the 
future. This may happen, approximately every five years from the time that 
your baby reaches the age of 5 years. 
 
The data will be stored for following NHS guidelines: at least 25 years and 
possibly longer. 
  
18.   What will happen to any samples I give?  
The fibronectin test will be done using the vaginal swab. The swab will be 
destroyed thereafter.  
  
19.   Will any genetic tests be done?    
No. 
DOI: 10.3310/hta22350 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 35
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Norman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
211
20.  What will happen to the results of the research study?  
The results of the study will be published in a medical journal, and on the 
study website in due course (www.opptimum.org.uk). You will not be identified 
in any report/publication.  
  
21. Who is organising and funding the research?    
The study is being funded by the UK Medical Research Council: NIHR Efficacy 
and Mechanism Evaluation (EME). It is organised and sponsored by the 
University of Edinburgh/NHS Lothian. The sponsors of this study will 
contribute to the expenses of the hospital for including you in this study.  
   
 22. Who has reviewed the study?   
This study was given a favourable ethical opinion for conduct in the NHS by 
the Scotland A Research Ethics Committee.  
 
23.  Who should I contact? 
If you are interested in participating in Opptimum or would like further 
information, please contact: 
 
Name of local 
Doctor 
 
Hospital:  
Address:  
  
  
Telephone:  
Email:  
 
You will be given a copy of this information sheet and a copy of your signed 
consent form to keep. 
 
Thank you for or taking time to read this sheet and for 
considering taking part 
Version 7, January 2012 
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 PARTICIPANT INFORMATION LEAFLET (MAIN) 
 
Additional Information to help you 
decide whether or not to join the 
treatment part of our study 
 
 
1. Study Title  
Does progesterone prophylaxis to prevent preterm labour improve outcome? 
– A randomised double blind placebo controlled trial “OPPTIMUM”.  
  
Short title: Does progesterone to prevent preterm labour improve outcome? 
 
2. Invitation Paragraph  
You are being invited to join the treatment part of the Opptimum study;, before 
you decide to participate it is important for you to understand why the 
research is being done and what it will involve.  Please take time to read the 
following information carefully. Talk to others about the study if you wish. Ask 
your doctor if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not you wish to take part.  
 
3. What is the purpose of the study?  
The purpose of the study is to see if giving progesterone to women at high 
risk of preterm delivery is good for mother’s and baby’s health. We plan to 
look at your health during your pregnancy and the baby’s health until the baby 
is two years of age. We will also ask you to complete questionnaires about 
your experience of using the treatment.  These questionnaires will also ask 
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about you, and your baby’s, health following the pregnancy, in order to assess 
the effects of giving progesterone.  It is possible these questionnaires may 
also indicate if this treatment is costly or money-saving for the NHS.  
 
4. Why have I been chosen?  
You have been invited because the fetal fibronectin test was positive or 
because you had a spontaneous preterm labour resulting in a birth ≤ 34 
weeks gestation or a short cervix in this pregnancy, (defined as cervical length 
≤ 25mm) and we therefore believe that you might be at higher than average 
risk of preterm delivery. Fibronectin is a substance made naturally by the body 
in pregnancy. It binds the fetal membranes (around the amniotic fluid) to the 
lining of the womb. If it is found in high quantities in your vagina in pregnancy, 
you are more likely to deliver preterm.  
 
We hope that 1250 women in your situation will agree to participate in the 
study, of whom 625 will be treated with progesterone and 625 will be treated 
with a placebo (dummy) treatment.  
 
5. Do I have to take part?  
No.  It is up to you to decide whether or not to take part.  If you do, you will be 
given this information sheet to keep and will be asked to sign another consent 
form. You are free to withdraw at any time and without giving a reason.  A 
decision to withdraw at any time, or a decision not to take part, will not affect 
the care you receive.  
 
6. What will happen to me if I take part?  
Sometimes we don’t know which way of treating patients is best. To find out, 
we need to make comparisons between different treatments. We do this by 
putting people into groups and give each group a different treatment; the 
results are then compared to see if one is better. To try to make sure the 
groups are the same to start with, each patient is put into a group by chance 
(randomly). The results are then compared.   
 
If you agree to take part we will give you a pack of study medication. The 
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study medication is in the form of a capsule. The capsule will either contain 
progesterone or a “placebo”. A placebo is a “dummy treatment”, which looks 
like the genuine medicine but contains no active ingredient. One capsule 
should be inserted into the vagina every evening before going to bed, using 
your finger.  
 
The study doctor / midwife will write down the date you should start 
medication and also when to stop taking the medication; this will be recorded 
in the patient diary we will ask you to keep. Most women will start taking the 
treatment between 22 and 24 weeks of pregnancy. All women will be asked to 
stop taking the treatment when they are 34 weeks pregnant.  
 
You will not know which treatment group you are in.  The trial is a double blind 
trial, and so neither you nor your doctor will know which treatment group you 
are (although, if your doctor needs to find out he/she can do so). 
 
We hope that you will agree to stay in this study until after you have had your 
baby. Participation in this study may require around three extra visits to 
hospital during your pregnancy, each of which will last 30 minutes. During this 
time you will have a check up and will be asked some questions about your 
health. We will also ask you to fill in questionnaires to tell us how you are 
getting on, after you have had your baby. We may also ask you to take part in 
an interview telling us what you think about your experience of using the 
treatment. We will collect some information from your medical notes about 
your health. 
 
 We would also like to collect information about the baby’s health. We can 
(with your permission) get most of this from the baby’s notes. We will ask your 
permission to do an ultrasound scan of the baby’s head when he / she is born 
and ask you to fill in further questionnaires when your baby is approximately 
one year old, to tell us about their health and experience. Additionally, we 
would like to see your baby again when he / she is two years old to see how 
he / she is getting on.  
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Lastly, we would like your permission to contact you in the future to see how 
your baby gets on as he / she grows up; and to access information in health 
records about you and your baby. We cannot be certain when this would 
happen, but it may be approximately every five years from the time that your 
baby reaches the age of 5 years.  
 
7. What do I have to do?  
We ask you to take the study medication as directed, and attend the extra 
clinic visits we invite you to. We also ask that you complete the study related 
diary and questionnaires.   
 
8. What is the drug, device or procedure that is being tested?  
The drug that is being tested is called progesterone. There is some evidence 
to suggest that it might be helpful in preventing preterm delivery but further 
research is needed to understand its long term effects. The treatment dose 
being tested is 200mg (one capsule) per day inserted in to the vagina every 
evening.  
 
9. What are the alternatives for diagnosis or treatment?  
At present, there are no licensed or recommended treatments for the 
prevention of preterm delivery in women at high risk.   
 
10. What are the side effects of any treatment received when taking 
part? 
These are unlikely but possible side effects of this treatment are: acne, 
flushing, rashes, fluid retention, weight changes, tummy upset, changes in 
libido, breast discomfort, migraine, tiredness and premenstrual symptoms. If 
you agree to participate in the main study and have side effects that concern 
you, please contact the local study team. 
 
11. What are the other possible disadvantages and risks of taking part?  
The other disadvantage is the inconvenience for you in making extra hospital 
visits during your pregnancy, completing questionnaires and bringing your 
child in for follow up studies in the future.  
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12. What are the possible benefits of taking part?  
We cannot promise the study will help you but the information we obtain might 
help improve the treatment of women with a high risk of preterm delivery in 
the future.  
  
13. What happens when the research study stops?  
At the end of the study in 2015, we will be able to inform you of the study 
results if you wish. If you wish us to do so, please inform your study doctor. 
The results will also be published on the study website and in medical 
journals. We will keep the information about you for as long as possible: at 
least 25 years. 
 
 
14.   What will happen if I don’t want to carry on with the study?  
You can withdraw from treatment but you may wish to keep in contact with us 
to let us know your progress. If you do withdraw from treatment, the 
information already collected about you will still be used.  We are required to 
follow up each case, to collect information about your pregnancy up until the 
time your baby is born. We will collect this information from your notes, unless 
you tell us otherwise.    
 
15.    What if there is a problem?  
If you have a concern about any aspect of this study, you should ask to speak 
with the local researchers who will do their best to answer your questions. If 
you remain unhappy and wish to complain formally, you can do this through 
the NHS Complaints Procedure.  Details can be obtained from the hospital.  
  
In the event that something does go wrong and you are harmed during the 
research study there are no special compensation arrangements.  If you are 
harmed and this is due to someone’s negligence then you may have grounds 
for a legal action for compensation against (your local hospital or the Study 
Sponsors: University of Edinburgh/NHS Lothian) but you may have to pay 
your legal costs.  The normal National Health Service complaints mechanisms 
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will still be available to you (if appropriate). 
 
16. Will my taking part in this study be kept confidential?  
Yes, all information that is collected about you during the course of the 
research will be kept strictly confidential. The Medical Research Council: 
NIHR Efficacy and Mechanism Evaluation (EME) who fund this study may ask 
us to share the information with other approved researchers; however, your 
identity (eg name, date of birth) will not be passed on.  
 
We plan to send the details of you and your baby to the National Health 
Service Care Register (NHSCR) so that we can be informed of any major 
illnesses that you or your baby have in future. In order to be able to contact 
you about your own and your baby’s health in future, your name and contact 
details, those of a relative or friend, and your GP details will be requested. 
These contacts will be kept securely, with access restricted on a secure 
database managed by the University of Glasgow. This information will be 
used only to contact you about the study by the study doctor or researchers 
running this trial. You will not be named or otherwise identified in any study 
publication.   
 
In addition, with your consent we will notify your own GP of your participation 
in the study. We may also ask your GP how you and your baby are getting on 
in the future.  
 
17.   Will any genetic tests be done?    
Yes. Once you have had the baby we would like your permission to store a 
sample of the placenta (afterbirth) and placental DNA. We may keep some of 
these samples in a tissue bank for future research. Ethical permission will be 
sought for any future research projects. Although the placenta may need to be 
examined as part of your care, it is optional whether you agree to the use of 
the surplus tissue and DNA for future research.  
 
18. What will happen to the results of the research study?  
 The results of the study will be published in a medical journal, and on the 
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study website in due course (www.opptimum.org.uk). You will not be identified 
in any report/publication.  
 
19. Who is organising and funding the research?    
The study is being funded by the NIHR Efficacy and Mechanism Evaluation 
(EME). It is organised and sponsored by the University of Edinburgh/NHS 
Lothian.  The sponsors of this study will contribute towards the expenses of 
the hospital for including you in this study  
 
20. Who has reviewed the study?   
This study was given a favourable ethical opinion for conduct in the NHS by 
the Scotland A Research Ethics Committee. Each hospital participating in the 
study also reviews the study and must agree to your Doctor taking part 
 
21.  Who should I contact? 
If you are interested in participating in Opptimum main study or would like 
further information, please contact: 
Name of local 
Doctor 
 
Hospital:  
Address:  
  
  
Telephone:  
Email:  
 
You will be given a copy of the information sheet and a copy of your signed 
consent form to keep. 
Thank you for or taking time to read this sheet and for 
considering taking part. 
  
Version 7, January 2012 
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Appendix 5 Informed consent form
A consent form for each of the main and screening phases of the study is attached.
a) 
 
Title of study: Does progesterone prophylaxis to prevent preterm labour 
improve outcome? 
CONSENT FORM (FIBRONECTIN TESTING)  
 
Insert name of local researcher (PI): 
__________________________________ 
 
 
TO BE COMPLETED BY THE PARTICIPANT: If you agree to the following statements, 
please confirm by  initialling boxes below: 
 
1. I confirm that I have read and understand the OPPTIMUM Study 
Patient Information entitled “Participation Information Leaflet 
(Fibronectin testing)” dated January 2012 (Version 7.0) for the above 
study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical 
care or legal rights being affected. 
 
 
3. I understand that relevant sections of my, and my baby’s, medical 
notes and data collected during the study may be looked at by 
individuals from the University of Edinburgh, the University of Glasgow, 
from regulatory authorities or from the NHS Organisation, where it is 
relevant to my taking part in this research study. I give permission for 
these individuals to have access to my records. 
 
4.  I agree to take part in the above study.  
5. I would like my GP to be informed of my participation in the study.  
Signature of 
Person 
taking 
Consent: 
 Date: 
 
 
PRINT 
NAME: 
    
Participant’s 
signature: 
 Date: 
 
 
PRINT 
NAME: 
   
Version 7, January 2012 
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b) Title of study: Does progesterone prophylaxis to prevent preterm labour 
improve outcome? 
CONSENT FORM (MAIN) 
Insert name of local researcher (PI) ________________________________  
 
TO BE COMPLETED BY THE PARTICIPANT : If you agree to the following statements, 
please confirm by  initialling boxes below: 
1. I confirm that I have read and understand the OPPTIMUM Study Patient 
Information entitled “Participation Information Leaflet (Main)” dated January 
2012 (Version 7.0) for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
 
 
2. I confirm that I agree to sections of placental tissue being examined.  
 
 
 
3. I confirm that I agree to placental DNA stored for use in subsequent 
research. 
 
4. I confirm that I agree to to my baby having a neonatal head scan.  
 
5. I understand that my, and my baby’s, participation is voluntary, that the study 
will last until my baby is two years of age; and that I and my baby are free to 
withdraw at any time without giving any reason, without our medical care or 
legal rights being affected.  
 
 
6. I understand that relevant sections of my, and my baby’s, medical notes and 
data collected during the study may be looked at by individuals from the 
University of Edinburgh, the University of Glasgow, from regulatory 
authorities or from the NHS Organisation, where it is relevant to my taking 
part in this research study. I give permission for these individuals to have 
access to my records 
7.  I agree to take part in the above study.  
8. I would like my GP to be informed of my participation in the study.  
Participant’s signature: Date: 
PRINT NAME:    
Signature of Person 
taking Consent: 
 Date: 
 
 
PRINT NAME:    
Version 7, January 2012
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Appendix 6 Case report forms
Parts of this appendix have been reproduced with permission from Sharon Kean, Robertson Centre forBiostatistics, 2018, personal communication.
DOI: 10.3310/hta22350 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 35
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Norman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
223
OPPTIMUM 
 
Annotated CRF 
Version 2.0 
 
 
 
 
Does progesterone prophylaxis to prevent preterm labour improve outcome? 
 
 
Isobel Docherty, Robertson Centre for Biostatistics 
09 March 2013 
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5. 
 
a. Pregnancy Complications – See Section 2  (h) 
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c. Hospital Admissions – Threatened Preterm Labour or  PPROM 
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6. 
 
a. Pregnancy Complications – See Section 2  (h) 
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a. Contact Details – See Section 3 (j) 
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Appendix 7 Approval letters
The ethics committee approval (initial approval letter and approval for final amendment), MHRA approvalletter and regulatory approvals are attached.
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21 October 2013 
 
Professor Jane Norman 
 
Dear Prof Norman 
 
 
The above amendment was reviewed held in correspondence by the Sub-Committee. 
Ethical opinion 
The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chairman Dr Ian Zealley 
Vice-Chairman Dr Colin Selby
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The documents reviewed and approved at the meeting were: 
 
Document Version Date 
Covering Letter 04 October 2013 
European Commission Notification of Substantial 
Amendment Form 
04 October 2013 
Letter to woman from sites V1 30 September 
2013 
Expenses Letter at 2 years V1 26 September 
2013 
Protocol with and without tracked changes V15 04 October 2013 
 
 
 
The members of the Committee who took part in the review are listed on the attached 
sheet. 
 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
 
 
This Committee is recognised by the United Kingdom Ethics Committee Authority under 
the Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry 
out the ethical review of clinical trials of investigational medicinal products. 
 
The Committee is fully compliant with the Regulations as they relate to ethics committees 
and the conditions and principles of good clinical practice. 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK. 
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We are pleased to welcome researchers and R & D staff at our NRES committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/ 
 
 
Yours sincerely 
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Scotland A REC 
 
Attendance at Sub-Committee 
of the REC meeting 
 
Name Profession Capacity 
Dr Anthony Pottage Retired Physician/Clinical 
Pharmacologist 
Expert 
Dr Colin Selby Consultant Physician Expert 
Mrs Margaret Thomson Retired Lay Plus 
 
Also in attendance: 
 
Name Position (or reason for attending) 
Dr Alex Bailey Scientific Officer 
Mrs Dorothy Garrow Sub-Committee Coordinator 
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Appendix 8 Results letters
Letters provided to participants to share results of study and drug allocation are attached.
a)
DOI: 10.3310/hta22350 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 35
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Norman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
295
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
296
DOI: 10.3310/hta22350 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 35
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Norman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
297
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
298
DOI: 10.3310/hta22350 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 35
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Norman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
299
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